[go: up one dir, main page]

US20230331725A1 - Compounds for treating huntington's disease - Google Patents

Compounds for treating huntington's disease Download PDF

Info

Publication number
US20230331725A1
US20230331725A1 US18/211,134 US202318211134A US2023331725A1 US 20230331725 A1 US20230331725 A1 US 20230331725A1 US 202318211134 A US202318211134 A US 202318211134A US 2023331725 A1 US2023331725 A1 US 2023331725A1
Authority
US
United States
Prior art keywords
amino
alkyl
triazin
pyridinyl
phenol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US18/211,134
Inventor
Nadiya Sydorenko
Md Rauful Alam
Lukiana Amedzo
Suresh Babu
Ramil Y. Baiazitov
Scott J. Barraza
Anuradha Bhattacharyya
Gary Mitchell Karp
Nathaniel T. Kenton
Anthony R. Mazzotti
Young-Choon Moon
Nicholas W. Mszar
Jana Narasimhan
Sudipta Pal
Jigar S. Patel
Anthony Turpoff
Matthew G. Woll
Zhenrong Xu
Nanjing Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics Inc
Original Assignee
PTC Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PTC Therapeutics Inc filed Critical PTC Therapeutics Inc
Priority to US18/211,134 priority Critical patent/US20230331725A1/en
Publication of US20230331725A1 publication Critical patent/US20230331725A1/en
Assigned to PTC THERAPEUTICS, INC. reassignment PTC THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PAL, Sudipta, AMEDZO, Lukiana, KENTON, Nathaniel T., XU, ZHENRONG, KARP, GARY MITCHELL, BABU, SURESH, BAIAZITOV, RAMIL Y., WOLL, MATTHEW G., BHATTACHARYYA, ANURADHA, ALAM, RAUFUL, MD, Barraza, Scott J., Mazzotti, Anthony R., MOON, YOUNG-CHOON, MSZAR, Nicholas W., NARASIMHAN, JANA, PATEL, Jigar S., SYDORENKO, NADIYA, TURPOFF, ANTHONY, ZHANG, NANJING
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Definitions

  • An aspect of the present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof useful for treating or ameliorating Huntington's disease.
  • another aspect of the present description relates to substituted monocyclic heteroaryl compounds, forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
  • Huntington's disease is a progressive, autosomal dominant neurodegenerative disorder of the brain, having symptoms characterized by involuntary movements, cognitive impairment, and mental deterioration. Death, typically caused by pneumonia or coronary artery disease, usually occurs 13 to 15 years after the onset of symptoms. The prevalence of HD is between three and seven individuals per 100,000 in populations of western European descent. In North America, an estimated 30,000 people have HD, while an additional 200,000 people are at risk of inheriting the disease from an affected parent.
  • the disease is caused by an expansion of uninterrupted trinucleotide CAG repeats in the “mutant” huntingtin (Htt) gene, leading to production of HTT (Htt protein) with an expanded poly-glutamine (polyQ) stretch, also known as a “CAG repeat” sequence.
  • Htt huntingtin
  • polyQ poly-glutamine
  • An aspect of the present description includes compounds comprising, a compound of Formula (I) or Formula (II):
  • An aspect of the present description includes a method for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a method for use of a compound of Formula (I) or Formula (II) or a form or composition thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form or composition thereof.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof in the manufacture of a medicament for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the medicament.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof in a combination product with one or more therapeutic agents for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form thereof in combination with an effective amount of the one or more agents.
  • An aspect of the present description relates to compounds comprising, a compound of Formula (I) or Formula (II):
  • Another aspect of the present description includes a compound of Formula (I) or Formula (II):
  • One aspect includes a compound of Formula (I) or Formula (II), wherein X is selected from CHR 1a , C ⁇ O, O, NR 1b , and a bond.
  • Another aspect includes a compound of Formula (I) wherein X is CHR 1a .
  • Another aspect includes a compound of Formula (I) or Formula (II) wherein X is C ⁇ O.
  • Another aspect includes a compound of Formula (I) or Formula (II) wherein X is O.
  • Another aspect includes a compound of Formula (I) or Formula (II) wherein X is NR 1b .
  • Another aspect includes a compound of Formula (I) or Formula (II) wherein X is a bond.
  • One aspect includes a compound of Formula (I) or Formula (II), wherein R 1a is selected from hydrogen, halogen, hydroxyl, cyano, C 1-4 alkyl, deutero-C 1-4 alkyl, halo-C 1-4 alkyl, amino, and hydroxyl-C 1-4 alkyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 1a is selected from hydrogen, cyano, C 1-4 alkyl, and amino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 1a is hydrogen.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 1a is cyano.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 1a is C 1-4 alkyl selected from methyl, ethyl, propyl, isopropyl, butyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 1a methyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 1a is amino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 1b is selected from hydrogen and C 1-4 alkyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 1b is hydrogen.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 1b is C 1-4 alkyl selected from methyl, ethyl, propyl, isopropyl, butyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 1b is methyl.
  • One aspect includes a compound of Formula (I) or Formula (II), wherein B is heterocyclyl,
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein B is heterocyclyl selected from azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, 1,4-diazepanyl, 1,2-dihydropyridinyl, 1,2,5,6-tetrahydropyridinyl, 1,2,3,6-tetrahydropyridinyl, hexahydrocyclopentapyrrol-(1H)-yl, hexahydropyrrolo[3,2-b]pyrrol-(2H)-yl, hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein B is heterocyclyl selected from pyrrolidinyl, piperidinyl, piperazinyl, hexahydrocyclopentapyrrol-(1H)-yl, hexahydropyrrolo[3,2-b]pyrrol-(2H)-yl, hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, octahydro-2H-pyrrolo[3,4-c]pyridinyl, octahydro-5H-pyrrolo[3,2-c]pyridinyl, octahydro-6H-pyrrolo[3,4-b]pyridinyl,
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein B is heterocyclyl selected from pyrrolidinyl, piperidinyl, and 2,7-diazaspiro[3.5]nonanyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R 2 .
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein B is heterocyclyl selected from azetidin-1-yl, tetrahydrofuran-3-yl, pyrrolidin-1-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, 1,4-diazepan-1-yl, 1,2-dihydropyridin-2-yl, 1,2-dihydropyridin-3-yl, 1,2-dihydropyridin-4-yl, 1,2-dihydropyridin-5-yl, 1,2-dihydropyridin-6-yl, 1,2,5,6-tetrahydropyridin-5-yl, 1,2,3,6-tetrahydropyridin-4-yl, hexahydrocyclopentapyrrol-2(1H)-yl, hexahydropyrrolo[3,
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein B is heterocyclyl selected from pyrrolidin-1-yl, pyrrolidin-3-yl, piperidin-4-yl, piperazin-1-yl, hexahydrocyclopentapyrrol-2(1H)-yl, hexahydropyrrolo[3,2-b]pyrrol-1(2H)-yl, hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl, hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl, octahydro-2H-pyrrolo[3,4-c]pyridin-2-yl, octahydro-5H-pyrrolo[3,2-c]pyridin-5-yl, octahydr
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein B is heterocyclyl selected from pyrrolidin-1-yl, pyrrolidin-3-yl, piperidin-4-yl, 2,7-diazaspiro[3.5]nonan-2-yl, and 2,7-diazaspiro[3.5]nonan-7-yl, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R 2 .
  • B is heterocyclyl selected from pyrrolidin-1-yl, pyrrolidin-3-yl, piperidin-4-yl, 2,7-diazaspiro[3.5]nonan-2-yl, and 2,7-diazaspiro[3.5]nonan-7-yl, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R 2 .
  • R 2 is selected from halogen, hydroxyl, cyano, C 1-4 alkyl, deutero-C 1-4 alkyl, halo-C 1-4 alkyl, amino, C 1-4 alkyl-amino, (C 1-6 alkyl) 2 -amino, halo-C 1-4 alkyl-amino, (halo-C 1-6 alkyl) 2 -amino, hydroxy-C 1-4 alkyl-amino, C 1-4 alkoxy-C 1-4 alkyl-amino, amino-C 1-4 alkyl, C 1-4 alkyl-amino-C 1-4 alkyl, (C 1-4 alkyl-amino) 2 -C 1-4 alkyl, C 1-4 alkoxy, halo-C 1-4 alkoxy, hydroxyl-C 1-4 alkoxy, C 1-4 alkyl-C 1-4 alkoxy, C 3-10 cycl
  • R 2 is selected from halogen, hydroxyl, C 1-4 alkyl, amino, C 1-4 alkyl-amino, (C 1-6 alkyl) 2 -amino, halo-C 1-4 alkyl-amino, hydroxy-C 1-4 alkyl-amino, C 1-4 alkoxy-C 1-4 alkyl-amino, C 1-4 alkyl-amino-C 1-4 alkyl, (C 1-4 alkyl-amino) 2 -C 1-4 alkyl, C 1-4 alkoxy, C 3-10 cycloalkyl-amino, C 3-10 cycloalkyl-amino-C 1-4 alkyl, heteroaryl-C 1-4 alkyl-amino, heterocyclyl-amino, heterocyclyl-amino-C 1-4 alkyl, and heterocyclyl-amino-C 3-10 cycloalkyl
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is halogen selected from bromo, chloro, fluoro, and iodo.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is fluoro.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is hydroxyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is C 1-4 alkyl selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is C 1-4 alkyl selected from methyl or ethyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is methyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is ethyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is amino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is C 1-6 alkyl-amino, wherein C 1-6 alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, 2-methylbutyl, and 3-methylpentyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is C 1-6 alkyl-amino, wherein C 1-6 alkyl is selected from methyl, ethyl, isopropyl, tert-butyl, 2-methylbutyl, and 3-methylpentyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is methylamino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is ethylamino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is isopropylamino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is tert-butylamino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is 2-methylbutyl-2-amino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is 3-methylpentyl-3-amino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is (C 1-6 alkyl) 2 -amino, wherein C 1-4 alkyl is each independently selected from selected from methyl, ethyl, isopropyl, tert-butyl, 2-methylbutyl, and 3-methylpentyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is (C 1-6 alkyl) 2 -amino, wherein C 1-4 alkyl is methyl or ethyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is dimethylamino or diethylamino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is dimethylamino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is diethylamino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is halo-C 1-4 alkyl-amino, wherein C 1-4 alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl, partially or completely substituted with one or more halogen atoms where allowed by available valences.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is halo-C 1-4 alkyl-amino, wherein C 1-4 alkyl is selected from isopropyl and tert-butyl, partially or completely substituted with one or more halogen atoms where allowed by available valences.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is 1-fluoro-2-methylpropan-2-amino or 1-fluoropropan-2-amino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is hydroxy-C 1-4 alkyl-amino, wherein C 1-4 alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl, partially or completely substituted with one or more hydroxy groups where allowed by available valences.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is hydroxy-C 1-4 alkyl-amino, wherein C 1-4 alkyl is selected from ethyl and propyl, partially or completely substituted with one or more hydroxy groups where allowed by available valences.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is 2-hydroxyethylamino or 3-hydroxypropylamino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is C 1-4 alkoxy-C 1-4 alkyl-amino, wherein C 1-4 alkoxy is selected from methoxy, ethoxy, propoxy, isopropoxy, butoxy and tert-butoxy, and C 1-4 alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is C 1-4 alkoxy-C 1-4 alkyl-amino, wherein C 1-4 alkoxy is methoxy and C 1-4 alkyl is selected propyl, isopropyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is 1-methoxypropan-2-amino or 1-methoxy-2-methylpropan-2-amino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is C 1-4 alkyl-amino-C 1-4 alkyl, wherein each C 1-4 alkyl is independently selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is C 1-4 alkyl-amino-C 1-4 alkyl, wherein each C 1-4 alkyl is independently selected from methyl, ethyl, isopropyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is methylaminomethyl, propan-2-yl-aminomethyl, propan-2-yl-aminoethyl, or tert-butylaminomethyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is (C 1-4 alkyl-amino) 2 -C 1-4 alkyl, wherein each C 1-4 alkyl is independently selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is (C 1-4 alkyl-amino) 2 -C 1-4 alkyl, wherein each C 1-4 alkyl is methyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is dimethylaminomethyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is C 1-4 alkoxy selected from methoxy, ethoxy, propoxy, isopropoxy, butoxy and tert-butoxy.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 methoxy.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is C 3-10 cycloalkyl-amino, wherein C 3-10 cycloalkyl is selected from cyclopropyl, cylcobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]hexanyl, and adamantyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is C 3-10 cycloalkyl-amino, wherein C 3-10 cycloalkyl is selected from cyclopropyl, cylcobutyl, cyclopentyl, bicyclo[2.2.1]hexanyl, and adamantyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is C 3-10 cycloalkyl-amino-C 1-4 alkyl, wherein C 3-10 cycloalkyl is selected from cyclopropyl, cylcobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]hexanyl, and adamantyl and C 1-4 alkyl is selected from methyl, ethyl, propyl, and butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is C 3-10 cycloalkyl-amino-C 1-4 alkyl, wherein C 3-10 cycloalkyl is selected from cyclopropyl, cylcobutyl, and cyclopentyl, and C 1-4 alkyl is methyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is cyclopropylaminomethyl, cyclobutylaminomethyl, or cyclopentylaminomethyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is heteroaryl-C 1-4 alkyl-amino, wherein heteroaryl is selected from thienyl, 1H-pyrazolyl, 1H-imidazolyl, 1,3-thiazolyl, oxazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-thiadiazolyl, 1H-tetrazolyl, 2H-tetrazolyl, pyridinyl, pyrimidinyl, pyridazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1H-indolyl, 1H-indazolyl, 2H-indazolyl, indolizinyl, benzofuranyl, benzothienyl, 1H-benzimidazolyl, 1,3-benzoxazolyl, 1,3-benzothiazolyl
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is heteroaryl-C 1-4 alkyl-amino, wherein heteroaryl is pyridinyl, and C 1-4 alkyl is methyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is pyridin-2-yl-methylamino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is heterocyclyl-amino, wherein heterocyclyl is selected from azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, tetrahydropyranyl, 8-azabicyclo[3.2.1]octanyl, and 8-oxabicyclo[3.2.1]octanyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is heterocyclyl-amino, wherein heterocyclyl is selected from oxetanyl and tetrahydropyranyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is oxetanylamino or tetrahyropyranylamino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is heterocyclyl-amino-C 1-4 alkyl, wherein heterocyclyl is selected from azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, oxanyl, 8-azabicyclo[3.2.1]octanyl, and 8-oxabicyclo[3.2.1]octanyl, and C 1-4 alkyl is selected from methyl, ethyl, propyl, and butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is heterocyclyl-amino-C 1-4 alkyl, wherein heterocyclyl is selected from tetrahydrofuranyl, oxanyl, and 8-oxabicyclo[3.2.1]octanyl, and C 1-4 alkyl is methyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is oxanylaminomethyl, tetrahydrofuranylaminomethyl, and 8-oxabicyclo[3.2.1]octanylamino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is heterocyclyl-amino-C 3-10 cycloalkyl, wherein heterocyclyl is selected from azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, oxanyl, 8-azabicyclo[3.2.1]octanyl, and 8-oxabicyclo[3.2.1]octanyl, and C 3-10 cycloalkyl is selected from cyclopropyl, cylcobutyl, cyclopentyl, and cyclohexyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is heterocyclyl-amino-C 3-10 cycloalkyl, wherein heterocyclyl is oxanyl, and C 3-10 cycloalkyl is cyclopropyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is oxanylaminocyclopropyl.
  • One aspect includes a compound of Formula (I) or Formula (II), wherein R 3 is halogen, hydroxyl, cyano, C 1-4 alkyl, deutero-C 1-4 alkyl, halo-C 1-4 alkyl, amino, C 1-4 alkoxy, and halo-C 1-4 alkoxy.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 3 is halogen and C 1-4 alkyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 3 is halogen selected from bromo, chloro, fluoro, and iodo.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 3 is fluoro.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 3 is C 1-4 alkyl selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 3 is methyl.
  • One aspect includes a compound of Formula (I) or Formula (II), wherein R 4 is selected from halogen, hydroxyl, cyano, C 1-4 alkyl, deutero-C 1-4 alkyl, halo-C 1-4 alkyl, amino, C 1-4 alkyl-amino, (C 1-4 alkyl) 2 -amino, C 1-4 alkoxy, halo-C 1-4 alkoxy, heteroaryl, heterocyclyl, and phenyl,
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 4 is selected from halogen, C 1-4 alkoxy, heteroaryl, and phenyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 4 is halogen selected from bromo, chloro, fluoro, and iodo.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 4 is fluoro.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 4 is C 1-4 alkoxy selected from methoxy, ethoxy, propoxy, isopropoxy, butoxy, and tert-butoxy.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 4 methoxy.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 4 is heteroaryl,
  • R 4 is heteroaryl selected from thienyl, 1H-pyrazolyl, 1H-imidazolyl, 1,3-thiazolyl, oxazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-thiadiazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl, 1H-tetrazolyl, 2H-tetrazolyl, pyridinyl, pyridin-2(1H)-on-yl, pyrimidinyl, pyrimidin-4(3H)-on-yl, pyridazinyl, pyridazin-3(2H)-on-yl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1H-indolyl, 1H-
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 4 is heteroaryl selected from thienyl, 1H-pyrazolyl, 1H-imidazolyl, 1,3-thiazolyl, oxazolyl, 1,3,4-oxadiazolyl, 1,2,4-thiadiazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl, 2H-tetrazolyl, pyridinyl, pyrimidinyl, pyrimidin-4(3H)-on-yl, pyridazinyl, pyridazin-3(2H)-on-yl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1H-indazolyl, 1H-benzimidazolyl, 1,3-benzoxazolyl, 1,3-benzodioxolyl, 1,2,3-benz
  • R 4 is heteroaryl selected from thien-2-yl, thien-3-yl, 1H-pyrazol-1-yl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, 1H-pyrazol-5-yl, 1H-imidazol-1-yl, 1H-imidazol-4-yl, 1,3-thiazol-2-yl, 1,3-thiazol-5-yl, 1,3-oxazol-2-yl, 1,3-oxazol-4-yl, 1,3-oxazol-5-yl, 1,2,4-oxadiazol-3-yl, 1,3,4-oxadiazol-2-yl, 1,2,4-thiadiazol-5-yl, 1H-1,2,3-triazol-1-yl, 1H-1,2,3-triazol-4-yl, 1H-1,2,3-triazol-5-yl, 2H-1
  • R 4 is heteroaryl selected from thien-2-yl, 1H-pyrazol-1-yl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, 1H-imidazol-1-yl, 1H-imidazol-4-yl, 1,3-thiazol-2-yl, 1,3-thiazol-5-yl, 1,3-oxazol-2-yl, 1,3-oxazol-5-yl, 1,3,4-oxadiazol-2-yl, 1,2,4-thiadiazol-5-yl, 1H-1,2,3-triazol-4-yl, 2H-1,2,3-triazol-2-yl, 2H-1,2,3-triazol-4-yl, 1H-1,2,4-triazol-1-yl, 2H-tetrazol-2-yl, 2H-tetrazol-5-yl, pyridin-2-yl
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 4 is phenyl, 1 or 2 substituents each selected from R 5 .
  • One aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is selected from halogen, hydroxyl, cyano, nitro, C 1-4 alkyl, deutero-C 1-4 alkyl, halo-C 1-4 alkyl, amino, C 1-4 alkyl-amino, (C 1-4 alkyl) 2 -amino, amino-C 1-4 alkyl, hydroxyl-C 1-4 alkyl, C 1-4 alkyl-carbonyl, C 1-4 alkoxy, C 1-4 alkylthio, halo-C 1-4 alkoxy, and C 3-10 cycloalkyl.
  • R 5 is selected from halogen, hydroxyl, cyano, nitro, C 1-4 alkyl, deutero-C 1-4 alkyl, halo-C 1-4 alkyl, amino, C 1-4 alkyl-amino, (C 1-4 alkyl) 2 -amino, amino-C 1-4 alkyl,
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is selected from halogen, hydroxyl, cyano, nitro, C 1-4 alkyl, deutero-C 1-4 alkyl, amino, C 1-4 alkyl-amino, amino-C 1-4 alkyl, hydroxyl-C 1-4 alkyl, C 1-4 alkyl-carbonyl, C 1-4 alkoxy, C 1-4 alkylthio, and C 3-10 cycloalkyl.
  • R 5 is selected from halogen, hydroxyl, cyano, nitro, C 1-4 alkyl, deutero-C 1-4 alkyl, amino, C 1-4 alkyl-amino, amino-C 1-4 alkyl, hydroxyl-C 1-4 alkyl, C 1-4 alkyl-carbonyl, C 1-4 alkoxy, C 1-4 alkylthio, and C 3-10 cycloalkyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is halogen selected from bromo, chloro, fluoro, and iodo.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is halogen selected from bromo, chloro and fluoro.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is chloro.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is fluoro.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is hydroxy.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is cyano.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is nitro.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is C 1-4 alkyl selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is methyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is deutero-C 1-4 alkyl wherein C 1-4 alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl partially or completely substituted with one or more deuterium atoms where allowed by available valences.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is ( 2 H3)methyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is amino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is C 1-6 alkyl-amino wherein C 1-6 alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, 2-methylbutyl, and 3-methylpentyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is C 1-4 alkyl-amino wherein C 1-4 alkyl is methyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is methylamino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is amino-C 1-4 alkyl wherein C 1-4 alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is amino-C 1-4 alkyl wherein C 1-4 alkyl is methyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is aminomethyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is hydroxyl-C 1-4 alkyl, wherein C 1-4 alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl partially or completely substituted with one or more hydroxyl groups where allowed by available valences.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is hydroxyl-C 1-4 alkyl, wherein C 1-4 alkyl is methyl substituted with one hydroxyl group.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is hydroxymethyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is C 1-4 alkyl-carbonyl, wherein C 1-4 alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is C 1-4 alkyl-carbonyl, wherein C 1-4 alkyl is methyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is CH 3 C(O)—.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is C 1-4 alkoxy selected from methoxy, ethoxy, propoxy, isopropoxy, butoxy, and tert-butoxy.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 methoxy.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is C 1-4 alkylthio selected from methylthio, ethylthio, propylthio, isopropylthio, butylthio, and tert-butylthio.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 methylthio.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is C 3-10 cycloalkyl selected from cyclopropyl, cylcobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]hexanyl, and adamantyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is cyclopropyl.
  • Another aspect of the compound of Formula (I) or Formula (II) includes the compound of Formula (I):
  • Another aspect of the compound of Formula (I) or Formula (II) includes the compound of Formula (II):
  • An aspect of the compound of Formula (I) or Formula (II) or a form thereof includes a compound selected from the group consisting of:
  • An aspect the compound of Formula (I) or Formula (II) or a form thereof includes a compound selected from the group consisting of:
  • Another aspect of the compound of Formula (I) or Formula (II) or a form thereof is a compound salt selected from the group consisting of:
  • An aspect of the present description includes a method for preventing, treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a method for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound of Formula (I) or Formula (II) or a form thereof.
  • Another aspect of the present description includes a method for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound salt of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a method for use of a compound of Formula (I) or Formula (II) or a form or composition thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form or composition thereof.
  • Another aspect of the present description includes a method for use of a compound salt of Formula (I) or Formula (II) or a form or composition thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound salt of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form thereof.
  • Another aspect of the present description includes a use for a compound salt of Formula (I) or Formula (II) or a form thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound salt of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof in the manufacture of a medicament for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the medicament.
  • Another aspect of the present description includes a use for a compound salt of Formula (I) or Formula (II) or a form thereof in the manufacture of a medicament for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the medicament.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof in a combination product with one or more therapeutic agents for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form thereof in combination with an effective amount of the one or more agents.
  • Another aspect of the present description includes a use for a compound salt of Formula (I) or Formula (II) or a form thereof in a combination product with one or more therapeutic agents for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound salt of Formula (I) or Formula (II) or a form thereof in combination with an effective amount of the one or more agents.
  • C 1-4 alkyl generally refers to saturated hydrocarbon radicals having from one to four carbon atoms in a straight or branched chain configuration, including, but not limited to, methyl, ethyl, n-propyl (also referred to as propyl or propanyl), isopropyl, n-butyl (also referred to as butyl or butanyl), isobutyl, sec-butyl, tert-butyl and the like.
  • a C 1-4 alkyl radical is optionally substituted with substituent species as described herein where allowed by available valences.
  • C 2-4 alkenyl generally refers to partially unsaturated hydrocarbon radicals having from two to four carbon atoms in a straight or branched chain configuration and one or more carbon-carbon double bonds therein, including, but not limited to, ethenyl (also referred to as vinyl), allyl, propenyl and the like.
  • a C 2-4 alkenyl radical is optionally substituted with substituent species as described herein where allowed by available valences.
  • C 2-8 alkynyl generally refers to partially unsaturated hydrocarbon radicals having from two to eight carbon atoms in a straight or branched chain configuration and one or more carbon-carbon triple bonds therein, including, but not limited to, ethynyl, propynyl, butynyl and the like.
  • C 2-8 alkynyl includes, but is not limited to, C 2-6 alkynyl, C 2-4 alkynyl and the like.
  • a C 2-8 alkynyl radical is optionally substituted with substituent species as described herein where allowed by available valences.
  • C 1-4 alkoxy generally refers to saturated hydrocarbon radicals having from one to four carbon atoms in a straight or branched chain configuration of the formula: —O—C 1-4 alkyl, including, but not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy and the like.
  • a C 1-4 alkoxy radical is optionally substituted with substituent species as described herein where allowed by available valences.
  • C 3-10 cycloalkyl generally refers to a saturated or partially unsaturated monocyclic, bicyclic or polycyclic hydrocarbon radical, including, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, and the like.
  • a C 3-10 cycloalkyl radical is optionally substituted with substituent species as described herein where allowed by available valences.
  • aryl generally refers to a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure radical, including, but not limited to, phenyl, naphthyl, anthracenyl, fluorenyl, azulenyl, phenanthrenyl and the like.
  • An aryl radical is optionally substituted with substituent species as described herein where allowed by available valences.
  • heteroaryl generally refers to a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure radical in which one or more carbon atom ring members have been replaced, where allowed by structural stability, with one or more heteroatoms, such as an O, S or N atom, including, but not limited to, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, isothiazolyl, oxazolyl, 1,3-thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, indolyl, indazolyl, indolizinyl, isoindolyl, benzofuranyl, benzothienyl, benzoimidazolyl,
  • heteroaryl radical may differ, such as in non-limiting examples where furanyl may also be referred to as furyl, thienyl may also be referred to as thiophenyl, pyridinyl may also be referred to as pyridyl, benzothienyl may also be referred to as benzothiophenyl and 1,3-benzoxazolyl may also be referred to as 1,3-benzooxazolyl.
  • the term for a heteroaryl radical may also include other regioisomers, such as in non-limiting examples where the term pyrrolyl may also include 2H-pyrrolyl, 3H-pyrrolyl and the like, the term pyrazolyl may also include 1H-pyrazolyl and the like, the term imidazolyl may also include 1H-imidazolyl and the like, the term triazolyl may also include 1H-1,2,3-triazolyl and the like, the term oxadiazolyl may also include 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl and the like, the term tetrazolyl may also include 1H-tetrazolyl, 2H-tetrazolyl and the like, the term indolyl may also include 1H-indolyl and the like, the term indazolyl may also include 1H-indazolyl and the like, the term indazolyl may also include 1H-in
  • heterocyclyl generally refers to a saturated or partially unsaturated monocyclic, bicyclic or polycyclic carbon atom ring structure radical in which one or more carbon atom ring members have been replaced, where allowed by structural stability, with a heteroatom, such as an O, S or N atom, including, but not limited to, oxiranyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, isoxazolinyl, isoxazolidinyl, isothiazolinyl, isothiazolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, triazolinyl, triazolidinyl, triazolidinyl,
  • heterocyclyl radical may differ, such as in non-limiting examples where 1,3-benzodioxolyl may also be referred to as benzo[d][1,3]dioxolyl and 2,3-dihydro-1,4-benzodioxinyl may also be referred to as 2,3-dihydrobenzo[b][1,4]dioxinyl.
  • C 1-4 alkoxy-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-O—C 1-4 alkyl.
  • C 1-4 alkoxy-C 1-4 alkyl-amino refers to a radical of the formula: —NH—C 1-4 alkyl-O—C 1-4 alkyl.
  • (C 1-4 alkoxy-C 1-4 alkyl) 2 -amino refers to a radical of the formula: —N(C 1-4 alkyl-O—C 1-4 alkyl) 2 .
  • C 1-4 alkoxy-C 1-4 alkyl-amino-C 1-4 alkoxy refers to a radical of the formula: —O—C 1-4 alkyl-NH—C 1-4 alkyl-O—C 1-4 alkyl.
  • (C 1-4 alkoxy-C 1-4 alkyl) 2 -amino-C 1-4 alkoxy refers to a radical of the formula: —O—C 1-4 alkyl-N(C 1-4 alkyl-O—C 1-4 alkyl) 2 .
  • (C 1-4 alkoxy-C 1-4 alkyl)(C 1-4 alkyl)amino-C 1-4 alkoxy refers to a radical of the formula: —O—C 1-4 alkyl-N(C 1-4 alkyl)(C 1-4 alkyl-O—C 1-4 alkyl).
  • C 1-4 alkoxy-C 1-4 alkyl-amino-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-NH—C 1-4 alkyl-O—C 1-4 alkyl.
  • (C 1-4 alkoxy-C 1-4 alkyl) 2 -amino-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-N(C 1-4 alkyl-O—C 1-4 alkyl) 2 .
  • (C 1-4 alkoxy-C 1-4 alkyl)(C 1-4 alkyl)amino-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-N(C 1-4 alkyl)(C 1-4 alkyl-O—C 1-4 alkyl).
  • C 1-4 alkoxy-carbonyl refers to a radical of the formula: —C(O)—O—C 1-4 alkyl.
  • C 1-4 alkoxy-carbonyl-C 2-8 alkenyl refers to a radical of the formula: —C 2-8 alkenyl-C(O)—O—C 1-4 alkyl.
  • C 1-4 alkoxy-carbonyl-amino refers to a radical of the formula: —NH—C(O)—O—C 1-4 alkyl.
  • C 1-4 alkyl-amino refers to a radical of the formula: —NH—C 1-4 alkyl.
  • (C 1-4 alkyl) 2 -amino refers to a radical of the formula: —N(C 1-4 alkyl) 2 .
  • C 1-4 alkyl-amino-C 2-8 alkenyl refers to a radical of the formula: —C 2-8 alkenyl-NH—C 1-4 alkyl.
  • (C 1-4 alkyl) 2 -amino-C 2-8 alkenyl refers to a radical of the formula: —C 2-8 alkenyl-N(C 1-4 alkyl) 2 .
  • C 1-4 alkyl-amino-C 1-4 alkoxy refers to a radical of the formula: —O—C 1-4 alkyl-NH—C 1-4 alkyl.
  • (C 1-4 alkyl) 2 -amino-C 1-4 alkoxy refers to a radical of the formula: —O—C 1-4 alkyl-N(C 1-4 alkyl) 2 .
  • C 1-4 alkyl-amino-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-NH—C 1-4 alkyl.
  • (C 1-4 alkyl) 2 -amino-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-N(C 1-4 alkyl) 2 .
  • C 1-4 alkyl-amino-C 1-4 alkyl-amino refers to a radical of the formula: —NH—C 1-4 alkyl-NH—C 1-4 alkyl.
  • (C 1-4 alkyl) 2 -amino-C 1-4 alkyl-amino refers to a radical of the formula: —NH—C 1-4 alkyl-N(C 1-4 alkyl) 2 .
  • (C 1-4 alkyl-amino-C 1-4 alkyl) 2 -amino refers to a radical of the formula: —N(C 1-4 alkyl-NH—C 1-4 alkyl) 2 .
  • [(C 1-4 alkyl) 2 -amino-C 1-4 alkyl] 2 -amino refers to a radical of the formula: —N[C 1-4 alkyl-N(C 1-4 alkyl) 2]2.
  • (C 1-4 alkyl-amino-C 1-4 alkyl)(C 1-4 alkyl)amino refers to a radical of the formula: —N(C 1-4 alkyl)(C 1-4 alkyl-NH—C 1-4 alkyl).
  • the term “[(C 1-4 alkyl) 2 -amino-C 1-4 alkyl](C 1-4 alkyl)amino” refers to a radical of the formula: —N(C 1-4 alkyl)[C 1-4 alkyl-N(C 1-4 alkyl) 2 ].
  • C 1-4 alkyl-amino-C 2-8 alkynyl refers to a radical of the formula: —C 2-8 alkynyl-NH—C 1-4 alkyl.
  • (C 1-4 alkyl) 2 -amino-C 2-8 alkynyl refers to a radical of the formula: —C 2-8 alkynyl-N(C 1-4 alkyl) 2 .
  • C 1-4 alkyl-carbonyl refers to a radical of the formula: —C(O)—C 1-4 alkyl.
  • C 1-4 alkyl-carbonyl-amino refers to a radical of the formula: —NH—C(O)—C 1-4 alkyl.
  • C 1-4 alkyl-thio refers to a radical of the formula: —S—C 1-4 alkyl.
  • amino-C 2-8 alkenyl refers to a radical of the formula: —C 2-8 alkenyl-NH 2 .
  • amino-C 1-4 alkoxy refers to a radical of the formula: —O—C 1-4 alkyl-NH 2 .
  • amino-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-NH 2 .
  • amino-C 1-4 alkyl-amino refers to a radical of the formula: —NH—C 1-4 alkyl-NH 2 .
  • (amino-C 1-4 alkyl) 2 -amino” refers to a radical of the formula: —N(C 1-4 alkyl-NH 2 ) 2 .
  • (amino-C 1-4 alkyl)(C 1-4 alkyl)amino” refers to a radical of the formula: —N(C 1-4 alkyl)(C 1-4 alkyl-NH 2 ).
  • amino-C 2-8 alkynyl refers to a radical of the formula: —C 2-8 alkynyl-NH 2 .
  • aryl-C 1-4 alkoxy-carbonyl refers to a radical of the formula: —C(O)—O—C 1-4 alkyl-aryl.
  • aryl-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-aryl.
  • aryl-C 1-4 alkyl-amino refers to a radical of the formula: —NH—C 1-4 alkyl-aryl.
  • (aryl-C 1-4 alkyl) 2 -amino” refers to a radical of the formula: —N(C 1-4 alkyl-aryl) 2 .
  • (aryl-C 1-4 alkyl)(C 1-4 alkyl)amino refers to a radical of the formula: —N(C 1-4 alkyl)(C 1-4 alkyl-aryl).
  • aryl-C 1-4 alkyl-amino-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-NH—C 1-4 alkyl-aryl.
  • (aryl-C 1-4 alkyl) 2 -amino-C 1-4 alkyl” refers to a radical of the formula: —C 1-4 alkyl-N(C 1-4 alkyl-aryl) 2 .
  • (aryl-C 1-4 alkyl)(C 1-4 alkyl)amino-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-N(C 1-4 alkyl)(C 1-4 alkyl-aryl).
  • aryl-amino refers to a radical of the formula: —NH-aryl.
  • aryl-amino-carbonyl refers to a radical of the formula: —C(O)—NH-aryl.
  • aryl-sulfonyloxy-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-O—SO 2 -aryl.
  • benzoxy-carbonyl refers to a radical of the formula: —C(O)—O—CH 2 -phenyl.
  • C 3-14 cycloalkyl-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-C 3-14 cycloalkyl.
  • C 3-14 cycloalkyl-amino refers to a radical of the formula: —NH—C 3-14 cycloalkyl.
  • C 3-14 cycloalkyl-oxy refers to a radical of the formula: —O—C 3-14 cycloalkyl.
  • deutero-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-deutero, wherein C 1-4 alkyl is partially or completely substituted with one or more deuterium atoms where allowed by available valences.
  • halo or halogen generally refers to a halogen atom radical, including fluoro, chloro, bromo and iodo.
  • halo-C 1-4 alkoxy refers to a radical of the formula: —O—C 1-4 alkyl-halo, wherein C 1-4 alkyl is partially or completely substituted with one or more halogen atoms where allowed by available valences.
  • halo-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-halo, wherein C 1-4 alkyl is partially or completely substituted with one or more halogen atoms where allowed by available valences.
  • halo-C 1-4 alkyl-amino refers to a radical of the formula: —NH—C 1-4 alkyl-halo.
  • halo-C 1-4 alkyl)(C 1-4 alkyl)amino refers to a radical of the formula: —N(C 1-4 alkyl)(C 1-4 alkyl-halo).
  • (halo-C 1-4 alkyl) 2 -amino refers to a radical of the formula: —N(C 1-4 alkyl-halo) 2 .
  • heteroaryl-C 1-4 alkoxy refers to a radical of the formula: —O—C 1-4 alkyl-heteroaryl.
  • heteroaryl-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-heteroaryl.
  • heteroaryl-C 1-4 alkyl-amino refers to a radical of the formula: —NH—C 1-4 alkyl-heteroaryl.
  • heteroaryl-C 1-4 alkyl) 2 -amino refers to a radical of the formula: —N(C 1-4 alkyl-heteroaryl) 2 .
  • heteroaryl-C 1-4 alkyl)(C 1-4 alkyl)amino refers to a radical of the formula: —N(C 1-4 alkyl)(C 1-4 alkyl-heteroaryl).
  • heteroaryl-C 1-4 alkyl-amino-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-NH—C 1-4 alkyl-heteroaryl.
  • heteroaryl-C 1-4 alkyl) 2 -amino-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-N(C 1-4 alkyl-heteroaryl) 2 .
  • heteroaryl-C 1-4 alkyl)(C 1-4 alkyl)amino-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-N(C 1-4 alkyl)(C 1-4 alkyl-heteroaryl).
  • heteroaryl-amino refers to a radical of the formula: —NH-heteroaryl.
  • heterocyclyl-C 1-4 alkoxy refers to a radical of the formula: —O—C 1-4 alkyl-heterocyclyl.
  • heterocyclyl-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-heterocyclyl.
  • heterocyclyl-C 1-4 alkyl-amino refers to a radical of the formula: —NH—C 1-4 alkyl-heterocyclyl.
  • heterocyclyl-C 1-4 alkyl) 2 -amino refers to a radical of the formula: —N(C 1-4 alkyl-heterocyclyl) 2 .
  • heterocyclyl-C 1-4 alkyl)(C 1-4 alkyl)amino refers to a radical of the formula: —N(C 1-4 alkyl)(C 1-4 alkyl-heterocyclyl).
  • heterocyclyl-C 1-4 alkyl-amino-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-NH—C 1-4 alkyl-heterocyclyl.
  • heterocyclyl-C 1-4 alkyl) 2 -amino-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-N(C 1-4 alkyl-heterocyclyl) 2 .
  • heterocyclyl-C 1-4 alkyl)(C 1-4 alkyl)amino-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-N(C 1-4 alkyl)(C 1-4 alkyl-heterocyclyl).
  • heterocyclyl-amino refers to a radical of the formula: —NH-heterocyclyl.
  • heterocyclyl (C 1-4 alkyl)amino” refers to a radical of the formula: —N(C 1-4 alkyl)(heterocyclyl).
  • heterocyclyl-amino-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-NH-heterocyclyl.
  • heterocyclyl-carbonyl refers to a radical of the formula: —C(O)-heterocyclyl.
  • heterocyclyl-carbonyl-oxy refers to a radical of the formula: —O—C(O)-heterocyclyl.
  • heterocyclyl-oxy refers to a radical of the formula: —O-heterocyclyl.
  • hydroxy refers to a radical of the formula: —OH.
  • hydroxy-C 1-4 alkoxy-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-O—C 1-4 alkyl-OH.
  • hydroxy-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-OH, wherein C 1-4 alkyl is partially or completely substituted with one or more hydroxy radicals where allowed by available valences.
  • hydroxy-C 1-4 alkyl-amino refers to a radical of the formula: —NH—C 1-4 alkyl-OH.
  • (hydroxy-C 1-4 alkyl) 2 -amino refers to a radical of the formula: —N(C 1-4 alkyl-OH) 2 .
  • (hydroxy-C 1-4 alkyl)(C 1-4 alkyl)amino refers to a radical of the formula: —N(C 1-4 alkyl)(C 1-4 alkyl-OH).
  • hydroxy-C 1-4 alkyl-amino-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-NH—C 1-4 alkyl-OH.
  • (hydroxy-C 1-4 alkyl) 2 -amino-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-N(C 1-4 alkyl-OH) 2 .
  • (hydroxy-C 1-4 alkyl)(C 1-4 alkyl)amino-C 1-4 alkyl refers to a radical of the formula: —C 1-4 alkyl-N(C 1-4 alkyl)(C 1-4 alkyl-OH).
  • hydroxy-C 1-4 alkyl-amino-C 1-4 alkoxy refers to a radical of the formula: —O—C 1-4 alkyl-NH—C 1-4 alkyl-OH.
  • (hydroxy-C 1-4 alkyl) 2 -amino-C 1-4 alkoxy refers to a radical of the formula: —O—C 1-4 alkyl-N(C 1-4 alkyl-OH) 2 .
  • hydroxy-C 1-4 alkyl)(C 1-4 alkyl)amino-C 1-4 alkoxy refers to a radical of the formula: —O—C 1-4 alkyl-N(C 1-4 alkyl)(C 1-4 alkyl-OH).
  • hydroxy-C 1-4 alkyl-amino-C 1-4 alkyl-amino refers to a radical of the formula: —NH—C 1-4 alkyl-NH—C 1-4 alkyl-OH.
  • hydroxy-C 1-4 alkyl-amino-C 1-4 alkyl) 2 -amino refers to a radical of the formula: —N(C 1-4 alkyl-NH—C 1-4 alkyl-OH) 2 .
  • (hydroxy-C 1-4 alkyl) 2 -amino-C 1-4 alkyl-amino” refers to a radical of the formula: —NH—C 1-4 alkyl-N(C 1-4 alkyl-OH) 2 .
  • hydroxy-C 1-4 alkyl-amino-C 1-4 alkyl)(C 1-4 alkyl)amino refers to a radical of the formula: —N(C 1-4 alkyl)(C 1-4 alkyl-NH—C 1-4 alkyl-OH).
  • the term “[(hydroxy-C 1-4 alkyl) 2 -amino-C 1-4 alkyl](C 1-4 alkyl)amino” refers to a radical of the formula: —N(C 1-4 alkyl)[C 1-4 alkyl-N(C 1-4 alkyl-OH) 2 ].
  • (hydroxy-C 1-4 alkyl)(C 1-4 alkyl)amino-C 1-4 alkyl-amino refers to a radical of the formula: —NH—C 1-4 alkyl-N(C 1-4 alkyl, C 1-4 alkyl-OH).
  • the term “[(hydroxy-C 1-4 alkyl)(C 1-4 alkyl)amino-C 1-4 alkyl]-(C 1-4 alkyl)amino” refers to a radical of the formula: —N(C 1-4 alkyl)[C 1-4 alkyl-N(C 1-4 alkyl)-(C 1-4 alkyl-OH)].
  • substituted means positional variables on the atoms of a core molecule that are substituted at a designated atom position, replacing one or more hydrogens on the designated atom, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • any carbon as well as heteroatom with valences that appear to be unsatisfied as described or shown herein is assumed to have a sufficient number of hydrogen atom(s) to satisfy the valences described or shown.
  • substituents having a double bond e.g., “oxo” or “ ⁇ O” as the point of attachment may be described, shown or listed herein within a substituent group, wherein the structure may only show a single bond as the point of attachment to the core structure of Formula (I) or Formula (II).
  • oxo or “ ⁇ O”
  • ⁇ O double bond
  • the term “and the like,” with reference to the definitions of chemical terms provided herein, means that variations in chemical structures that could be expected by one skilled in the art include, without limitation, isomers (including chain, branching or positional structural isomers), hydration of ring systems (including saturation or partial unsaturation of monocyclic, bicyclic or polycyclic ring structures) and all other variations where allowed by available valences which result in a stable compound.
  • each functionality appearing at any location within the disclosed compound may be independently selected, and as appropriate, independently and/or optionally substituted.
  • the terms “independently selected,” or “each selected” refer to functional variables in a substituent list that may occur more than once on the structure of Formula (I) or Formula (II), the pattern of substitution at each occurrence is independent of the pattern at any other occurrence.
  • a generic substituent variable on any formula or structure for a compound described herein is understood to include the replacement of the generic substituent with species substituents that are included within the particular genus, e.g., aryl may be replaced with phenyl or naphthalenyl and the like, and that the resulting compound is to be included within the scope of the compounds described herein.
  • each instance of or “in each instance, when present,” when used preceding a phrase such as “ . . . C 3-14 cycloalkyl, C 3-14 cycloalkyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, heterocyclyl and heterocyclyl-C 1-4 alkyl,” are intended to refer to the C 3-14 cycloalkyl, aryl, heteroaryl and heterocyclyl ring systems when each are present either alone or as a substituent.
  • the term “form” means a compound of Formula (I) or Formula (II) having a form selected from the group consisting of a free acid, free base, prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
  • the form of the compound of Formula (I) or Formula (II) is a free acid, free base or salt thereof.
  • the form of the compound of Formula (I) or Formula (II) is a salt thereof.
  • the form of the compound of Formula (I) or Formula (II) is an isotopologue thereof.
  • the form of the compound of Formula (I) or Formula (II) is a stereoisomer, racemate, enantiomer or diastereomer thereof.
  • the form of the compound of Formula (I) or Formula (II) is a tautomer thereof.
  • the form of the compound of Formula (I) or Formula (II) is a pharmaceutically acceptable form.
  • the compound of Formula (I) or Formula (II) or a form thereof is isolated for use.
  • isolated means the physical state of a compound of Formula (I) or Formula (II) or a form thereof after being isolated and/or purified from a synthetic process (e.g., from a reaction mixture) or natural source or combination thereof according to an isolation or purification process or processes described herein or which are well known to the skilled artisan (e.g., chromatography, recrystallization and the like) in sufficient purity to be characterized by standard analytical techniques described herein or well known to the skilled artisan.
  • protecting means that a functional group in a compound of Formula (I) or Formula (II) or a form thereof is in a form modified to preclude undesired side reactions at the protected site when the compound is subjected to a reaction.
  • Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T.W. Greene et al, Protective Groups in organic Synthesis (1991), Wiley, New York.
  • Such functional groups include hydroxy, phenol, amino and carboxylic acid.
  • Suitable protecting groups for hydroxy or phenol include trialkylsilyl or diarylalkylsilyl (e.g., t-butyldimethylsilyl, t-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, substituted benzyl, methyl, methoxymethanol, and the like.
  • Suitable protecting groups for amino, amidino and guanidino include t-butoxycarbonyl, benzyloxycarbonyl, and the like.
  • Suitable protecting groups for carboxylic acid include alkyl, aryl or arylalkyl esters.
  • the protecting group may also be a polymer resin, such as a Wang resin or a 2-chlorotrityl-chloride resin.
  • Protecting groups may be added or removed in accordance with standard techniques, which are well-known to those skilled in the art and as described herein. It will also be appreciated by those skilled in the art, although such protected derivatives of compounds described herein may not possess pharmacological activity as such, they may be administered to a subject and thereafter metabolized in the body to form compounds described herein which are pharmacologically active. Such derivatives may therefore be described as “prodrugs”. All prodrugs of compounds described herein are included within the scope of the use described herein.
  • prodrug means a form of an instant compound (e.g., a drug precursor) that is transformed in vivo to yield an active compound of Formula (I) or Formula (II) or a form thereof.
  • the transformation may occur by various mechanisms (e.g., by metabolic and/or non-metabolic chemical processes), such as, for example, by hydrolysis and/or metabolism in blood, liver and/or other organs and tissues.
  • metabolic and/or non-metabolic chemical processes such as, for example, by hydrolysis and/or metabolism in blood, liver and/or other organs and tissues.
  • a prodrug when a compound of Formula (I) or Formula (II) or a form thereof contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a functional group such as alkyl and the like.
  • a prodrug form when a compound of Formula (I) or Formula (II) or a form thereof contains a hydroxyl functional group, a prodrug form can be prepared by replacing the hydrogen atom of the hydroxyl with another functional group such as alkyl, alkylcarbonyl or a phosphonate ester and the like.
  • a prodrug form can be prepared by replacing one or more amine hydrogen atoms with a functional group such as alkyl or substituted carbonyl.
  • Pharmaceutically acceptable prodrugs of compounds of Formula (I) or Formula (II) or a form thereof include those compounds substituted with one or more of the following groups: carboxylic acid esters, sulfonate esters, amino acid esters, phosphonate esters and mono-, di- or triphosphate esters or alkyl substituents, where appropriate. As described herein, it is understood by a person of ordinary skill in the art that one or more of such substituents may be used to provide a compound of Formula (I) or Formula (II) or a form thereof as a prodrug.
  • One or more compounds described herein may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and the description herein is intended to embrace both solvated and unsolvated forms.
  • solvate means a physical association of a compound described herein with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. As used herein, “solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like.
  • hydrate means a solvate wherein the solvent molecule is water.
  • the compounds of Formula (I) or Formula (II) can form salts, which are intended to be included within the scope of this description.
  • Reference to a compound of Formula (I) or Formula (II) or a form thereof herein is understood to include reference to salt forms thereof, unless otherwise indicated.
  • the term “salt(s)”, as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases.
  • a compound of Formula (I) or Formula (II) or a form thereof contains both a basic moiety, such as, without limitation an amine moiety, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions (“inner salts”) may be formed and are included within the term “salt(s)” as used herein.
  • salts of the compounds of the Formula (I) or Formula (II) may be formed, for example, by reacting a compound of Formula (I) or Formula (II) or a form thereof with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
  • Pharmaceutically acceptable salts include one or more salts of acidic or basic groups present in compounds described herein. Particular aspects of acid addition salts include, and are not limited to, acetate, ascorbate, benzoate, benzenesulfonate, bisulfate, bitartrate, borate, bromide, butyrate, chloride, citrate, camphorate, camphorsulfonate, ethanesulfonate, formate, fumarate, gentisinate, gluconate, glucaronate, glutamate, iodide, isonicotinate, lactate, maleate, methanesulfonate, naphthalenesulfonate, nitrate, oxalate, pamoate, pantothenate, phosphate, propionate, saccharate, salicylate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate (also known as tosylate), trifluor
  • Suitable basic salts include, but are not limited to, aluminum, ammonium, calcium, lithium, magnesium, potassium, sodium and zinc salts.
  • the compounds of Formula (I) or Formula (II) or a form thereof may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms.
  • the present description is intended to include all stereoisomeric forms of the compounds of Formula (I) or Formula (II) as well as mixtures thereof, including racemic mixtures.
  • the compounds described herein may include one or more chiral centers, and as such may exist as racemic mixtures (R S) or as substantially pure enantiomers and diastereomers.
  • the compounds may also exist as substantially pure (R) or (S) enantiomers (when one chiral center is present).
  • the compounds described herein are (S) isomers and may exist as enantiomerically pure compositions substantially comprising only the (S) isomer.
  • the compounds described herein are (R) isomers and may exist as enantiomerically pure compositions substantially comprising only the (R) isomer.
  • the compounds described herein may also exist as a (R,R), (R,S), (S,R) or (S,S) isomer, as defined by IUPAC Nomenclature Recommendations.
  • substantially pure refers to compounds consisting substantially of a single isomer in an amount greater than or equal to 90%, in an amount greater than or equal to 92%, in an amount greater than or equal to 95%, in an amount greater than or equal to 98%, in an amount greater than or equal to 99%, or in an amount equal to 100% of the single isomer.
  • a compound of Formula (I) or Formula (II) or a form thereof is a substantially pure (S) enantiomer form present in an amount greater than or equal to 90%, in an amount greater than or equal to 92%, in an amount greater than or equal to 95%, in an amount greater than or equal to 98%, in an amount greater than or equal to 99%, or in an amount equal to 100%.
  • a compound of Formula (I) or Formula (II) or a form thereof is a substantially pure (R) enantiomer form present in an amount greater than or equal to 90%, in an amount greater than or equal to 92%, in an amount greater than or equal to 95%, in an amount greater than or equal to 98%, in an amount greater than or equal to 99%, or in an amount equal to 100%.
  • racemate is any mixture of isometric forms that are not “enantiomerically pure”, including mixtures such as, without limitation, in a ratio of about 50/50, about 60/40, about 70/30, or about 80/20.
  • the present description embraces all geometric and positional isomers.
  • a compound of Formula (I) or Formula (II) or a form thereof incorporates a double bond or a fused ring
  • both the cis- and trans-forms, as well as mixtures are embraced within the scope of the description.
  • Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization.
  • Enantiomers can be separated by use of chiral HPLC column or other chromatographic methods known to those skilled in the art.
  • Enantiomers can also be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers.
  • an appropriate optically active compound e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride
  • converting e.g., hydrolyzing
  • some of the compounds of Formula (I) or Formula (II) may be atropisomers (e.g., substituted biaryls) and are considered as part of this description.
  • All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this description, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl).
  • Individual stereoisomers of the compounds described herein may, for example, be substantially free of other isomers, or may be present in a racemic mixture, as described supra.
  • salt is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or isotopologues of the instant compounds.
  • isotopologue refers to isotopically-enriched compounds described herein which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into compounds described herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O 31 P, 32 P, 35 S, 18 F, 35 Cl and 36 Cl, respectively, each of which are also within the scope of this description.
  • Certain isotopically-enriched compounds described herein are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3 H) and carbon-14 (i.e., 14 C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances.
  • Polymorphic crystalline and amorphous forms of the compounds of Formula (I) or Formula (II) and of the salts, solvates, hydrates, esters and prodrugs of the compounds of Formula (I) or Formula (II) are further intended to be included in the present description.
  • aspects of the present description include compounds that have been identified and have been demonstrated to be useful in selectively preventing, treating or ameliorating HD and have been provided for use for preventing, treating or ameliorating HD.
  • An aspect of the present description includes a method for preventing, treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a method for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a method for preventing HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a method for treating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a method for ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound of Formula (I) or Formula (II) or a form thereof.
  • Another aspect of the present description includes a method for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound salt of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a method for use of a compound of Formula (I) or Formula (II) or a form or composition thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form or composition thereof.
  • Another aspect of the present description includes a method for use of a compound salt of Formula (I) or Formula (II) or a form or composition thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound salt of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form thereof.
  • Another aspect of the present description includes a use for a compound salt of Formula (I) or Formula (II) or a form thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound salt of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof in the manufacture of a medicament for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the medicament.
  • Another aspect of the present description includes a use for a compound salt of Formula (I) or Formula (II) or a form thereof in the manufacture of a medicament for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the medicament.
  • An aspect of the present description includes in vitro or in vivo use of the compound of Formula (I) or Formula (II) or a form thereof having activity toward HD.
  • An aspect of the present description includes a use of the compound of Formula (I) or Formula (II) or a form thereof in a combination therapy to provide additive or synergistic activity, thus enabling the development of a combination product for treating or ameliorating HD.
  • Another aspect of the present description includes a combination therapy comprising compounds described herein in combination with one or more known drugs or one or more known therapies may be used to treat HD regardless of whether HD is responsive to the known drug.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof in a combination product with one or more therapeutic agents for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form thereof in combination with an effective amount of the one or more agents.
  • Another aspect of the present description includes a use for a compound salt of Formula (I) or Formula (II) or a form thereof in a combination product with one or more therapeutic agents for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound salt of Formula (I) or Formula (II) or a form thereof in combination with an effective amount of the one or more agents.
  • compounds of Formula (I) or Formula (II) or a form thereof used in combination with one or more additional agents can be administered to a subject or contacted with a subject or patient cell(s) prior to, concurrently with, or subsequent to administering to the subject or patient or contacting the cell with an additional agent(s).
  • a compound(s) of Formula (I) or Formula (II) or a form thereof and an additional agent(s) can be administered to a subject or contacted with a cell in single composition or different compositions.
  • a compound(s) of Formula (I) or Formula (II) or a form thereof is used in combination with gene therapy to inhibit HTT expression (using, e.g., viral delivery vectors) or the administration of another small molecule HTT inhibitor.
  • a compound(s) of Formula (I) or Formula (II) or a form thereof are used in combination with cell replacement using differentiated non-mutant HTT stem cells.
  • a compound(s) of Formula (I) or Formula (II) or a form thereof are used in combination with cell replacement using differentiated HTT stem cells.
  • provided herein is the use of compounds of Formula (I) or Formula (II) or a form thereof in combination with supportive standard of care therapies, including palliative care.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof in the preparation of a kit for treating or ameliorating HD in a subject in need thereof comprising, the compound of Formula (I) or Formula (II) or a form thereof and instructions for administering an effective amount of the compound of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof in the preparation of a kit for treating or ameliorating HD in a subject in need thereof comprising, the compound of Formula (I) or Formula (II) or a form thereof and instructions for administering an effective amount of the compound of Formula (I) or Formula (II) or a form thereof; and optionally, for administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form thereof in a combination product with an effective amount of one or more therapeutic agents.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof in the preparation of a kit for treating or ameliorating HD in a subject in need thereof comprising, the compound of Formula (I) or Formula (II) or a form thereof and instructions for administering an effective amount of the compound of Formula (I) or Formula (II) or a form thereof; and optionally, for administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form thereof in a combination product with an effective amount of the one or more therapeutic agents; and optionally, for administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form thereof in a combination product with an effective amount of the one or more therapeutic agents in a combination therapy with a standard of care supportive therapy, wherein the standard of care supportive therapy is palliative care.
  • the subject is treatment naive. In another respect, for each of such aspects, the subject is not treatment naive.
  • the term “preventing” refers to keeping a disease, disorder or condition from occurring in a subject that may be predisposed to the disease, disorder and/or condition but has not yet been diagnosed as having the disease, disorder and/or condition.
  • treating refers to inhibiting the progression of a disease, disorder or condition in a subject already exhibiting the symptoms of the disease, disorder and/or condition, i.e., arresting the development of a disease, disorder and/or condition that has already affected the subject.
  • the term “ameliorating” refers to relieving the symptoms of a disease, disorder or condition in a subject already exhibiting the symptoms of the disease, disorder and/or condition, i.e., causing regression of the disease, disorder and/or condition that has already affected the subject.
  • the term “subject” refers to an animal or any living organism having sensation and the power of voluntary movement, and which requires oxygen and organic food.
  • Nonlimiting examples include members of the human, primate, equine, porcine, bovine, murine, rattus, canine and feline specie.
  • the subject is a mammal or a warm-blooded vertebrate animal. In other aspects, the subject is a human.
  • the term “patient” may be used interchangeably with “subject” and “human”.
  • the terms “effective amount” or “therapeutically effective amount” mean an amount of compound of Formula (I) or Formula (II) or a form, composition or medicament thereof that achieves a target plasma concentration that is effective in treating or ameliorating HD as described herein and thus producing the desired therapeutic, ameliorative, inhibitory or preventative effect in a subject in need thereof.
  • the effective amount may be the amount required to treat HD in a subject or patient, more specifically, in a human.
  • the concentration-biological effect relationships observed with regard to a compound of Formula (I) or Formula (II) or a form thereof indicate a target plasma concentration ranging from approximately 0.001 ⁇ g/mL to approximately 50 ⁇ g/mL, from approximately 0.01 ⁇ g/mL to approximately 20 ⁇ g/mL, from approximately 0.05 ⁇ g/mL to approximately 10 ⁇ g/mL, or from approximately 0.1 ⁇ g/mL to approximately 5 ⁇ g/mL.
  • the compounds described herein may be administered at doses that vary, such as, for example, without limitation, from 1.0 ng to 10,000 mg.
  • the dose administered to achieve an effective target plasma concentration may be administered based upon subject or patient specific factors, wherein the doses administered on a weight basis may be in the range of from about 0.001 mg/kg/day to about 3500 mg/kg/day, or about 0.001 mg/kg/day to about 3000 mg/kg/day, or about 0.001 mg/kg/day to about 2500 mg/kg/day, or about 0.001 mg/kg/day to about 2000 mg/kg/day, or about 0.001 mg/kg/day to about 1500 mg/kg/day, or about 0.001 mg/kg/day to about 1000 mg/kg/day, or about 0.001 mg/kg/day to about 500 mg/kg/day, or about 0.001 mg/kg/day to about 250 mg/kg/day, or about 0.001 mg/kg/day to about 200 mg/kg/day, or about 0.001 mg/kg/day to about 150 mg/kg/day, or about 0.001 mg/kg/day to about 100 mg/kg/day,
  • Effective amounts for a given subject may be determined by routine experimentation that is within the skill and judgment of a clinician or a practitioner skilled in the art in light of factors related to the subject. Dosage and administration may be adjusted to provide sufficient levels of the active agent(s) or to maintain the desired effect. Factors which may be taken into account include genetic screening, severity of the disease state, status of disease progression, general health of the subject, ethnicity, age, weight, gender, diet, time of day and frequency of administration, drug combination(s), reaction sensitivities, experience with other therapies, and tolerance/response to therapy.
  • the dose administered to achieve an effective target plasma concentration may be orally administered once (once in approximately a 24 hour period; i.e., “q.d.”), twice (once in approximately a 12 hour period; i.e., “b.i.d.” or “q.12h”), thrice (once in approximately an 8 hour period; i.e., “t.i.d.” or “q.8h”), or four times (once in approximately a 6 hour period; i.e., “q.d.s.”, “q.i.d.” or “q.6h”) daily.
  • the dose administered to achieve an effective target plasma concentration may also be administered in a single, divided, or continuous dose for a patient or subject having a weight in a range of between about 40 to about 200 kg (which dose may be adjusted for patients or subjects above or below this range, particularly children under 40 kg).
  • the typical adult subject is expected to have a median weight in a range of about 70 kg.
  • Long-acting pharmaceutical compositions may be administered every 2, 3 or 4 days, once every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.
  • the compounds and compositions described herein may be administered to the subject via any drug delivery route known in the art.
  • Nonlimiting examples include oral, ocular, rectal, buccal, topical, nasal, sublingual, transdermal, subcutaneous, intramuscular, intraveneous (bolus and infusion), intracerebral, and pulmonary routes of administration.
  • the dose administered may be adjusted based upon a dosage form described herein formulated for delivery at about 0.02, 0.025, 0.03, 0.05, 0.06, 0.075, 0.08, 0.09, 0.10, 0.20, 0.25, 0.30, 0.50, 0.60, 0.75, 0.80, 0.90, 1.0, 1.10, 1.20, 1.25, 1.50, 1.75, 2.0, 3.0, 5.0, 10, 20, 30, 40, 50, 100, 150, 200, 250, 300, 400, 500, 1000, 1500, 2000, 2500, 3000 or 4000 mg/day.
  • the effective amount can be estimated initially either in cell culture assays or in relevant animal models, such as a mouse, guinea pig, chimpanzee, marmoset or tamarin animal model. Relevant animal models may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
  • Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED 50 (the dose therapeutically effective in 50% of the population) and LD 50 (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is therapeutic index, and can be expressed as the ratio, LD 50 /ED 50 .
  • the effective amount is such that a large therapeutic index is achieved.
  • the dosage is within a range of circulating concentrations that include an ED 50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.
  • HTT bypassingtin protein
  • methods for modulating the amount of HTT comprising contacting a human cell with a compound of Formula (I) or Formula (II) or a form thereof.
  • methods for modulating the amount of HTT comprising contacting a human cell with a compound of Formula (I) or Formula (II) or a form thereof that modulates the expression of HTT.
  • the human cell can be contacted with a compound of Formula (I) or Formula (II) or a form thereof in vitro, or in vivo, e.g., in a non-human animal or in a human.
  • the human cell is from or in a human.
  • the human cell is from or in a human with HD. In another specific aspect, the human cell is from or in a human with HD, caused by a CAG repeat in the Htt gene, resulting in a loss of HTT expression and/or function. In another aspect, the human cell is from a human with HD. In another aspect, the human cell is in a human with HD. In one aspect, the compound is a form of the compound of Formula (I) or Formula (II).
  • a method for enhancing the inhibition of mutant HTT transcribed from the Htt gene comprising contacting a human cell with a compound of Formula (I) or Formula (II) or a form thereof.
  • the human cell can be contacted with a compound of Formula (I) or Formula (II) or a form thereof in vitro, or in vivo, e.g., in a non-human animal or in a human.
  • the human cell is from or in a human.
  • the human cell is from or in a human with HD.
  • the human cell is from or in a human with HD, caused by a CAG repeat in the Htt gene, resulting in a loss of wild-type “normal” HTT expression and/or function.
  • the human cell is from a human with HD.
  • the human cell is in a human with HD.
  • the compound is a form of the compound of Formula (I) or Formula (II).
  • provided herein is a method for modulating the inhibition of mutant HTT transcribed from the Htt gene, comprising administering to a non-human animal model for HD a compound of Formula (I) or Formula (II) or a form thereof.
  • a method for modulating the inhibition of mutant HTT transcribed from the Htt gene comprising administering to a non-human animal model for HD a compound of Formula (I) or Formula (II) or a form thereof.
  • the compound is a form of the compound of Formula (I) or Formula (II).
  • provided herein is a method for decreasing the amount of mutant HTT, comprising contacting a human cell with a compound of Formula (I) or Formula (II) or a form thereof.
  • a method for decreasing the amount of mutant HTT comprising contacting a human cell with a compound of Formula (I) or Formula (II) that inhibits the transcription of mutant HTT (huntingtin mRNA) from the Htt gene.
  • a method for decreasing the amount of HTT comprising contacting a human cell with a compound of Formula (I) or Formula (II) that inhibits the expression of mutant HTT transcribed from the Htt gene.
  • the human cell can be contacted with a compound of Formula (I) or Formula (II) or a form thereof in vitro, or in vivo, e.g., in a non-human animal or in a human.
  • the human cell is from or in a human.
  • the human cell is from or in a human with HD.
  • the human cell is from or in a human with HD, caused by a CAG repeat in the Htt gene, resulting in a loss of HTT expression and/or function.
  • the human cell is from a human with HD.
  • the human cell is in a human with HD.
  • the compound is a form of the compound of Formula (I) or Formula (II).
  • treating or ameliorating HD with a compound of Formula (I) or Formula (II) or a form thereof (alone or in combination with an additional agent) has a therapeutic effect and/or beneficial effect.
  • treating HD with a compound of Formula (I) or Formula (II) or a form thereof (alone or in combination with an additional agent) results in one, two or more of the following effects: (i) reduces or ameliorates the severity of HD; (ii) delays onset of HD; (iii) inhibits the progression of HD; (iv) reduces hospitalization of a subject; (v) reduces hospitalization length for a subject; (vi) increases the survival of a subject; (vii) improves the quality of life for a subject; (viii) reduces the number of symptoms associated with HD; (ix) reduces or ameliorates the severity of a symptom(s) associated with HD; (x) reduces the duration of a symptom associated with HD; (xi) prevents the recurrence of a
  • the description includes the use of compounds produced by a process comprising contacting a compound described herein with a mammalian tissue or a mammal for a period of time sufficient to yield a metabolic product thereof.
  • Such products typically are identified by preparing a radio-labeled isotopologue (e.g., 1 C or 3 H) of a compound described herein, administering the radio-labeled compound in a detectable dose (e.g., greater than about 0.5 mg/kg) to a mammal such as a rat, mouse, guinea pig, dog, monkey or human, allowing sufficient time for metabolism to occur (typically about 30 seconds to about 30 hours), and identifying the metabolic conversion products from urine, bile, blood or other biological samples.
  • a detectable dose e.g., greater than about 0.5 mg/kg
  • a mammal such as a rat, mouse, guinea pig, dog, monkey or human
  • the conversion products are easily isolated since they are “radiolabeled” by virtue of being isotopically-enriched (others are isolated by the use of antibodies capable of binding epitopes surviving in the metabolite).
  • the metabolite structures are determined in conventional fashion, e.g., by MS or NMR analysis. In general, analysis of metabolites may be done in the same way as conventional drug metabolism studies well-known to those skilled in the art.
  • the conversion products so long as they are not otherwise found in vivo, are useful in diagnostic assays for therapeutic dosing of the compounds described herein even if they possess no biological activity of their own.
  • aspects of the present description include compounds that have been identified and have been demonstrated to be useful in selectively preventing, treating or ameliorating HD and have been provided for use as one or more pharmaceutical compositions for preventing, treating or ameliorating HD.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof in the preparation of a pharmaceutical composition for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form thereof in admixture with one or more pharmaceutically acceptable excipients.
  • An aspect of the present description includes a use for a pharmaceutical composition of the compound of Formula (I) or Formula (II) or a form thereof in the preparation of a kit for treating or ameliorating HD in a subject in need thereof comprising, the pharmaceutical composition of the compound of Formula (I) or Formula (II) or a form thereof and instructions for administering the pharmaceutical composition.
  • composition means a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • the pharmaceutical composition may be formulated to achieve a physiologically compatible pH, ranging from about pH 3 to about pH 11. In certain aspects, the pharmaceutical composition is formulated to achieve a pH of from about pH 3 to about pH 7. In other aspects, the pharmaceutical composition is formulated to achieve a pH of from about pH 5 to about pH 8.
  • pharmaceutically acceptable excipient refers to an excipient for administration of a pharmaceutical agent, such as the compounds described herein.
  • the term refers to any pharmaceutical excipient that may be administered without undue toxicity.
  • Pharmaceutically acceptable excipients may be determined in part by the particular composition being administered, as well as by the particular mode of administration and/or dosage form.
  • Nonlimiting examples of pharmaceutically acceptable excipients include carriers, solvents, stabilizers, adjuvants, diluents, etc. Accordingly, there exists a wide variety of suitable formulations of pharmaceutical compositions for the instant compounds described herein (see, e.g., Remington's Pharmaceutical Sciences).
  • Suitable excipients may be carrier molecules that include large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive antibodies.
  • Other exemplary excipients include antioxidants such as ascorbic acid; chelating agents such as EDTA; carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose (e.g., hydroxypropylmethylcellulose, also known as HPMC), stearic acid; liquids such as oils, water, saline, glycerol and ethanol; wetting or emulsifying agents; pH buffering substances; and the like. Liposomes are also included within the definition of pharmaceutically acceptable excipients.
  • compositions described herein may be formulated in any form suitable for the intended use described herein.
  • suitable formulations for oral administration include solids, liquid solutions, emulsions and suspensions, while suitable inhalable formulations for pulmonary administration include liquids and powders.
  • Alternative formulations include syrups, creams, ointments, tablets, and lyophilized solids which can be reconstituted with a physiologically compatible solvent prior to administration.
  • compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents including sweetening agents, flavoring agents, coloring agents, and preserving agents, in order to provide a palatable preparation.
  • compositions suitable for use in conjunction with tablets include, for example, inert diluents, such as celluloses, calcium or sodium carbonate, lactose, calcium or sodium phosphate; disintegrating agents, such as croscarmellose sodium, cross-linked povidone, maize starch, or alginic acid; binding agents, such as povidone, starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid, or talc. Tablets may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.
  • inert diluents such as celluloses, calcium or sodium carbonate, lactose, calcium or sodium phosphate
  • disintegrating agents such
  • Formulations for oral use may be also presented as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent, for example celluloses, lactose, calcium phosphate, or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with non-aqueous or oil medium, such as glycerin, propylene glycol, polyethylene glycol, peanut oil, liquid paraffin, or olive oil.
  • an inert solid diluent for example celluloses, lactose, calcium phosphate, or kaolin
  • non-aqueous or oil medium such as glycerin, propylene glycol, polyethylene glycol, peanut oil, liquid paraffin, or olive oil.
  • compositions described herein may be formulated as suspensions comprising a compound of Formula (I) or Formula (II) or a form thereof in admixture with one or more pharmaceutically acceptable excipients suitable for the manufacture of a suspension.
  • pharmaceutical compositions described herein may be formulated as dispersible powders and granules suitable for preparation of a suspension by the addition of one or more excipients.
  • Excipients suitable for use in connection with suspensions include suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcelluose, sodium alginate, polyvinylpyrrolidone, gum tragacanth, gum acacia, dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycethanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan monooleate); and thickening agents, such as carbomer, beeswax, hard paraffin, or cetyl alcohol.
  • suspending agents such as sodium carboxymethyl
  • the suspensions may also contain one or more preservatives such as acetic acid, methyl and/or n-propyl p-hydroxy-benzoate; one or more coloring agents; one or more flavoring agents; and one or more sweetening agents such as sucrose or saccharin.
  • preservatives such as acetic acid, methyl and/or n-propyl p-hydroxy-benzoate
  • coloring agents such as acetic acid, methyl and/or n-propyl p-hydroxy-benzoate
  • flavoring agents such as sucrose or saccharin.
  • sweetening agents such as sucrose or saccharin.
  • the pharmaceutical compositions described herein may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these.
  • Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth; naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids; hexitol anhydrides, such as sorbitan monooleate; and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate.
  • the emulsion may also contain sweetening and flavoring agents.
  • Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
  • sweetening agents such as glycerol, sorbitol or sucrose.
  • Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
  • compositions described herein may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous emulsion or oleaginous suspension.
  • a sterile injectable preparation such as a sterile injectable aqueous emulsion or oleaginous suspension.
  • emulsion or suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,2-propanediol.
  • the sterile injectable preparation may also be prepared as a lyophilized powder.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile fixed oils may be employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or di-glycerides.
  • fatty acids such as oleic acid may likewise be used in the preparation of injectables.
  • the compounds described herein may be substantially insoluble in water and sparingly soluble in most pharmaceutically acceptable protic solvents and vegetable oils, but generally soluble in medium-chain fatty acids (e.g., caprylic and capric acids) or triglycerides and in propylene glycol esters of medium-chain fatty acids.
  • medium-chain fatty acids e.g., caprylic and capric acids
  • propylene glycol esters of medium-chain fatty acids e.g., caprylic and capric acids
  • contemplated in the description are compounds which have been modified by substitutions or additions of chemical or biochemical moieties which make them more suitable for delivery (e.g., increase solubility, bioactivity, palatability, decrease adverse reactions, etc.), for example by esterification, glycosylation, PEGylation, etc.
  • the compound described herein is formulated for oral administration in a lipid-based composition suitable for low solubility compounds.
  • Lipid-based formulations can generally enhance the oral bioavailability of such compounds.
  • pharmaceutical compositions described herein may comprise a effective amount of a compound of Formula (I) or Formula (II) or a form thereof, together with at least one pharmaceutically acceptable excipient selected from medium chain fatty acids or propylene glycol esters thereof (e.g., propylene glycol esters of edible fatty acids such as caprylic and capric fatty acids) and pharmaceutically acceptable surfactants, such as polysorbate 20 or 80 (also referred to as Tween® 20 or Tween® 80, respectively) or polyoxyl 40 hydrogenated castor oil.
  • pharmaceutically acceptable excipient selected from medium chain fatty acids or propylene glycol esters thereof (e.g., propylene glycol esters of edible fatty acids such as caprylic and capric fatty acids) and pharmaceutically acceptable surfactants, such as polysorbate
  • the bioavailability of low solubility compounds may be enhanced using particle size optimization techniques including the preparation of nanoparticles or nanosuspensions using techniques known to those skilled in the art.
  • the compound forms present in such preparations include amorphous, partially amorphous, partially crystalline or crystalline forms.
  • the pharmaceutical composition may further comprise one or more aqueous solubility enhancer(s), such as a cyclodextrin.
  • a cyclodextrin include hydroxypropyl, hydroxyethyl, glucosyl, maltosyl and maltotriosyl derivatives of ⁇ -, ⁇ -, and T-cyclodextrin, and hydroxypropyl- ⁇ -cyclodextrin (HIPBC).
  • the pharmaceutical composition further comprises HPBC in a range of from about 0.1% to about 20%, from about 1% to about 15%, or from about 2.5% to about 10%.
  • the amount of solubility enhancer employed may depend on the amount of the compound in the composition.
  • Compounds of Formula (I), wherein B is heterocyclyl, X is O, NH or NR 1b , where R 1b is C 1-4 alkyl, may be prepared as described in Scheme A below.
  • Compound A1 (where W 1 is bromine, chlorine and the like) is converted to Compound A2 by a nucleophilic substitution with a primary or secondary amine or an alcohol (BXH) in the presence of a suitable base (such as Et 3 N and the like) in a suitable solvent (such as DMF and the like).
  • Compound A1 is converted to Compound A2 via cross coupling with a primary or a secondary amine in the presence of a suitable catalyst (such as RuPhos Pd G2 and the like) and base (such as sodium tert-butoxide and the like) in an appropriate solvent such as 1,4-dioxane and the like).
  • a suitable catalyst such as RuPhos Pd G2 and the like
  • base such as sodium tert-butoxide and the like
  • Compound A2 is converted to Compound A3 by halogenation upon treatment with an appropriate reagent (such as bromine and the like) in an appropriate solvent (such as methanol and the like).
  • Compound A3 is converted to Compound A4 by a Suzuki coupling with an aryl- or heteroaryl-boronic acid (or pinacol boronic ester) in the presence of a catalyst (such as Pd(dppf)Cl 2 and the like) and base (such as aqueous K 2 CO 3 and the like) in a suitable solvent (such as 1,4-dioxane and the like).
  • a catalyst such as Pd(dppf)Cl 2 and the like
  • base such as aqueous K 2 CO 3 and the like
  • a suitable solvent such as 1,4-dioxane and the like.
  • Compound A3 is converted to Compound A4 by a Stille coupling with an aryl- or heteroaryl-stannane in the presence of a catalyst (such as Pd 2 (dba) 3 and the like), a ligand (such as X-Phos and the like) and a base (such as CsF and the like) in a suitable solvent (such as 1,4-dioxane and the like).
  • a catalyst such as Pd 2 (dba) 3 and the like
  • a ligand such as X-Phos and the like
  • a base such as CsF and the like
  • Any protecting groups may be removed upon treatment with a suitable reagent (such as HCl in dioxane for a Boc protecting group and the like) in a suitable solvent (such as dioxane and the like).
  • Compound B1 (where W 1 is bromine, chlorine and the like) is converted to Compound B3 by a Suzuki coupling with an aryl-boronic acid (or pinacol boronic ester) B2 (where W 2 is bromine, chlorine and the like; (R 4 ) n is hydrogen, halogen, hydroxy, or C 1-4 alkoxy, and PG is a protecting group such as MOM and the like) in the presence of a catalyst (such as Pd(dppf)Cl 2 and the like) and base (such as aqueous K 2 CO 3 and the like) in a suitable solvent (such as 1,4-dioxane and the like).
  • a catalyst such as Pd(dppf)Cl 2 and the like
  • base such as aqueous K 2 CO 3 and the like
  • suitable solvent such as 1,4-dioxane and the like
  • Compound B3 is converted to Compound B4 by treatment with an oxidizing agent (such as mCPBA or oxone and the like) in a suitable solvent (such as dichloromethane and the like).
  • Compound B4 is converted to Compound B5 by a nucleophilic substitution with a primary or a secondary amine or an alcohol (BXH, where X is O, NH or NR 1b , where R 1b is C 1-4 alkyl) in the presence of a suitable base (such as Et 3 N and the like) in a suitable solvent (such as DMF and the like).
  • Compound B5 is converted to Compound B6 by a Suzuki coupling with an aryl- or heteroaryl-boronic acid (or pinacol boronic ester) in the presence of a catalyst (such as Pd(dppf)Cl 2 and the like) and a base (such as aqueous K 2 CO 3 and the like) in a suitable solvent (such as 1,4-dioxane and the like).
  • a catalyst such as Pd(dppf)Cl 2 and the like
  • a base such as aqueous K 2 CO 3 and the like
  • suitable solvent such as 1,4-dioxane and the like.
  • Compound B5 is converted to Compound B6 by a Stille coupling with an aryl- or heteroaryl-stannane in the presence of a catalyst (such as Pd 2 (dba) 3 and the like), a ligand (such as X-Phos and the like) and a base (such as CsF and the like) in a suitable solvent (such as 1,4-dioxane and the like).
  • a catalyst such as Pd 2 (dba) 3 and the like
  • a ligand such as X-Phos and the like
  • a base such as CsF and the like
  • suitable solvent such as 1,4-dioxane and the like
  • Compound B5 is converted to Compound B6 by treatment with pinacolatodiboron and a base (such as KOAc and the like) in the presence of a catalyst (such as Pd(dppf)Cl 2 and the like) in an appropriate solvent (such as 1,4-dioxane and the like), followed by addition of an aryl- or heteroaryl-halide.
  • a catalyst such as Pd(dppf)Cl 2 and the like
  • an appropriate solvent such as 1,4-dioxane and the like
  • Compound B5 is converted to Compound B6 by a Buchwald-Hartwig coupling with a heteroaryl or amine in the presence of a catalyst (such as Pd 2 (dba) 3 and the like), a ligand (such as tBuX-Phos and the like) and a base (such as K 3 PO 4 and the like) in a suitable solvent (such as 1,4-dioxane and the like).
  • a catalyst such as Pd 2 (dba) 3 and the like
  • a ligand such as tBuX-Phos and the like
  • a base such as K 3 PO 4 and the like
  • Compound B6 is converted to Compound B7 upon treatment with conditions appropriate to the removal of the protecting groups (such as HCl in dioxane for a MOM protecting group) in a suitable solvent (such as dioxane and the like).
  • Compound D1 (where W 1 , is bromine, chlorine and the like; (R 4 ) n is hydrogen, halogen, hydroxy, or C 1-4 alkoxy; and PG is a protecting group such as MOM and the like) is converted to Compound D2 by a condensation/cyclization sequence in presence of hydrazine in a suitable solvent (such as ethanol and the like).
  • Compound D2 is converted to Compound D3 by treatment with a dehydrative halogenating agent (such as POCl 3 and the like) followed by treatment with an oxidizing agent (such as manganese dioxide and the like).
  • Compound D3 is converted to Compound D4 by a nucleophilic substitution with a primary or a secondary amine or an alcohol (BXH, where X is O, NH or NR 1b , where R 1b is C 1-4 alkyl) in the presence of a suitable base (such as Et 3 N and the like) in a suitable solvent (such as DMF and the like).
  • a suitable base such as Et 3 N and the like
  • a suitable solvent such as DMF and the like
  • Compound D3 is converted to Compound D4 via cross coupling with a primary amine or a secondary amine or an alcohol in the presence of a suitable catalyst (such as RuPhos Pd G2 and the like) and base (such as sodium tert-butoxide and the like) in an appropriate solvent such as 1,4-dioxane and the like).
  • a suitable catalyst such as RuPhos Pd G2 and the like
  • base such as sodium tert-butoxide and the like
  • Compound D4 is converted to Compound D5 by a Suzuki coupling with an aryl- or heteroaryl-boronic acid (or pinacol boronic ester) in the presence of a catalyst (such as Pd(dppf)Cl 2 and the like) and base (such as aqueous K 2 CO 3 and the like) in a suitable solvent (such as 1,4-dioxane and the like).
  • a catalyst such as Pd(dppf)Cl 2 and the like
  • base such as aqueous K 2 CO 3 and the like
  • suitable solvent such as 1,4-dioxane and the like.
  • Compound D4 is converted to Compound D5 by a Stille coupling with an aryl- or heteroaryl-stannane in the presence of a catalyst (such as Pd 2 (dba) 3 and the like), a ligand (such as X-Phos and the like) and a base (such as CsF and the like) in a suitable solvent (such as 1,4-dioxane and the like).
  • a catalyst such as Pd 2 (dba) 3 and the like
  • a ligand such as X-Phos and the like
  • a base such as CsF and the like
  • suitable solvent such as 1,4-dioxane and the like
  • Compound D4 is converted to Compound D5 by treatment with pinacolatodiboron and a base (such as KOAc and the like) in the presence of a catalyst (such as Pd(dppf)Cl 2 and the like) in an appropriate solvent (such as 1,4-dioxane and the like), followed by addition of an aryl- or heteroaryl-halide.
  • a catalyst such as Pd(dppf)Cl 2 and the like
  • an appropriate solvent such as 1,4-dioxane and the like
  • Compound D4 is converted to Compound D5 by a Buchwald-Hartwig coupling with a heteroaryl or amine in the presence of a catalyst (such as Pd 2 (dba) 3 and the like), a ligand (such as tBuX-Phos and the like) and a base (such as K 3 PO 4 and the like) in a suitable solvent (such as 1,4-dioxane and the like).
  • a catalyst such as Pd 2 (dba) 3 and the like
  • a ligand such as tBuX-Phos and the like
  • a base such as K 3 PO 4 and the like
  • a suitable solvent such as 1,4-dioxane and the like
  • a screw-cap tube was charged with 3-(4-iodo-2,3-dimethoxy-phenyl)-1-methyl-pyrazole (48 mg, 0.14 mmol), bis(pinacolato)diboron (0.04 ml, 0.30 mmol), triethylamine (0.05 ml, 0.40 mmol) and 1,4-dioxane (0.3 ml) and the headspace was purged with N 2 gas for 30 minutes. Then palladium(II) acetate (1.80 mg, 0.008 mmol) and 2-(dicyclohexylphosphino)biphenyl (5.2 mg, 0.02 mmol) were added and the reaction stirred at 80° C. for 1 h.
  • 1,4-dioxane (0.3 mL) and 2-(dicyclohexylphosphino)biphenyl (4.5 mg, 0.013 mmol) was dissolved in 1,4-dioxane (0.3 mL) was added and the reaction was heated at 90° C. for 12 hours.
  • 6-Bromo-3-chloro-2-fluoro-phenol (900 mg, 4.0 mmol) was dissolved in DMF (4.5 mL) at 0° C.
  • Sodium tert-pentoxide (2.5 M in THF, 2 mL, 5.0 mmol) was added dropwise, followed by dropwise addition of chloromethyl methyl ether (405 ⁇ L, 5.34 mmol) and the reaction was stirred overnight at room temperature.
  • the reaction mixture was partitioned between water and EtOAc. The organic layer was washed with water, and then brine. The organic layer was dried over MgSO 4 , filtered, and concentrated under vacuum.
  • N-fluorobenzensulfonimide (42.6 g, 135 mol) was added potion wise as a solid over 20 min under nitrogen. The reaction was then gradually warmed to room temperature, and the mixture was further stirred at room temperature for 16 hours. The reaction was filtered to remove solid, and then the mixture was concentrated, and purified by flash chromatography using EtOAc and petroleum ether (0-10% EtOAc) as eluent to afford 3-fluoro-2,2,6,6-tetramethylpiperidin-4-one as a pale yellow solid (10.0 g, 45.5%). MS m/z: 174.1 [M+H] + .
  • Racemic (3S,4S)-3-fluoro-N-[(4-methoxyphenyl)methyl]-2,2,6,6-tetramethyl-piperidin-4-amine (5.0 g, 12.7 mmol) was dissolved in methanol (80 mL), then di-tert-butyl dicarbonate (4.1 g, 19.5 mmol) and triethyl amine (2.7 mmol, 19.5 mmol) were added sequentially. The resultant mixture was stirred at room temperature for 3 h.
  • Step 4 The crude tert-butyl ((3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl)carbamate (1.5 g, 0.54 mmol) obtained in step 3 was dissolved in CH 2 Cl 2 (20 mL), and then 2 mL of HCl in dioxane (4 mol/L) was added, and the mixture was stirred at room temperature for 16 h. The precipitate was filtered, washed with 5 mL of CH 2 Cl 2 and dried to yield (3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-amine (533 mg, HCl salt, 47% yield) as a white solid.
  • Benzyl N-(2,2,6,6-tetramethyl-3-oxo-4-piperidyl)carbamate (1.20 g, 3.95 mmol) was dissolved in MeOH (5 mL), followed by the addition of sodium borohydride (247 mg, 6.54 mmol). The reaction was stirred at room temperature for 1 h, then acetone (3 mL) was added slowly and the reaction was concentrated. The residue was partitioned between EtOAc and H 2 O and the layers were separated. The aqueous layer was extracted four times with EtOAc.
  • Racemic tert-butyl 4-oxo-1,3,3a,5,6,6a-hexahydrocyclopenta[c]pyrrole-2-carboxylate 523.8 mg, 2.325 mmol
  • dichloromethane 5 mL
  • aqueous dimethylamine 2.0 mL, 40 wt. %, 6.8 equiv
  • sodium triacetoxyborohydride 2.06 g, 9.72 mmol, 4.18 equiv
  • Racemic tert-butyl (3aR,4R,6aS)-4-(dimethylamino)-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxylate (43.1 mg, 0.169 mmol) was dissolved in TFA (2 mL) and stirred at room temperature for 4 h. The reaction was concentrated and the residue used directly in subsequent reactions, assuming a quantitative yield of racemic (3aR,4R,6aS)-N,N-dimethyl-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrol-4-amine 2,2,2-trifluoroacetic acid. MS m/z 155.3 [M+H] + .
  • step 1 To the mixture from step 1 was added dry methanol (40 mL) and the reaction was cooled to 0° C. in an ice bath. NaBH 4 (1.6 g, 42.3 mmol) was added slowly in portions (caution: very exothermic reaction). Once evolution of the gas subsided, the mixture was warmed to room temperature and stirred for 2h at room temperature. Upon completion, 0.1M NaOH solution (20 mL) was added to precipitate the titanium salts. The biphasic mixture was filtered through celite and washed with methanol.
  • N-Methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,2,4-triazin-3-amine prepared in step 1 was dissolved in 10 mL of MeOH and 5 mL of water. Bromine (200 ⁇ L, 3.9 mmol) was added, and the reaction mixture was stirred for 30 min at room temperature until UPLC showed full conversion. The solvents were removed under reduced pressure. The residue was dissolved in EtOAc (20 mL) and washed with water followed by brine.
  • the flask was sealed with a rubber septum and then evacuated and backfilled with argon.
  • Dioxane (2 mL) and water (0.5 mL) were added, and the reaction was heated to 90° C. for 16 h.
  • the reaction was cooled to room temperature, diluted with water, and extracted with EtOAc.
  • the flask was sealed with a rubber septum, and then evacuated and backfilled with argon. Dioxane (2 mL) and water (0.5 mL) were added, and the reaction was heated to 90° C. for 16 h. The reaction was cooled to room temperature, diluted with water, and extracted with EtOAc.
  • the flask was sealed with a rubber septum, and then evacuated and backfilled with argon. Dioxane (4 mL) and water (1 mL) were added and the reaction was heated to 90° C. for 16 h. The reaction was cooled to room temperature, diluted with water (5 mL), and extracted with EtOAc.
  • the flask was sealed with a rubber septum and then evacuated and backfilled with argon.
  • Dioxane (2 mL) and water (0.5 mL) were added and the reaction was heated to 90° C. for 16 h.
  • the reaction was cooled to room temperature, diluted with water, and extracted with EtOAc.
  • 6-(4-chloro-2-(methoxymethoxy)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,2,4-triazin-3-amine could be used as a starting material for step 1.
  • XPhos Pd G3 (10 mol %) could be used as catalyst in this case, otherwise following the above procedure.
  • reaction mixture was concentrated and purified by column chromatography eluting with MeOH/CH 2 Cl 2 (10-30% MeOH) to afford 2-(3-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,2,4-triazin-6-yl)-5-(2-methyl-2H-1,2,3-triazol-4-yl)phenol (11.5 mg, 50% over 3 steps).
  • Tris(dibenzylideneacetone)dipalladium(0) (4.5 mg, 0.005 mmol) and 2-di-tert-butylphosphino-3,4,5,6-tetramethyl-2′,4′,6′-triisopropyl-1,1′-biphenyl (6.0 mg, 0.0125 mmol) were suspended in 5:1 toluene/dioxane (1 mL). The purple solution was sparged with argon for 5 minutes, then heated to 120° C. for 5 minutes.
  • 6-(4-chloro-2-(methoxymethoxy)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,2,4-triazin-3-amine could be used as a starting material for step 1.
  • reaction mixture was concentrated, and the product was purified by chromatography on silica gel (ISCO), eluting with 530 MeOH in CH 2 Cl 2 to afford 2-(3-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,2,4-triazin-6-yl)-5-(2H-1,2,3-triazol-2-yl)phenol (25 mg, 8000 yield) as an orange solid.
  • ISCO silica gel
  • a dry screw cap vial was equipped with a magnetic stir bar and charged with 6-bromo-3-(methylthio)-1,2,4-triazine (0.2 g, 0.9 mmol, 1.0 equiv), 4-(3-(methoxymethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (0.4 g, 1.0 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dicholoropalladium(II) (0.08 g, 0.1 mmol), and K 2 CO 3 (0.4 g, 2.6 mmol) and was purged with argon.
  • a vial was equipped with a magnetic stir bar and charged with 6-(2-(methoxymethoxy)-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)phenyl)-3-(methylsulfonyl)-1,2,4-triazine (0.06 g, 0.13 mmol), 2,2,6,6-tetramethylpiperidin-4-amine (0.03 g, 0.18 mmol), and dichloroethane (5 mL) and the reaction was stirred at room temperature for 48 h.
  • 6-bromo-3-methylsulfanyl-1,2,4-triazine (7.0 g, 34.0 mmol)
  • 2-[4-chloro-2-(methoxymethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (10 g, 33.5 mmol)
  • K 2 CO 3 (9.5 g, 68 mmol)
  • PddppfCl2 3.8 g, 5.1 mmol
  • reaction mixture was purified directly by silica-gel column chromatography using 20% MeOH/CH 2 Cl 2 eluent to provide the desired product 6-[4-chloro-2-(methoxymethoxy)phenyl]-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidyl)-1,2,4-triazin-3-amine (980 mg, 79% yield) as a yellow solid.
  • the mixture was degassed with argon for 10 min, and then dioxane (2 mL) and water (0.5 mL) were added and the reaction was heated at 90° C. for 16 h (overnight). The reaction was cooled to room temperature, partitioned between EtOAc and water, and the organic phase was dried over Na 2 SO 4 and concentrated.
  • Racemic tert-butyl (3aR,4R,6aS)-4-hydroxy-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxylate (583 mg, 2.56 mmol) was cycled under N 2 , followed by the addition of CH 2 Cl 2 (5 mL). The reaction was cooled to ⁇ 78° C. with stirring. Methanesulfonyl chloride (0.34 mL, 4.39 mmol) was added followed by trimethylamine (0.69 mL, 4.95 mmol) and the reaction was stirred at ⁇ 78° C. for 30 minutes, and then allowed to warm to room temperature over 3h.
  • Racemic tert-butyl (3aR,4S,6aS)-4-azido-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxylate 70 mg, 0.28 mmol was dissolved in TFA (2.0 mL) and stirred at room temperature for 10 minutes. The reaction was concentrated, azeotroped with CH 2 Cl 2 , and then carried forward without purification. MS m/z 153.3 [M+H] + .
  • step 4 containing racemic (3aR,4S,6aS)-4-azido-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrole; 2,2,2-trifluoroacetic acid (106 mg, 0.28 mmol) was dissolved in DMF (2 mL), followed by the addition of N,N-diisopropylethylamine (0.4 mL, 2.29 mmol) and 6-[2-(methoxymethoxy)-4-(1-tetrahydropyran-2-ylpyrazol-4-yl)phenyl]-3-methylsulfonyl-1,2,4-triazine (86.0 mg, 0.19 mmol).
  • Racemic (3aR,4S,6aS)-2-[6-[2-(methoxymethoxy)-4-(1-tetrahydropyran-2-ylpyrazol-4-yl)phenyl]-1,2,4-triazin-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-4-amine (3 mg, 0.0053 mmol) was dissolved in methanol (0.5 mL) and a hydrogen chloride solution in dioxane (2.0 mL, 4.0 M) and stirred at room temperature for 1 h. The reaction was concentrated, and the residue was dissolved in MeOH, followed by Et 2 O addition to precipitate solid.
  • Example 1 The Endogenous Huntingtin Protein assay used in Example 1 was developed using the ELISA-based MSD electrochemiluminescence assay platform.
  • MSD Meso Scale Discovery
  • test compounds described herein had the following IC 50 values, an IC 50 value between >3 ⁇ M and ⁇ 9 ⁇ M is indicated by a single star (*), an IC 50 value between >1 ⁇ M and ⁇ 3 ⁇ M is indicated by two stars (**), an IC 50 value between >0.5 ⁇ M and ⁇ 1 ⁇ M is indicated by three stars (***), an IC 50 value between >0.1 ⁇ M and ⁇ 0.5 ⁇ M is indicated by four stars (****) and an IC 50 value of ⁇ 0.1 ⁇ M is indicated by five stars (*****).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
Figure US20230331725A1-20231019-C00001
In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I) or Formula (II), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. application Ser. No. 17/040,104, filed Sep. 22, 2020, which is the U.S. National Stage filing under 35 U.S.C. § 371 of International Application No. PCT/US2019/024278, filed Mar. 27, 2019, which in turn claims priority to U.S. Provisional Application No. 62/648,699, filed Mar. 27, 2018, the entire contents of which are incorporated by reference herein.
  • An aspect of the present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof useful for treating or ameliorating Huntington's disease. In particular, another aspect of the present description relates to substituted monocyclic heteroaryl compounds, forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
    • BACKGROUND
  • Huntington's disease (HD) is a progressive, autosomal dominant neurodegenerative disorder of the brain, having symptoms characterized by involuntary movements, cognitive impairment, and mental deterioration. Death, typically caused by pneumonia or coronary artery disease, usually occurs 13 to 15 years after the onset of symptoms. The prevalence of HD is between three and seven individuals per 100,000 in populations of western European descent. In North America, an estimated 30,000 people have HD, while an additional 200,000 people are at risk of inheriting the disease from an affected parent. The disease is caused by an expansion of uninterrupted trinucleotide CAG repeats in the “mutant” huntingtin (Htt) gene, leading to production of HTT (Htt protein) with an expanded poly-glutamine (polyQ) stretch, also known as a “CAG repeat” sequence. There are no current small molecule therapies targeting the underlying cause of the disease, leaving a high unmet need for medications that can be used for treating or ameliorating HD. Consequently, there remains a need to identify and provide small molecule compounds for treating or ameliorating HD.
  • All other documents referred to herein are incorporated by reference into the present application as though fully set forth herein.
    • SUMMARY
  • An aspect of the present description includes compounds comprising, a compound of Formula (I) or Formula (II):
  • Figure US20230331725A1-20231019-C00002
  • or a form thereof, wherein X, B, R4, and n are as defined herein.
  • An aspect of the present description includes a method for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a method for use of a compound of Formula (I) or Formula (II) or a form or composition thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form or composition thereof.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof in the manufacture of a medicament for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the medicament.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof in a combination product with one or more therapeutic agents for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form thereof in combination with an effective amount of the one or more agents.
    • DETAILED DESCRIPTION
  • An aspect of the present description relates to compounds comprising, a compound of Formula (I) or Formula (II):
  • Figure US20230331725A1-20231019-C00003
      • or a form thereof, wherein:
      • X is CHR1a, C═O, O, NR1b, or a bond; R1a is hydrogen, halogen, hydroxyl, cyano, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl, amino or hydroxyl-C1-4alkyl;
      • R1b is hydrogen, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl or hydroxyl-C1-4alkyl; B is heterocyclyl,
      • wherein heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2;
      • R2 is independently selected from halogen, hydroxyl, cyano, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl, amino, C1-4alkyl-amino, (C1-6alkyl)2-amino, halo-C1-4alkyl-amino, (halo-C1-6alkyl)2-amino, hydroxy-C1-4alkyl-amino, C1-4alkoxy-C1-4alkyl-amino, amino-C1-4alkyl, C1-4alkyl-amino-C1-4alkyl, (C1-4alkyl-amino)2-C1-4alkyl, C1-4alkoxy, halo-C1-4alkoxy, hydroxyl-C1-4alkoxy, C1-4alkyl-C1-4alkoxy, C3-10cycloalkyl, C3-10cycloalkyl-amino, C3-10cycloalkyl-amino-C1-4alkyl, heteroaryl-C1-4alkyl, heteroaryl-amino, heteroaryl-C1-4alkyl-amino, heterocyclyl, heterocyclyl-C1-4alkyl, heterocyclyl-amino, heterocyclyl-amino-C1-4alkyl, heterocyclyl-C1-4alkoxy, heterocyclyl-amino-C3-10cycloalkyl, phenyl, and phenyl-C1-4alkoxy,
      • wherein heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, or S,
      • wherein heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S,
      • wherein C3-10cycloalkyl is a saturated or partially unsaturated 3-7 membered monocyclic ring system, and
      • wherein each instance of phenyl, heteroaryl, heterocyclyl, or C3-10cycloalkyl is optionally substituted with 1 or 2 substituents each selected from R3;
      • R3 is independently selected from halogen, hydroxyl, cyano, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl, amino, C1-4alkoxy, and halo-C1-4alkoxy;
      • n is 0, 1, or 2;
      • R4 is independently selected from halogen, hydroxyl, cyano, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl, amino, C1-4alkyl-amino, (C1-4alkyl)2-amino, C1-4alkoxy, halo-C1-4alkoxy, heteroaryl, heterocyclyl, and phenyl,
      • wherein heteroaryl is a saturated 3-6 membered monocyclic or 9-10 membered bicyclic ring system having 1, 2, 3, or 4 heteroatom ring members selected from N, O, and S,
      • wherein heterocyclyl is a saturated or partially unsaturated 3-6 membered monocyclic or 9-10 membered bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and
      • wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R5;
      • R5 is independently selected from halogen, hydroxyl, cyano, nitro, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl, amino, C1-4alkyl-amino, (C1-4alkyl)2-amino, amino-C1-4alkyl, hydroxyl-C1-4alkyl, C1-4alkyl-carbonyl, C1-4alkoxy, C1-4alkylthio, halo-C1-4alkoxy, and C3-10cycloalkyl;
      • wherein a form of the compound is selected from the group consisting of a salt, hydrate, solvate, racemate, enantiomer, diastereomer, stereoisomer, and tautomer form thereof.
    ASPECTS OF THE DESCRIPTION
  • Another aspect of the present description includes a compound of Formula (I) or Formula (II):
  • Figure US20230331725A1-20231019-C00004
      • or a form thereof, wherein:
      • X is CHR1a, C═O, O, NR1b, or a bond;
      • R1a is hydrogen, halogen, hydroxyl, cyano, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl, amino or hydroxyl-C1-4alkyl;
      • R1b is hydrogen, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl or hydroxyl-C1-4alkyl; B is heterocyclyl,
      • wherein heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2;
      • R2 is independently selected from halogen, hydroxyl, cyano, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl, amino, C1-4alkyl-amino, (C1-6alkyl)2-amino, halo-C1-4alkyl-amino, (halo-C1-6alkyl)2-amino, hydroxy-C1-4alkyl-amino, C1-4alkoxy-C1-4alkyl-amino, amino-C1-4alkyl, C1-4alkyl-amino-C1-4alkyl, (C1-4alkyl-amino)2-C1-4alkyl, C1-4alkoxy, halo-C1-4alkoxy, hydroxyl-C1-4alkoxy, C1-4alkyl-C1-4alkoxy, C3-10cycloalkyl, C3-10cycloalkyl-amino, C3-10cycloalkyl-amino-C1-4alkyl, heteroaryl-C1-4alkyl, heteroaryl-amino, heteroaryl-C1-4alkyl-amino, heterocyclyl, heterocyclyl-C1-4alkyl, heterocyclyl-amino, heterocyclyl-amino-C1-4alkyl, heterocyclyl-C1-4alkoxy, heterocyclyl-amino-C3-10cycloalkyl, phenyl, and phenyl-C1-4alkoxy,
      • wherein heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, or S,
      • wherein heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S,
      • wherein C3-10cycloalkyl is a saturated or partially unsaturated 3-7 membered monocyclic ring system, and
      • wherein each instance of phenyl, heteroaryl, heterocyclyl, or C3-10cycloalkyl is optionally substituted with 1 or 2 substituents each selected from R3;
      • R3 is independently selected from halogen, hydroxyl, cyano, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl, amino, C1-4alkoxy, and halo-C1-4alkoxy;
      • n is 0, 1, or 2;
      • R4 is independently selected from halogen, hydroxyl, cyano, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl, amino, C1-4alkyl-amino, (C1-4alkyl)2-amino, C1-4alkoxy, halo-C1-4alkoxy, heteroaryl, heterocyclyl, and phenyl,
      • wherein heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, or S,
      • wherein heterocyclyl is a saturated or partially unsaturated 3-6 membered monocyclic or 9-10 membered bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and
      • wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R5;
      • R5 is independently selected from halogen, hydroxyl, cyano, nitro, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl, amino, C1-6alkyl-amino, (C1-6alkyl)2-amino, amino-C1-4alkyl, hydroxyl-C1-4alkyl, C1-4alkyl-carbonyl, C1-4alkoxy, C1-4alkylthio, halo-C1-4alkoxy, and C3-10cycloalkyl.
  • One aspect includes a compound of Formula (I) or Formula (II), wherein X is selected from CHR1a, C═O, O, NR1b, and a bond.
  • Another aspect includes a compound of Formula (I) wherein X is CHR1a.
  • Another aspect includes a compound of Formula (I) or Formula (II) wherein X is C═O.
  • Another aspect includes a compound of Formula (I) or Formula (II) wherein X is O.
  • Another aspect includes a compound of Formula (I) or Formula (II) wherein X is NR1b.
  • Another aspect includes a compound of Formula (I) or Formula (II) wherein X is a bond.
  • One aspect includes a compound of Formula (I) or Formula (II), wherein R1a is selected from hydrogen, halogen, hydroxyl, cyano, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl, amino, and hydroxyl-C1-4alkyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R1a is selected from hydrogen, cyano, C1-4alkyl, and amino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R1a is hydrogen.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R1a is cyano.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R1a is C1-4alkyl selected from methyl, ethyl, propyl, isopropyl, butyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R1a methyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R1a is amino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R1b is selected from hydrogen and C1-4alkyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R1b is hydrogen.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R1b is C1-4alkyl selected from methyl, ethyl, propyl, isopropyl, butyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R1b is methyl.
  • One aspect includes a compound of Formula (I) or Formula (II), wherein B is heterocyclyl,
      • wherein heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein B is heterocyclyl selected from azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, 1,4-diazepanyl, 1,2-dihydropyridinyl, 1,2,5,6-tetrahydropyridinyl, 1,2,3,6-tetrahydropyridinyl, hexahydrocyclopentapyrrol-(1H)-yl, hexahydropyrrolo[3,2-b]pyrrol-(2H)-yl, hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, (3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, octahydro-2H-pyrrolo[3,4-c]pyridinyl, octahydro-5H-pyrrolo[3,2-c]pyridinyl, octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, hexahydropyrrolo[1,2-a]pyrazin-(2H)-one, hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (7R,8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, hexahydro-1H-cyclobuta[1.2-c:1,4-c′]dipyrrol-(3H)-yl, (8aS)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, octahydro-2H-pyrido[1,2-a]pyrazinyl, hexahydropyrrolo[3,4-b][1,4]oxazin-(2H)-yl, 5-azaspiro[2.4]heptanyl, 2-oxa-6-azaspiro[3.4]octanyl, 3-azabicyclo[3.1.0]hexanyl, 8-azabicyclo[3.2.1]octanyl, (1R,5S)-8-azabicyclo[3.2.1]octanyl, 8-azabicyclo[3.2.1]oct-2-en-yl, (1R,5S)-8-azabicyclo[3.2.1]oct-2-en-yl, 9-azabicyclo[3.3.1]nonanyl, (1R,5S)-9-azabicyclo[3.3.1]nonanyl, 2,5-diazabicyclo[2.2.1]heptanyl, (1S,4S)-2,5-diazabicyclo[2.2.1]heptanyl, 1,4-diazabicyclo[3.1.1]heptanyl, 3,6-diazabicyclo[3.2.0]heptanyl, 2,5-diazabicyclo[2.2.2]octanyl, 1,4-diazabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, (1R,5S)-3,8-diazabicyclo[3.2.1]octanyl, 1,4-diazabicyclo[3.2.2]nonanyl, azaspiro[3.3]heptanyl, 4,7-diazaspiro[2.5]octanyl, 2,6-diazaspiro[3.3]heptanyl, 2,6-diazaspiro[3.4]octanyl, 1,7,-diazaspiro[4.4]nonanyl, 1,7-diazaspiro[3.5]nonanyl, 2,6-diazaspiro[3.5]nonanyl, 2,7-diazaspiro[3.5]nonanyl, 5,8-diazaspiro[3.5]nonanyl, 2,7-diazaspiro[4.4]nonanyl, 2,7-diazaspiro[4.5]decanyl, 2,8-diazaspiro[4.5]decanyl, 6,9-diazaspiro[4.5]decyl, 6-oxa-2,9-diazaspiro[4.5]decanyl, 2,9-diazaspiro[5.5]undecanyl, and 7-azadispiro[5.1.58.36]hexadecanyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein B is heterocyclyl selected from pyrrolidinyl, piperidinyl, piperazinyl, hexahydrocyclopentapyrrol-(1H)-yl, hexahydropyrrolo[3,2-b]pyrrol-(2H)-yl, hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, octahydro-2H-pyrrolo[3,4-c]pyridinyl, octahydro-5H-pyrrolo[3,2-c]pyridinyl, octahydro-6H-pyrrolo[3,4-b]pyridinyl, hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, hexahydropyrrolo[3,4-b][1,4]oxazin-(2H)-yl, 5-azaspiro[2.4]heptanyl, 2-oxa-6-azaspiro[3.4]octanyl, 3-azabicyclo[3.1.0]hexanyl, 8-azabicyclo[3.2.1]octanyl, 9-azabicyclo[3.3.1]nonanyl, 2,6-diazaspiro[3.3]heptanyl, 2,6-diazaspiro[3.4]octanyl, 1,7,-diazaspiro[4.4]nonanyl, 1,7-diazaspiro[3.5]nonanyl, 2,6-diazaspiro[3.5]nonanyl, 2,7-diazaspiro[3.5]nonanyl, 2,7-diazaspiro[4.4]nonanyl, 2,7-diazaspiro[4.5]decanyl, 2,8-diazaspiro[4.5]decanyl, 6-oxa-2,9-diazaspiro[4.5]decanyl, and 2,9-diazaspiro[5.5]undecanyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein B is heterocyclyl selected from pyrrolidinyl, piperidinyl, and 2,7-diazaspiro[3.5]nonanyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein B is heterocyclyl selected from azetidin-1-yl, tetrahydrofuran-3-yl, pyrrolidin-1-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, 1,4-diazepan-1-yl, 1,2-dihydropyridin-2-yl, 1,2-dihydropyridin-3-yl, 1,2-dihydropyridin-4-yl, 1,2-dihydropyridin-5-yl, 1,2-dihydropyridin-6-yl, 1,2,5,6-tetrahydropyridin-5-yl, 1,2,3,6-tetrahydropyridin-4-yl, hexahydrocyclopentapyrrol-2(1H)-yl, hexahydropyrrolo[3,2-b]pyrrol-1(2H)-yl, hexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl, hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl, hexahydropyrrolo[3,4-c]pyrrol-1(1H)-yl, hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl, hexahydropyrrolo[3,4-c]pyrrol-5(1H)-yl, (3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl, octahydro-2H-pyrrolo[3,4-c]pyridin-2-yl, octahydro-5H-pyrrolo[3,2-c]pyridin-5-yl, octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, (4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, hexahydropyrrolo[1,2-a]pyrazin-6(2H)-one, hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, (7R,8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, (8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, (8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, hexahydro-1H-cyclobuta[1.2-c:1,4-c′]dipyrrol-2(3H)-yl, (8aS)-octahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, (8aR)-octahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, octahydro-2H-pyrido[1,2-a]pyrazin-2-yl, hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl, 5-azaspiro[2.4]heptan-5-yl, 2-oxa-6-azaspiro[3.4]octan-6-yl, 3-azabicyclo[3.1.0]hexan-3-yl, 8-azabicyclo[3.2.1]octan-3-yl, (1R,5S)-8-azabicyclo[3.2.1]octan-3-yl, 8-azabicyclo[3.2.1]oct-2-en-3-yl, (1R,5S)-8-azabicyclo[3.2.1]oct-2-en-3-yl, 9-azabicyclo[3.3.1]nonan-3-yl, (1R,5S)-9-azabicyclo[3.3.1]nonan-3-yl, 2,5-diazabicyclo[2.2.1]heptan-2-yl, (1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl, 1,4-diazabicyclo[3.1.1]heptan-4-yl, 3,6-diazabicyclo[3.2.0]heptan-3-yl, 3,6-diazabicyclo[3.2.0]heptan-6-yl, 2,5-diazabicyclo[2.2.2]octan-2-yl, 1,4-diazabicyclo[3.2.1]octan-4-yl, 3,8-diazabicyclo[3.2.1]octan-3-yl, (1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl, 1,4-diazabicyclo[3.2.2]nonan-4-yl, azaspiro[3.3]heptan-2-yl, 4,7-diazaspiro[2.5]octan-4-yl, 4,7-diazaspiro[2.5]octan-7-yl, 2,6-diazaspiro[3.3]heptan-2-yl, 2,6-diazaspiro[3.4]octan-2-yl, 2,6-diazaspiro[3.4]octan-6-yl, 1,7,-diazaspiro[4.4]nonan-1-yl, 1,7,-diazaspiro[4.4]nonan-7-yl, 1,7-diazaspiro[3.5]nonan-7-yl, 2,6-diazaspiro[3.5]nonan-2-yl, 2,6-diazaspiro[3.5]nonan-6-yl, 1,7-diazaspiro[3.5]nonan-7-yl, 2,7-diazaspiro[3.5]nonan-2-yl, 2,7-diazaspiro[3.5]nonan-7-yl, 5,8-diazaspiro[3.5]nonan-8-yl, 2,7-diazaspiro[4.4]nonan-2-yl, 2,7-diazaspiro[4.5]decan-2-yl, 2,7-diazaspiro[4.5]decan-7-yl, 2,8-diazaspiro[4.5]decan-8-yl, 6,9-diazaspiro[4.5]dec-9-yl, 6-oxa-2,9-diazaspiro[4.5]decan-2-yl, 2,9-diazaspiro[5.5]undecan-9-yl, and 7-azadispiro[5.1.58.36]hexadecan-15-yl, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein B is heterocyclyl selected from pyrrolidin-1-yl, pyrrolidin-3-yl, piperidin-4-yl, piperazin-1-yl, hexahydrocyclopentapyrrol-2(1H)-yl, hexahydropyrrolo[3,2-b]pyrrol-1(2H)-yl, hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl, hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl, octahydro-2H-pyrrolo[3,4-c]pyridin-2-yl, octahydro-5H-pyrrolo[3,2-c]pyridin-5-yl, octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl, 5-azaspiro[2.4]heptan-5-yl, 2-oxa-6-azaspiro[3.4]octan-6-yl, 3-azabicyclo[3.1.0]hexan-3-yl, 8-azabicyclo[3.2.1]octan-3-yl, 9-azabicyclo[3.3.1]nonan-3-yl, 2,6-diazaspiro[3.3]heptan-2-yl, 2,6-diazaspiro[3.4]octan-6-yl, 1,7,-diazaspiro[4.4]nonan-7-yl, 1,7-diazaspiro[3.5]nonan-7-yl, 2,6-diazaspiro[3.5]nonan-2-yl, 1,7-diazaspiro[3.5]nonan-7-yl, 2,7-diazaspiro[3.5]nonan-2-yl, 2,7-diazaspiro[3.5]nonan-7-yl, 2,7-diazaspiro[4.4]nonan-2-yl, 2,7-diazaspiro[4.5]decan-2-yl, 2,8-diazaspiro[4.5]decan-8-yl, 6-oxa-2,9-diazaspiro[4.5]decan-2-yl, and 2,9-diazaspiro[5.5]undecan-9-yl, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein B is heterocyclyl selected from pyrrolidin-1-yl, pyrrolidin-3-yl, piperidin-4-yl, 2,7-diazaspiro[3.5]nonan-2-yl, and 2,7-diazaspiro[3.5]nonan-7-yl, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2.
  • One aspect includes a compound of Formula (I) or Formula (II), wherein R2 is selected from halogen, hydroxyl, cyano, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl, amino, C1-4alkyl-amino, (C1-6alkyl)2-amino, halo-C1-4alkyl-amino, (halo-C1-6alkyl)2-amino, hydroxy-C1-4alkyl-amino, C1-4alkoxy-C1-4alkyl-amino, amino-C1-4alkyl, C1-4alkyl-amino-C1-4alkyl, (C1-4alkyl-amino)2-C1-4alkyl, C1-4alkoxy, halo-C1-4alkoxy, hydroxyl-C1-4alkoxy, C1-4alkyl-C1-4alkoxy, C3-10cycloalkyl, C3-10cycloalkyl-amino, C3-10cycloalkyl-amino-C1-4alkyl, heteroaryl-C1-4alkyl, heteroaryl-amino, heteroaryl-C1-4alkyl-amino, heterocyclyl, heterocyclyl-C1-4alkyl, heterocyclyl-amino, heterocyclyl-amino-C1-4alkyl, heterocyclyl-C1-4alkoxy, heterocyclyl-amino-C3-10cycloalkyl, phenyl, and phenyl-C1-4alkoxy,
      • wherein heteroaryl is a saturated 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic ring system having 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, or S,
      • wherein heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S,
      • wherein C3-10cycloalkyl is a saturated or partially unsaturated 3-7 membered monocyclic ring system, and
      • wherein each instance of phenyl, heteroaryl, heterocyclyl, or C3-10cycloalkyl is optionally substituted with 1 or 2 substituents each selected from R3.
  • One aspect includes a compound of Formula (I) or Formula (II), wherein R2 is selected from halogen, hydroxyl, C1-4alkyl, amino, C1-4alkyl-amino, (C1-6alkyl)2-amino, halo-C1-4alkyl-amino, hydroxy-C1-4alkyl-amino, C1-4alkoxy-C1-4alkyl-amino, C1-4alkyl-amino-C1-4alkyl, (C1-4alkyl-amino)2-C1-4alkyl, C1-4alkoxy, C3-10cycloalkyl-amino, C3-10cycloalkyl-amino-C1-4alkyl, heteroaryl-C1-4alkyl-amino, heterocyclyl-amino, heterocyclyl-amino-C1-4alkyl, and heterocyclyl-amino-C3-10cycloalkyl,
      • wherein heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, or S,
      • wherein heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S,
      • wherein C3-10cycloalkyl is a saturated or partially unsaturated 3-7 membered monocyclic ring system, and
      • wherein each instance of heteroaryl, heterocyclyl, or C3-10cycloalkyl is optionally substituted with 1 or 2 substituents each selected from R3.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is halogen selected from bromo, chloro, fluoro, and iodo.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is fluoro.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is hydroxyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is C1-4alkyl selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is C1-4alkyl selected from methyl or ethyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is methyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is ethyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is amino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is C1-6alkyl-amino, wherein C1-6alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, 2-methylbutyl, and 3-methylpentyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is C1-6alkyl-amino, wherein C1-6alkyl is selected from methyl, ethyl, isopropyl, tert-butyl, 2-methylbutyl, and 3-methylpentyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is methylamino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is ethylamino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is isopropylamino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is tert-butylamino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is 2-methylbutyl-2-amino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is 3-methylpentyl-3-amino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is (C1-6alkyl)2-amino, wherein C1-4alkyl is each independently selected from selected from methyl, ethyl, isopropyl, tert-butyl, 2-methylbutyl, and 3-methylpentyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is (C1-6alkyl)2-amino, wherein C1-4alkyl is methyl or ethyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is dimethylamino or diethylamino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is dimethylamino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is diethylamino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is halo-C1-4alkyl-amino, wherein C1-4alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl, partially or completely substituted with one or more halogen atoms where allowed by available valences.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is halo-C1-4alkyl-amino, wherein C1-4alkyl is selected from isopropyl and tert-butyl, partially or completely substituted with one or more halogen atoms where allowed by available valences.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is 1-fluoro-2-methylpropan-2-amino or 1-fluoropropan-2-amino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is hydroxy-C1-4alkyl-amino, wherein C1-4alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl, partially or completely substituted with one or more hydroxy groups where allowed by available valences.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is hydroxy-C1-4alkyl-amino, wherein C1-4alkyl is selected from ethyl and propyl, partially or completely substituted with one or more hydroxy groups where allowed by available valences.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is 2-hydroxyethylamino or 3-hydroxypropylamino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is C1-4alkoxy-C1-4alkyl-amino, wherein C1-4alkoxy is selected from methoxy, ethoxy, propoxy, isopropoxy, butoxy and tert-butoxy, and C1-4alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is C1-4alkoxy-C1-4alkyl-amino, wherein C1-4alkoxy is methoxy and C1-4alkyl is selected propyl, isopropyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is 1-methoxypropan-2-amino or 1-methoxy-2-methylpropan-2-amino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is C1-4alkyl-amino-C1-4alkyl, wherein each C1-4alkyl is independently selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is C1-4alkyl-amino-C1-4alkyl, wherein each C1-4alkyl is independently selected from methyl, ethyl, isopropyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is methylaminomethyl, propan-2-yl-aminomethyl, propan-2-yl-aminoethyl, or tert-butylaminomethyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is (C1-4alkyl-amino)2-C1-4alkyl, wherein each C1-4alkyl is independently selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is (C1-4alkyl-amino)2-C1-4alkyl, wherein each C1-4alkyl is methyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is dimethylaminomethyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is C1-4alkoxy selected from methoxy, ethoxy, propoxy, isopropoxy, butoxy and tert-butoxy.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 methoxy.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is C3-10cycloalkyl-amino, wherein C3-10cycloalkyl is selected from cyclopropyl, cylcobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]hexanyl, and adamantyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is C3-10cycloalkyl-amino, wherein C3-10cycloalkyl is selected from cyclopropyl, cylcobutyl, cyclopentyl, bicyclo[2.2.1]hexanyl, and adamantyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is C3-10cycloalkyl-amino-C1-4alkyl, wherein C3-10cycloalkyl is selected from cyclopropyl, cylcobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]hexanyl, and adamantyl and C1-4alkyl is selected from methyl, ethyl, propyl, and butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is C3-10cycloalkyl-amino-C1-4alkyl, wherein C3-10cycloalkyl is selected from cyclopropyl, cylcobutyl, and cyclopentyl, and C1-4alkyl is methyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is cyclopropylaminomethyl, cyclobutylaminomethyl, or cyclopentylaminomethyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is heteroaryl-C1-4alkyl-amino, wherein heteroaryl is selected from thienyl, 1H-pyrazolyl, 1H-imidazolyl, 1,3-thiazolyl, oxazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-thiadiazolyl, 1H-tetrazolyl, 2H-tetrazolyl, pyridinyl, pyrimidinyl, pyridazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1H-indolyl, 1H-indazolyl, 2H-indazolyl, indolizinyl, benzofuranyl, benzothienyl, 1H-benzimidazolyl, 1,3-benzoxazolyl, 1,3-benzothiazolyl, 1,3-benzodioxolyl, 1,2,3-benzotriazolyl, 9H-purinyl, quinolinyl, isoquinolinyl, and quinoxalinyl, and C1-4alkyl is selected from methyl, ethyl, propyl, and butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is heteroaryl-C1-4alkyl-amino, wherein heteroaryl is pyridinyl, and C1-4alkyl is methyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is pyridin-2-yl-methylamino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is heterocyclyl-amino, wherein heterocyclyl is selected from azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, tetrahydropyranyl, 8-azabicyclo[3.2.1]octanyl, and 8-oxabicyclo[3.2.1]octanyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is heterocyclyl-amino, wherein heterocyclyl is selected from oxetanyl and tetrahydropyranyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is oxetanylamino or tetrahyropyranylamino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is heterocyclyl-amino-C1-4alkyl, wherein heterocyclyl is selected from azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, oxanyl, 8-azabicyclo[3.2.1]octanyl, and 8-oxabicyclo[3.2.1]octanyl, and C1-4alkyl is selected from methyl, ethyl, propyl, and butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is heterocyclyl-amino-C1-4alkyl, wherein heterocyclyl is selected from tetrahydrofuranyl, oxanyl, and 8-oxabicyclo[3.2.1]octanyl, and C1-4alkyl is methyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is oxanylaminomethyl, tetrahydrofuranylaminomethyl, and 8-oxabicyclo[3.2.1]octanylamino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is heterocyclyl-amino-C3-10cycloalkyl, wherein heterocyclyl is selected from azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, oxanyl, 8-azabicyclo[3.2.1]octanyl, and 8-oxabicyclo[3.2.1]octanyl, and C3-10cycloalkyl is selected from cyclopropyl, cylcobutyl, cyclopentyl, and cyclohexyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is heterocyclyl-amino-C3-10cycloalkyl, wherein heterocyclyl is oxanyl, and C3-10cycloalkyl is cyclopropyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is oxanylaminocyclopropyl.
  • One aspect includes a compound of Formula (I) or Formula (II), wherein R3 is halogen, hydroxyl, cyano, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl, amino, C1-4alkoxy, and halo-C1-4alkoxy.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R3 is halogen and C1-4alkyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R3 is halogen selected from bromo, chloro, fluoro, and iodo.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R3 is fluoro.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R3 is C1-4alkyl selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R3 is methyl.
  • One aspect includes a compound of Formula (I) or Formula (II), wherein R4 is selected from halogen, hydroxyl, cyano, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl, amino, C1-4alkyl-amino, (C1-4alkyl)2-amino, C1-4alkoxy, halo-C1-4alkoxy, heteroaryl, heterocyclyl, and phenyl,
      • wherein heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, or S, wherein heterocyclyl is a saturated or partially unsaturated 3-6 membered monocyclic or 9-10 membered bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and
      • wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1 or 2 substituents each selected from R5.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R4 is selected from halogen, C1-4alkoxy, heteroaryl, and phenyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R4 is halogen selected from bromo, chloro, fluoro, and iodo.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R4 is fluoro.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R4 is C1-4alkoxy selected from methoxy, ethoxy, propoxy, isopropoxy, butoxy, and tert-butoxy.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R4 methoxy.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R4 is heteroaryl,
      • wherein heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, or S, optionally substituted with 1 or 2 substituents each selected from R5.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R4 is heteroaryl selected from thienyl, 1H-pyrazolyl, 1H-imidazolyl, 1,3-thiazolyl, oxazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-thiadiazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl, 1H-tetrazolyl, 2H-tetrazolyl, pyridinyl, pyridin-2(1H)-on-yl, pyrimidinyl, pyrimidin-4(3H)-on-yl, pyridazinyl, pyridazin-3(2H)-on-yl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1H-indolyl, 1H-indazolyl, 2H-indazolyl, indolizinyl, benzofuranyl, benzothienyl, 1H-benzimidazolyl, 1,3-benzoxazolyl, 1,3-benzothiazolyl, 1,3-benzodioxolyl, 1,2,3-benzotriazolyl, 9H-purinyl, furo[3,2-b]pyridinyl, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, 1,3-oxazolo[5,4-b]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-d]pyrimidinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-c]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, pyrrolo[1,2-a]pyrazinyl, pyrrolo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyridin-yl, pyrazolo[1,5-a]pyridinyl, 1H-pyrazolo[3,4-b]pyrazinyl, 1H-pyrazolo[3,4-b]pyridinyl, 1H-pyrazolo[3,4-b]pyridinyl, 1H-pyrazolo[3,4-c]pyridinyl, 1H-pyrazolo[3,4-c]pyridinyl, 1H-pyrazolo[4,3-b]pyridinyl, 1H-pyrazolo[4,3-b]pyridinyl, 1H-pyrazolo[4,3-d]pyrimidinyl, 2H-pyrazolo[4,3-b]pyridinyl, 2H-pyrazolo[4,3-c]pyridin-yl, 5H-pyrrolo[2,3-b]pyrazinyl, pyrazolo[1,5-a]pyrazinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-c]pyrimidinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, imidazo[1,2-a]pyrazinyl, 1H-imidazo[4,5-b]pyridinyl, 3H-imidazo[4,5-b]pyridinyl, imidazo[2,1-b][1,3]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, [1,3]oxazolo[4,5-b]pyridinyl, [1,2,3]triazolo[1,5-a]pyridinyl, [1,2,3]triazolo[1,5-a]pyridinyl, 1H-[1,2,3]triazolo[4,5-b]pyridinyl, 3H-[1,2,3]triazolo[4,5-b]pyridinyl, tetrazolo[1,5-a]pyridinyl, tetrazolo[1,5-b]pyridazinyl, quinolinyl, isoquinolinyl, and quinoxalinyl, optionally substituted with 1 or 2 substituents each selected from R5.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R4 is heteroaryl selected from thienyl, 1H-pyrazolyl, 1H-imidazolyl, 1,3-thiazolyl, oxazolyl, 1,3,4-oxadiazolyl, 1,2,4-thiadiazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl, 2H-tetrazolyl, pyridinyl, pyrimidinyl, pyrimidin-4(3H)-on-yl, pyridazinyl, pyridazin-3(2H)-on-yl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1H-indazolyl, 1H-benzimidazolyl, 1,3-benzoxazolyl, 1,3-benzodioxolyl, 1,2,3-benzotriazolyl, 1,3-oxazolo[5,4-b]pyridinyl, 1H-pyrazolo[3,4-b]pyrazinyl, 1H-pyrazolo[3,4-b]pyridinyl, 1H-pyrazolo[3,4-c]pyridinyl, 1H-pyrazolo[4,3-b]pyridinyl, 1H-pyrazolo[4,3-d]pyrimidinyl, 5H-pyrrolo[2,3-b]pyrazinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, 1H-imidazo[4,5-b]pyridinyl, 3H-imidazo[4,5-b]pyridinyl, [1,2,3]triazolo[1,5-a]pyridinyl, 1H-[1,2,3]triazolo[4,5-b]pyridinyl, 3H-[1,2,3]triazolo[4,5-b]pyridinyl, tetrazolo[1,5-a]pyridinyl, tetrazolo[1,5-b]pyridazinyl, and quinolinyl, optionally substituted with 1 or 2 substituents each selected from R5.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R4 is heteroaryl selected from thien-2-yl, thien-3-yl, 1H-pyrazol-1-yl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, 1H-pyrazol-5-yl, 1H-imidazol-1-yl, 1H-imidazol-4-yl, 1,3-thiazol-2-yl, 1,3-thiazol-5-yl, 1,3-oxazol-2-yl, 1,3-oxazol-4-yl, 1,3-oxazol-5-yl, 1,2,4-oxadiazol-3-yl, 1,3,4-oxadiazol-2-yl, 1,2,4-thiadiazol-5-yl, 1H-1,2,3-triazol-1-yl, 1H-1,2,3-triazol-4-yl, 1H-1,2,3-triazol-5-yl, 2H-1,2,3-triazol-2-yl, 2H-1,2,3-triazol-4-yl, 1H-1,2,4-triazol-1-yl, 1H-1,2,4-triazol-3-yl, 1H-1,2,4-triazol-5-yl, 1H-tetrazol-1-yl, 1H-tetrazol-5-yl, 2H-tetrazol-2-yl, 2H-tetrazol-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridin-2(1H)-on-4-yl, pyridin-2(1H)-on-5-yl, pyridin-2(1H)-on-6-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrimidin-4(3H)-on-6-yl, pyridazin-3-yl, pyridazin-4-yl, pyridazin-3(2H)-on-5-yl, 1,2,4-triazin-3-yl, 1,3,5-triazin-2-yl, 1H-indol-3-yl, 1H-indol-4-yl, 1H-indol-5-yl, 1H-indol-6-yl, 1H-indazol-5-yl, 2H-indazol-5-yl, indolizin-2-yl, benzofuran-2-yl, benzofuran-5-yl, benzothien-2-yl, benzothien-3-yl, 1H-benzimidazol-2-yl, 1H-benzimidazol-5-yl, 1H-benzimidazol-6-yl, 1,3-benzoxazol-2-yl, 1,3-benzoxazol-5-yl, 1,3-benzoxazol-6-yl, 1,3-benzothiazol-2-yl, 1,3-benzothiazol-5-yl, 1,3-benzothiazol-6-yl, 1,3-benzodioxol-5-yl, 1,2,3-benzotriazol-5-yl, 9H-purin-8-yl, furo[3,2-b]pyridin-2-yl, furo[3,2-c]pyridin-2-yl, furo[2,3-c]pyridin-2-yl, 1,3-oxazolo[5,4-b]pyridine-5-yl, thieno[3,2-c]pyridin-2-yl, thieno[2,3-d]pyrimidin-6-yl, 1H-pyrrolo[2,3-b]pyridin-5-yl, 1H-pyrrolo[2,3-c]pyridin-4-yl, pyrrolo[1,2-a]pyrimidin-7-yl, pyrrolo[1,2-a]pyrazin-7-yl, pyrrolo[1,2-b]pyridazin-2-yl, pyrazolo[1,5-a]pyridin-2-yl, pyrazolo[1,5-a]pyridin-5-yl, 1H-pyrazolo[3,4-b]pyrazin-5-yl, 1H-pyrazolo[3,4-b]pyridin-5-yl, 1H-pyrazolo[3,4-b]pyridin-6-yl, 1H-pyrazolo[3,4-c]pyridin-1-yl, 1H-pyrazolo[3,4-c]pyridin-5-yl, 1H-pyrazolo[4,3-b]pyridin-5-yl, 1H-pyrazolo[4,3-b]pyridin-6-yl, 1H-pyrazolo[4,3-d]pyrimidin-5-yl, 2H-pyrazolo[4,3-b]pyridin-5-yl, 2H-pyrazolo[4,3-c]pyridin-5-yl, 5H-pyrrolo[2,3-b]pyrazin-2-yl, pyrazolo[1,5-a]pyrazin-2-yl, imidazo[1,2-a]pyridin-2-yl, imidazo[1,2-a]pyridin-6-yl, imidazo[1,2-a]pyrimidin-2-yl, imidazo[1,2-a]pyrimidin-6-yl, imidazo[1,2-c]pyrimidin-2-yl, imidazo[1,2-b]pyridazin-2-yl, imidazo[1,2-b]pyridazin-6-yl, imidazo[1,2-a]pyrazin-2-yl, imidazo[1,2-a]pyrazin-6-yl, 1H-imidazo[4,5-b]pyridin-5-yl, 3H-imidazo[4,5-b]pyridin-5-yl, imidazo[2,1-b][1,3]thiazol-6-yl, imidazo[2,1-b][1,3,4]thiadiazol-6-yl, [1,3]oxazolo[4,5-b]pyridin-2-yl, [1,2,3]triazolo[1,5-a]pyridin-5-yl, [1,2,3]triazolo[1,5-a]pyridin-6-yl, 1H-[1,2,3]triazolo[4,5-b]pyridin-5-yl, 3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl, tetrazolo[1,5-a]pyridin-7-yl, tetrazolo[1,5-b]pyridazin-7-yl, quinolin-6-yl, isoquinolin-6-yl, and quinoxalin-2-yl, optionally substituted with 1 or 2 substituents each selected from R5.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R4 is heteroaryl selected from thien-2-yl, 1H-pyrazol-1-yl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, 1H-imidazol-1-yl, 1H-imidazol-4-yl, 1,3-thiazol-2-yl, 1,3-thiazol-5-yl, 1,3-oxazol-2-yl, 1,3-oxazol-5-yl, 1,3,4-oxadiazol-2-yl, 1,2,4-thiadiazol-5-yl, 1H-1,2,3-triazol-4-yl, 2H-1,2,3-triazol-2-yl, 2H-1,2,3-triazol-4-yl, 1H-1,2,4-triazol-1-yl, 2H-tetrazol-2-yl, 2H-tetrazol-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrimidin-4(3H)-on-6-yl, pyridazin-3-yl, pyridazin-4-yl, pyridazin-3(2H)-on-5-yl, 1,2,4-triazin-3-yl, 1,3,5-triazin-2-yl, 1H-indazol-5-yl, 1H-benzimidazol-5-yl, 1,3-benzoxazol-6-yl, 1,3-benzodioxol-5-yl, 1,2,3-benzotriazol-5-yl, 1,3-oxazolo[5,4-b]pyridine-5-yl, 1H-pyrazolo[3,4-b]pyrazin-5-yl, 1H-pyrazolo[3,4-b]pyridin-5-yl, 1H-pyrazolo[3,4-b]pyridin-6-yl, 1H-pyrazolo[3,4-c]pyridin-1-yl, 1H-pyrazolo[3,4-c]pyridin-5-yl, 1H-pyrazolo[4,3-b]pyridin-5-yl, 1H-pyrazolo[4,3-b]pyridin-6-yl, 1H-pyrazolo[4,3-d]pyrimidin-5-yl, 5H-pyrrolo[2,3-b]pyrazin-2-yl, imidazo[1,2-a]pyridin-2-yl, imidazo[1,2-b]pyridazin-6-yl, imidazo[1,2-a]pyrazin-2-yl, imidazo[1,2-a]pyrazin-6-yl, 1H-imidazo[4,5-b]pyridin-5-yl, 3H-imidazo[4,5-b]pyridin-5-yl, [1,2,3]triazolo[1,5-a]pyridin-5-yl, [1,2,3]triazolo[1,5-a]pyridin-6-yl, 1H-[1,2,3]triazolo[4,5-b]pyridin-5-yl, 3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl, tetrazolo[1,5-a]pyridin-7-yl, tetrazolo[1,5-b]pyridazin-7-yl, quinolin-6-yl, and isoquinolin-6-yl, optionally substituted with 1 or 2 substituents each selected from R5.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R4 is phenyl, 1 or 2 substituents each selected from R5.
  • One aspect includes a compound of Formula (I) or Formula (II), wherein R5 is selected from halogen, hydroxyl, cyano, nitro, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl, amino, C1-4alkyl-amino, (C1-4alkyl)2-amino, amino-C1-4alkyl, hydroxyl-C1-4alkyl, C1-4alkyl-carbonyl, C1-4alkoxy, C1-4alkylthio, halo-C1-4alkoxy, and C3-10cycloalkyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is selected from halogen, hydroxyl, cyano, nitro, C1-4alkyl, deutero-C1-4alkyl, amino, C1-4alkyl-amino, amino-C1-4alkyl, hydroxyl-C1-4alkyl, C1-4alkyl-carbonyl, C1-4alkoxy, C1-4alkylthio, and C3-10cycloalkyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is halogen selected from bromo, chloro, fluoro, and iodo.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is halogen selected from bromo, chloro and fluoro.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is chloro.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is fluoro.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is hydroxy.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is cyano.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is nitro.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is C1-4alkyl selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is methyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is deutero-C1-4alkyl wherein C1-4alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl partially or completely substituted with one or more deuterium atoms where allowed by available valences.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is (2H3)methyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is amino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is C1-6alkyl-amino wherein C1-6alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, 2-methylbutyl, and 3-methylpentyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is C1-4alkyl-amino wherein C1-4alkyl is methyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is methylamino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is amino-C1-4alkyl wherein C1-4alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is amino-C1-4alkyl wherein C1-4alkyl is methyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is aminomethyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is hydroxyl-C1-4alkyl, wherein C1-4alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl partially or completely substituted with one or more hydroxyl groups where allowed by available valences.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is hydroxyl-C1-4alkyl, wherein C1-4alkyl is methyl substituted with one hydroxyl group.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is hydroxymethyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is C1-4alkyl-carbonyl, wherein C1-4alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is C1-4alkyl-carbonyl, wherein C1-4alkyl is methyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is CH3C(O)—.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is C1-4alkoxy selected from methoxy, ethoxy, propoxy, isopropoxy, butoxy, and tert-butoxy.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 methoxy.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is C1-4alkylthio selected from methylthio, ethylthio, propylthio, isopropylthio, butylthio, and tert-butylthio.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 methylthio.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is C3-10cycloalkyl selected from cyclopropyl, cylcobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]hexanyl, and adamantyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is cyclopropyl.
  • Another aspect of the compound of Formula (I) or Formula (II) includes the compound of Formula (I):
  • Figure US20230331725A1-20231019-C00005
  • or a form thereof.
  • Another aspect of the compound of Formula (I) or Formula (II) includes the compound of Formula (II):
  • Figure US20230331725A1-20231019-C00006
  • or a form thereof.
  • An aspect of the compound of Formula (I) or Formula (II) or a form thereof includes a compound selected from the group consisting of:
  • Figure US20230331725A1-20231019-C00007
    Figure US20230331725A1-20231019-C00008
    Figure US20230331725A1-20231019-C00009
    Figure US20230331725A1-20231019-C00010
    Figure US20230331725A1-20231019-C00011
    Figure US20230331725A1-20231019-C00012
    Figure US20230331725A1-20231019-C00013
    Figure US20230331725A1-20231019-C00014
    Figure US20230331725A1-20231019-C00015
    Figure US20230331725A1-20231019-C00016
    Figure US20230331725A1-20231019-C00017
    Figure US20230331725A1-20231019-C00018
    Figure US20230331725A1-20231019-C00019
    Figure US20230331725A1-20231019-C00020
    Figure US20230331725A1-20231019-C00021
    Figure US20230331725A1-20231019-C00022
    Figure US20230331725A1-20231019-C00023
    Figure US20230331725A1-20231019-C00024
    Figure US20230331725A1-20231019-C00025
    Figure US20230331725A1-20231019-C00026
    Figure US20230331725A1-20231019-C00027
    Figure US20230331725A1-20231019-C00028
    Figure US20230331725A1-20231019-C00029
    Figure US20230331725A1-20231019-C00030
    Figure US20230331725A1-20231019-C00031
    Figure US20230331725A1-20231019-C00032
    Figure US20230331725A1-20231019-C00033
    Figure US20230331725A1-20231019-C00034
    Figure US20230331725A1-20231019-C00035
    Figure US20230331725A1-20231019-C00036
    Figure US20230331725A1-20231019-C00037
    Figure US20230331725A1-20231019-C00038
    Figure US20230331725A1-20231019-C00039
    Figure US20230331725A1-20231019-C00040
    Figure US20230331725A1-20231019-C00041
    Figure US20230331725A1-20231019-C00042
    Figure US20230331725A1-20231019-C00043
    Figure US20230331725A1-20231019-C00044
    Figure US20230331725A1-20231019-C00045
    Figure US20230331725A1-20231019-C00046
    Figure US20230331725A1-20231019-C00047
    Figure US20230331725A1-20231019-C00048
    Figure US20230331725A1-20231019-C00049
    Figure US20230331725A1-20231019-C00050
    Figure US20230331725A1-20231019-C00051
    Figure US20230331725A1-20231019-C00052
    Figure US20230331725A1-20231019-C00053
    Figure US20230331725A1-20231019-C00054
    Figure US20230331725A1-20231019-C00055
  • Figure US20230331725A1-20231019-C00056
    Figure US20230331725A1-20231019-C00057
    Figure US20230331725A1-20231019-C00058
    Figure US20230331725A1-20231019-C00059
    Figure US20230331725A1-20231019-C00060
    Figure US20230331725A1-20231019-C00061
    Figure US20230331725A1-20231019-C00062
    Figure US20230331725A1-20231019-C00063
    Figure US20230331725A1-20231019-C00064
    Figure US20230331725A1-20231019-C00065
    Figure US20230331725A1-20231019-C00066
    Figure US20230331725A1-20231019-C00067
    Figure US20230331725A1-20231019-C00068
    Figure US20230331725A1-20231019-C00069
    Figure US20230331725A1-20231019-C00070
    Figure US20230331725A1-20231019-C00071
    Figure US20230331725A1-20231019-C00072
    Figure US20230331725A1-20231019-C00073
    Figure US20230331725A1-20231019-C00074
    Figure US20230331725A1-20231019-C00075
    Figure US20230331725A1-20231019-C00076
    Figure US20230331725A1-20231019-C00077
    Figure US20230331725A1-20231019-C00078
    Figure US20230331725A1-20231019-C00079
    Figure US20230331725A1-20231019-C00080
    Figure US20230331725A1-20231019-C00081
    Figure US20230331725A1-20231019-C00082
    Figure US20230331725A1-20231019-C00083
    Figure US20230331725A1-20231019-C00084
    Figure US20230331725A1-20231019-C00085
    Figure US20230331725A1-20231019-C00086
    Figure US20230331725A1-20231019-C00087
    Figure US20230331725A1-20231019-C00088
    Figure US20230331725A1-20231019-C00089
    Figure US20230331725A1-20231019-C00090
    Figure US20230331725A1-20231019-C00091
    Figure US20230331725A1-20231019-C00092
    Figure US20230331725A1-20231019-C00093
    Figure US20230331725A1-20231019-C00094
    Figure US20230331725A1-20231019-C00095
    Figure US20230331725A1-20231019-C00096
    Figure US20230331725A1-20231019-C00097
    Figure US20230331725A1-20231019-C00098
    Figure US20230331725A1-20231019-C00099
    Figure US20230331725A1-20231019-C00100
      • wherein a form of the compound is selected from the group consisting of a salt, hydrate, solvate, racemate, enantiomer, diastereomer, stereoisomer, and tautomer form thereof.
  • An aspect the compound of Formula (I) or Formula (II) or a form thereof (wherein compound number (#1) indicates that the salt form was isolated) includes a compound selected from the group consisting of:
  • Cpd Name
      11 5-(5-methyl-1,3-oxazol-2-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
      21 5-(6-methoxypyrimidin-4-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
      31 5-(2-methoxypyridin-4-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
     4 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-1,2,3-
    triazol-4-yl)phenol
     5 4-(3-hydroxy-4-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino}-1,2,4-triazin-6-
    yl}phenyl)pyridin-2-ol
      61 5-(3-methyl-1H-pyrazol-4-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
     7 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1,3-
    oxazol-2-yl)phenol
     8 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(pyridin-
    4-yl)phenol
     9 5-(2-methylpyridin-4-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol
      101 5-(4-methyl-1H-imidazol-1-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
      111 5-(1H-pyrazol-4-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]-1,2,4-triazin-6-
    yl}phenol
      121 5-(3-fluoro-1H-pyrazol-4-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
      131 5-(1H-pyrazol-4-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-
    yl}phenol
      141 5-[1-(2H3)methyl-1H-pyrazol-4-yl]-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol
      151 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazol-4-yl)phenol
      161 5-(1-methyl-1H-pyrazol-4-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino1-
    1,2,4-triazin-6-yl}phenol
      171 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazol-1-yl)phenol
      181 5-(3-fluoro-1-methyl-1H-pyrazol-4-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol
      191 2-{3-[methyl(piperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-yl)phenol
      201 2-{3-[methyl(piperidin-3-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-yl)phenol
     21 2-(3-{[(1R,3S,5S)-8-azabicyclo[3.2.1]octan-3-yl](methyl)amino}-1,2,4-triazin-6-yl)-5-
    (1H-pyrazol-4-yl)phenol
     22 2-(3-{[(1R,3S,5S)-9-azabicyclo[3.3.1]nonan-3-yl](methyl)amino}-1,2,4-triazin-6-yl)-5-
    (1H-pyrazol-4-yl)phenol
      231 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(2-methyl-
    2H-1,2,3-triazol-4-yl)phenol
      241 2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-3-yl}-5-(1H-
    pyrazol-4-yl)phenol
     25 (6-(2-hydroxy-4-(1H-pyrazol-4-yl)phenyl)-1,2,4-triazin-3-yl)(2,2,6,6-
    tetramethylpiperidin-4-yl)methanone
     26 (3-(2-hydroxy-4-(1H-pyrazol-4-yl)phenyl)-1,2,4-triazin-6-yl)(2,2,6,6-
    tetramethylpiperidin-4-yl)methanone
     27 2-(6-(2-hydroxy-4-(1H-pyrazol-4-yl)phenyl)-1,2,4-triazin-3-yl)-2-(2,2,6,6-
    tetramethylpiperidin-4-yl)acetonitrile
     28 2-(3-(2-hydroxy-4-(1H-pyrazol-4-yl)phenyl)-1,2,4-triazin-6-yl)-2-(2,2,6,6-
    tetramethylpiperidin-4-yl)acetonitrile
     29 2-(3-(amino(2,2,6,6-tetramethylpiperidin-4-yl)methyl)-1,2,4-triazin-6-yl)-5-(1H-
    pyrazol-4-yl)phenol
     30 2-(6-(amino(2,2,6,6-tetramethylpiperidin-4-yl)methyl)-1,2,4-triazin-3-yl)-5-(1H-
    pyrazol-4-yl)phenol
     31 2-(3-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,2,4-triazin-6-yl)-5-(1,3,5-
    triazin-2-yl)phenol
     32 2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,2,4-triazin-3-yl)-5-(1,3,5-
    triazin-2-yl)phenol
      331 4-(3-hydroxy-4-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-
    yl}phenyl)-1,3,5-triazin-2-ol
     34 4-(3-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,2,4-triazin-3-
    yl)phenyl)-1,3,5-triazin-2-ol
     35 5-(4-amino-1,3,5-triazin-2-yl)-2-(3-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-
    1,2,4-triazin-6-yl)phenol
     36 5-(4-amino-1,3,5-triazin-2-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-
    1,2,4-triazin-3-yl)phenol
     37 5-(4-chloro-1,3,5-triazin-2-yl)2-(3-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-
    1,2,4-triazin-6-yl)phenol
     38 5-(4-chloro-1,3,5-triazin-2-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-
    1,2,4-triazin-3-yl)phenol
     39 2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,2,4-triazin-3-yl)-5-(5-methyl-
    1H-pyrazol-4-yl)phenol
     40 5-(5-chloro-1H-pyrazol-4-yl)-2-(3-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-
    1,2,4-triazin-6-yl)phenol
     41 5-(5-chloro-1H-pyrazol-4-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-
    1,2,4-triazin-3-yl)phenol
     42 4-(3-hydroxy-4-(3-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,2,4-triazin-6-
    yl)phenyl)-1H-pyrazole-5-carbonitrile
     43 4-(3-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,2,4-triazin-3-
    yl)phenyl)-1H-pyrazole-5-carbonitrile
     44 5-(1,5-dimethyl-1H-pyrazol-4-yl)-2-(3-(methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino)-1,2,4-triazin-6-yl)phenol
     45 5-(1,5-dimethyl-1H-pyrazol-4-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino)-1,2,4-triazin-3-yl)phenol
     46 5-(5-chloro-1-methyl-1H-pyrazol-4-yl)-2-(3-(methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino)-1,2,4-triazin-6-yl)phenol
     47 5-(5-chloro-l-methyl-1H-pyrazol-4-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino)-1,2,4-triazin-3-yl)phenol
     48 4-(3-hydroxy-4-(3-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,2,4-triazin-6-
    yl)phenyl)-1-methyl-1H-pyrazole-5-carbonitrile
     49 4-(3-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,2,4-triazin-3-
    yl)phenyl)-1-methyl-1H-pyrazole-5-carbonitrile
      501 5-(4-fluoro-1H-imidazol-1-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
      511 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(3-methyl-
    1H-1,2,4-triazol-1-yl)phenol
      521 2-{3-[(1-methylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-yl)phenol
     53 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(thiophen-
    2-yl)phenol
     54 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(4-
    methylthiophen-2-yl)phenol
      551 5-(4-methoxy-1H-pyrazol-1-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol
     56 4-(3-hydroxy-4-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino1-1,2,4-triazin-6-
    yl}phenyl)-1-methylpyridin-2(1H)-one
      571 5-(3-chloro-1H-pyrazol-4-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
      581 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1,3-
    thiazol-2-yl)phenol
      591 5-(4-chloro-1H-imidazol-1-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
      601 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-
    (pyridazin-4-yl)phenol
      611 5-(6-methylpyridazin-4-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
      621 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1-methyl-
    1H-1,2,4-triazol-3-yl)phenol
      631 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(2H-1,2,3-
    triazol-2-yl)phenol
     64 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(2-methyl-
    1,3-thiazol-5-yl)phenol
      651 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1,2,4-
    thiadiazol-5-yl)phenol
      661 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(3-methyl-
    1,2,4-thiadiazol-5-yl)phenol
      671 2-{3-[(3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl)(methyl)amino]-1,2,4-triazin-6-yl}-5-
    (1H-pyrazol-4-yl)phenol
      681 1-[1-(3-hydroxy-4-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-
    6-yl}phenyl)-1H-pyrazol-4-yl]ethan-l-one
      691 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(4-methyl-
    2H-1,2,3-triazol-2-yl)phenol
     70 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(pyridin-
    3-yl)phenol
      711 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(pyridin-
    2-yl)phenol
      721 5-(3-fluoro-1H-pyrazol-4-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]-1,2,4-
    triazin-6-yl}phenol
      731 5-(3-fluoro-1H-pyrazol-4-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol
      741 5-(2-methyl-1,3-oxazol-5-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
      751 5-(1-methyl-1H-imidazol-4-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
      761 5-(1-methyl-1H-pyrazol-3-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
      771 2-{3-{[(1R,3s,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]amino}-1,2,4-triazin-6-yl)-
    5-(1H-pyrazol-4-yl)phenol
     78 2-{3-{[1R,3r,5S)-8-azabicyclo[3.2.1]octan-3-yl]amino}-1,2,4-triazin-6-yl)-5-(1H-
    pyrazol-4-yl)phenol
      791 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-1,2,4-
    triazol-1-yl)phenol
      801 5-(imidazo[1,2-a]pyrazin-6-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
      811 5-(5-methyl-1,3,4-oxadiazol-2-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol
      821 2-{3-[(2,6-dimethylpiperidin-4-yl)oxy]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-yl)phenol
     83 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(pyrazin-
    2-yl)phenol
      841 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-
    (pyridazin-3-yl)phenol
     85 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-
    (pyrimidin-2-yl)phenol
      861 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-
    (pyrimidin-5-yl)phenol
     87 2-(3-{methyl[(1R,3s,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]amino}-1,2,4-triazin-
    6-yl)-5-(1H-pyrazol-4-yl)phenol
      881 5-(4-methoxy-1,3,5-triazin-2-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol
      891 5-(1H-imidazol-1-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol
      901 1-(3-hydroxy-4-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-
    yl}phenyl)-1H-pyrazol-4-ol
      911 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1,3-
    oxazol-5-yl)phenol
      921 5-(imidazo[1,2-b]pyridazin-6-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol
      931 5-(4-fluoro-1H-pyrazol-1-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
      941 5-(4-methyl-1H-pyrazol-1-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
      951 2-[3-(2,7-diazaspiro[3.5]nonan-7-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol
      961 2-[3-(2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol
      971 5-(1H-indazol-5-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol
     98 5-(4-fluoropyridin-2-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol
      991 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(4-nitro-
    2H-1,2,3-triazol-2-yl)phenol
    100 2-[3-(6-amino-3-azabicyclo[3.1.0]hexan-3-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-
    yl)phenol
     1011 5-(1-cyclopropyl-1H-pyrazol-4-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol
     1021 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-
    (pyrimidin-4-yl)phenol
     1031 4-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}[1,1'-
    biphenyl]-3,4’-diol
    104 5-(3-hydroxy-4-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-
    yl}phenyl)pyridin-2(1H)-one
     1051 6-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}quinolin-7-ol
    106 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1,3,4-
    oxadiazol-2-yl)phenol
     1071 5-(1H-pyrazol-3-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]-1,2,4-triazin-6-
    yl}phenol
     1081 5-(1-methyl-1H-pyrazol-3-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]-1,2,4-
    triazin-6-yl}phenol
     1091 2-[3-(2,6-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol
     1101 2-[3-(2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol
     1111 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazol-3-yl)phenol
     1121 5-(5-fluoropyrimidin-2-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
     1131 2-[3-(1-methyl-1,7-diazaspiro[3.5]nonan-7-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-
    yl)phenol
     1141 2-{3-[(3S)-3-(methylamino)pyrrolidin-l-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-
    yl)phenol
     1151 2-{3-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-
    yl)phenol
     1161 2-{3-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazol-4-yl)phenol
     1171 2-{3-[(3aR,6aR)-1-methylhexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]-1,2,4-triazin-6-yl}-
    5-(1H-pyrazol-4-yl)phenol
     1181 2-[3-(2,6-diazaspiro[3.3]heptan-2-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol
     1191 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(5-methyl-
    2H-tetrazol-2-yl)phenol
     1201 2-{3-[(2R,4s,6S)-2,6-diethylpiperidin-4-yl]oxy}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol
     1211 2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(2H-1,2,3-triazol-
    2-yl)phenol
     1221 2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]-1,2,4-triazin-6-yl}-5-(2H-1,2,3-triazol-2-
    yl)phenol
     1231 5-(6-chloropyridazin-3-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
     1241 5-(1-methyl-1H-pyrazol-5-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
    125 4-fluoro-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-
    (1H-pyrazol-5-yl)phenol
     1261 2-{3-[(3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazol-4-yl)phenol
     1271 2-{3-[6-(diethylamino)-3-azabicyclo[3.1.0]hexan-3-yl]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazol-4-yl)phenol
     1281 5-(5-methylpyrimidin-2-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
     1291 5-(4-methylpyrimidin-2-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
     1301 5-(2-chloropyrimidin-4-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
    131 5-(1H-benzimidazol-5-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
     1321 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazolo[3,4-b]pyridin-5-yl)phenol
     1331 5-(3-chloro-1H-1,2,4-triazol-1-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol
     1341 6-(3-hydroxy-4-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-
    yl}phenyl)pyridazin-3-ol
    135 1-(3-hydroxy-4-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-
    yl}phenyl)-1H-pyrazole-4-carbonitrile
    136 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazolo[4,3-b]pyridin-5-yl)phenol
    137 2-{3-[3-(cyclopropylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-
    yl)phenol
    138 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-
    yl)phenol
    139 1-(3-hydroxy-4-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-
    yl}phenyl)-1H-imidazole-4-carbonitrile
     1401 1-[1-(3-hydroxy-4-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-
    6-yl}phenyl)-1H-imidazol-4-yl]ethan-l-one
     1411 5-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-2-{3-[methyl(2,2,6,6-
    tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}phenol
     1421 5-(2-methylimidazo[1,2-b]pyridazin-6-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-
    4-yl)amino]-1,2,4-triazin-6-yl}phenol
     1431 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(2-methyl-
    2H-tetrazol-5-yl)phenol
    144 5-(6-methoxy-1,2,4-triazin-3-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol
    145 5-(1,3-benzoxazol-6-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol
     1461 6-(3-hydroxy-4-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-
    yl}phenyl)-3-methylpyrimidin-4(3H)-one
     1471 5-(3-hydroxy-4-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-
    yl}phenyl)-2-methylpyridazin-3(2H)-one
     1481 2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol
    149 5-(3-fluoro-1H-pyrazol-4-yl)-2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-
    triazin-6-yl]phenol
    150 5-(3-fluoro-1H-pyrazol-4-yl)-2-{3-[(3aS,7aR)-octahydro-5H-pyrrolo[3,2-c]pyridin-5-
    yl]-1,2,4-triazin-6-yl}phenol
     1511 2-[3-(2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(3-fluoro-1H-pyrazol-4-
    yl)phenol
     1521 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-
    ([1,2,3]triazolo[1,5-a]pyridin-5-yl)phenol
     1531 5-(3-fluoro-1H-pyrazol-4-yl)-2-{3-[(3aS,7aR)-1-methyloctahydro-5H-pyrrolo[3,2-
    c]pyridin-5-yl]-1,2,4-triazin-6-yl}phenol
    154 2-(3-{3-[(2-methylbutan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-
    pyrazol-4-yl)phenol
     1551 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-
    (tetrazolo[1,5-a]pyridin-7-yl)phenol
     1561 5-(4-fluoro-1H-pyrazol-3-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
     1571 2-(3-{3-[(adamantan-1-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol
     1581 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(5H-
    pyrrolo[2,3-b]pyrazin-2-yl)phenol
     1591 2-(3-{3-[(adamantan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol
     1601 2-(3-{3-[(3,5-dimethyladamantan-1-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-
    (1H-pyrazol-4-yl)phenol
     1611 5-[4-(hydroxymethyl)-1H-pyrazol-1-yl]-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol
     1621 2-{3-[(3aR,4R,6aS)-4-(dimethylamino)hexahydrocyclopenta[c]pyrrol-2(1H)-yl]-1,2,4-
    triazin-6-yl}-5-(1H-pyrazol-4-yl)phenol
    163 5-(3-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-2-{3-[methyl(2,2,6,6-
    tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}phenol
     1641 5-(1-methyl-1H-imidazo[4,5-b]pyridin-5-yl)-2-{3-[methyl(2,2,6,6-
    tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}phenol
     1651 2-{3-[(3aR,4S,6aS)-4-aminohexahydrocyclopenta[c]pyrrol-2(1H)-yl]-1,2,4-triazin-6-
    yl}-5-(1H-pyrazol-4-yl)phenol
     1661 2-[3-(5-methyloctahydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-1,2,4-triazin-6-yl]-5-(1H-
    pyrazol-4-yl)phenol
     1671 2-{3-[(3aR,4S,6aS)-4-(dimethylamino)hexahydrocyclopenta[c]pyrrol-2(1H)-yl]-1,2,4-
    triazin-6-yl}-5-(1H-pyrazol-4-yl)phenol
     1681 3-amino-6-(3-hydroxy-4-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenyl)-4-methylpyridin-2-ol
     1691 5-(2,7-dimethyl[1,3]oxazolo[5,4-b]pyridin-5-yl)-2-{3-[methyl(2,2,6,6-
    tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}phenol
    170 2-(3-{3-[(3-methylpentan-3-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-
    pyrazol-4-yl)phenol
    171 2-{3-[4-(tert-butylamino)-2-methylpyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-
    4-yl)phenol
     1721 5-[4-(hydroxymethyl)-2H-1,2,3-triazol-2-yl]-2-{3-[methyl(2,2,6,6-
    tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}phenol
     1731 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-543-methyl-
    3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)phenol
     1741 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(3-fluoro-1H-pyrazol-4-
    yl)phenol
     1751 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1-methyl-1H-pyrazol-
    3-yl)phenol
     1761 5-(1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-2-{3-[methyl(2,2,6,6-
    tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}phenol
     1771 5-(1-methyl-1H-indazol-5-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
     1781 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-
    (tetrazolo[1,5-b]pyridazin-6-yl)phenol
     1791 5-[6-(hydroxymethyl)pyrimidin-4-yl]-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol
     1801 2-[3-(2,9-diazaspiro[5.5]undecan-9-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol
     1811 2-[3-(2,8-diazaspiro[4.5]decan-8-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol
     1821 2-[3-(2-methyl-2,9-diazaspiro[5.5]undecan-9-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-
    yl)phenol
     1831 2-[3-(2-methyl-2,8-diazaspiro[5.5]decan-8-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-
    yl)phenol
     1841 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazolo[3,4-c]pyridin-5-yl)phenol
     1851 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(quinolin-
    6-yl)phenol
     1861 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1-methyl-
    1H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)phenol
     1871 2-{3-[3-(tert-butylamino)pyrrolidin-l-yl]-1,2,4-triazin-6-yl}-5-(1H-imidazol-1-
    yl)phenol
     1881 5-(2H-1,3-benzodioxo1-5-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
     1891 5-(3-fluoro-1H-pyrazol-4-yl)-2-(3-{[(3R,4R)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-
    yl]amino}-1,2,4-triazin-6-yl)phenol
     1901 2-{3-{[(2S)-2-aminopropyl](methyl)amino}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol
     1911 5-(5-fluoro-1H-pyrazol-4-yl)-2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-3-yl}phenol
    192 5-[1-(2H3)methyl-1H-pyrazol-4-yl]-2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-3-yl}phenol
     1931 2-{3-[(3aR,4R,6aS)-4-(tert-butylamino)hexahydrocyclopenta[c]pyrrol-2(1H)-yl]-1,2,4-
    triazin-6-yl}-5-(1H-pyrazol-4-yl)phenol
     1941 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazolo[3,4-b]pyrazin-5-yl)phenol
     1951 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazolo[4,3-d]pyrimidin-5-yl)phenol
     1961 5-(1-methyl-1H-pyrazol-4-yl)-2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-3-yl}phenol
     1971 2-{3-[3-(tert-butylamino)pyrrolidin-l-yl]-1,2,4-triazin-6-yl}-5-(4-methyl-1H-imidazol-
    1-yl)phenol
     1981 5-(1-methyl-1H-pyrazolo[4,3-b]pyridin-5-yl)-2-{3-[methyl(2,2,6,6-
    tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}phenol
     1991 5-(1-methyl-1H-pyrazol-4-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol
     2001 5-(1-methyl-1H-benzotriazol-5-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol
    201 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (1-methyl-1H-pyrazol-4-yl)phenol
     2021 2-{3-[3-(tert-butylamino)pyrrolidin-l-yl]-1,2,4-triazin-6-yl}-5-(1-methyl-1H-pyrazol-
    4-yl)phenol
     2031 5-(1-methyl-1H-pyrazol-4-yl)-2-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-
    triazin-6-yl)phenol
     2041 2-{3-[3-(tert-butylamino)pyrrolidin-l-yl]-1,2,4-triazin-6-yl}-5-(2H-1,2,3-triazol-2-
    yl)phenol
     2051 2-{3-[3-(methylamino)pyrrolidin-l-yl]-1,2,4-triazin-6-yl}-5-(1-methyl-1H-pyrazol-4-
    yl)phenol
     2061 2-{3-[4-(tert-butylamino)piperidin-l-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-yl)phenol
     2071 2-{3-[3-(tert-butylamino)pyrrolidin-l-yl]-1,2,4-triazin-6-yl}-5-([1,2,3]triazolo[1,5-
    a]pyridin-5-yl)phenol
     2081 2-{3-[3-(tert-butylamino)pyrrolidin-l-yl]-1,2,4-triazin-6-yl}-5-(1-methyl-1H-indazol-
    5-yl)phenol
     2091 2-{3-[3-(tert-butylamino)pyrrolidin-l-yl]-1,2,4-triazin-6-yl}-5-(pyrimidin-2-yl)phenol
     2101 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(2-methyl-2H-1,2,3-
    triazol-4-yl)phenol
     2111 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(2-methyl-2H-tetrazol-
    5-yl)phenol
     2121 2-{3-[3-(tert-butylamino)piperidin-1-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-yl)phenol
     2131 5-(1-methyl-1H-pyrazol-3-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-
    triazin-6-yl)phenol
     2141 4-(4-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-3-hydroxyphenyl)-1-
    methylpyridin-2(1H)-one
     2151 2-{3-[3-(tert-butylamino)pyrrolidin1-yl]-1,2,4-triazin-6-yl}-5-(1-methyl-1H-
    [1,2,3]triazolo[4,5-b]pyridin-5-yl)phenol
     2161 6-(4-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-3-hydroxyphenyl)-3-
    methylpyrimidin-4(3H)-one
     2171 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(6-methoxypyrimidin-4-
    yl)phenol
     2181 2-{3-[3-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(2H-1,2,3-triazol-2-
    yl)phenol
     2191 5-(4-fluoro-1H-pyrazol-1-yl)-2-{3-[3-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-
    yl}phenol
     2201 5-(1H-imidazol-1-yl)-2-{3-[3-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}phenol
     2211 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1-methyl-1H-
    pyrazolo[3,4-b]pyridin-5-yl)phenol
     2221 5-(1-methyl-1H-pyrazolo[3,4-c]pyridin-5-yl)-2-{3-[methyl(2,2,6,6-
    tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}phenol
     2231 2-{3-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(1-methyl-1H-
    indazol-5-yl)phenol
     2241 2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(1-methyl-1H-
    pyrazolo[3,4-b]pyridin-5-yl)phenol
    225 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1H-1,2,3-triazol-4-
    yl)phenol
     2261 2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(1-methyl-1H-
    pyrazol-4-yl)phenol
     2271 4-[3-hydroxy-4-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)phenyl]-
    1-methylpyridin-2(1H)-one
     2281 2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(4-methyl-1H-
    imidazol-1-yl)phenol
     2291 5-(4-fluoro-1H-pyrazol-1-yl)-2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-
    triazin-6-yl]phenol
     2301 5-(4-fluoro-1H-imidazol-1-yl)-2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-
    triazin-6-yl]phenol
     2311 5-(1H-imidazol-1-yl)-2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-
    yl]phenol
     2321 2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(2H-1,2,3-triazol-
    2-yl)phenol
     2331 2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(1-methyl-1H-
    pyrazol-3-yl)phenol
     2341 6-[3-hydroxy-4-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)phenyl]-
    3-methylpyrimidin-4(3H)-one
     2351 5-(5-fluoro-1H-pyrazol-4-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-
    triazin-6-yl)phenol
     2361 5-(2-methyl-2H-1,2,3-triazol-4-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-
    1,2,4-triazin-6-yl)phenol
     2371 2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1,2,4-thiadiazol-5-
    yl)phenol
     2381 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (1H-imidazol-1-yl)phenol
     2391 2-{3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (4-methyl-1H-imidazol-1-yl)phenol
     2401 5-(4-fluoro-1H-imidazol-1-yl)-2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-
    yl]amino}-1,2,4-triazin-6-yl)phenol
     2411 4-{3-hydroxy-4-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-
    yl]phenyl}-1-methylpyridin-2(1H)-one
     2421 2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(2-methyl-2H-
    1,2,3-triazol-4-yl)phenol
     2431 5-(6-methoxypyrimidin-4-yl)-2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-
    triazin-6-yl]phenol
     2441 2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(pyrimidin-2-
    yl)phenol
     2451 2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(1H-1,2,3-triazol-
    4-yl)phenol
     2461 6-[4-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-
    yl)-3-hydroxyphenyl]-3-methylpyrimidin-4(3H)-one
     2471 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (1H-1,2,3-triazol-4-yl)phenol
    248 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (imidazo[1,2-a]pyrazin-6-yl)phenol
     2491 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (imidazo[1,2-b]pyridazin-6-yl)phenol
     2501 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1,3-oxazol-2-yl)phenol
     2511 2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(2-methyl-2H-
    tetrazol-5-yl)phenol
     2521 2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(1,3-oxazol-2-
    yl)phenol
     2531 5-(1-methyl-1H-pyrazol-3-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol
     2541 5-(6-methoxypyrimidin-4-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol
    255 2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-3-yl}-5-(2H-1,2,3-
    triazol-2-yl)phenol
     2561 5-(imidazo[1,2-b]pyridazin-6-yl)-2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-
    triazin-6-yl]phenol
     2571 5-(imidazo[1,2-a]pyrazin-6-yl)-2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-
    triazin-6-yl]phenol
     2581 2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-1,2,3-triazol-4-
    yl)phenol
     2591 5-(2-methyl-2H-tetrazol-5-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-
    triazin-6-yl)phenol
     2601 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (1-methyl-1H-indazol-5-yl)phenol
     2611 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (1-methyl-1H-pyrazol-3-yl)phenol
     2621 2-[3-(3,5-dimethylpiperazin-1-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol
     2631 2-[3-(3,5-dimethylpiperazin-1-yl)-1,2,4-triazin-6-yl]-5-(1-methyl-1H-pyrazol-3-
    yl)phenol
     2641 2-(3-{3-(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(2H-1,2,3-triazol-2-
    yl)phenol
     2651 5-(6-methoxypyrimidin-4-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-
    triazin-6-yl)phenol
     2661 5-(2-methyl-2H-1,2,3-triazol-4-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
     2671 5-(2-methyl-2H-tetrazol-5-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol
     2681 5-(6-methoxypyrimidin-4-yl)-2-{3-[(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-
    yl}phenol
     2691 2-{3-[3-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1,2,4-thiadiazol-5-
    yl)phenol
     2701 2-{3-[3-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(pyrimidin-2-yl)phenol
     2711 2-{3-[3-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1-methyl-1H-
    pyrazolo[3,4-b]pyridin-5-yl)phenol
     2721 2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(1,2,4-thiadiazol-5-
    yl)phenol
     2731 5-(1H-imidazol-1-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-
    yl}phenol
     2741 5-(4-methyl-1H-imidazol-1-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol
     2751 5-(4-fluoro-1H-imidazol-1-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol
     2761 5-(4-fluoro-1H-pyrazol-1-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol
     2771 5-(2-methyl-1,3-oxazol-5-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]1,2,4-
    triazin-6-yl}phenol
     2781 2-{3-[3-(tert-butylamino)-4-fluoropyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-
    yl)phenol
     2791 5-(pyrimidin-2-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-
    yl}phenol
    280 5-(7-fluoro-1H-benzimidazol-5-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol
    281 5-(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-2-{3-[methyl(2,2,6,6-
    tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}phenol
     2821 5-(1H-pyrazol-4-yl)-2-[3-(3,3,5,5-tetramethylpiperazin-1-yl)-1,2,4-triazin-6-yl]phenol
     2831 5-(imidazo[1,2-a]pyrazin-6-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-
    triazin-6-yl)phenol
     2841 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (1-methyl-1H-pyrazolo]3,4-b]pyridin-5-yl)phenol
     2851 5-(1-methyl-1H-benzimidazol-5-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol
    286 2-(3-{[(3S,4S)-3-methoxy-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-
    5-(1H-pyrazol-4-yl)phenol
     2871 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (2-methyl-2H-1,2,3-triazol-4-yl)phenol
     2881 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (1,3-oxazol-2-yl)phenol
     2891 5-(2-methyl-1,3-oxazol-5-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-l-yl}-1,2,4-
    triazin-6-yl)phenol
     2901 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (6-methoxypyrimidin-4-yl)phenol
     2911 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (2-methyl-2H-tetrazol-5-yl)phenol
     2921 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (1,2,4-thiadiazol-5-yl)phenol
     2931 2-(3-{[(3S,4S)-3-methoxy-2,2,6,6-tetramethylpiperidin-4-yl](methyl)amino}-1,2,4-
    triazin-6-yl)-5-(1H-pyrazol-4-yl)phenol
     2941 5-(imidazo]1,2-Npyridazin-6-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-l-yl}-1,2,4-
    triazin-6-yl)phenol
     2951 2-{3-[3-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(2-methyl-2H-1,2,3-
    triazol-4-yl)phenol
     2961 2-{3-[3-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1-methyl-1H-pyrazol-3-
    yl)phenol
     2971 2-(3-{3-[(2-methylpropyl)aminolpyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol
     2981 (3S,4S)-4-({6-[2-hydroxy-4-(1H-pyrazol-4-yl)phenyl]-1,2,4-triazin-3-yl}amino)-
    2,2,6,6-tetramethylpiperidin-3-ol
     2991 2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(2-methyl-1,3-
    oxazol-5-yl)phenol
     3001 5-(7-fluoro-1-methyl-1H-benzimidazol-5-yl)-2-{3-[methyl(2,2,6,6-
    tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}phenol
     3011 5-(6,7-difluoro-1H-benzimidazol-5-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol
     3021 5-(6,7-difluoro-1-methyl-1H-benzimidazol-5-yl)-2-{3-[methyl(2,2,6,6-
    tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}phenol
     3031 5-(8-methylimidazo[1,2-b]pyridazin-6-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-
    4-yl)amino]-1,2,4-triazin-6-yl}phenol
     3041 5-(8-methoxyimidazo[1,2-b]pyridazin-6-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-
    4-yl)amino]-1,2,4-triazin-6-yl}phenol
     3051 2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1,2,4-triazin-6-
    yl)phenol
     3061 2-{3-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazol-4-yl)phenol
     3071 5-(1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-
    1-yl}-1,2,4-triazin-6-yl)phenol
     3081 5-(1,3-oxazol-2-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-l-yl}-1,2,4-triazin-6-
    yl)phenol
     3091 2-(3-{[(3S)-1-methylpyrrolidin-3-yl]oxy}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol
     3101 2-{3-[(4aS,7aS)-1-methyloctahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-1,2,4-triazin-6-yl}-
    5-(1H-pyrazol-4-yl)phenol
     3111 2-{3-[(4aS,7aR)-4-methylhexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl]-1,2,4-triazin-
    6-yl}-5-(1H-pyrazol-4-yl)phenol
    312 2-(3-{3-[(oxetan-3-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol
    313 5-(1-methyl-1H-pyrazol-4-yl)-2-(3-{3-[(oxetan-3-yl)amino]pyrrolidin-1-yl}-1,2,4-
    triazin-6-yl)phenol
     3141 5-(pyridazin-4-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-
    yl}phenol
     3151 5-[(pyridin-3-yl)amino]2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-
    6-yl}phenol
     3161 2-(3-{3-[(1-fluoro-2-methylpropan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-
    (1H-pyrazol-4-yl)phenol
     3171 2-{3-[3-(ethylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-yl)phenol
     3181 2-{3-[3-(dimethylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-yl)phenol
     3191 5-(1-methyl-1H-indazol-5-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol
     3201 2-{3-[3-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(2-methyl-2H-tetrazol-5-
    yl)phenol
     3211 5-(1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol
     3221 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (1H-pyrazol-4-yl)phenol
     3231 2-(3-{[(3R,4R)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (1H-pyrazol-4-yl)phenol
     3241 2-{3-[(3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(2H-
    1,2,3-triazol-2-yl)phenol
    325 2-{3-[(3-methyloxetan-3-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-
    pyrazol-4-yl)phenol
     3261 5-(4-methyl-1H-imidazol-1-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-
    triazin-6-yl)phenol
     3271 2-{3-[(3aR,7aR)-octahydro-2H-pyrrolo[3,4-c]pyridin-2-yl]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazol-4-yl)phenol
     3281 2-[3-(piperazin-1-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol
     3291 2-{3-[(3S)-3-{[(2R)-1-fluoropropan-2-yl]amino}pyrrolidin-l-yl]-1,2,4-triazin-6-yl}-5-
    (1H-pyrazol-4-yl)phenol
     3301 5-(1-methyl-1H-indazol-5-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-
    triazin-6-yl)phenol
     3311 5-(1H-imidazol-1-yl)-2-(3-{3-(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-
    yl)phenol
     3321 2-{3-[(3aR,6aS)-hexahydropyrrolo[3,2-b]pyrrol-1(2H)-yl]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazol-4-yl)phenol
     3331 2-(3-{3-[(2-hydroxyethyl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol
     3341 2-[3-(8-amino-2-oxa-6-azaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-
    yl)phenol
     3351 2-(3-{3-[(oxan-4-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol
     3361 2-(3-{3-[(1-methoxypropan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-
    pyrazol-4-yl)phenol
     3371 2-[3-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-
    yl)phenol
     3381 5-(4-fluoro-1H-pyrazol-1-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-
    triazin-6-yl)phenol
     3391 2-[3-(1,7-diazaspiro[4.4]nonan-7-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol
     3401 2-(3-{3-[(1-methylcyclopropyl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-
    pyrazol-4-yl)phenol
     3411 2-(3-{3-[(1-methoxy-2-methylpropan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-
    5-(1H-pyrazol-4-yl)phenol
    342 5-(1-methyl-1H-indazol-5-yl)-2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-3-yl}phenol
    343 5-(1-methyl-1H-pyrazol-3-yl)-2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-3-yl}phenol
     3441 6-(3-hydroxy-4-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-
    yl}phenyl)imidazo[1,2-b]pyridazine-8-carbonitrile
     3451 2-(3-{[(3R,4S)-3-fluoropiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol
     3461 2-{3-[(3R,4R)-3-methoxy-4-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazol-4-yl)phenol
     3471 2-(3-{(3S)-3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol
     3481 2-(3-{(3R)-3-[(propan-2-yl)amino]pyrrolidin-l-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-
    4-yl)phenol
     3491 2-(3-{3-[(bicyclo[1.1.1]pentan-1-yl)amino]pyrrolidin-l-yl}-1,2,4-triazin-6-yl)-5-(1H-
    pyrazol-4-yl)phenol
     3501 2-{3-[3-(methylamino)pyrrolidin-l-yl]-1,2,4-triazin-6-yl}-5-(2-methyl-1,3-oxazol-5-
    yl)phenol
     3511 5-[8-(aminomethyl)imidazo[1,2-b]pyridazin-6-yl]-2-{3-[methyl(2,2,6,6-
    tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}phenol
     3521 5-(1,3-oxazol-2-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-
    yl}phenol
     3531 2-[3-(6-oxa-2,9-diazaspiro[4.5]decan-2-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-
    yl)phenol
     3541 2-[3-(2,7-diazaspirol{4.4}nonan-2-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol
     3551 2-{3-[(3S)-3-(tert-butylamino)pyrrolidin-l-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-
    yl)phenol
     3561 2-{3-[(3R)-3-(tert-butylamino)pyrrolidin-l-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-
    yl)phenol
     3571 2-{3-[3-(cyclopentylamino)pyrrolidin-l-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-
    yl)phenol
     3581 2-{3-[3-(methylamino)pyrrolidin-l-yl]-1,2,4-triazin-6-yl}-5-(1,3-oxazol-2-yl)phenol
     3591 5-(imidazo[1,2-a]pyrazin-2-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol
     3601 5-(imidazo[1,2-a]pyridin-2-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol
     3611 2-[3-(3-{[(propan-2-yl)amino]methyl}pyrrolidin-l-yl)-1,2,4-triazin-6-yl]-5-(1H-
    pyrazol-4-yl)phenol
     3621 2-(3-{3-[(4-methyloxan-4-yl)amino]pyrrolidin-l-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-
    4-yl)phenol
     3631 2-{6-[3-(tert-butylamino)pyrrolidin-l-yl]-1,2,4-triazin-3-yl}-5-(1H-pyrazol-4-
    yl)phenol
     3641 2-{3-[3-(methylamino)pyrrolidin-l-yl]-1,2,4-triazin-6-yl}-5-[6-
    (methylsulfanyl)pyrimidin-4-yl]phenol
     3651 2-{3-[3-(tert-butylamino)pyrrolidin-l-yl]-1,2,4-triazin-6-yl}-5-(3-chloro-1H-pyrazol-4-
    yl)phenol
     3661 4-(4-{3-[3-(tert-butylamino)pyrrolidin-l-yl]-1,2,4-triazin-6-yl]-3-hydroxyphenyl)-1H-
    pyrazole-3-carbonitrile
     3671 2-{3-[3-(tert-butylamino)pyrrolidin-l-yl]-1,2,4-triazin-6-yl}-5-[1-(2H3)methyl-1H-
    pyrazol-4-yl]phenol
     3681 3-(1-methyl-1H-pyrazol-3-yl)-6-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}benzene-1,2-diol
     3691 2-[3-(2,7-diazaspiro[4.5]decan-2-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol
     3701 2-[3-(hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-
    yl)phenol
     3711 2-(3-{3-[(3-hydroxypropyl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol
     3721 2-[3-(3-{[(oxan-4-yl)amino]methyl}pyrrolidin-1-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-
    4-yl)phenol
     3731 5-[1-(2H3)methyl-1H-pyrazol-4-yl]-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
     3741 2-{6-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-3-yl}-5-(3-fluoro-1H-pyrazol-4-
    yl)phenol
     3751 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(3-methyl-1H-pyrazol-
    4-yl)phenol
     3761 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-3-methoxy-5-(1H-
    pyrazol-4-yl)phenol
     3771 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    [1-(2H3)methyl-1H-pyrazol-4-yl]phenol
     3781 2-{3-[(3S)-3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(3-fluoro-1H-
    pyrazol-4-yl)phenol
     3791 2-{3-[(3R)-3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(3-fluoro-1H-
    pyrazol-4-yl)phenol
    380 5-[6-(methylamino)pyrimidin-4-yl]-2-{3-[3-(methylamino)pyrrolidin-1-yl]-1,2,4-
    triazin-6-yl}phenol
     3811 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazolo[3,4-c]pyridin-1-yl)phenol
    382 2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-3-yl}-5-(pyridin-
    4-yl)phenol
    383 5-(7-fluoro-1H-indazol-5-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol
    384 2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-3-yl}-5-(pyridin-
    3-yl)phenol
     3851 2-{3-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-1,2,4-triazin-6-yl}-5-(imidazo[1,2-
    b]pyridazin-6-yl)phenol
     3861 2-(3-{3-[(cyclopentylamino)methyl]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-
    4-yl)phenol
     3871 2-[3-([2,3’-bipyrrolidin]-l’-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol
     3881 5-(1H-pyrazol-4-yl)-2-{3-[-({[(pyridin-2-yl)methyl]amino}methyl)pyrrolidin-1-yl]-
    1,2,4-triazin-6-yl}phenol
    389 2-[3-(3-amino-3-methylpyrrolidin-1-yl)-1,2,4-triazin-6-yl]-5-(1-methyl-1H-pyrazol-4-
    yl)phenol
     3901 2-(3-{3-[(tert-butylamino)methyl]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol
     3911 2-[3-(3-{[(4-methyloxan-4-yl)amino]methyl}pyrrolidin-1-yl)-1,2,4-triazin-6-yl]-5-(1H-
    pyrazol-4-yl)phenol
     3921 2-(3-{3-[(cyclopropylamino)methyl]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-
    4-yl)phenol
    393 2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-3-yl}-5-(pyridin-
    2-yl)phenol
    394 5-(1-methyl-1H-pyrazolo[4,3-b]pyridin-5-yl)-2-{6-[methyl(2,2,6,6-
    tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-3-yl}phenol
     3951 2-[3-(3-{[(oxolan-3-yl)amino]methyl}pyrrolidin-1-yl)-1,2,4-triazin-6-yl]-5-(1H-
    pyrazol-4-yl)phenol
     3961 5-(1H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-3-
    yl}phenol
    397 2-{3-[(3S)-3-{[(oxan-4-yl)amino]methyl}pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazol-4-yl)phenol
    398 2-{3-[(3R)-3-{[(oxan-4-yl)amino]methyl}pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazol-4-yl)phenol
     3991 2-{3-[(3R)-3-(cyclobutylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-
    yl)phenol
     4001 2-{3-[(3S)-3-(cyclobutylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-
    yl)phenol
     4011 2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-3-yl}-5-(2H-1,2,3-triazol-
    2-yl)phenol
    402 2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-3-yl}-5-
    (pyrimidin-2-yl)phenol
     4031 2-[3-(3-{[(3-fluorooxan-4-yl)amino]methyl}pyrrolidin-1-yl)-1,2,4-triazin-6-yl]-5-(1H-
    pyrazol-4-yl)phenol
     4041 2-[3-(3-{[(oxan-3-yl)amino]methyl}pyrrolidin-1-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-
    4-yl)phenol
     4051 2-[3-(3-{[(8-oxabicyclo[3.2.1]octan-3-yl)amino]methyl}pyrrolidin-1-yl)-1,2,4-triazin-
    6-yl]-5-(1H-pyrazol-4-yl)phenol
     4061 2-{3-[(3R)-3-(cyclobutylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1-methyl-1H-
    pyrazol-4-yl)phenol
     4071 2-{3-[(3S)-3-(cyclobutylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1-methyl-1H-
    pyrazol-4-yl)phenol
     4081 2-(3-[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl](methyl)amino}-1,2,4-
    triazin-6-yl)-5-(1-methyl-1H-pyrazol-4-yl)phenol
     4091 2-(3-{3-[(3,3-difluorocyclopentyl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-
    pyrazol-4-yl)phenol
     4101 2-(3-{3-[(dimethylamino)methyl]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol
    411 2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-3-yl}-5-
    (pyrimidin-4-yl)phenol
    412 2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-3-yl}-5-(pyrazin-
    2-yl)phenol
     4131 2-(3-{3-[(methylamino)methyl]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol
     4141 2-[3-(3-{1-[(propan-2-yl)amino]ethyl}pyrrolidin-1-yl)-1,2,4-triazin-6-yl]-5-(1H-
    pyrazol-4-yl)phenol
     4151 2-(3-{3-[(cyclobutylamino)methyl]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-
    4-yl)phenol
     4161 2-(3-{3-[(cyclobutylamino)methyl}pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1-methyl-1H-
    pyrazol-4-yl)phenol
     4171 2-(3-{[1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl}(methyl)amino}-1,2,4-
    triazin-6-yl)-5-(2H-1,2,3-triazol-2-yl)phenol
     4181 6-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-2-fluoro-3-(1H-pyrazol-4-
    yl)phenol
     4191 5-(1H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]-1,2,4-triazin-3-
    yl}phenol
     4201 2-(3-{3-[(3-fluorocyclopentyl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-
    pyrazol-4-yl)phenol
     4211 2-[3-(3-{1-[(oxan-4-yl)amino]cyclopropyl}pyrrolidin-1-yl)-1,2,4-triazin-6-yl]-5-(1H-
    pyrazol-4-yl)phenol
     4221 2-(3-{3-methyl-3-[(propan-2-yl)aminolpyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1-
    methyl-1H-pyrazol-4-yl)phenol
     4231 2-{6-[(3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-3-yl}-5-(1H-
    pyrazol-4-yl)phenol,and
     4241 5-[1-(2H3)methyl-1H-pyrazol-4-yl]-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-3-yl}phenol;
    425 2-(3-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,2,4-triazin-6-yl)-5-(5-methyl-
    1H-pyrazol-4-yl)phenol
      • wherein a form of the compound is selected from the group consisting of a salt, hydrate, solvate, racemate, enantiomer, diastereomer, stereoisomer, and tautomer form thereof.
  • Another aspect of the compound of Formula (I) or Formula (II) or a form thereof is a compound salt selected from the group consisting of:
  • Cpd Name
    1 5-(5-methyl-1,3-oxazol-2-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol hydrobromide
    2 5-(6-methoxypyrimidin-4-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol formate
    3 5-(2-methoxypyridin-4-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol formate
    6 5-(3-methyl-1H-pyrazol-4-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol formate
    10 5-(4-methyl-1H-imidazol-1-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol hydrochloride
    11 5-(1H-pyrazol-4-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]-1,2,4-triazin-6-
    yl}phenol dihydrochloride
    12 5-(3-fluoro-1H-pyrazol-4-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol ditrifluoroacetate
    13 5-(1H-pyrazol-4-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-
    yl}phenol dihydrochloride
    14 5-[1-(2H3)methyl-1H-pyrazol-4-yl]-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol dihydrochloride
    15 6-[2,3-difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-
    4-yl)-1,2,4-triazin-3-amine hydrochloride
    16 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazol-4-yl)phenol hydrochloride
    18 5-(1-methyl-1H-pyrazol-4-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol dihydrochloride
    19 5-(3-fluoro-1-methyl-1H-pyrazol-4-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol hydrochloride
    20 2-{3-[methyl(piperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-yl)phenol
    dihydrochloride
    23 2-{3-[methyl(piperidin-3-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-yl)phenol
    dihydrochloride
    24 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(2-methyl-
    2H-1,2,3-triazol-4-yl)phenol hydrochloride
    50 5-(4-fluoro-1H-imidazol-1-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol dihydrochloride
    51 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(3-methyl-
    1H-1,2,4-triazol-1-yl)phenol hydrochloride
    52 2-{3-[(1-methylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-yl)phenol
    trihydrochloride
    55 5-(4-methoxy-1H-pyrazol-1-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol dihydrochloride
    57 5-(3-chloro-1H-pyrazol-4-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol hydrochloride
    58 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1,3-
    thiazol-2-yl)phenol hydrochloride
    59 5-(4-chloro-1H-imidazol-1-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol dihydrochloride
    60 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-
    (pyridazin-4-yl)phenol dihydrochloride
    61 5-(6-methylpyridazin-4-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol dihydrochloride
    62 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1-methyl-
    1H-1,2,4-triazol-3-yl)phenol dihydrochloride
    63 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(2H-1,2,3-
    triazol-2-yl)phenol dihydrochloride
    65 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1,2,4-
    thiadiazol-5-yl)phenol hydrochloride
    66 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(3-methyl-
    1,2,4-thiadiazol-5-yl)phenol hydrochloride
    67 2-{3-[(3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl)(methyl)amino]-1,2,4-triazin-6-yl}-5-
    (1H-pyrazol-4-yl)phenol dihydrochloride
    68 1-[1-(3-hydroxy-4-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-
    6-yl}phenyl)-1H-pyrazol-4-yl]ethan-1-one dihydrochloride
    69 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(4-methyl-
    2H-1,2,3-triazol-2-yl)phenol dihydrochloride
    71 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(pyridin-
    2-yl)phenol formate
    72 5-(3-fluoro-1H-pyrazol-4-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]-1,2,4-
    triazin-6-yl}phenol dihydrochloride
    73 5-(3-fluoro-1H-pyrazol-4-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol trihydrochloride
    74 5-(2-methyl-1,3-oxazol-5-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol hydrochloride
    75 5-(1-methyl-1H-imidazol-4-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol hydrochloride
    76 5-(1-methyl-1H-pyrazol-3-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol hydrochloride
    77 2-(3-{[(1R,3s,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)amino}-1,2,4-triazin-6-yl)-
    5-(1H-pyrazol-4-yl)phenol dihydrochloride
    79 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-1,2,4-
    triazol-1-yl)phenol dihydrochloride
    80 5-(imidazo[1,2-a]pyrazin-6-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol hydrochloride
    81 5-(5-methyl-1,3,4-oxadiazol-2-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol hydrochloride
    82 2-{3-[(2,6-dimethylpiperidin-4-yl)oxy]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-yl)phenol
    dihydrochloride
    84 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-
    (pyridazin-3-yl)phenol formate
    86 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-
    (pyrimidin-5-yl)phenol formate
    88 5-(4-methoxy-1,3,5-triazin-2-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol dihydrochloride
    89 5-(1H-imidazol-1-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol dihydrochloride
    90 1-(3-hydroxy-4-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-
    yl}phenyl)-1H-pyrazol-4-ol dihydrochloride
    91 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1,3-
    oxazol-5-yl)phenol hydrochloride
    92 5-(imidazo[1,2-b]pyridazin-6-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol hydrochloride
    93 5-(4-fluoro-1H-pyrazol-1-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol dihydrochloride
    94 5-(4-methyl-1H-pyrazol-1-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol dihydrochloride
    95 2-[3-(2,7-diazaspiro[3.5]nonan-7-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol
    dihydrochloride
    96 2-[3-(2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol
    dihydrochloride
    97 5-(1H-indazol-5-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol dihydrochloride
    99 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(4-nitro-
    2H-1,2,3-triazol-2-yl)phenol dihydrochloride
    101 5-(1-cyclopropyl-1H-pyrazol-4-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol hydrochloride
    102 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-
    (pyrimidin-4-yl)phenol formate
    103 4-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}[1,1′-
    biphenyl]-3,4′-diol formate
    105 6-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}quinolin-7-ol
    hydrobromide
    107 5-(1H-pyrazol-3-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]-1,2,4-triazin-6-
    yl}phenol ditrifluoroacetate
    108 5-(1-methyl-1H-pyrazol-3-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]-1,2,4-
    triazin-6-yl}phenol trifluoroacetate
    109 2-[3-(2,6-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol
    dihydrochloride
    110 2-[3-(2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol
    dihydrochloride
    111 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazol-3-yl)phenol trifluoroacetate
    112 5-(5-fluoropyrimidin-2-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol hydrochloride
    113 2-[3-(1-methyl-1,7-diazaspiro[3.5]nonan-7-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-
    yl)phenol dihydrochloride
    114 2-{3-[(3S)-3-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-
    yl)phenol dihydrochloride
    115 2-{3-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-
    yl)phenol dihydrochloride
    116 2-{3-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazol-4-yl)phenol dihydrochloride
    117 2-{3-[(3aR,6aR)-1-methylhexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]-1,2,4-triazin-6-yl}-
    5-(1H-pyrazol-4-yl)phenol dihydrochloride
    118 2-[3-(2,6-diazaspiro[3.3]heptan-2-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol
    dihydrochloride
    119 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(5-methyl-
    2H-tetrazol-2-yl)phenol dihydrochloride
    120 2-(3-{[(2R,4s,6S)-2,6-diethylpiperidin-4-yl]oxy}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol trifluoroacetate
    121 2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(2H-1,2,3-triazol-
    2-yl)phenol dihydrochloride
    122 2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]-1,2,4-triazin-6-yl}-5-(2H-1,2,3-triazol-2-
    yl)phenol hydrochloride
    123 5-(6-chloropyridazin-3-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol hydrochloride
    124 5-(1-methyl-1H-pyrazol-5-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol dihydrochloride
    126 2-{3-[(3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazol-4-yl)phenol dihydrochloride
    127 2-{3-[6-(diethylamino)-3-azabicyclo[3.1.0]hexan-3-yl]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazol-4-yl)phenol hydrochloride
    128 5-(5-methylpyrimidin-2-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol hydrochloride
    129 5-(4-methylpyrimidin-2-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol hydrochloride
    130 5-(2-chloropyrimidin-4-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol hydrochloride
    132 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazolo[3,4-b]pyridin-5-yl)phenol formate
    133 5-(3-chloro-1H-1,2,4-triazol-1-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol dihydrochloride
    134 6-(3-hydroxy-4-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-
    yl}phenyl)pyridazin-3-ol hydrochloride
    140 1-[1-(3-hydroxy-4-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-
    6-yl}phenyl)-1H-imidazol-4-yl]ethan-1-one dihydrochloride
    141 5-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-2-{3-[methyl(2,2,6,6-
    tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}phenol dihydrochloride
    142 5-(2-methylimidazo[1,2-b]pyridazin-6-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-
    4-yl)amino]-1,2,4-triazin-6-yl}phenol dihydrochloride
    143 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(2-methyl-
    2H-tetrazol-5-yl)phenol dihydrochloride
    146 6-(3-hydroxy-4-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-
    yl}phenyl)-3-methylpyrimidin-4(3H)-one dihydrochloride
    147 5-(3-hydroxy-4-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-
    yl}phenyl)-2-methylpyridazin-3(2H)-one dihydrochloride
    148 2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol hydrochloride
    151 2-[3-(2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(3-fluoro-1H-pyrazol-4-
    yl)phenol dihydrochloride
    152 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-
    ([1,2,3]triazolo[1,5-a]pyridin-5-yl)phenol dihydrochloride
    153 5-(3-fluoro-1H-pyrazol-4-yl)-2-{3-[(3aS,7aR)-1-methyloctahydro-5H-pyrrolo[3,2-
    c]pyridin-5-yl]-1,2,4-triazin-6-yl}phenol dihydrochloride
    155 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-
    (tetrazolo[1,5-a]pyridin-7-yl)phenol dihydrochloride
    156 5-(4-fluoro-1H-pyrazol-3-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol trifluoroacetate
    157 2-(3-{3-[(adamantan-1-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol ditrifluoroacetate
    158 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(5H-
    pyrrolo[2,3-b]pyrazin-2-yl)phenol formate
    159 2-(3-{3-[(adamantan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol ditrifluoroacetate
    160 2-(3-{3-[(3,5-dimethyladamantan-1-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-
    (1H-pyrazol-4-yl)phenol ditrifluoroacetate
    161 5-[4-(hydroxymethyl)-1H-pyrazol-1-yl]-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol hydrochloride
    162 2-{3-[(3aR,4R,6aS)-4-(dimethylamino)hexahydrocyclopenta[c]pyrrol-2(1H)-yl]-1,2,4-
    triazin-6-yl}-5-(1H-pyrazol-4-yl)phenol dihydrochloride
    164 5-(1-methyl-1H-imidazo[4,5-b]pyridin-5-yl)-2-{3-[methyl(2,2,6,6-
    tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}phenol hydrochloride
    165 2-{3-[(3aR,4S,6aS)-4-aminohexahydrocyclopenta[c]pyrrol-2(1H)-yl]-1,2,4-triazin-6-
    yl}-5-(1H-pyrazol-4-yl)phenol dihydrochloride
    166 2-[3-(5-methyloctahydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-1,2,4-triazin-6-yl]-5-(1H-
    pyrazol-4-yl)phenol dihydrochloride
    167 2-{3-[(3aR,4S,6aS)-4-(dimethylamino)hexahydrocyclopenta[c]pyrrol-2(1H)-yl]-1,2,4-
    triazin-6-yl}-5-(1H-pyrazol-4-yl)phenol dihydrochloride
    168 3-amino-6-(3-hydroxy-4-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenyl)-4-methylpyridin-2-ol dihydrochloride
    169 5-(2,7-dimethyl[1,3]oxazolo[5,4-b]pyridin-5-yl)-2-{3-[methyl(2,2,6,6-
    tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}phenol diformate
    172 5-[4-(hydroxymethyl)-2H-1,2,3-triazol-2-yl]-2-{3-[methyl(2,2,6,6-
    tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}phenol hydrochloride
    173 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(3-methyl-
    3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)phenol hydrochloride
    174 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(3-fluoro-1H-pyrazol-4-
    yl)phenol hydrochloride
    175 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1-methyl-1H-pyrazol-
    3-yl)phenol trifluoroacetate
    176 5-(1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-2-{3-[methyl(2,2,6,6-
    tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}phenol formate
    177 5-(1-methyl-1H-indazol-5-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol formate
    178 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-
    (tetrazolo[1,5-b]pyridazin-6-yl)phenol dihydrochloride
    179 5-[6-(hydroxymethyl)pyrimidin-4-yl]-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol hydrochloride
    180 2-[3-(2,9-diazaspiro[5.5]undecan-9-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol
    dihydrochloride
    181 2-[3-(2,8-diazaspiro[4.5]decan-8-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol
    dihydrochloride
    182 2-[3-(2-methyl-2,9-diazaspiro[5.5]undecan-9-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-
    yl)phenol dihydrochloride
    183 2-[3-(2-methyl-2,8-diazaspiro[4.5]decan-8-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-
    yl)phenol dihydrochloride
    184 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazolo[3,4-c]pyridin-5-yl)phenol formate
    185 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(quinolin-
    6-yl)phenol trifluoroacetate
    186 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1-methyl-
    1H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)phenol hydrochloride
    187 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1H-imidazol-1-
    yl)phenol ditrifluoroacetate
    188 5-(2H-1,3-benzodioxol-5-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol dihydrochloride
    189 5-(3-fluoro-1H-pyrazol-4-yl)-2-(3-{[(3R,4R)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-
    yl]amino}-1,2,4-triazin-6-yl)phenol dihydrochloride
    190 2-(3-{[(2S)-2-aminopropyl](methyl)amino}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol dihydrochloride
    191 5-(5-fluoro-1H-pyrazol-4-yl)-2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-3-yl}phenol hydrochloride
    193 2-{3-[(3aR,4R,6aS)-4-(tert-butylamino)hexahydrocyclopenta[c]pyrrol-2(1H)-yl]-1,2,4-
    triazin-6-yl}-5-(1H-pyrazol-4-yl)phenol dihydrochloride
    194 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazolo[3,4-b]pyrazin-5-yl)phenol formate
    195 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazolo[4,3-d]pyrimidin-5-yl)phenol formate
    196 5-(1-methyl-1H-pyrazol-4-yl)-2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-3-yl}phenol hydrochloride
    197 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(4-methyl-1H-imidazol-
    1-yl)phenol ditrifluoroacetate
    198 5-(1-methyl-1H-pyrazolo[4,3-b]pyridin-5-yl)-2-{3-[methyl(2,2,6,6-
    tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}phenol formate
    199 5-(1-methyl-1H-pyrazol-4-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol hydrochloride
    200 5-(1-methyl-1H-benzotriazol-5-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol hydrochloride
    202 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1-methyl-1H-pyrazol-
    4-yl)phenol hydrochloride
    203 5-(1-methyl-1H-pyrazol-4-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-
    triazin-6-yl)phenol hydrochloride
    204 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(2H-1,2,3-triazol-2-
    yl)phenol hydrochloride
    205 2-{3-[3-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1-methyl-1H-pyrazol-4-
    yl)phenol hydrochloride
    206 2-{3-[4-(tert-butylamino)piperidin-1-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-yl)phenol
    trifluoroacetate
    207 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-([1,2,3]triazolo[1,5-
    a]pyridin-5-yl)phenol dihydrochloride
    208 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1-methyl-1H-indazol-
    5-yl)phenol dihydrochloride
    209 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(pyrimidin-2-yl)phenol
    dihydrochloride
    210 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(2-methyl-2H-1,2,3-
    triazol-4-yl)phenol dihydrochloride
    211 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(2-methyl-2H-tetrazol-
    5-yl)phenol dihydrochloride
    212 2-{3-[3-(tert-butylamino)piperidin-1-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-yl)phenol
    trifluoroacetate
    213 5-(1-methyl-1H-pyrazol-3-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-
    triazin-6-yl)phenol hydrochloride
    214 4-(4-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-3-hydroxyphenyl)-1-
    methylpyridin-2(1H)-one hydrochloride
    215 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1-methyl-1H-
    [1,2,3]triazolo[4,5-b]pyridin-5-yl)phenol hydrochloride
    216 6-(4-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-3-hydroxyphenyl)-3-
    methylpyrimidin-4(3H)-one hydrochloride
    217 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(6-methoxypyrimidin-4-
    yl)phenol ditrifluoroacetate
    218 2-{3-[3-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(2H-1,2,3-triazol-2-
    yl)phenol trihydrochloride
    219 5-(4-fluoro-1H-pyrazol-1-yl)-2-{3-[3-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-
    yl}phenol trihydrochloride
    220 5-(1H-imidazol-1-yl)-2-{3-[3-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}phenol
    trihydrochloride
    221 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1-methyl-1H-
    pyrazolo[3,4-b]pyridin-5-yl)phenol dihydrochloride
    222 5-(1-methyl-1H-pyrazolo[3,4-c]pyridin-5-yl)-2-{3-[methyl(2,2,6,6-
    tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}phenol dihydrochloride
    223 2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(1-methyl-1H-
    indazol-5-yl)phenol trifluoroacetate
    224 2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(1-methyl-1H-
    pyrazolo[3,4-b]pyridin-5-yl)phenol trifluoroacetate
    226 2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(1-methyl-1H-
    pyrazol-4-yl)phenol trifluoroacetate
    227 4-[3-hydroxy-4-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)phenyl]-
    1-methylpyridin-2(1H)-one hydrochloride
    228 2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(4-methyl-1H-
    imidazol-1-yl)phenol hydrochloride
    229 5-(4-fluoro-1H-pyrazol-1-yl)-2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-
    triazin-6-yl]phenol hydrochloride
    230 5-(4-fluoro-1H-imidazol-1-yl)-2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-
    triazin-6-yl]phenol hydrochloride
    231 5-(1H-imidazol-1-yl)-2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-
    yl]phenol hydrochloride
    232 2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(2H-1,2,3-triazol-
    2-yl)phenol hydrochloride
    233 2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(1-methyl-1H-
    pyrazol-3-yl)phenol hydrochloride
    234 6-[3-hydroxy-4-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)phenyl]-
    3-methylpyrimidin-4(3H)-one hydrochloride
    235 5-(5-fluoro-1H-pyrazol-4-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-
    triazin-6-yl)phenol hydrochloride
    236 5-(2-methyl-2H-1,2,3-triazol-4-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-
    1,2,4-triazin-6-yl)phenol hydrochloride
    237 2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1,2,4-thiadiazol-5-
    yl)phenol hydrochloride
    238 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (1H-imidazol-1-yl)phenol dihydrochloride
    239 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (4-methyl-1H-imidazol-1-yl)phenol dihydrochloride
    240 5-(4-fluoro-1H-imidazol-1-yl)-2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-
    yl]amino}-1,2,4-triazin-6-yl)phenol dihydrochloride
    241 4-{3-hydroxy-4-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-
    yl]phenyl}-1-methylpyridin-2(1H)-one hydrochloride
    242 2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(2-methyl-2H-
    1,2,3-triazol-4-yl)phenol trifluoroacetate
    243 5-(6-methoxypyrimidin-4-yl)-2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-
    triazin-6-yl]phenol ditrifluoroacetate
    244 2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(pyrimidin-2-
    yl)phenol trifluoroacetate
    245 2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(1H-1,2,3-triazol-
    4-yl)phenol trifluoroacetate
    246 6-[4-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-
    yl)-3-hydroxyphenyl]-3-methylpyrimidin-4(3H)-one dihydrochloride
    247 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (1H-1,2,3-triazol-4-yl)phenol dihydrochloride
    249 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (imidazo[1,2-b]pyridazin-6-yl)phenol dihydrochloride
    250 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1,3-oxazol-2-yl)phenol
    hydrochloride
    251 2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(2-methyl-2H-
    tetrazol-5-yl)phenol trifluoroacetate
    252 2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(1,3-oxazol-2-
    yl)phenol trifluoroacetate
    253 5-(1-methyl-1H-pyrazol-3-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol formate
    254 5-(6-methoxypyrimidin-4-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol formate
    256 5-(imidazo[1,2-b]pyridazin-6-yl)-2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-
    triazin-6-yl]phenol trifluoroacetate
    257 5-(imidazo[1,2-a]pyrazin-6-yl)-2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-
    triazin-6-yl]phenol hydrochloride
    258 2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-1,2,3-triazol-4-
    yl)phenol ditrifluoroacetate
    259 5-(2-methyl-2H-tetrazol-5-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-
    triazin-6-yl)phenol trifluoroacetate
    260 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (1-methyl-1H-indazol-5-yl)phenol dihydrochloride
    261 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (1-methyl-1H-pyrazol-3-yl)phenol dihydrochloride
    262 2-[3-(3,5-dimethylpiperazin-1-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol
    dihydrochloride
    263 2-[3-(3,5-dimethylpiperazin-1-yl)-1,2,4-triazin-6-yl]-5-(1-methyl-1H-pyrazol-3-
    yl)phenol hydrochloride
    264 2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(2H-1,2,3-triazol-2-
    yl)phenol hydrochloride
    265 5-(6-methoxypyrimidin-4-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-
    triazin-6-yl)phenol hydrochloride
    266 5-(2-methyl-2H-1,2,3-triazol-4-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol dihydrochloride
    267 5-(2-methyl-2H-tetrazol-5-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol dihydrochloride
    268 5-(6-methoxypyrimidin-4-yl)-2-{3-[3-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-
    yl}phenol ditrifluoroacetate
    269 2-{3-[3-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1,2,4-thiadiazol-5-
    yl)phenol dihydrochloride
    270 2-{3-[3-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(pyrimidin-2-yl)phenol
    dihydrochloride
    271 2-{3-[3-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1-methyl-1H-
    pyrazolo[3,4-b]pyridin-5-yl)phenol dihydrochloride
    272 2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(1,2,4-thiadiazol-5-
    yl)phenol trifluoroacetate
    273 5-(1H-imidazol-1-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-
    yl}phenol hydrochloride
    274 5-(4-methyl-1H-imidazol-1-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol hydrochloride
    275 5-(4-fluoro-1H-imidazol-1-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol hydrochloride
    276 5-(4-fluoro-1H-pyrazol-1-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol hydrochloride
    277 5-(2-methyl-1,3-oxazol-5-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol hydrochloride
    278 2-{3-[3-(tert-butylamino)-4-fluoropyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-
    yl)phenol hydrochloride
    279 5-(pyrimidin-2-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-
    yl}phenol formate
    282 5-(1H-pyrazol-4-yl)-2-[3-(3,3,5,5-tetramethylpiperazin-1-yl)-1,2,4-triazin-6-yl]phenol
    dihydrochloride
    283 5-(imidazo[1,2-a]pyrazin-6-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-
    triazin-6-yl)phenol hydrochloride
    284 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)phenol dihydrochloride
    285 5-(1-methyl-1H-benzimidazol-5-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol formate
    287 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (2-methyl-2H-1,2,3-triazol-4-yl)phenol trifluoroacetate
    288 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (1,3-oxazol-2-yl)phenol trifluoroacetate
    289 5-(2-methyl-1,3-oxazol-5-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-
    triazin-6-yl)phenol hydrochloride
    290 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (6-methoxypyrimidin-4-yl)phenol trifluoroacetate
    291 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (2-methyl-2H-tetrazol-5-yl)phenol trifluoroacetate
    292 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (1,2,4-thiadiazol-5-yl)phenol trifluoroacetate
    293 2-(3-{[(3S,4S)-3-methoxy-2,2,6,6-tetramethylpiperidin-4-yl](methyl)amino}-1,2,4-
    triazin-6-yl)-5-(1H-pyrazol-4-yl)phenol dihydrochloride
    294 5-(imidazo[1,2-b]pyridazin-6-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-
    triazin-6-yl)phenol hydrochloride
    295 2-{3-[3-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(2-methyl-2H-1,2,3-
    triazol-4-yl)phenol dihydrochloride
    296 2-{3-[3-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1-methyl-1H-pyrazol-3-
    yl)phenol dihydrochloride
    297 2-(3-{3-[(2-methylpropyl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol dihydrochloride
    298 (3S,4S)-4-({6-[2-hydroxy-4-(1H-pyrazol-4-yl)phenyl]-1,2,4-triazin-3-yl}amino)-
    2,2,6,6-tetramethylpiperidin-3-ol dihydrochloride
    299 2-[3-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(2-methyl-1,3-
    oxazol-5-yl)phenol trifluoroacetate
    300 5-(7-fluoro-1-methyl-1H-benzimidazol-5-yl)-2-{3-[methyl(2,2,6,6-
    tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}phenol formate
    301 5-(6,7-difluoro-1H-benzimidazol-5-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol formate
    302 5-(6,7-difluoro-1-methyl-1H-benzimidazol-5-yl)-2-{3-[methyl(2,2,6,6-
    tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}phenol formate
    303 5-(8-methylimidazo[1,2-b]pyridazin-6-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-
    4-yl)amino]-1,2,4-triazin-6-yl}phenol formate
    304 5-(8-methoxyimidazo[1,2-b]pyridazin-6-yl)-2-{3-[methyl(2,2,6,6-tetramethylpiperidin-
    4-yl)amino]-1,2,4-triazin-6-yl}phenol formate
    305 2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1,2,4-triazin-6-
    yl)phenol trifluoroacetate
    306 2-{3-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazol-4-yl)phenol dihydrochloride
    307 5-(1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-
    1-yl}-1,2,4-triazin-6-yl)phenol hydrochloride
    308 5-(1,3-oxazol-2-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-
    yl)phenol hydrochloride
    309 2-(3-{[(3S)-1-methylpyrrolidin-3-yl]oxy}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol hydrochloride
    310 2-{3-[(4aS,7aS)-1-methyloctahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-1,2,4-triazin-6-yl}-
    5-(1H-pyrazol-4-yl)phenol trihydrochloride
    311 2-{3-[(4aS,7aR)-4-methylhexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl]-1,2,4-triazin-
    6-yl}-5-(1H-pyrazol-4-yl)phenol trihydrochloride
    314 5-(pyridazin-4-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-
    yl}phenol formate
    315 5-[(pyridin-3-yl)amino]-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-
    6-yl}phenol formate
    316 2-(3-{3-[(1-fluoro-2-methylpropan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-
    (1H-pyrazol-4-yl)phenol hydrochloride
    317 2-{3-[3-(ethylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-yl)phenol
    dihydrochloride
    318 2-{3-[3-(dimethylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-yl)phenol
    dihydroiodide
    319 5-(1-methyl-1H-indazol-5-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol trihydrochloride
    320 2-{3-[3-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(2-methyl-2H-tetrazol-5-
    yl)phenol trihydrochloride
    321 5-(1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-
    yl)amino]-1,2,4-triazin-6-yl}phenol trihydrochloride
    322 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (1H-pyrazol-4-yl)phenol dihydrochloride
    323 2-(3-{[(3R,4R)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    (1H-pyrazol-4-yl)phenol dihydrochloride
    324 2-{3-[(3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(2H-
    1,2,3-triazol-2-yl)phenol dihydrochloride
    326 5-(4-methyl-1H-imidazol-1-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-
    triazin-6-yl)phenol hydrochloride
    327 2-{3-[(3aR,7aR)-octahydro-2H-pyrrolo[3,4-c]pyridin-2-yl]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazol-4-yl)phenol trihydrochloride
    328 2-[3-(piperazin-1-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol dihydrochloride
    329 2-{3-[(3S)-3-{[(2R)-1-fluoropropan-2-yl]amino}pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-
    (1H-pyrazol-4-yl)phenol dihydrochloride
    330 5-(1-methyl-1H-indazol-5-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-
    triazin-6-yl)phenol hydrochloride
    331 5-(1H-imidazol-1-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-
    yl)phenol hydrochloride
    332 2-{3-[(3aR,6aS)-hexahydropyrrolo[3,2-b]pyrrol-1(2H)-yl]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazol-4-yl)phenol dihydrochloride
    333 2-(3-{3-[(2-hydroxyethyl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol dihydrochloride
    335 2-(3-{3-[(oxan-4-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol dihydrochloride
    336 2-(3-{3-[(1-methoxypropan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-
    pyrazol-4-yl)phenol dihydrochloride
    337 2-[3-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-
    yl)phenol dihydrochloride
    338 5-(4-fluoro-1H-pyrazol-1-yl)-2-(3-{3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-
    triazin-6-yl)phenol hydrochloride
    339 2-[3-(1,7-diazaspiro[4.4]nonan-7-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol
    dihydrochloride
    340 2-(3-{3-[(1-methylcyclopropyl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-
    pyrazol-4-yl)phenol dihydrochloride
    341 2-(3-{3-[(1-methoxy-2-methylpropan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-
    5-(1H-pyrazol-4-yl)phenol dihydrochloride
    344 6-(3-hydroxy-4-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-
    yl}phenyl)imidazo[1,2-b]pyridazine-8-carbonitrile formate
    345 2-(3-{[(3R,4S)-3-fluoropiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol dihydrochloride
    346 2-{3-[(3R,4R)-3-methoxy-4-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazol-4-yl)phenol dihydrochloride
    347 2-(3-{(3S)-3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol trifluoroacetate
    348 2-(3-{(3R)-3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-
    4-yl)phenol trifluoroacetate
    349 2-[3-{3-[(bicyclo[1.1.1]pentan-1-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-
    pyrazol-4-yl)phenol trifluoroacetate
    350 2-{3-[3-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(2-methyl-1,3-oxazol-5-
    yl)phenol dihydrochloride
    351 5-[8-(aminomethyl)imidazo[1,2-b]pyridazin-6-yl]-2-{3-[methyl(2,2,6,6-
    tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}phenol formate
    352 5-(1,3-oxazol-2-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-
    yl}phenol formate
    353 2-[3-(6-oxa-2,9-diazaspiro[4.5]decan-2-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-
    yl)phenol dihydrochloride
    354 2-[3-(2,7-diazaspiro[4.4]nonan-2-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol
    dihydrochloride
    355 2-{3-[(3S)-3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-
    yl)phenol dihydrochloride
    356 2-{3-[(3R)-3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-
    yl)phenol dihydrochloride
    357 2-{3-[3-(cyclopentylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-
    yl)phenol dihydrochloride
    358 2-{3-[3-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1,3-oxazol-2-yl)phenol
    dihydrochloride
    359 5-(imidazo[1,2-a]pyrazin-2-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol hydrochloride
    360 5-(imidazo[1,2-a]pyridin-2-yl)-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-
    triazin-6-yl}phenol hydrochloride
    361 2-[3-(3-{[(propan-2-yl)amino]methyl}pyrrolidin-1-yl)-1,2,4-triazin-6-yl]-5-(1H-
    pyrazol-4-yl)phenol dihydrochloride
    362 2-(3-{3-[(4-methyloxan-4-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-
    4-yl)phenol ditrifluoroacetate
    363 2-{6-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-3-yl}-5-(1H-pyrazol-4-
    yl)phenol dihydrochloride
    364 2-{3-[3-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-[6-
    (methylsulfanyl)pyrimidin-4-yl]phenol trihydrochloride
    365 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(3-chloro-1H-pyrazol-4-
    yl)phenol dihydrochloride
    366 4-(4-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-3-hydroxyphenyl)-1H-
    pyrazole-3-carbonitrile dihydrochloride
    367 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-[1-(2H3)methyl-1H-
    pyrazol-4-yl]phenol hydrochloride
    368 3-(1-methyl-1H-pyrazol-3-yl)-6-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}benzene-1,2-diol trifluoroacetate
    369 2-[3-(2,7-diazaspiro[4.5]decan-2-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol
    dihydrochloride
    370 2-[3-(hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-
    yl)phenol dihydrochloride
    371 2-(3-{3-[(3-hydroxypropyl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol dihydrochloride
    372 2-[3-(3-{[(oxan-4-yl)amino]methyl}pyrrolidin-1-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-
    4-yl)phenol ditrifluoroacetate
    373 5-[1-(2H3)methyl-1H-pyrazol-4-yl]-2-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-6-yl}phenol hydrochloride
    374 2-{6-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-3-yl}-5-(3-fluoro-1H-pyrazol-4-
    yl)phenol dihydrochloride
    375 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(3-methyl-1H-pyrazol-
    4-yl)phenol dihydrochloride
    376 2-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-3-methoxy-5-(1H-
    pyrazol-4-yl)phenol trifluoroacetate
    377 2-(3-{[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino}-1,2,4-triazin-6-yl)-5-
    [1-(2H3)methyl-1H-pyrazol-4-yl]phenol hydrochloride
    378 2-{3-[(3S)-3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(3-fluoro-1H-
    pyrazol-4-yl)phenol dihydrochloride
    379 2-{3-[(3R)-3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(3-fluoro-1H-
    pyrazol-4-yl)phenol dihydrochloride
    381 2-{3-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl}-5-(1H-
    pyrazolo[3,4-c]pyridin-1-yl)phenol formate
    385 2-{3-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-1,2,4-triazin-6-yl}-5-(imidazo[1,2-
    b]pyridazin-6-yl)phenol trifluoroacetate
    386 2-(3-{3-[(cyclopentylamino)methyl]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-
    4-yl)phenol dihydrochloride
    387 2-[3-([2,3′-bipyrrolidin]-1′-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol
    dihydrochloride
    388 5-(1H-pyrazol-4-yl)-2-{3-[3-({[(pyridin-2-yl)methyl]amino}methyl)pyrrolidin-1-yl]-
    1,2,4-triazin-6-yl}phenol ditrifluoroacetate
    390 2-(3-{3-[(tert-butylamino)methyl]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol dihydrochloride
    391 2-[3-(3-{[(4-methyloxan-4-yl)amino]methyl}pyrrolidin-1-yl)-1,2,4-triazin-6-yl]-5-(1H-
    pyrazol-4-yl)phenol trifluoroacetate
    392 2-(3-{3-[(cyclopropylamino)methyl]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-
    4-yl)phenol formate
    395 2-[3-(3-{[(oxolan-3-yl)amino]methyl}pyrrolidin-1-yl)-1,2,4-triazin-6-yl]-5-(1H-
    pyrazol-4-yl)phenol hydrochloride
    396 5-(1H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-3-
    yl}phenol hydrochloride
    399 2-{3-[(3R)-3-(cyclobutylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-
    yl)phenol dihydrochloride
    400 2-{3-[(3S)-3-(cyclobutylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1H-pyrazol-4-
    yl)phenol dihydrochloride
    401 2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-3-yl}-5-(2H-1,2,3-triazol-
    2-yl)phenol hydrochloride
    403 2-[3-(3-{[(3-fluorooxan-4-yl)amino]methyl}pyrrolidin-1-yl)-1,2,4-triazin-6-yl]-5-(1H-
    pyrazol-4-yl)phenol hydrochloride
    404 2-[3-(3-{[(oxan-3-yl)amino]methyl}pyrrolidin-1-yl)-1,2,4-triazin-6-yl]-5-(1H-pyrazol-
    4-yl)phenol hydrochloride
    405 2-[3-(3-{[(8-oxabicyclo[3.2.1]octan-3-yl)amino]methyl}pyrrolidin-1-yl)-1,2,4-triazin-
    6-yl]-5-(1H-pyrazol-4-yl)phenol hydrochloride
    406 2-{3-[(3R)-3-(cyclobutylamino)pyrrolidin-1-yl]-l,2,4-triazin-6-yl}-5-(1-methyl-1H-
    pyrazol-4-yl)phenol hydrochloride
    407 2-{3-[(3S)-3-(cyclobutylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-5-(1-methyl-1H-
    pyrazol-4-yl)phenol hydrochloride
    408 2-(3-{[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl](methyl)amino}-1,2,4-
    triazin-6-yl)-5-(1-methyl-1H-pyrazol-4-yl)phenol trifluoroacetate
    409 2-(3-{3-[(3,3-difluorocyclopentyl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-
    pyrazol-4-yl)phenol dihydrochloride
    410 2-(3-{3-[(dimethylamino)methyl]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol dihydrochloride
    413 2-(3-{3-[(methylamino)methyl]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-4-
    yl)phenol dihydrochloride
    414 2-[3-(3-{1-[(propan-2-yl)amino]ethyl}pyrrolidin-1-yl)-1,2,4-triazin-6-yl]-5-(1H-
    pyrazol-4-yl)phenol dihydrochloride
    415 2-(3-{3-[(cyclobutylamino)methyl]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-pyrazol-
    4-yl)phenol dihydrochloride
    416 2-(3-{3-[(cyclobutylamino)methyl]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1-methyl-1H-
    pyrazol-4-yl)phenol hydrochloride
    417 2-(3-{[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl](methyl)amino}-1,2,4-
    triazin-6-yl)-5-(2H-1,2,3-triazol-2-yl)phenol trifluoroacetate
    418 6-{3-[3-(tert-butylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl}-2-fluoro-3-(1H-pyrazol-4-
    yl)phenol dihydrochloride
    419 5-(1H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]-1,2,4-triazin-3-
    yl}phenol hydrochloride
    420 2-(3-{3-[(3-fluorocyclopentyl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1H-
    pyrazol-4-yl)phenol dihydrochloride
    421 2-[3-(3-{1-[(oxan-4-yl)amino]cyclopropyl}pyrrolidin-1-yl)-1,2,4-triazin-6-yl]-5-(1H-
    pyrazol-4-yl)phenol dihydrochloride
    422 2-(3-{3-methyl-3-[(propan-2-yl)amino]pyrrolidin-1-yl}-1,2,4-triazin-6-yl)-5-(1-
    methyl-1H-pyrazol-4-yl)phenol trifluoroacetate
    423 2-{6-[(3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-3-yl}-5-(1H-
    pyrazol-4-yl)phenol hydrochloride, and
    424 5-[1-(2H3)methyl-1H-pyrazol-4-yl]-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-
    1,2,4-triazin-3-yl}phenol hydrochloride;
      • wherein a form of the compound is selected from the group consisting of a salt, hydrate, solvate, racemate, enantiomer, diastereomer, stereoisomer, and tautomer form thereof.
  • An aspect of the present description includes a method for preventing, treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a method for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound of Formula (I) or Formula (II) or a form thereof.
  • Another aspect of the present description includes a method for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound salt of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a method for use of a compound of Formula (I) or Formula (II) or a form or composition thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form or composition thereof.
  • Another aspect of the present description includes a method for use of a compound salt of Formula (I) or Formula (II) or a form or composition thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound salt of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form thereof.
  • Another aspect of the present description includes a use for a compound salt of Formula (I) or Formula (II) or a form thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound salt of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof in the manufacture of a medicament for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the medicament.
  • Another aspect of the present description includes a use for a compound salt of Formula (I) or Formula (II) or a form thereof in the manufacture of a medicament for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the medicament.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof in a combination product with one or more therapeutic agents for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form thereof in combination with an effective amount of the one or more agents.
  • Another aspect of the present description includes a use for a compound salt of Formula (I) or Formula (II) or a form thereof in a combination product with one or more therapeutic agents for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound salt of Formula (I) or Formula (II) or a form thereof in combination with an effective amount of the one or more agents.
    • Chemical Definitions
  • The chemical terms used above and throughout the description herein, unless specifically defined otherwise, shall be understood by one of ordinary skill in the art to have the following indicated meanings.
  • As used herein, the term “C1-4alkyl” generally refers to saturated hydrocarbon radicals having from one to four carbon atoms in a straight or branched chain configuration, including, but not limited to, methyl, ethyl, n-propyl (also referred to as propyl or propanyl), isopropyl, n-butyl (also referred to as butyl or butanyl), isobutyl, sec-butyl, tert-butyl and the like. A C1-4alkyl radical is optionally substituted with substituent species as described herein where allowed by available valences.
  • As used herein, the term “C2-4alkenyl” generally refers to partially unsaturated hydrocarbon radicals having from two to four carbon atoms in a straight or branched chain configuration and one or more carbon-carbon double bonds therein, including, but not limited to, ethenyl (also referred to as vinyl), allyl, propenyl and the like. A C2-4alkenyl radical is optionally substituted with substituent species as described herein where allowed by available valences.
  • As used herein, the term “C2-8alkynyl” generally refers to partially unsaturated hydrocarbon radicals having from two to eight carbon atoms in a straight or branched chain configuration and one or more carbon-carbon triple bonds therein, including, but not limited to, ethynyl, propynyl, butynyl and the like. In certain aspects, C2-8alkynyl includes, but is not limited to, C2-6alkynyl, C2-4alkynyl and the like. A C2-8alkynyl radical is optionally substituted with substituent species as described herein where allowed by available valences.
  • As used herein, the term “C1-4alkoxy” generally refers to saturated hydrocarbon radicals having from one to four carbon atoms in a straight or branched chain configuration of the formula: —O—C1-4alkyl, including, but not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy and the like. A C1-4alkoxy radical is optionally substituted with substituent species as described herein where allowed by available valences.
  • As used herein, the term “C3-10cycloalkyl” generally refers to a saturated or partially unsaturated monocyclic, bicyclic or polycyclic hydrocarbon radical, including, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, and the like. A C3-10cycloalkyl radical is optionally substituted with substituent species as described herein where allowed by available valences.
  • As used herein, the term “aryl” generally refers to a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure radical, including, but not limited to, phenyl, naphthyl, anthracenyl, fluorenyl, azulenyl, phenanthrenyl and the like. An aryl radical is optionally substituted with substituent species as described herein where allowed by available valences.
  • As used herein, the term “heteroaryl” generally refers to a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure radical in which one or more carbon atom ring members have been replaced, where allowed by structural stability, with one or more heteroatoms, such as an O, S or N atom, including, but not limited to, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, isothiazolyl, oxazolyl, 1,3-thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, indolyl, indazolyl, indolizinyl, isoindolyl, benzofuranyl, benzothienyl, benzoimidazolyl, 1,3-benzothiazolyl, 1,3-benzoxazolyl, purinyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, 1,3-diazinyl, 1,2-diazinyl, 1,2-diazolyl, 1,4-diazanaphthalenyl, acridinyl, furo[3,2-b]pyridinyl, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, 6H-thieno[2,3-b]pyrrolyl, thieno[3,2-c]pyridinyl, thieno[2,3-d]pyrimidinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-c]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, pyrrolo[1,2-a]pyrazinyl, pyrrolo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrazinyl, imidazo[1,2-a]pyridinyl, 3H-imidazo[4,5-b]pyridinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-c]pyrimidinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, imidazo[2,1-b][1,3]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, [1,2,4]triazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl and the like. A heteroaryl radical is optionally substituted on a carbon or nitrogen atom ring member with substituent species as described herein where allowed by available valences.
  • In certain aspects, the nomenclature for a heteroaryl radical may differ, such as in non-limiting examples where furanyl may also be referred to as furyl, thienyl may also be referred to as thiophenyl, pyridinyl may also be referred to as pyridyl, benzothienyl may also be referred to as benzothiophenyl and 1,3-benzoxazolyl may also be referred to as 1,3-benzooxazolyl.
  • In certain other aspects, the term for a heteroaryl radical may also include other regioisomers, such as in non-limiting examples where the term pyrrolyl may also include 2H-pyrrolyl, 3H-pyrrolyl and the like, the term pyrazolyl may also include 1H-pyrazolyl and the like, the term imidazolyl may also include 1H-imidazolyl and the like, the term triazolyl may also include 1H-1,2,3-triazolyl and the like, the term oxadiazolyl may also include 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl and the like, the term tetrazolyl may also include 1H-tetrazolyl, 2H-tetrazolyl and the like, the term indolyl may also include 1H-indolyl and the like, the term indazolyl may also include 1H-indazolyl, 2H-indazolyl and the like, the term benzoimidazolyl may also include 1H-benzoimidazolyl and the term purinyl may also include 9H-purinyl and the like.
  • As used herein, the term “heterocyclyl” generally refers to a saturated or partially unsaturated monocyclic, bicyclic or polycyclic carbon atom ring structure radical in which one or more carbon atom ring members have been replaced, where allowed by structural stability, with a heteroatom, such as an O, S or N atom, including, but not limited to, oxiranyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, isoxazolinyl, isoxazolidinyl, isothiazolinyl, isothiazolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, triazolinyl, triazolidinyl, oxadiazolinyl, oxadiazolidinyl, thiadiazolinyl, thiadiazolidinyl, tetrazolinyl, tetrazolidinyl, pyranyl, dihydro-2H-pyranyl, thiopyranyl, 1,3-dioxanyl, 1,2,5,6-tetrahydropyridinyl, 1,2,3,6-tetrahydropyridinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,4-diazepanyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl, 2,3-dihydro-1,4-benzodioxinyl, hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, (3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, octahydro-5H-pyrrolo[3,2-c]pyridinyl, octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (7R,8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aS)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, hexahydropyrrolo[1,2-a]pyrazin-(2H)-one, octahydro-2H-pyrido[1,2-a]pyrazinyl, 3-azabicyclo[3.1.0]hexyl, (1R,5S)-3-azabicyclo[3.1.0]hexyl, 8-azabicyclo[3.2.1]octyl, (1R,5S)-8-azabicyclo[3.2.1]octyl, 8-azabicyclo[3.2.1]oct-2-enyl, (1R,5S)-8-azabicyclo[3.2.1]oct-2-enyl, 9-azabicyclo[3.3.1]nonyl, (1R,5S)-9-azabicyclo[3.3.1]nonyl, 2,5-diazabicyclo[2.2.1]heptyl, (1S,4S)-2,5-diazabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.2]octyl, 3,8-diazabicyclo[3.2.1]octyl, (1R,5S)-3,8-diazabicyclo[3.2.1]octyl, 1,4-diazabicyclo[3.2.2]nonyl, azaspiro[3.3]heptyl, 2,6-diazaspiro[3.3]heptyl, 2,6-diazaspiro[3.4]octyl, 2,7-diazaspiro[3.5]nonyl, 5,8-diazaspiro[3.5]nonyl, 2,7-diazaspiro[4.4]nonyl, 6,9-diazaspiro[4.5]decyl, 7-azadispiro[5.1.58.36]hexadecanyl and the like. A heterocyclyl radical is optionally substituted on a carbon or nitrogen atom ring member with substituent species as described herein where allowed by available valences.
  • In certain aspects, the nomenclature for a heterocyclyl radical may differ, such as in non-limiting examples where 1,3-benzodioxolyl may also be referred to as benzo[d][1,3]dioxolyl and 2,3-dihydro-1,4-benzodioxinyl may also be referred to as 2,3-dihydrobenzo[b][1,4]dioxinyl.
  • As used herein, the term “C1-4alkoxy-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-O—C1-4alkyl.
  • As used herein, the term “C1-4alkoxy-C1-4alkyl-amino” refers to a radical of the formula: —NH—C1-4alkyl-O—C1-4alkyl.
  • As used herein, the term “(C1-4alkoxy-C1-4alkyl)2-amino” refers to a radical of the formula: —N(C1-4alkyl-O—C1-4alkyl)2.
  • As used herein, the term “C1-4alkoxy-C1-4alkyl-amino-C1-4alkoxy” refers to a radical of the formula: —O—C1-4alkyl-NH—C1-4alkyl-O—C1-4alkyl.
  • As used herein, the term “(C1-4alkoxy-C1-4alkyl)2-amino-C1-4alkoxy” refers to a radical of the formula: —O—C1-4alkyl-N(C1-4alkyl-O—C1-4alkyl)2.
  • As used herein, the term “(C1-4alkoxy-C1-4alkyl)(C1-4alkyl)amino-C1-4alkoxy” refers to a radical of the formula: —O—C1-4alkyl-N(C1-4alkyl)(C1-4alkyl-O—C1-4alkyl).
  • As used herein, the term “C1-4alkoxy-C1-4alkyl-amino-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-NH—C1-4alkyl-O—C1-4alkyl.
  • As used herein, the term “(C1-4alkoxy-C1-4alkyl)2-amino-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-N(C1-4alkyl-O—C1-4alkyl)2.
  • As used herein, the term “(C1-4alkoxy-C1-4alkyl)(C1-4alkyl)amino-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-N(C1-4alkyl)(C1-4alkyl-O—C1-4alkyl).
  • As used herein, the term “C1-4alkoxy-carbonyl” refers to a radical of the formula: —C(O)—O—C1-4alkyl.
  • As used herein, the term “C1-4alkoxy-carbonyl-C2-8alkenyl” refers to a radical of the formula: —C2-8alkenyl-C(O)—O—C1-4alkyl.
  • As used herein, the term “C1-4alkoxy-carbonyl-amino” refers to a radical of the formula: —NH—C(O)—O—C1-4alkyl.
  • As used herein, the term “C1-4alkyl-amino” refers to a radical of the formula: —NH—C1-4alkyl.
  • As used herein, the term “(C1-4alkyl)2-amino” refers to a radical of the formula: —N(C1-4alkyl)2.
  • As used herein, the term “C1-4alkyl-amino-C2-8alkenyl” refers to a radical of the formula: —C2-8alkenyl-NH—C1-4alkyl.
  • As used herein, the term “(C1-4alkyl)2-amino-C2-8alkenyl” refers to a radical of the formula: —C2-8alkenyl-N(C1-4alkyl)2.
  • As used herein, the term “C1-4alkyl-amino-C1-4alkoxy” refers to a radical of the formula: —O—C1-4alkyl-NH—C1-4alkyl.
  • As used herein, the term “(C1-4alkyl)2-amino-C1-4alkoxy” refers to a radical of the formula: —O—C1-4alkyl-N(C1-4alkyl)2.
  • As used herein, the term “C1-4alkyl-amino-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-NH—C1-4alkyl.
  • As used herein, the term “(C1-4alkyl)2-amino-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-N(C1-4alkyl)2.
  • As used herein, the term “C1-4alkyl-amino-C1-4alkyl-amino” refers to a radical of the formula: —NH—C1-4alkyl-NH—C1-4alkyl.
  • As used herein, the term “(C1-4alkyl)2-amino-C1-4alkyl-amino” refers to a radical of the formula: —NH—C1-4alkyl-N(C1-4alkyl)2.
  • As used herein, the term “(C1-4alkyl-amino-C1-4alkyl)2-amino” refers to a radical of the formula: —N(C1-4alkyl-NH—C1-4alkyl)2.
  • As used herein, the term “[(C1-4alkyl)2-amino-C1-4alkyl]2-amino” refers to a radical of the formula: —N[C1-4alkyl-N(C1-4alkyl)2]2.
  • As used herein, the term “(C1-4alkyl-amino-C1-4alkyl)(C1-4alkyl)amino” refers to a radical of the formula: —N(C1-4alkyl)(C1-4alkyl-NH—C1-4alkyl).
  • As used herein, the term “[(C1-4alkyl)2-amino-C1-4alkyl](C1-4alkyl)amino” refers to a radical of the formula: —N(C1-4alkyl)[C1-4alkyl-N(C1-4alkyl)2].
  • As used herein, the term “C1-4alkyl-amino-C2-8alkynyl” refers to a radical of the formula: —C2-8alkynyl-NH—C1-4alkyl.
  • As used herein, the term “(C1-4alkyl)2-amino-C2-8alkynyl” refers to a radical of the formula: —C2-8alkynyl-N(C1-4alkyl)2.
  • As used herein, the term “C1-4alkyl-carbonyl” refers to a radical of the formula: —C(O)—C1-4alkyl.
  • As used herein, the term “C1-4alkyl-carbonyl-amino” refers to a radical of the formula: —NH—C(O)—C1-4alkyl.
  • As used herein, the term “C1-4alkyl-thio” refers to a radical of the formula: —S—C1-4alkyl. As used herein, the term “amino-C2-8alkenyl” refers to a radical of the formula: —C2-8alkenyl-NH2.
  • As used herein, the term “amino-C1-4alkoxy” refers to a radical of the formula: —O—C1-4alkyl-NH2.
  • As used herein, the term “amino-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-NH2.
  • As used herein, the term “amino-C1-4alkyl-amino” refers to a radical of the formula: —NH—C1-4alkyl-NH2.
  • As used herein, the term “(amino-C1-4alkyl)2-amino” refers to a radical of the formula: —N(C1-4alkyl-NH2)2.
  • As used herein, the term “(amino-C1-4alkyl)(C1-4alkyl)amino” refers to a radical of the formula: —N(C1-4alkyl)(C1-4alkyl-NH2).
  • As used herein, the term “amino-C2-8alkynyl” refers to a radical of the formula: —C2-8alkynyl-NH2.
  • As used herein, the term “aryl-C1-4alkoxy-carbonyl” refers to a radical of the formula: —C(O)—O—C1-4alkyl-aryl.
  • As used herein, the term “aryl-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-aryl.
  • As used herein, the term “aryl-C1-4alkyl-amino” refers to a radical of the formula: —NH—C1-4alkyl-aryl.
  • As used herein, the term “(aryl-C1-4alkyl)2-amino” refers to a radical of the formula: —N(C1-4alkyl-aryl)2.
  • As used herein, the term “(aryl-C1-4alkyl)(C1-4alkyl)amino” refers to a radical of the formula: —N(C1-4alkyl)(C1-4alkyl-aryl).
  • As used herein, the term “aryl-C1-4alkyl-amino-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-NH—C1-4alkyl-aryl.
  • As used herein, the term “(aryl-C1-4alkyl)2-amino-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-N(C1-4alkyl-aryl)2.
  • As used herein, the term “(aryl-C1-4alkyl)(C1-4alkyl)amino-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-N(C1-4alkyl)(C1-4alkyl-aryl).
  • As used herein, the term “aryl-amino” refers to a radical of the formula: —NH-aryl.
  • As used herein, the term “aryl-amino-carbonyl” refers to a radical of the formula: —C(O)—NH-aryl.
  • As used herein, the term “aryl-sulfonyloxy-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-O—SO2-aryl.
  • As used herein, the term “benzoxy-carbonyl” refers to a radical of the formula: —C(O)—O—CH2-phenyl.
  • As used herein, the term “C3-14cycloalkyl-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-C3-14cycloalkyl.
  • As used herein, the term “C3-14cycloalkyl-amino” refers to a radical of the formula: —NH—C3-14cycloalkyl.
  • As used herein, the term “C3-14cycloalkyl-oxy” refers to a radical of the formula: —O—C3-14cycloalkyl.
  • As used herein, the term “deutero-C1-4alkyl,” refers to a radical of the formula: —C1-4alkyl-deutero, wherein C1-4alkyl is partially or completely substituted with one or more deuterium atoms where allowed by available valences.
  • As used herein, the term “halo” or “halogen” generally refers to a halogen atom radical, including fluoro, chloro, bromo and iodo.
  • As used herein, the term “halo-C1-4alkoxy” refers to a radical of the formula: —O—C1-4alkyl-halo, wherein C1-4alkyl is partially or completely substituted with one or more halogen atoms where allowed by available valences.
  • As used herein, the term “halo-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-halo, wherein C1-4alkyl is partially or completely substituted with one or more halogen atoms where allowed by available valences.
  • As used herein, the term “halo-C1-4alkyl-amino” refers to a radical of the formula: —NH—C1-4alkyl-halo.
  • As used herein, the term “(halo-C1-4alkyl)(C1-4alkyl)amino” refers to a radical of the formula: —N(C1-4alkyl)(C1-4alkyl-halo).
  • As used herein, the term “(halo-C1-4alkyl)2-amino” refers to a radical of the formula: —N(C1-4alkyl-halo)2.
  • As used herein, the term “heteroaryl-C1-4alkoxy” refers to a radical of the formula: —O—C1-4alkyl-heteroaryl.
  • As used herein, the term “heteroaryl-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-heteroaryl.
  • As used herein, the term “heteroaryl-C1-4alkyl-amino” refers to a radical of the formula: —NH—C1-4alkyl-heteroaryl.
  • As used herein, the term “(heteroaryl-C1-4alkyl)2-amino” refers to a radical of the formula: —N(C1-4alkyl-heteroaryl)2.
  • As used herein, the term “(heteroaryl-C1-4alkyl)(C1-4alkyl)amino” refers to a radical of the formula: —N(C1-4alkyl)(C1-4alkyl-heteroaryl).
  • As used herein, the term “heteroaryl-C1-4alkyl-amino-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-NH—C1-4alkyl-heteroaryl.
  • As used herein, the term “(heteroaryl-C1-4alkyl)2-amino-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-N(C1-4alkyl-heteroaryl)2.
  • As used herein, the term “(heteroaryl-C1-4alkyl)(C1-4alkyl)amino-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-N(C1-4alkyl)(C1-4alkyl-heteroaryl).
  • As used herein, the term “heteroaryl-amino” refers to a radical of the formula: —NH-heteroaryl.
  • As used herein, the term “heterocyclyl-C1-4alkoxy” refers to a radical of the formula: —O—C1-4alkyl-heterocyclyl.
  • As used herein, the term “heterocyclyl-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-heterocyclyl.
  • As used herein, the term “heterocyclyl-C1-4alkyl-amino” refers to a radical of the formula: —NH—C1-4alkyl-heterocyclyl.
  • As used herein, the term “(heterocyclyl-C1-4alkyl)2-amino” refers to a radical of the formula: —N(C1-4alkyl-heterocyclyl)2.
  • As used herein, the term “(heterocyclyl-C1-4alkyl)(C1-4alkyl)amino” refers to a radical of the formula: —N(C1-4alkyl)(C1-4alkyl-heterocyclyl).
  • As used herein, the term “heterocyclyl-C1-4alkyl-amino-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-NH—C1-4alkyl-heterocyclyl.
  • As used herein, the term “(heterocyclyl-C1-4alkyl)2-amino-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-N(C1-4alkyl-heterocyclyl)2.
  • As used herein, the term “(heterocyclyl-C1-4alkyl)(C1-4alkyl)amino-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-N(C1-4alkyl)(C1-4alkyl-heterocyclyl).
  • As used herein, the term “heterocyclyl-amino” refers to a radical of the formula: —NH-heterocyclyl.
  • As used herein, the term “(heterocyclyl)(C1-4alkyl)amino” refers to a radical of the formula: —N(C1-4alkyl)(heterocyclyl).
  • As used herein, the term “heterocyclyl-amino-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-NH-heterocyclyl.
  • As used herein, the term “heterocyclyl-carbonyl” refers to a radical of the formula: —C(O)-heterocyclyl.
  • As used herein, the term “heterocyclyl-carbonyl-oxy” refers to a radical of the formula: —O—C(O)-heterocyclyl.
  • As used herein, the term “heterocyclyl-oxy” refers to a radical of the formula: —O-heterocyclyl.
  • As used herein, the term “hydroxy” refers to a radical of the formula: —OH.
  • As used herein, the term “hydroxy-C1-4alkoxy-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-O—C1-4alkyl-OH.
  • As used herein, the term “hydroxy-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-OH, wherein C1-4alkyl is partially or completely substituted with one or more hydroxy radicals where allowed by available valences.
  • As used herein, the term “hydroxy-C1-4alkyl-amino” refers to a radical of the formula: —NH—C1-4alkyl-OH.
  • As used herein, the term “(hydroxy-C1-4alkyl)2-amino” refers to a radical of the formula: —N(C1-4alkyl-OH)2.
  • As used herein, the term “(hydroxy-C1-4alkyl)(C1-4alkyl)amino” refers to a radical of the formula: —N(C1-4alkyl)(C1-4alkyl-OH).
  • As used herein, the term “hydroxy-C1-4alkyl-amino-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-NH—C1-4alkyl-OH.
  • As used herein, the term “(hydroxy-C1-4alkyl)2-amino-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-N(C1-4alkyl-OH)2.
  • As used herein, the term “(hydroxy-C1-4alkyl)(C1-4alkyl)amino-C1-4alkyl” refers to a radical of the formula: —C1-4alkyl-N(C1-4alkyl)(C1-4alkyl-OH).
  • As used herein, the term “hydroxy-C1-4alkyl-amino-C1-4alkoxy” refers to a radical of the formula: —O—C1-4alkyl-NH—C1-4alkyl-OH.
  • As used herein, the term “(hydroxy-C1-4alkyl)2-amino-C1-4alkoxy” refers to a radical of the formula: —O—C1-4alkyl-N(C1-4alkyl-OH)2.
  • As used herein, the term “(hydroxy-C1-4alkyl)(C1-4alkyl)amino-C1-4alkoxy” refers to a radical of the formula: —O—C1-4alkyl-N(C1-4alkyl)(C1-4alkyl-OH).
  • As used herein, the term “hydroxy-C1-4alkyl-amino-C1-4alkyl-amino” refers to a radical of the formula: —NH—C1-4alkyl-NH—C1-4alkyl-OH.
  • As used herein, the term “(hydroxy-C1-4alkyl-amino-C1-4alkyl)2-amino” refers to a radical of the formula: —N(C1-4alkyl-NH—C1-4alkyl-OH)2.
  • As used herein, the term “(hydroxy-C1-4alkyl)2-amino-C1-4alkyl-amino” refers to a radical of the formula: —NH—C1-4alkyl-N(C1-4alkyl-OH)2.
  • As used herein, the term “(hydroxy-C1-4alkyl-amino-C1-4alkyl)(C1-4alkyl)amino” refers to a radical of the formula: —N(C1-4alkyl)(C1-4alkyl-NH—C1-4alkyl-OH).
  • As used herein, the term “[(hydroxy-C1-4alkyl)2-amino-C1-4alkyl](C1-4alkyl)amino” refers to a radical of the formula: —N(C1-4alkyl)[C1-4alkyl-N(C1-4alkyl-OH)2].
  • As used herein, the term “(hydroxy-C1-4alkyl)(C1-4alkyl)amino-C1-4alkyl-amino” refers to a radical of the formula: —NH—C1-4alkyl-N(C1-4alkyl, C1-4alkyl-OH).
  • As used herein, the term “[(hydroxy-C1-4alkyl)(C1-4alkyl)amino-C1-4alkyl]-(C1-4alkyl)amino” refers to a radical of the formula: —N(C1-4alkyl)[C1-4alkyl-N(C1-4alkyl)-(C1-4alkyl-OH)].
  • As used herein, the term “substituent” means positional variables on the atoms of a core molecule that are substituted at a designated atom position, replacing one or more hydrogens on the designated atom, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. A person of ordinary skill in the art should note that any carbon as well as heteroatom with valences that appear to be unsatisfied as described or shown herein is assumed to have a sufficient number of hydrogen atom(s) to satisfy the valences described or shown. In certain instances one or more substituents having a double bond (e.g., “oxo” or “═O”) as the point of attachment may be described, shown or listed herein within a substituent group, wherein the structure may only show a single bond as the point of attachment to the core structure of Formula (I) or Formula (II). A person of ordinary skill in the art would understand that, while only a single bond is shown, a double bond is intended for those substituents.
  • As used herein, the term “and the like,” with reference to the definitions of chemical terms provided herein, means that variations in chemical structures that could be expected by one skilled in the art include, without limitation, isomers (including chain, branching or positional structural isomers), hydration of ring systems (including saturation or partial unsaturation of monocyclic, bicyclic or polycyclic ring structures) and all other variations where allowed by available valences which result in a stable compound.
  • For the purposes of this description, where one or more substituent variables for a compound of Formula (I) or Formula (II) or a form thereof encompass functionalities incorporated into a compound of Formula (I) or Formula (II), each functionality appearing at any location within the disclosed compound may be independently selected, and as appropriate, independently and/or optionally substituted.
  • As used herein, the terms “independently selected,” or “each selected” refer to functional variables in a substituent list that may occur more than once on the structure of Formula (I) or Formula (II), the pattern of substitution at each occurrence is independent of the pattern at any other occurrence. Further, the use of a generic substituent variable on any formula or structure for a compound described herein is understood to include the replacement of the generic substituent with species substituents that are included within the particular genus, e.g., aryl may be replaced with phenyl or naphthalenyl and the like, and that the resulting compound is to be included within the scope of the compounds described herein.
  • As used herein, the terms “each instance of” or “in each instance, when present,” when used preceding a phrase such as “ . . . C3-14cycloalkyl, C3-14cycloalkyl-C1-4alkyl, aryl, aryl-C1-4alkyl, heteroaryl, heteroaryl-C1-4alkyl, heterocyclyl and heterocyclyl-C1-4alkyl,” are intended to refer to the C3-14cycloalkyl, aryl, heteroaryl and heterocyclyl ring systems when each are present either alone or as a substituent.
  • As used herein, the term “optionally substituted” means optional substitution with the specified substituent variables, groups, radicals or moieties.
    • Compound Forms
  • As used herein, the term “form” means a compound of Formula (I) or Formula (II) having a form selected from the group consisting of a free acid, free base, prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
  • In certain aspects described herein, the form of the compound of Formula (I) or Formula (II) is a free acid, free base or salt thereof.
  • In certain aspects described herein, the form of the compound of Formula (I) or Formula (II) is a salt thereof.
  • In certain aspects described herein, the form of the compound of Formula (I) or Formula (II) is an isotopologue thereof.
  • In certain aspects described herein, the form of the compound of Formula (I) or Formula (II) is a stereoisomer, racemate, enantiomer or diastereomer thereof.
  • In certain aspects described herein, the form of the compound of Formula (I) or Formula (II) is a tautomer thereof.
  • In certain aspects described herein, the form of the compound of Formula (I) or Formula (II) is a pharmaceutically acceptable form.
  • In certain aspects described herein, the compound of Formula (I) or Formula (II) or a form thereof is isolated for use.
  • As used herein, the term “isolated” means the physical state of a compound of Formula (I) or Formula (II) or a form thereof after being isolated and/or purified from a synthetic process (e.g., from a reaction mixture) or natural source or combination thereof according to an isolation or purification process or processes described herein or which are well known to the skilled artisan (e.g., chromatography, recrystallization and the like) in sufficient purity to be characterized by standard analytical techniques described herein or well known to the skilled artisan.
  • As used herein, the term “protected” means that a functional group in a compound of Formula (I) or Formula (II) or a form thereof is in a form modified to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T.W. Greene et al, Protective Groups in organic Synthesis (1991), Wiley, New York. Such functional groups include hydroxy, phenol, amino and carboxylic acid. Suitable protecting groups for hydroxy or phenol include trialkylsilyl or diarylalkylsilyl (e.g., t-butyldimethylsilyl, t-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, substituted benzyl, methyl, methoxymethanol, and the like. Suitable protecting groups for amino, amidino and guanidino include t-butoxycarbonyl, benzyloxycarbonyl, and the like. Suitable protecting groups for carboxylic acid include alkyl, aryl or arylalkyl esters. In certain instances, the protecting group may also be a polymer resin, such as a Wang resin or a 2-chlorotrityl-chloride resin. Protecting groups may be added or removed in accordance with standard techniques, which are well-known to those skilled in the art and as described herein. It will also be appreciated by those skilled in the art, although such protected derivatives of compounds described herein may not possess pharmacological activity as such, they may be administered to a subject and thereafter metabolized in the body to form compounds described herein which are pharmacologically active. Such derivatives may therefore be described as “prodrugs”. All prodrugs of compounds described herein are included within the scope of the use described herein.
  • As used herein, the term “prodrug” means a form of an instant compound (e.g., a drug precursor) that is transformed in vivo to yield an active compound of Formula (I) or Formula (II) or a form thereof. The transformation may occur by various mechanisms (e.g., by metabolic and/or non-metabolic chemical processes), such as, for example, by hydrolysis and/or metabolism in blood, liver and/or other organs and tissues. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, “Pro-drugs as Novel Delivery Systems,” Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
  • In one example, when a compound of Formula (I) or Formula (II) or a form thereof contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a functional group such as alkyl and the like. In another example, when a compound of Formula (I) or Formula (II) or a form thereof contains a hydroxyl functional group, a prodrug form can be prepared by replacing the hydrogen atom of the hydroxyl with another functional group such as alkyl, alkylcarbonyl or a phosphonate ester and the like. In another example, when a compound of Formula (I) or Formula (II) or a form thereof contains an amine functional group, a prodrug form can be prepared by replacing one or more amine hydrogen atoms with a functional group such as alkyl or substituted carbonyl. Pharmaceutically acceptable prodrugs of compounds of Formula (I) or Formula (II) or a form thereof include those compounds substituted with one or more of the following groups: carboxylic acid esters, sulfonate esters, amino acid esters, phosphonate esters and mono-, di- or triphosphate esters or alkyl substituents, where appropriate. As described herein, it is understood by a person of ordinary skill in the art that one or more of such substituents may be used to provide a compound of Formula (I) or Formula (II) or a form thereof as a prodrug.
  • One or more compounds described herein may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and the description herein is intended to embrace both solvated and unsolvated forms.
  • As used herein, the term “solvate” means a physical association of a compound described herein with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. As used herein, “solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like.
  • As used herein, the term “hydrate” means a solvate wherein the solvent molecule is water.
  • The compounds of Formula (I) or Formula (II) can form salts, which are intended to be included within the scope of this description. Reference to a compound of Formula (I) or Formula (II) or a form thereof herein is understood to include reference to salt forms thereof, unless otherwise indicated. The term “salt(s)”, as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when a compound of Formula (I) or Formula (II) or a form thereof contains both a basic moiety, such as, without limitation an amine moiety, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions (“inner salts”) may be formed and are included within the term “salt(s)” as used herein.
  • The term “pharmaceutically acceptable salt(s)”, as used herein, means those salts of compounds described herein that are safe and effective (i.e., non-toxic, physiologically acceptable) for use in mammals and that possess biological activity, although other salts are also useful. Salts of the compounds of the Formula (I) or Formula (II) may be formed, for example, by reacting a compound of Formula (I) or Formula (II) or a form thereof with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
  • Pharmaceutically acceptable salts include one or more salts of acidic or basic groups present in compounds described herein. Particular aspects of acid addition salts include, and are not limited to, acetate, ascorbate, benzoate, benzenesulfonate, bisulfate, bitartrate, borate, bromide, butyrate, chloride, citrate, camphorate, camphorsulfonate, ethanesulfonate, formate, fumarate, gentisinate, gluconate, glucaronate, glutamate, iodide, isonicotinate, lactate, maleate, methanesulfonate, naphthalenesulfonate, nitrate, oxalate, pamoate, pantothenate, phosphate, propionate, saccharate, salicylate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate (also known as tosylate), trifluoroacetate salts and the like. Certain particular aspects of acid addition salts include chloride or dichloride.
  • Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al, Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley-VCH; S. Berge et al, Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33, 201-217; Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (Food & Drug Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference thereto.
  • Suitable basic salts include, but are not limited to, aluminum, ammonium, calcium, lithium, magnesium, potassium, sodium and zinc salts.
  • All such acid salts and base salts are intended to be included within the scope of pharmaceutically acceptable salts as described herein. In addition, all such acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of this description.
  • Compounds of Formula (I) or Formula (II) and forms thereof, may further exist in a tautomeric form. All such tautomeric forms are contemplated and intended to be included within the scope of the compounds of Formula (I) or Formula (II) or a form thereof as described herein.
  • The compounds of Formula (I) or Formula (II) or a form thereof may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. The present description is intended to include all stereoisomeric forms of the compounds of Formula (I) or Formula (II) as well as mixtures thereof, including racemic mixtures.
  • The compounds described herein may include one or more chiral centers, and as such may exist as racemic mixtures (R S) or as substantially pure enantiomers and diastereomers. The compounds may also exist as substantially pure (R) or (S) enantiomers (when one chiral center is present). In one particular aspect, the compounds described herein are (S) isomers and may exist as enantiomerically pure compositions substantially comprising only the (S) isomer. In another particular aspect, the compounds described herein are (R) isomers and may exist as enantiomerically pure compositions substantially comprising only the (R) isomer. As one of skill in the art will recognize, when more than one chiral center is present, the compounds described herein may also exist as a (R,R), (R,S), (S,R) or (S,S) isomer, as defined by IUPAC Nomenclature Recommendations.
  • As used herein, the term “substantially pure” refers to compounds consisting substantially of a single isomer in an amount greater than or equal to 90%, in an amount greater than or equal to 92%, in an amount greater than or equal to 95%, in an amount greater than or equal to 98%, in an amount greater than or equal to 99%, or in an amount equal to 100% of the single isomer.
  • In one aspect of the description, a compound of Formula (I) or Formula (II) or a form thereof is a substantially pure (S) enantiomer form present in an amount greater than or equal to 90%, in an amount greater than or equal to 92%, in an amount greater than or equal to 95%, in an amount greater than or equal to 98%, in an amount greater than or equal to 99%, or in an amount equal to 100%.
  • In one aspect of the description, a compound of Formula (I) or Formula (II) or a form thereof is a substantially pure (R) enantiomer form present in an amount greater than or equal to 90%, in an amount greater than or equal to 92%, in an amount greater than or equal to 95%, in an amount greater than or equal to 98%, in an amount greater than or equal to 99%, or in an amount equal to 100%.
  • As used herein, a “racemate” is any mixture of isometric forms that are not “enantiomerically pure”, including mixtures such as, without limitation, in a ratio of about 50/50, about 60/40, about 70/30, or about 80/20.
  • In addition, the present description embraces all geometric and positional isomers. For example, if a compound of Formula (I) or Formula (II) or a form thereof incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the description. Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by use of chiral HPLC column or other chromatographic methods known to those skilled in the art. Enantiomers can also be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Also, some of the compounds of Formula (I) or Formula (II) may be atropisomers (e.g., substituted biaryls) and are considered as part of this description.
  • All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this description, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl). Individual stereoisomers of the compounds described herein may, for example, be substantially free of other isomers, or may be present in a racemic mixture, as described supra.
  • The use of the terms “salt”, “solvate”, “ester”, “prodrug” and the like, is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or isotopologues of the instant compounds.
  • The term “isotopologue” refers to isotopically-enriched compounds described herein which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds described herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as 2H, 3H, 13C, 14C, 15N, 18O, 17O 31P, 32P, 35S, 18F, 35Cl and 36Cl, respectively, each of which are also within the scope of this description.
  • Certain isotopically-enriched compounds described herein (e.g., those labeled with 3H and 14C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3H) and carbon-14 (i.e., 14C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances.
  • Polymorphic crystalline and amorphous forms of the compounds of Formula (I) or Formula (II) and of the salts, solvates, hydrates, esters and prodrugs of the compounds of Formula (I) or Formula (II) are further intended to be included in the present description.
    • Compound Uses
  • In accordance with the intended scope of the present description, aspects of the present description include compounds that have been identified and have been demonstrated to be useful in selectively preventing, treating or ameliorating HD and have been provided for use for preventing, treating or ameliorating HD.
  • An aspect of the present description includes a method for preventing, treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a method for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a method for preventing HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a method for treating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a method for ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound of Formula (I) or Formula (II) or a form thereof.
  • Another aspect of the present description includes a method for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound salt of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a method for use of a compound of Formula (I) or Formula (II) or a form or composition thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form or composition thereof.
  • Another aspect of the present description includes a method for use of a compound salt of Formula (I) or Formula (II) or a form or composition thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound salt of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form thereof.
  • Another aspect of the present description includes a use for a compound salt of Formula (I) or Formula (II) or a form thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound salt of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof in the manufacture of a medicament for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the medicament.
  • Another aspect of the present description includes a use for a compound salt of Formula (I) or Formula (II) or a form thereof in the manufacture of a medicament for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the medicament.
  • An aspect of the present description includes in vitro or in vivo use of the compound of Formula (I) or Formula (II) or a form thereof having activity toward HD.
  • An aspect of the present description includes a use of the compound of Formula (I) or Formula (II) or a form thereof in a combination therapy to provide additive or synergistic activity, thus enabling the development of a combination product for treating or ameliorating HD.
  • Another aspect of the present description includes a combination therapy comprising compounds described herein in combination with one or more known drugs or one or more known therapies may be used to treat HD regardless of whether HD is responsive to the known drug.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof in a combination product with one or more therapeutic agents for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form thereof in combination with an effective amount of the one or more agents.
  • Another aspect of the present description includes a use for a compound salt of Formula (I) or Formula (II) or a form thereof in a combination product with one or more therapeutic agents for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound salt of Formula (I) or Formula (II) or a form thereof in combination with an effective amount of the one or more agents.
  • In an aspect of a use or method provided herein, compounds of Formula (I) or Formula (II) or a form thereof used in combination with one or more additional agents can be administered to a subject or contacted with a subject or patient cell(s) prior to, concurrently with, or subsequent to administering to the subject or patient or contacting the cell with an additional agent(s). A compound(s) of Formula (I) or Formula (II) or a form thereof and an additional agent(s) can be administered to a subject or contacted with a cell in single composition or different compositions. In a specific aspect, a compound(s) of Formula (I) or Formula (II) or a form thereof is used in combination with gene therapy to inhibit HTT expression (using, e.g., viral delivery vectors) or the administration of another small molecule HTT inhibitor. In another specific aspect, a compound(s) of Formula (I) or Formula (II) or a form thereof are used in combination with cell replacement using differentiated non-mutant HTT stem cells. In another specific aspect, a compound(s) of Formula (I) or Formula (II) or a form thereof are used in combination with cell replacement using differentiated HTT stem cells.
  • In one aspect, provided herein is the use of compounds of Formula (I) or Formula (II) or a form thereof in combination with supportive standard of care therapies, including palliative care.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof in the preparation of a kit for treating or ameliorating HD in a subject in need thereof comprising, the compound of Formula (I) or Formula (II) or a form thereof and instructions for administering an effective amount of the compound of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof in the preparation of a kit for treating or ameliorating HD in a subject in need thereof comprising, the compound of Formula (I) or Formula (II) or a form thereof and instructions for administering an effective amount of the compound of Formula (I) or Formula (II) or a form thereof; and optionally, for administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form thereof in a combination product with an effective amount of one or more therapeutic agents.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof in the preparation of a kit for treating or ameliorating HD in a subject in need thereof comprising, the compound of Formula (I) or Formula (II) or a form thereof and instructions for administering an effective amount of the compound of Formula (I) or Formula (II) or a form thereof; and optionally, for administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form thereof in a combination product with an effective amount of the one or more therapeutic agents; and optionally, for administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form thereof in a combination product with an effective amount of the one or more therapeutic agents in a combination therapy with a standard of care supportive therapy, wherein the standard of care supportive therapy is palliative care.
  • In one respect, for each of such aspects, the subject is treatment naive. In another respect, for each of such aspects, the subject is not treatment naive.
  • As used herein, the term “preventing” refers to keeping a disease, disorder or condition from occurring in a subject that may be predisposed to the disease, disorder and/or condition but has not yet been diagnosed as having the disease, disorder and/or condition.
  • As used herein, the term “treating” refers to inhibiting the progression of a disease, disorder or condition in a subject already exhibiting the symptoms of the disease, disorder and/or condition, i.e., arresting the development of a disease, disorder and/or condition that has already affected the subject.
  • As used herein, the term “ameliorating” refers to relieving the symptoms of a disease, disorder or condition in a subject already exhibiting the symptoms of the disease, disorder and/or condition, i.e., causing regression of the disease, disorder and/or condition that has already affected the subject.
  • As used herein, the term “subject” refers to an animal or any living organism having sensation and the power of voluntary movement, and which requires oxygen and organic food. Nonlimiting examples include members of the human, primate, equine, porcine, bovine, murine, rattus, canine and feline specie. In certain aspects, the subject is a mammal or a warm-blooded vertebrate animal. In other aspects, the subject is a human. As used herein, the term “patient” may be used interchangeably with “subject” and “human”.
  • As used herein, the terms “effective amount” or “therapeutically effective amount” mean an amount of compound of Formula (I) or Formula (II) or a form, composition or medicament thereof that achieves a target plasma concentration that is effective in treating or ameliorating HD as described herein and thus producing the desired therapeutic, ameliorative, inhibitory or preventative effect in a subject in need thereof. In one aspect, the effective amount may be the amount required to treat HD in a subject or patient, more specifically, in a human.
  • In another aspect, the concentration-biological effect relationships observed with regard to a compound of Formula (I) or Formula (II) or a form thereof indicate a target plasma concentration ranging from approximately 0.001 μg/mL to approximately 50 μg/mL, from approximately 0.01 μg/mL to approximately 20 μg/mL, from approximately 0.05 μg/mL to approximately 10 μg/mL, or from approximately 0.1 μg/mL to approximately 5 μg/mL. To achieve such plasma concentrations, the compounds described herein may be administered at doses that vary, such as, for example, without limitation, from 1.0 ng to 10,000 mg.
  • In one aspect, the dose administered to achieve an effective target plasma concentration may be administered based upon subject or patient specific factors, wherein the doses administered on a weight basis may be in the range of from about 0.001 mg/kg/day to about 3500 mg/kg/day, or about 0.001 mg/kg/day to about 3000 mg/kg/day, or about 0.001 mg/kg/day to about 2500 mg/kg/day, or about 0.001 mg/kg/day to about 2000 mg/kg/day, or about 0.001 mg/kg/day to about 1500 mg/kg/day, or about 0.001 mg/kg/day to about 1000 mg/kg/day, or about 0.001 mg/kg/day to about 500 mg/kg/day, or about 0.001 mg/kg/day to about 250 mg/kg/day, or about 0.001 mg/kg/day to about 200 mg/kg/day, or about 0.001 mg/kg/day to about 150 mg/kg/day, or about 0.001 mg/kg/day to about 100 mg/kg/day, or about 0.001 mg/kg/day to about 75 mg/kg/day, or about 0.001 mg/kg/day to about 50 mg/kg/day, or about 0.001 mg/kg/day to about 25 mg/kg/day, or about 0.001 mg/kg/day to about 10 mg/kg/day, or about 0.001 mg/kg/day to about 5 mg/kg/day, or about 0.001 mg/kg/day to about 1 mg/kg/day, or about 0.001 mg/kg/day to about 0.5 mg/kg/day, or about 0.001 mg/kg/day to about 0.1 mg/kg/day, or from about 0.01 mg/kg/day to about 3500 mg/kg/day, or about 0.01 mg/kg/day to about 3000 mg/kg/day, or about 0.01 mg/kg/day to about 2500 mg/kg/day, or about 0.01 mg/kg/day to about 2000 mg/kg/day, or about 0.01 mg/kg/day to about 1500 mg/kg/day, or about 0.01 mg/kg/day to about 1000 mg/kg/day, or about 0.01 mg/kg/day to about 500 mg/kg/day, or about 0.01 mg/kg/day to about 250 mg/kg/day, or about 0.01 mg/kg/day to about 200 mg/kg/day, or about 0.01 mg/kg/day to about 150 mg/kg/day, or about 0.01 mg/kg/day to about 100 mg/kg/day, or about 0.01 mg/kg/day to about 75 mg/kg/day, or about 0.01 mg/kg/day to about 50 mg/kg/day, or about 0.01 mg/kg/day to about 25 mg/kg/day, or about 0.01 mg/kg/day to about 10 mg/kg/day, or about 0.01 mg/kg/day to about 5 mg/kg/day, or about 0.01 mg/kg/day to about 1 mg/kg/day, or about 0.01 mg/kg/day to about 0.5 mg/kg/day, or about 0.01 mg/kg/day to about 0.1 mg/kg/day, or from about 0.1 mg/kg/day to about 3500 mg/kg/day, or about 0.1 mg/kg/day to about 3000 mg/kg/day, or about 0.1 mg/kg/day to about 2500 mg/kg/day, or about 0.1 mg/kg/day to about 2000 mg/kg/day, or about 0.1 mg/kg/day to about 1500 mg/kg/day, or about 0.1 mg/kg/day to about 1000 mg/kg/day, or about 0.1 mg/kg/day to about 500 mg/kg/day, or about 0.1 mg/kg/day to about 250 mg/kg/day, or about 0.1 mg/kg/day to about 200 mg/kg/day, or about 0.1 mg/kg/day to about 150 mg/kg/day, or about 0.1 mg/kg/day to about 100 mg/kg/day, or about 0.1 mg/kg/day to about 75 mg/kg/day, or about 0.1 mg/kg/day to about 50 mg/kg/day, or about 0.1 mg/kg/day to about 25 mg/kg/day, or about 0.1 mg/kg/day to about 10 mg/kg/day, or about 0.1 mg/kg/day to about 5 mg/kg/day, or about 0.1 mg/kg/day to about 1 mg/kg/day, or about 0.1 mg/kg/day to about 0.5 mg/kg/day.
  • Effective amounts for a given subject may be determined by routine experimentation that is within the skill and judgment of a clinician or a practitioner skilled in the art in light of factors related to the subject. Dosage and administration may be adjusted to provide sufficient levels of the active agent(s) or to maintain the desired effect. Factors which may be taken into account include genetic screening, severity of the disease state, status of disease progression, general health of the subject, ethnicity, age, weight, gender, diet, time of day and frequency of administration, drug combination(s), reaction sensitivities, experience with other therapies, and tolerance/response to therapy.
  • The dose administered to achieve an effective target plasma concentration may be orally administered once (once in approximately a 24 hour period; i.e., “q.d.”), twice (once in approximately a 12 hour period; i.e., “b.i.d.” or “q.12h”), thrice (once in approximately an 8 hour period; i.e., “t.i.d.” or “q.8h”), or four times (once in approximately a 6 hour period; i.e., “q.d.s.”, “q.i.d.” or “q.6h”) daily.
  • In certain aspects, the dose administered to achieve an effective target plasma concentration may also be administered in a single, divided, or continuous dose for a patient or subject having a weight in a range of between about 40 to about 200 kg (which dose may be adjusted for patients or subjects above or below this range, particularly children under 40 kg). The typical adult subject is expected to have a median weight in a range of about 70 kg. Long-acting pharmaceutical compositions may be administered every 2, 3 or 4 days, once every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.
  • The compounds and compositions described herein may be administered to the subject via any drug delivery route known in the art. Nonlimiting examples include oral, ocular, rectal, buccal, topical, nasal, sublingual, transdermal, subcutaneous, intramuscular, intraveneous (bolus and infusion), intracerebral, and pulmonary routes of administration.
  • In another aspect, the dose administered may be adjusted based upon a dosage form described herein formulated for delivery at about 0.02, 0.025, 0.03, 0.05, 0.06, 0.075, 0.08, 0.09, 0.10, 0.20, 0.25, 0.30, 0.50, 0.60, 0.75, 0.80, 0.90, 1.0, 1.10, 1.20, 1.25, 1.50, 1.75, 2.0, 3.0, 5.0, 10, 20, 30, 40, 50, 100, 150, 200, 250, 300, 400, 500, 1000, 1500, 2000, 2500, 3000 or 4000 mg/day.
  • For any compound, the effective amount can be estimated initially either in cell culture assays or in relevant animal models, such as a mouse, guinea pig, chimpanzee, marmoset or tamarin animal model. Relevant animal models may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is therapeutic index, and can be expressed as the ratio, LD50/ED50. In certain aspects, the effective amount is such that a large therapeutic index is achieved. In further particular aspects, the dosage is within a range of circulating concentrations that include an ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.
  • In one aspect, provided herein are methods for modulating the amount of HTT (huntingtin protein), comprising contacting a human cell with a compound of Formula (I) or Formula (II) or a form thereof. In a specific aspect, provided herein are methods for modulating the amount of HTT, comprising contacting a human cell with a compound of Formula (I) or Formula (II) or a form thereof that modulates the expression of HTT. The human cell can be contacted with a compound of Formula (I) or Formula (II) or a form thereof in vitro, or in vivo, e.g., in a non-human animal or in a human. In a specific aspect, the human cell is from or in a human. In another specific aspect, the human cell is from or in a human with HD. In another specific aspect, the human cell is from or in a human with HD, caused by a CAG repeat in the Htt gene, resulting in a loss of HTT expression and/or function. In another aspect, the human cell is from a human with HD. In another aspect, the human cell is in a human with HD. In one aspect, the compound is a form of the compound of Formula (I) or Formula (II).
  • In a specific aspect, provided herein is a method for enhancing the inhibition of mutant HTT transcribed from the Htt gene, comprising contacting a human cell with a compound of Formula (I) or Formula (II) or a form thereof. The human cell can be contacted with a compound of Formula (I) or Formula (II) or a form thereof in vitro, or in vivo, e.g., in a non-human animal or in a human. In a specific aspect, the human cell is from or in a human. In another specific aspect, the human cell is from or in a human with HD. In another specific aspect, the human cell is from or in a human with HD, caused by a CAG repeat in the Htt gene, resulting in a loss of wild-type “normal” HTT expression and/or function. In another aspect, the human cell is from a human with HD. In another aspect, the human cell is in a human with HD. In one aspect, the compound is a form of the compound of Formula (I) or Formula (II).
  • In another aspect, provided herein is a method for modulating the inhibition of mutant HTT transcribed from the Htt gene, comprising administering to a non-human animal model for HD a compound of Formula (I) or Formula (II) or a form thereof. In a specific aspect, provided herein is a method for modulating the inhibition of mutant HTT transcribed from the Htt gene, comprising administering to a non-human animal model for HD a compound of Formula (I) or Formula (II) or a form thereof. In a specific aspect, the compound is a form of the compound of Formula (I) or Formula (II).
  • In another aspect, provided herein is a method for decreasing the amount of mutant HTT, comprising contacting a human cell with a compound of Formula (I) or Formula (II) or a form thereof. In a specific aspect, provided herein is a method for decreasing the amount of mutant HTT, comprising contacting a human cell with a compound of Formula (I) or Formula (II) that inhibits the transcription of mutant HTT (huntingtin mRNA) from the Htt gene. In another specific aspect, provided herein is a method for decreasing the amount of HTT, comprising contacting a human cell with a compound of Formula (I) or Formula (II) that inhibits the expression of mutant HTT transcribed from the Htt gene. The human cell can be contacted with a compound of Formula (I) or Formula (II) or a form thereof in vitro, or in vivo, e.g., in a non-human animal or in a human. In a specific aspect, the human cell is from or in a human. In another specific aspect, the human cell is from or in a human with HD. In another specific aspect, the human cell is from or in a human with HD, caused by a CAG repeat in the Htt gene, resulting in a loss of HTT expression and/or function. In another aspect, the human cell is from a human with HD. In another aspect, the human cell is in a human with HD. In one aspect, the compound is a form of the compound of Formula (I) or Formula (II).
  • In certain aspects, treating or ameliorating HD with a compound of Formula (I) or Formula (II) or a form thereof (alone or in combination with an additional agent) has a therapeutic effect and/or beneficial effect. In a specific aspect, treating HD with a compound of Formula (I) or Formula (II) or a form thereof (alone or in combination with an additional agent) results in one, two or more of the following effects: (i) reduces or ameliorates the severity of HD; (ii) delays onset of HD; (iii) inhibits the progression of HD; (iv) reduces hospitalization of a subject; (v) reduces hospitalization length for a subject; (vi) increases the survival of a subject; (vii) improves the quality of life for a subject; (viii) reduces the number of symptoms associated with HD; (ix) reduces or ameliorates the severity of a symptom(s) associated with HD; (x) reduces the duration of a symptom associated with HD; (xi) prevents the recurrence of a symptom associated with HD; (xii) inhibits the development or onset of a symptom of HD; and/or (xiii) inhibits of the progression of a symptom associated with HD.
    • Metabolites
  • Another aspect included within the scope of the present description are the use of in vivo metabolic products of the compounds described herein. Such products may result, for example, from the oxidation, reduction, hydrolysis, amidation, esterification and the like of the administered compound, primarily due to enzymatic processes. Accordingly, the description includes the use of compounds produced by a process comprising contacting a compound described herein with a mammalian tissue or a mammal for a period of time sufficient to yield a metabolic product thereof.
  • Such products typically are identified by preparing a radio-labeled isotopologue (e.g., 1C or 3H) of a compound described herein, administering the radio-labeled compound in a detectable dose (e.g., greater than about 0.5 mg/kg) to a mammal such as a rat, mouse, guinea pig, dog, monkey or human, allowing sufficient time for metabolism to occur (typically about 30 seconds to about 30 hours), and identifying the metabolic conversion products from urine, bile, blood or other biological samples. The conversion products are easily isolated since they are “radiolabeled” by virtue of being isotopically-enriched (others are isolated by the use of antibodies capable of binding epitopes surviving in the metabolite). The metabolite structures are determined in conventional fashion, e.g., by MS or NMR analysis. In general, analysis of metabolites may be done in the same way as conventional drug metabolism studies well-known to those skilled in the art. The conversion products, so long as they are not otherwise found in vivo, are useful in diagnostic assays for therapeutic dosing of the compounds described herein even if they possess no biological activity of their own.
    • Pharmaceutical Compositions
  • In accordance with the intended scope of the present description, aspects of the present description include compounds that have been identified and have been demonstrated to be useful in selectively preventing, treating or ameliorating HD and have been provided for use as one or more pharmaceutical compositions for preventing, treating or ameliorating HD.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof in the preparation of a pharmaceutical composition for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form thereof in admixture with one or more pharmaceutically acceptable excipients.
  • An aspect of the present description includes a use for a pharmaceutical composition of the compound of Formula (I) or Formula (II) or a form thereof in the preparation of a kit for treating or ameliorating HD in a subject in need thereof comprising, the pharmaceutical composition of the compound of Formula (I) or Formula (II) or a form thereof and instructions for administering the pharmaceutical composition.
  • As used herein, the term “composition” means a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • The pharmaceutical composition may be formulated to achieve a physiologically compatible pH, ranging from about pH 3 to about pH 11. In certain aspects, the pharmaceutical composition is formulated to achieve a pH of from about pH 3 to about pH 7. In other aspects, the pharmaceutical composition is formulated to achieve a pH of from about pH 5 to about pH 8.
  • The term “pharmaceutically acceptable excipient” refers to an excipient for administration of a pharmaceutical agent, such as the compounds described herein. The term refers to any pharmaceutical excipient that may be administered without undue toxicity. Pharmaceutically acceptable excipients may be determined in part by the particular composition being administered, as well as by the particular mode of administration and/or dosage form. Nonlimiting examples of pharmaceutically acceptable excipients include carriers, solvents, stabilizers, adjuvants, diluents, etc. Accordingly, there exists a wide variety of suitable formulations of pharmaceutical compositions for the instant compounds described herein (see, e.g., Remington's Pharmaceutical Sciences).
  • Suitable excipients may be carrier molecules that include large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive antibodies. Other exemplary excipients include antioxidants such as ascorbic acid; chelating agents such as EDTA; carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose (e.g., hydroxypropylmethylcellulose, also known as HPMC), stearic acid; liquids such as oils, water, saline, glycerol and ethanol; wetting or emulsifying agents; pH buffering substances; and the like. Liposomes are also included within the definition of pharmaceutically acceptable excipients.
  • The pharmaceutical compositions described herein may be formulated in any form suitable for the intended use described herein. Suitable formulations for oral administration include solids, liquid solutions, emulsions and suspensions, while suitable inhalable formulations for pulmonary administration include liquids and powders. Alternative formulations include syrups, creams, ointments, tablets, and lyophilized solids which can be reconstituted with a physiologically compatible solvent prior to administration.
  • When intended for oral use for example, tablets, troches, lozenges, aqueous or oil suspensions, non-aqueous solutions, dispersible powders or granules (including micronized particles or nanoparticles), emulsions, hard or soft capsules, syrups or elixirs may be prepared. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents including sweetening agents, flavoring agents, coloring agents, and preserving agents, in order to provide a palatable preparation.
  • Pharmaceutically acceptable excipients suitable for use in conjunction with tablets include, for example, inert diluents, such as celluloses, calcium or sodium carbonate, lactose, calcium or sodium phosphate; disintegrating agents, such as croscarmellose sodium, cross-linked povidone, maize starch, or alginic acid; binding agents, such as povidone, starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid, or talc. Tablets may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.
  • Formulations for oral use may be also presented as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent, for example celluloses, lactose, calcium phosphate, or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with non-aqueous or oil medium, such as glycerin, propylene glycol, polyethylene glycol, peanut oil, liquid paraffin, or olive oil.
  • In other aspects, pharmaceutical compositions described herein may be formulated as suspensions comprising a compound of Formula (I) or Formula (II) or a form thereof in admixture with one or more pharmaceutically acceptable excipients suitable for the manufacture of a suspension. In yet other aspects, pharmaceutical compositions described herein may be formulated as dispersible powders and granules suitable for preparation of a suspension by the addition of one or more excipients.
  • Excipients suitable for use in connection with suspensions include suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcelluose, sodium alginate, polyvinylpyrrolidone, gum tragacanth, gum acacia, dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycethanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan monooleate); and thickening agents, such as carbomer, beeswax, hard paraffin, or cetyl alcohol. The suspensions may also contain one or more preservatives such as acetic acid, methyl and/or n-propyl p-hydroxy-benzoate; one or more coloring agents; one or more flavoring agents; and one or more sweetening agents such as sucrose or saccharin.
  • The pharmaceutical compositions described herein may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these. Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth; naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids; hexitol anhydrides, such as sorbitan monooleate; and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. The emulsion may also contain sweetening and flavoring agents. Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
  • Additionally, the pharmaceutical compositions described herein may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous emulsion or oleaginous suspension. Such emulsion or suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,2-propanediol. The sterile injectable preparation may also be prepared as a lyophilized powder. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils may be employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid may likewise be used in the preparation of injectables.
  • The compounds described herein may be substantially insoluble in water and sparingly soluble in most pharmaceutically acceptable protic solvents and vegetable oils, but generally soluble in medium-chain fatty acids (e.g., caprylic and capric acids) or triglycerides and in propylene glycol esters of medium-chain fatty acids. Thus, contemplated in the description are compounds which have been modified by substitutions or additions of chemical or biochemical moieties which make them more suitable for delivery (e.g., increase solubility, bioactivity, palatability, decrease adverse reactions, etc.), for example by esterification, glycosylation, PEGylation, etc.
  • In certain aspects, the compound described herein is formulated for oral administration in a lipid-based composition suitable for low solubility compounds. Lipid-based formulations can generally enhance the oral bioavailability of such compounds. As such, pharmaceutical compositions described herein may comprise a effective amount of a compound of Formula (I) or Formula (II) or a form thereof, together with at least one pharmaceutically acceptable excipient selected from medium chain fatty acids or propylene glycol esters thereof (e.g., propylene glycol esters of edible fatty acids such as caprylic and capric fatty acids) and pharmaceutically acceptable surfactants, such as polysorbate 20 or 80 (also referred to as Tween® 20 or Tween® 80, respectively) or polyoxyl 40 hydrogenated castor oil.
  • In other aspects, the bioavailability of low solubility compounds may be enhanced using particle size optimization techniques including the preparation of nanoparticles or nanosuspensions using techniques known to those skilled in the art. The compound forms present in such preparations include amorphous, partially amorphous, partially crystalline or crystalline forms.
  • In alternative aspects, the pharmaceutical composition may further comprise one or more aqueous solubility enhancer(s), such as a cyclodextrin. Nonlimiting examples of cyclodextrin include hydroxypropyl, hydroxyethyl, glucosyl, maltosyl and maltotriosyl derivatives of α-, β-, and T-cyclodextrin, and hydroxypropyl-β-cyclodextrin (HIPBC). In certain aspects, the pharmaceutical composition further comprises HPBC in a range of from about 0.1% to about 20%, from about 1% to about 15%, or from about 2.5% to about 10%. The amount of solubility enhancer employed may depend on the amount of the compound in the composition.
    • Preparation of Compounds General Synthetic Methods
  • As disclosed herein, general methods for preparing the compounds of Formula (I) or Formula (II) or a form thereof as described herein are available via standard, well-known synthetic methodology. Many of the starting materials are commercially available or, when not available, can be prepared using the routes described below using techniques known to those skilled in the art. The synthetic schemes provided herein comprise multiple reaction steps, each of which is intended to stand on its own and can be carried out with or without any preceding or succeeding step(s). In other words, each of the individual reaction steps of the synthetic schemes provided herein in isolation is contemplated.
  • Figure US20230331725A1-20231019-C00101
  • Compounds of Formula (I), wherein B is heterocyclyl, X is O, NH or NR1b, where R1b is C1-4alkyl, may be prepared as described in Scheme A below.
    Compound A1 (where W1 is bromine, chlorine and the like) is converted to Compound A2 by a nucleophilic substitution with a primary or secondary amine or an alcohol (BXH) in the presence of a suitable base (such as Et3N and the like) in a suitable solvent (such as DMF and the like). Alternatively, Compound A1 is converted to Compound A2 via cross coupling with a primary or a secondary amine in the presence of a suitable catalyst (such as RuPhos Pd G2 and the like) and base (such as sodium tert-butoxide and the like) in an appropriate solvent such as 1,4-dioxane and the like). Compound A2 is converted to Compound A3 by halogenation upon treatment with an appropriate reagent (such as bromine and the like) in an appropriate solvent (such as methanol and the like). Compound A3 is converted to Compound A4 by a Suzuki coupling with an aryl- or heteroaryl-boronic acid (or pinacol boronic ester) in the presence of a catalyst (such as Pd(dppf)Cl2 and the like) and base (such as aqueous K2CO3 and the like) in a suitable solvent (such as 1,4-dioxane and the like). Alternatively, Compound A3 is converted to Compound A4 by a Stille coupling with an aryl- or heteroaryl-stannane in the presence of a catalyst (such as Pd2(dba)3 and the like), a ligand (such as X-Phos and the like) and a base (such as CsF and the like) in a suitable solvent (such as 1,4-dioxane and the like). Any protecting groups may be removed upon treatment with a suitable reagent (such as HCl in dioxane for a Boc protecting group and the like) in a suitable solvent (such as dioxane and the like).
  • Figure US20230331725A1-20231019-C00102
  • Compounds of Formula (I), wherein (R4)n is hydrogen, halogen, hydroxy, or C1-4alkoxy, n is 0 or 1, R4 is heterocyclyl, heteroaryl, or phenyl, B is heterocyclyl; X is O, NH or NR1b, and R1b is C1-4alkyl, may be prepared as described in Scheme B below.
  • Compound B1 (where W1 is bromine, chlorine and the like) is converted to Compound B3 by a Suzuki coupling with an aryl-boronic acid (or pinacol boronic ester) B2 (where W2 is bromine, chlorine and the like; (R4)n is hydrogen, halogen, hydroxy, or C1-4alkoxy, and PG is a protecting group such as MOM and the like) in the presence of a catalyst (such as Pd(dppf)Cl2 and the like) and base (such as aqueous K2CO3 and the like) in a suitable solvent (such as 1,4-dioxane and the like). Compound B3 is converted to Compound B4 by treatment with an oxidizing agent (such as mCPBA or oxone and the like) in a suitable solvent (such as dichloromethane and the like). Compound B4 is converted to Compound B5 by a nucleophilic substitution with a primary or a secondary amine or an alcohol (BXH, where X is O, NH or NR1b, where R1b is C1-4alkyl) in the presence of a suitable base (such as Et3N and the like) in a suitable solvent (such as DMF and the like). Compound B5 is converted to Compound B6 by a Suzuki coupling with an aryl- or heteroaryl-boronic acid (or pinacol boronic ester) in the presence of a catalyst (such as Pd(dppf)Cl2 and the like) and a base (such as aqueous K2CO3 and the like) in a suitable solvent (such as 1,4-dioxane and the like). Alternatively, Compound B5 is converted to Compound B6 by a Stille coupling with an aryl- or heteroaryl-stannane in the presence of a catalyst (such as Pd2(dba)3 and the like), a ligand (such as X-Phos and the like) and a base (such as CsF and the like) in a suitable solvent (such as 1,4-dioxane and the like). Alternatively, Compound B5 is converted to Compound B6 by treatment with pinacolatodiboron and a base (such as KOAc and the like) in the presence of a catalyst (such as Pd(dppf)Cl2 and the like) in an appropriate solvent (such as 1,4-dioxane and the like), followed by addition of an aryl- or heteroaryl-halide. Alternatively, Compound B5 is converted to Compound B6 by a Buchwald-Hartwig coupling with a heteroaryl or amine in the presence of a catalyst (such as Pd2(dba)3 and the like), a ligand (such as tBuX-Phos and the like) and a base (such as K3PO4 and the like) in a suitable solvent (such as 1,4-dioxane and the like). Compound B6 is converted to Compound B7 upon treatment with conditions appropriate to the removal of the protecting groups (such as HCl in dioxane for a MOM protecting group) in a suitable solvent (such as dioxane and the like).
  • Figure US20230331725A1-20231019-C00103
  • Following the general conditions described in Scheme B, but changing the order of steps 2 and 4, compound C1 can be converted to compound C7.
  • Figure US20230331725A1-20231019-C00104
  • Compounds of Formula (II), wherein (R4)n is hydrogen, halogen, hydroxy, or C1-4alkoxy, n is 0 or 1, R4 is heterocyclyl, heteroaryl, or phenyl, B is heterocyclyl; X is O, NH or NR1b, and R1b is C1-4alkyl, may be prepared as described in Scheme D below.
  • Compound D1 (where W1, is bromine, chlorine and the like; (R4)n is hydrogen, halogen, hydroxy, or C1-4alkoxy; and PG is a protecting group such as MOM and the like) is converted to Compound D2 by a condensation/cyclization sequence in presence of hydrazine in a suitable solvent (such as ethanol and the like). Compound D2 is converted to Compound D3 by treatment with a dehydrative halogenating agent (such as POCl3 and the like) followed by treatment with an oxidizing agent (such as manganese dioxide and the like). Compound D3 is converted to Compound D4 by a nucleophilic substitution with a primary or a secondary amine or an alcohol (BXH, where X is O, NH or NR1b, where R1b is C1-4alkyl) in the presence of a suitable base (such as Et3N and the like) in a suitable solvent (such as DMF and the like). Alternatively, Compound D3 is converted to Compound D4 via cross coupling with a primary amine or a secondary amine or an alcohol in the presence of a suitable catalyst (such as RuPhos Pd G2 and the like) and base (such as sodium tert-butoxide and the like) in an appropriate solvent such as 1,4-dioxane and the like). Compound D4 is converted to Compound D5 by a Suzuki coupling with an aryl- or heteroaryl-boronic acid (or pinacol boronic ester) in the presence of a catalyst (such as Pd(dppf)Cl2 and the like) and base (such as aqueous K2CO3 and the like) in a suitable solvent (such as 1,4-dioxane and the like). Alternatively, Compound D4 is converted to Compound D5 by a Stille coupling with an aryl- or heteroaryl-stannane in the presence of a catalyst (such as Pd2(dba)3 and the like), a ligand (such as X-Phos and the like) and a base (such as CsF and the like) in a suitable solvent (such as 1,4-dioxane and the like). Alternatively, Compound D4 is converted to Compound D5 by treatment with pinacolatodiboron and a base (such as KOAc and the like) in the presence of a catalyst (such as Pd(dppf)Cl2 and the like) in an appropriate solvent (such as 1,4-dioxane and the like), followed by addition of an aryl- or heteroaryl-halide. Alternatively, Compound D4 is converted to Compound D5 by a Buchwald-Hartwig coupling with a heteroaryl or amine in the presence of a catalyst (such as Pd2(dba)3 and the like), a ligand (such as tBuX-Phos and the like) and a base (such as K3PO4 and the like) in a suitable solvent (such as 1,4-dioxane and the like). Compound D5 is converted to Compound D6 upon treatment with conditions appropriate to the removal of the protecting groups (such as HCl in dioxane for a MOM protecting group) in a suitable solvent (such as dioxane and the like).
    • SPECIFIC SYNTHETIC EXAMPLES
  • To describe in more detail and assist in understanding, the following non-limiting examples are offered to more fully illustrate the scope of compounds described herein and are not to be construed as specifically limiting the scope thereof. Such variations of the compounds described herein that may be now known or later developed, which would be within the purview of one skilled in the art to ascertain, are considered to fall within the scope of the compounds as described herein and hereinafter claimed. These examples illustrate the preparation of certain compounds. Those of skill in the art will understand that the techniques described in these examples represent techniques, as described by those of ordinary skill in the art, that function well in synthetic practice, and as such constitute preferred modes for the practice thereof. However, it should be appreciated that those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific methods that are disclosed and still obtain a like or similar result without departing from the spirit and scope of the present description.
  • Other than in the following examples of the embodied compounds, unless indicated to the contrary, all numbers expressing quantities of ingredients, reaction conditions, experimental data, and so forth used in the specification and claims are to be understood as being modified by the term “about”. Accordingly, all such numbers represent approximations that may vary depending upon the desired properties sought to be obtained by a reaction or as a result of variable experimental conditions. Therefore, within an expected range of experimental reproducibility, the term “about” in the context of the resulting data, refers to a range for data provided that may vary according to a standard deviation from the mean. As well, for experimental results provided, the resulting data may be rounded up or down to present data consistently, without loss of significant figures. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed in light of the number of significant digits and rounding techniques used by those of skill in the art.
  • While the numerical ranges and parameters setting forth the broad scope of the present description are approximations, the numerical values set forth in the examples set forth below are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
  • The starting materials used in the examples provided are commercially available or can be prepared according to methods known to one skilled in the art or can be prepared by the procedures disclosed herein.
    • Compound Examples
  • As used above, and throughout the present description, the following abbreviations, unless otherwise indicated, shall be understood to have the following meanings:
  • Abbreviation Meaning
    Δ heating (chemistry) or deletion (biology)
    AcOH or HOAc acetic acid
    Ar argon
    ACN or CH3CN acetonitrile
    aq. aqueous
    atm atmosphere(s)
    BBr3 boron tribromide
    B2pin2 bis(pinacolato)diboron
    Boc tert-butoxy-carbonyl
    t-Bu tert-butyl
    t-BuOK or KOtBu postassium tert-butoxide
    BuOH or n-BuOH n-butanol
    ° C. degrees Centigrade
    Celite ® or Celite diatomaceous earth
    d/h/hr/hrs/min/s day(d)/hour(h, hr or hrs)/minute(min)/
    second(s)
    DCM or CH2Cl2 dichloromethane
    DMF dimethylformamide
    DMSO dimethylsulfoxide
    EtOAc ethyl acetate
    EtOH ethanol
    Et2O diethyl ether
    equiv equivalents
    H2 hydrogen
    HBr hydrobromic acid
    HCl hydrochloric acid
    H2SO4 sulfuric acid
    K2CO3 potassium carbonate
    KOAc potassium acetate
    KOH potassium hydroxide
    LC/MS, LCMS or liquid chromatographic mass spectroscopy
    LC-MS
    LiOt-Bu lithium tert-butoxide
    LiOH lithium hydroxide
    mCPBA meta-chloroperoxybenzoic acid
    MeOH methanol
    MeSO3H methanesulfonic acid
    MgSO4 magnesium sulfate
    mL milliliter
    MOM methoxymethyl
    MS mass spectroscopy
    NEt3 triethylamine
    NH4Cl ammonium chloride
    NH4OAc ammonium acetate
    Na2CO3 sodium carbonate
    NaH sodium hydride
    NaHCO3 sodium bicarbonate
    NaOH sodium hydroxide
    Na2SO4 sodium sulfate
    N2 nitrogen
    NH4Cl ammoniuim chloride
    NMP N-methylpyrrolidone
    NMR nuclear magnetic resonance
    Pd palladium
    Pd/C palladium on carbon
    Pd2(dba)3 tris(dibenzylideneacetone)dipalladium(0)
    Pd(dppf)Cl2 or [1,1′-
    Pd(dppf)Cl2—CH2Cl2 bis(diphenylphosphino)ferrocene]
    dichloropalladium(II),
    complex with dichloromethane
    PhMe toluene
    Psi pounds per square inch pressure
    QPhos 1,2,3,4,5-pentaphenyl-1′-
    (di-tert-butylphosphino)ferrocene
    Rt or rt room temperature
    S-Phos, SPhos or 2-dicyclohexylphosphino-2′,6′-
    Sphos dimethoxybiphenyl
    S-Phos G2 chloro(2-dicyclohexylphosphino-2′,6′-
    dimethoxy-1,1′-biphenyl)(2′-amino-1,1′-
    biphenyl-2-yl) palladium(II)
    TBAF tetrabutylammonium fluoride
    TBS tert-butyldimethylsilyl
    TEA, Et3N or NEt3 triethylamine
    Tf trifluoromethane sulfonyl or triflate
    TFA trifluoroacetic acid
    THF tetrahydrofuran
    THP tetrahydropyranyl
    TIPS tiisopropylsilane
    TLC thin layer chromatography
    UPLC Ulta performance liquid chromatography
    • Preparation of Starting Material: 4-(3-(Methoxymethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole
  • Figure US20230331725A1-20231019-C00105
    • Step 1:
  • 2-Bromo-5-iodophenol (54.9 g, 184 mmol), was dissolved in DMF (240 mL) at 0° C. Sodium tert-pentoxide (2.5 M in THF, 90 mL, 230 mmol) was added dropwise. This was stirred at 0° C. for 15 minutes after addition was complete. Chloromethyl methyl ether (18 mL, 225 mmol) was added dropwise over 30 minutes. The mixture was warmed to ambient temperature and was stirred for 16 hours. The mixture was diluted with 1.5 L of H2O and was extracted into 2×400 mL of EtOAc. The combined organic layers were washed with 300 mL of H2O, and then with brine. The organic layer was dried over MgSO4, filtered, and concentrated under vacuum. The residue was flushed through a silica plug using 0-10% CH2Cl2 in hexanes to yield 1-bromo-4-iodo-2-(methoxymethoxy)benzene (61 g, 97%) as a clear liquid.
  • 1H NMR (acetone-d6): δ 7.56 (d, J=2 Hz, 1H), 7.38 (d, J=8 Hz, 1H), 7.33 (dd, J=8 Hz, 2 Hz, 1H), 5.35 (s, 2H), 3.50 (s, 3H).
    • Step 2:
  • 1-Bromo-4-iodo-2-(methoxymethoxy)benzene (49 g, 143 mmol), 1-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (48.4 g, 174 mmol), Pd(dppf)Cl2-dichloromethane adduct (3.1 g, 3.6 mmol), dioxane (500 mL), and aqueous K2CO3 (1M, 350 mL, 350 mmol) were heated at 90° C. for 2 hours. The reaction mixture was then partitioned between H2O and EtOAc. The organic layer was dried over MgSO4, filtered, and concentrated under vacuum. The residue was purified by silica gel chromatography eluting with a EtOAc/hexanes gradient (20-50% EtOAc), followed by trituration with hexanes, yielding 4-(4-bromo-3-(methoxymethoxy)phenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (40.4 g, 77% yield) as an off-white solid.
  • 1H NMR (acetone-d6): δ 8.22 (s, 1H), 7.88 (s, 1H), 7.55 (d, J=8.5 Hz, 1H), 7.47 (d, J=2 Hz, 1H), 7.23 (dd, J=8.5 Hz, 2 Hz, 1H), 5.44 (dd, J=9.5 Hz, 2.5 Hz, 1H), 5.38 (s, 2H), 4.01 (m, 1H), 3.72 (m, 1H), 3.51 (s, 3H), 2.1-2.23 (m, 1H), 2.0-2.1 (m, 2H), 1.7-1.8 (m, 1H), 1.6-1.7 (m, 2H).
    • Step 3:
  • A flask containing potassium acetate (22 g, 224 mmol) was pumped dry at 180° C. for 2 hours, and then was filled with argon. 4-(4-Bromo-3-(methoxymethoxy)phenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (20 g, 54.5 mmol), Pd(dppf)Cl2-dichloromethane adduct (1.22 g, 1.47 mmol), bis(pinacolato)diboron (20.8 g, 81.9 mmol), and dry toluene (200 mL) were added. This mixture was heated at 110° C. for 48 h. After cooling, the mixture was filtered through celite, followed by rinsing with ether. The filtrate was concentrated under vacuum, re-dissolved in ether, and was filtered again through celite to remove solid impurities. Purification by silica gel chromatography eluting with a gradient of EtOAc/hexane (20-50% EtOAc) yielded 12 g of crude title product. The crude material was dissolved in 100 mL ether and was back-washed with 2×1.5 L of dilute aqueous NaHCO3. The ether layer was washed with brine, dried over MgSO4, and was filtered. The filtrate was concentrated to a glassy semi-solid. This material was hexane-triturated to yield 4-(3-(methoxymethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole as a white crystalline solid (7.05 g, 32% yield).
  • 1H NMR (acetone-d6): δ 8.24 (s, 1H), 7.90 (s, 1H), 7.65 (d, J=8 Hz, 1H), 7.33 (d, J=1.5 Hz, 1H), 7.29 (dd, J=8 Hz, 1.5 Hz, 1H), 5.45 (dd, J=10 Hz, 2.5 Hz, 1H), 5.25 (s, 2H), 4.01 (m, 1H), 3.69-3.74 (m, 1H), 3.52 (s, 3H), 2.15-2.2 (m, 1H), 2.0-2.1 (m, 2H), 1.7-1.8 (m, 1H), 1.6-1.68 (m, 2H), 1.35 (s, 12H).
  • Using the procedure described, additional compounds described herein may be prepared by substituting the appropriate starting material, suitable reagents and reaction conditions, obtaining compounds such as those selected from:
  • Structure Data
    Figure US20230331725A1-20231019-C00106
         		MS m/z 345.5 [M + H]+; 1H NMR (methanol-d4) δ: 7.94-8.03 (m, 1H), 7.84 (s, 1H), 7.64 (br d, J = 7.6 Hz, 1H), 7.25 (s, 1H), 7.20 (d, J = 7.3 Hz, 1H), 5.25 (s, 2H), 3.81-3.98 (m, 3H), 3.53 (s, 3H), 1.36 (s, 12H)
    Figure US20230331725A1-20231019-C00107
         		MS m/z 348.5 [M + H]+; 1H NMR (methanol-d4) δ: 8.00 (s, 1H), 7.85 (s, 1H), 7.64 (br d, J = 7.6 Hz, 1H), 7.26 (s, 1H), 7.22 (d, J = 7.6 Hz, 1H), 5.26 (s, 2H), 4.86 (s, 3H), 1.37 (s, 12H)
    Figure US20230331725A1-20231019-C00108
         		MS m/z 349.2 [M − THP + H]+
    Figure US20230331725A1-20231019-C00109
         		MS m/z 316.6 [M + H]+
    • Preparation of Starting Material: 1-(3-(Methoxymethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-4-methyl-1H-imidazole
  • Figure US20230331725A1-20231019-C00110
    • Step 1:
  • An oven-dried vial was equipped with a magnetic stir bar and charged with 1-bromo-4-iodo-2-(methoxymethoxy)benzene (0.7 g, 2.0 mmol), 4-methyl-1H-imidazole (0.2 g, 2.4 mmol), copper(I) oxide (0.015 g, 0.1 mmol), salicylaldoxime (0.057 g, 0.43 mmol), and cesium carbonate (1.35 g, 4.1 mmol). The reaction mixture was purged with argon, acetonitrile (6 mL) was added, and the reaction was stirred at 50° C. for 24 h. The reaction was diluted with water and then extracted with CH2C2. The organic layer was washed with water, dried over MgSO4, filtered, and concentrated under reduced pressure. The crude oil was purified by silica gel chromatography eluting with a MeOH/CH2Cl2 gradient (0-15% MeOH) to afford 1-(4-bromo-3-(methoxymethoxy)phenyl)-4-methyl-1H-imidazole (0.38 g, 1.28 mmol, 60%). MS m/z 297.1, 299.1 [M+H]+.
    • Step 2:
  • An oven-dried vial was equipped with a magnetic stir bar and charged with 1-(4-bromo-3-(methoxymethoxy)phenyl)-4-methyl-1H-imidazole (0.19 g, 0.64 mmol), bis(pinacolato)diboron (0.25 g, 0.98 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dicholoropalladium(II) (0.06 g, 0.07 mmol), and potassium acetate (0.19 g, 1.94 mmol) and was purged with argon. Dioxane (5 mL) was added, and the reaction was stirred at 90° C. for 2 h. The crude mixture was purified by silica gel chromatography eluting with a MeOH/CH2Cl2 gradient (0-10% MeOH) to afford 1-(3-(methoxymethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-4-methyl-1H-imidazole (0.11 g, 0.32 mmol, 50%). MS m/z 345.2 [M+H]+.
  • Using the procedure described, additional compounds described herein may be prepared by substituting the appropriate starting material, suitable reagents and reaction conditions, obtaining compounds such as those selected from:
  • Structure Data
    Figure US20230331725A1-20231019-C00111
         		MS m/z 349.4 [M + H]+
    • Preparation of Starting Material: 3-[2,3-Dimethoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1-methyl-pyrazole
  • Figure US20230331725A1-20231019-C00112
    • Step 1:
  • A 25 mL round bottom flask was charged with 1,4-diiodo-2,3-dimethoxybenzene (460 mg, 1.17 mmol), 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole (180 mg, 0.87 mmol), 1,1′-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (80 mg, 0.10 mmol) potassium carbonate (360 mg, 2.60 mmol), water (9.4 mL) and 1,4-dioxane (9.4 mL) and the reaction mixture was purged with N2 for 15 minutes. The mixture was then heated at 80° C. for 2 hours. The reaction was cooled, concentrated and purified by silica gel chromatography eluting with a gradient of EtOAc/hexanes (30-100% EtOAc) to give 3-(4-iodo-2,3-dimethoxy-phenyl)-1-methyl-pyrazole (104 mg, 35% yield). MS m/z 345.0 [M+H]+.
    • Step 2:
  • A screw-cap tube was charged with 3-(4-iodo-2,3-dimethoxy-phenyl)-1-methyl-pyrazole (48 mg, 0.14 mmol), bis(pinacolato)diboron (0.04 ml, 0.30 mmol), triethylamine (0.05 ml, 0.40 mmol) and 1,4-dioxane (0.3 ml) and the headspace was purged with N2 gas for 30 minutes. Then palladium(II) acetate (1.80 mg, 0.008 mmol) and 2-(dicyclohexylphosphino)biphenyl (5.2 mg, 0.02 mmol) were added and the reaction stirred at 80° C. for 1 h. The reaction was cooled, concentrated and purified by silica gel chromatography eluting with a EtOAc/hexanes gradient (0-100% EtOAc) to give 3-[2,3-dimethoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1-methyl-pyrazole (45 mg, 94% yield). MS m/z 345.2 [M+H]+.
    • Preparation of Starting Material: 4-[3,5-Dimethoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1-tetrahydropyran-2-yl-pyrazole
  • Figure US20230331725A1-20231019-C00113
    • Step 1.
  • A round bottom flask was charged with 5-bromobenzene-1,3-diol (600 mg, 3.02 mmol) 1-(tetrahydro-2h-pyran-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole (1.4 g, 4.8 mmol), chloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (220 mg, 0.302 mmol), potassium carbonate (1.3 g, 9.4 mmol), 1,4-dioxane (36 mL) and water (36 mL) and the reaction was purged with N2 for 15 minutes. The mixture was stirred at 80° C. for 1 hour. The reaction was cooled, concentrated and purified by silica gel chromatography eluting with a MeOH/CH2Cl2 gradient (0 to 30% MeOH), to give 5-(1-tetrahydropyran-2-ylpyrazol-4-yl)benzene-1,3-diol (600 mg, 77% yield). MS m/z 261.1 [M+H]+.
    • Step 2.
  • A solution of 5-(1-tetrahydropyran-2-ylpyrazol-4-yl)benzene-1,3-diol (600 mg, 2.31 mmol) in acetonitrile (4 mL) was cooled to 0° C. N-Iodosuccinimide (520 mg, 2.31 mmol) was added and the reaction was stirred at 0° C. for 5 minutes. The reaction was quenched with aqueous saturated sodium thiosulfate and extracted with dichloromethane. The organic layer was dried, concentrated and purified by silica gel chromatography eluting with a MeOH/CH2Cl2 gradient (0 to 30% MeOH) to give 2-iodo-5-(1-tetrahydropyran-2-ylpyrazol-4-yl)benzene-1,3-diol (800 mg, 90% yield). MS m/z 387.1 [M+H]+.
    • Step 3.
  • A round bottom flask was charged with 2-iodo-5-(1-tetrahydropyran-2-ylpyrazol-4-yl)benzene-1,3-diol (400 mg, 1.04 mmol), iodomethane (0.14 mL, 2.2 mmol), potassium carbonate (310 mg, 2.24 mmol) and acetone (3.3 mL) and the mixture was heated at 50° C. for 12 hours. The reaction was cooled, concentrated and purified by silica gel chromatography eluting with a gradient of EtOAc/hexanes (30-100% EtOAc) to give 4-(4-iodo-3,5-dimethoxy-phenyl)-1-tetrahydropyran-2-yl-pyrazole (300 mg, 0.72 mmol, 70% yield). MS m/z 415.1 [M+H]+.
    • Step 4.
  • A round bottom flask was charged with 4-(4-iodo-3,5-dimethoxy-phenyl)-1-tetrahydropyran-2-yl-pyrazole (50 mg, 0.12 mmol), bis(pinacolato)diboron (0.04 ml, 0.3 mmol), triethylamine (0.05 ml, 0.4 mmol), and 1,4-dioxane (0.3 ml) and the reaction was purged with N2 for 15 minutes. Then 1,4-dioxane (0.3 mL) and 2-(dicyclohexylphosphino)biphenyl (4.5 mg, 0.013 mmol) was dissolved in 1,4-dioxane (0.3 mL) was added and the reaction was heated at 90° C. for 12 hours. The mixture was cooled, concentrated and purified by silica gel chromatography eluting with a gradient of EtOAc/hexanes (0-100% EtOAc) to give 4-[3,5-dimethoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1-tetrahydropyran-2-yl-pyrazole (50 mg, 99% yield). MS m/z 415.4 [M+H]+.
    • Preparation of Starting Material: 2-[4-Chloro-3-fluoro-2-(methoxymethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
  • Figure US20230331725A1-20231019-C00114
    • Step 1:
  • 6-Bromo-3-chloro-2-fluoro-phenol (900 mg, 4.0 mmol) was dissolved in DMF (4.5 mL) at 0° C. Sodium tert-pentoxide (2.5 M in THF, 2 mL, 5.0 mmol) was added dropwise, followed by dropwise addition of chloromethyl methyl ether (405 μL, 5.34 mmol) and the reaction was stirred overnight at room temperature. The reaction mixture was partitioned between water and EtOAc. The organic layer was washed with water, and then brine. The organic layer was dried over MgSO4, filtered, and concentrated under vacuum. The residue was purified by silica gel chromatography eluting with a EtOAc/hexanes gradient (30-100% EtOAc) to yield 1-bromo-4-chloro-3-fluoro-2-(methoxymethoxy)benzene (1.01 g, 94% yield) as a clear oil.
  • 1H NMR (acetone-d6) δ: 7.50 (d, J=9 Hz, 1H), 7.28 (t, J=8 Hz, 1H), 5.26 (s, 2H), 3.62 (s, 3H).
    • Step 2:
  • A mixture of dry KOAc (1.5 g, 15 mmol), bis(pinacolato)diboron (1.02 g, 4.02 mmol), Pd(dppf)Cl2—CH2Cl2 (90 mg, 0.108 mmol), and a solution of 1-bromo-4-chloro-3-fluoro-2-(methoxymethoxy)benzene (900 mg, 3.3 mmol) in toluene (12 mL) was purged with argon for 15 min. The mixture was heated at 110° C. for 16 h. Upon completion, the reaction was diluted with EtOAc and was filtered through celite. The filtrate was concentrated and purified by silica chromatography eluting with a MeOH/CH2Cl2 gradient (0 to 5% MeOH) to yield 2-[4-chloro-3-fluoro-2-(methoxymethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (524 mg, 47% yield) as a light orange oil.
  • 1H NMR (acetone-d6) δ: 7.49 (d, J=8 Hz, 1H), 7.29 (t, J=7 Hz, 1H), 5.16 (s, 2H), 3.58 (s, 3H), 1.37 (s, 12H).
    • Preparation of Starting Material: 6-Chloro-8-methyl-imidazo[1,2-b]pyridazine
  • Figure US20230331725A1-20231019-C00115
    • Step 1
  • A mixture of 8-bromo-6-chloro-imidazo[1,2-b]pyridazine (232 mg, 1.0 mmol), 2,4,4,5,5-pentamethyl-1,3,2-dioxaborolane (142 mg, 1.0 mmol), Pd(dppf)Cl2 (150 mg, 0.20 mmol), and K2CO3 (285 mg, 2.1 mmol), in dioxane (5 mL) and water (1 mL) was purged with argon for 15 min and heated to 90° C. for 16 h. The reaction was diluted with water (50 mL), and then extracted with CH2Cl2 (3×30 mL). The organic layers were washed with brine (2×20 mL), dried over Na2SO4, and then filtered and concentrated. The residue was purified by silica gel column chromatography eluting with a MeOH/CH2Cl2 gradient (5 to 10% MeOH) to afford 6-chloro-8-methyl-imidazo[1,2-b]pyridazine (85 mg, 50% yield). MS m/z 168.0, 170.0 [M+H]+.
    • Preparation of Starting Material: 6-Chloro-8-methyl-imidazo[1,2-b]pyridazine and tert-Butyl ((6-chloroimidazo[1,2-b]pyridazin-8-yl)methyl)carbamate
  • Figure US20230331725A1-20231019-C00116
    • Step 1
  • A solution of 8-bromo-6-chloro-imidazo[1,2-b]pyridazine (232 mg, 1.0 mmol), dicyanozinc (150 mg, 1.2 mmol), and Pd(PPh3)4 (240 mg, 0.2 mmol) in dry DMF (4 mL) was heated in a microwave for 45 min at 100° C. The reaction was concentrated and purified by preparatory HPLC to afford 6-chloro-8-methyl-imidazo[1,2-b]pyridazine (85 mg, 50% yield). MS m/z 178.9, 181.1 [M+H]+.
    • Step 2
  • A solution of 6-chloro-8-methyl-imidazo[1,2-b]pyridazine (80 mg, 0.45 mmol), di-tert-butyl dicarbonate (147 mg, 0.67 mmol), and Ni (16 mg) in THE (5 mL) was stirred at room temperature for 16 h. The reaction was filtered and concentrated. The residue was purified by preparatory HPLC (10% MeOH in CH2Cl2), to afford tert-butyl ((6-chloroimidazo[1,2-b]pyridazin-8-yl)methyl)carbamate (36 mg, 28% yield). MS m/z 282.9, 284.8 [M+H]+.
    • Preparation of Starting Material: 6-Chloro-8-methoxy-imidazo[1,2-b]pyridazine
  • Figure US20230331725A1-20231019-C00117
    • Step 1
  • A solution of 8-bromo-6-chloro-imidazo[1,2-b]pyridazine (234 mg, 1.0 mmol) and sodium methoxide (108 mg, 1.2 mmol) in methanol (4 mL) was heated to reflux for 12 h. The reaction was cooled to room temperature, concentrated, and then the residue was purified by preparatory HPLC to afford 6-chloro-8-methoxy-imidazo[1,2-b]pyridazine (100 mg, 54% yield). MS m/z 184.0, 186.0 [M+H]+.
    • Preparation of Starting Material: 5-Bromo-7-fluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole
  • Figure US20230331725A1-20231019-C00118
    • Step 1
  • To a solution of 4-bromo-2-fluoro-6-nitroaniline (600 mg, 2.6 mmol) in tetrahydrofuran (5 mL), ethanol (5 mL), and water (1 mL) was added iron (1.5 g, 27 mmol), and ammonium chloride (1.5 g, 28 mmol). The mixture was heated to reflux for 16 hours, then cooled to room temperature, filtered and concentrated. The crude product was purified by silica gel chromatography eluting with a MeOH/CH2Cl2 gradient (0 to 10% MeOH) to yield 5-bromo-3-fluorobenzene-1,2-diamine as a brown solid (400 mg, 76%). MS m/z 204.8, 206.8 [M+H]+.
    • Step 2:
  • A mixture of 5-bromo-3-fluorobenzene-1,2-diamine (400 mg, 2.0 mmol) and formic acid (5 mL) was stirred at 120° C. for 16 hours. After cooling, the solvent was removed and the residue was partitioned between EtOAc (200 mL) and sat. aq. NaHCO3 (50 mL). The organic phase was dried over Na2SO4 and concentrated to afford crude 5-bromo-7-fluoro-1H-benzoimidazole as an off white solid (400 mg, 95%). MS m/z 215.0, 217.0 [M+H]+.
    • Step 3
  • A solution of 5-bromo-7-fluoro-1H-benzimidazole (200 mg, 0.93 mmol) in tetrahydrofuran (5 mL) was cooled to 0° C. and sodium hydride (15 mg, 0.60 mmol) was added. The reaction was stirred at 0° C. for 20 minutes, then 2-(trimethylsilyl)ethoxymethyl chloride (0.08 g, 0.48 mmol) was added. The mixture was stirred at room temperature for 2 h. The reaction was quenched with ice water, and the aqueous phase was extracted with EtOAc. The organic phase was dried over Na2SO4, concentrated and the residue was purified by silica gel chromatography eluting with a MeOH/CH2Cl2 gradient (0 to 10% MeOH) to afford 5-bromo-7-fluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole (210 mg, 65%). MS m/z 345.0, 347.0 [M+H]+.
    • Preparation of Starting Material: 5-Bromo-6,7-difluoro-1-methyl-benzimidazole
  • Figure US20230331725A1-20231019-C00119
    • Step 1
  • To a solution of 1,2,3-trifluoro-4-nitro-benzene (1.00 g, 5.65 mmol) and methylamine hydrochloride (409 mg, 5.94 mmol) in acetronitrile (10.0 mL) was added DIPEA (3.66 g, 28.2 mmol). The mixture was stirred for 3 hours at 70° C., then cooled to room temperature. The mixture was concentrated and the residue was purified by silica gel chromatography eluting with a EtOAc/hexanes gradient (0-5% EtOAc) to afford 2,3-difluoro-N-methyl-6-nitro-aniline (1.06 g, 99% yield) as a yellow solid. MS m/z 189.0 [M+H]+.
    • Step 2
  • To a solution of 2,3-difluoro-N-methyl-6-nitro-aniline (1.48 g, 7.87 mmol) in DMF (50.0 mL) was added NBS (1.79 g, 9.86 mmol). The mixture was stirred for 1 hour at 90° C., and then cooled to room temperature and quenched with brine (200 mL). The mixture was extracted with EtOAc (3×50 mL). The organic layers were dried over Na2SO4 and concentrated. The residue was purified by silica gel chromatography eluting with a EtOAc/hexanes gradient (0-5% EtOAc) to afford 4-bromo-2,3-difluoro-N-methyl-6-nitro-aniline (1.75 g, 83% yield) as a yellow solid. MS m/z 267.0, 269.0 [M+H]+.
    • Step 3
  • A solution of 4-bromo-2,3-difluoro-N-methyl-6-nitro-aniline (1.85 g, 6.93 mmol) in tetrahydrofuran (50.0 mL) and methanol (50.0 mL) was cooled to 0° C. Then, Raney-nickel (500 mg) was added, followed by dropwise addition of hydrazine (227 mg, 6.94 mmol). The mixture was stirred for 15 min at 0° C. and filtered. The filtrate was concentrated to give crude 4-bromo-5,6-difluoro-Ni-methylbenzene-1,2-diamine (1.58 g, 96% yield) as a pale brown oil. MS m/z 237.0, 239.0 [M+H]+.
    • Step 4:
  • 5-Bromo-3,4-difluoro-N2-methyl-benzene-1,2-diamine (1.58 g, 6.67 mmol) was suspended in formic acid (5 mL) and trimethyl orthoformate (5.0 mL, 46 mmol) was then added. The mixture was heated at reflux for 1 hour under a nitrogen atmosphere, and then cooled to room temperature. The mixture was concentrated and the residue was neutralized with sat. aq. NaHCO3 to pH 8. The mixture was extracted with EtOAc (3×50 mL) and the organic layers were dried over Na2SO4, concentrated and purified by silica gel chromatography eluting with a EtOAc/hexanes gradient (0-65% EtOAc) to afford 5-bromo-6,7-difluoro-1-methyl-benzimidazole (1.52 g, 92% yield) as a pale brown solid. MS m/z 247.0, 249.0 [M+H]+.
    • Preparation of Starting Material: Racemic (3S,4S)-3-fluoro-2,2,6,6-tetramethyl-piperidin-4-amine
  • Figure US20230331725A1-20231019-C00120
    • Step 1
  • To an oven-dried three-necked flask was added 2,2,6,6-tetramethylpiperidin-4-one (20.0 g, 129 mmol). After evacuating and back-filling with nitrogen 3 times, tetrahydrofuran (90 mL) was added under nitrogen. The solution was cooled to −78° C., and then lithium bis(trimethysilyl)amide in tetrahydrofuran (193 mL, 193 mmol, 1 mol/L) was added dropwise. Following complete reaction, the mixture was stirred at −78° C. for 30 min. N-fluorobenzensulfonimide (42.6 g, 135 mol) was added potion wise as a solid over 20 min under nitrogen. The reaction was then gradually warmed to room temperature, and the mixture was further stirred at room temperature for 16 hours. The reaction was filtered to remove solid, and then the mixture was concentrated, and purified by flash chromatography using EtOAc and petroleum ether (0-10% EtOAc) as eluent to afford 3-fluoro-2,2,6,6-tetramethylpiperidin-4-one as a pale yellow solid (10.0 g, 45.5%). MS m/z: 174.1 [M+H]+.
    • Step 2:
  • 3-Fluoro-2,2,6,6-tetramethylpiperidin-4-one (7.2 g, 41.6 mmol) and (4-methoxyphenyl)methanamine (6.3 g, 45.8 mmol) were dissolved in methanol (40 mL). Acetic acid (6 mL, 104 mmol) was then added. The resulting mixture was stirred at room temperature for 1 h, then NaBH3CN (3.9 g, 62.4 mmol) was added, and the mixture was stirred for an additional 16 hours. The solvent was removed under reduced pressure and the residue was purified by silica gel chromatography eluting with a EtOAc/hexanes gradient (10-30% EtOAc) to afford C-cis racemic (3S,4S)-3-fluoro-N-[(4-methoxyphenyl)methyl]-2,2,6,6-tetramethyl-piperidin-4-amine (5.0 g, 40.0%) and C-trans racemic (3S,4R)-3-fluoro-N-(4-methoxybenzyl)-2,2,6,6-tetramethylpiperidin-4-amine (2.7 g, 22.0%).
  • C-cis racemic (3S,4S)-3-fluoro-N-[(4-methoxyphenyl)methyl]-2,2,6,6-tetramethyl-piperidin-4-amine: MS m/z: 295.2 [M+H]+; 1H NMR (DMSO-d6) δ 7.23 (d, J=8.4 Hz, 2H), 6.86 (d, J=8.8 Hz, 2H), 3.95 (dd, J1=9.6 Hz, J2=51.2 Hz, 1H), 3.73-3.63 (m, 5H), 3.33 (br s, 1H), 3.03-2.97 (m, 1H), 1.87-1.83 (m, 2H), 1.65 (br, 1H), 1.09-1.04 (m, 12H).
  • C-trans racemic: (3S,4R)-3-fluoro-N-(4-methoxybenzyl)-2,2,6,6-tetramethylpiperidin-4-amine: MS m/z: 295.2 [M+H]+; 1H NMR (DMSO-d6) δ 7.25 (d, J=8.4 Hz, 2H), 6.86 (d, J=8.4 Hz, 2H), 4.33 (d, J=50.8 Hz, 1H), 3.72 (s, 5H), 3.33 (br s, 2H), 2.95 (dd, J1=15.6 Hz, J2=28.4 Hz, 1H), 1.53 (dd, J1=4.0 Hz, J2=8.8 Hz, 1H), 1.21-1.03 (m, 13H).
    • Step 3
  • To a three-neck round bottom flask charged with a thermometer, pressure drop funnel and hydrogen balloon was added racemic (3S,4S)-3-fluoro-N-[(4-methoxyphenyl)methyl]-2,2,6,6-tetramethyl-piperidin-4-amine (10.0 g, 33.97 mmol), MeOH (150 mL), palladium on carbon (10 wt %) (3.0 g, 2.8 mmol), and formic acid (0.20 g, 4.0 mmol). The flask was evacuated and backfilled with hydrogen twice. The mixture was stirred at 45° C. for 16 h. After cooling to room temperature, the mixture was filtered, and the filtrate was concentrated. The residue was purified by silica gel chromatography eluting with a gradient of MeOH/CH2Cl2 (0 to 100% MeOH) to yield racemic (3S,4S)-3-fluoro-2,2,6,6-tetramethyl-piperidin-4-amine (4.8 g, 81%). MS m/z 175.2 [M+H]+; 1H NMR (methanol-d4) δ: 4.91 (d, J=48 Hz, 1H), 4.25 (dd, J1=11.6 Hz, J2=30 Hz, 1H), 2.14-2.00 (m, 2H).1.62-1.57 (m, 12H); 3NHs not observed.
    • Preparation of Starting Material: (3S,4S)-3-Fluoro-2,2,6,6-tetramethylpiperidin-4-amine
  • Figure US20230331725A1-20231019-C00121
    • Step 1
  • Racemic (3S,4S)-3-fluoro-N-[(4-methoxyphenyl)methyl]-2,2,6,6-tetramethyl-piperidin-4-amine (5.0 g, 12.7 mmol) was dissolved in methanol (80 mL), then di-tert-butyl dicarbonate (4.1 g, 19.5 mmol) and triethyl amine (2.7 mmol, 19.5 mmol) were added sequentially. The resultant mixture was stirred at room temperature for 3 h. The solvent was removed under reduced pressure, the residue was purified by silica gel chromatography eluting with a EtOAc/hexanes gradient (0-50% EtOAc) to afford the desired tert-butyl ((3 S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl)(4-methoxybenzyl)carbamate (4.1 g, 61.0%) as a colorless oil. MS m/z: 395.2 [M+H]+.
    • Step 2:
  • A total of 5 g of racemic tert-butyl ((3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl)(4-methoxybenzyl)carbamate were separated by chiral-Prep-HPLC (SFC-200, Thar, Waters) using a WHELK 50*250 mm, 10 um (Daicel) column with CO2/IPA(0.2% Methanol Ammonia)=90/10 as the mobile phase to afford tert-butyl ((3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl)(4-methoxybenzyl)carbamate (2.2 g, 44% yield) and tert-butyl ((3R,4R)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl)(4-methoxybenzyl)carbamate (1.8 g, 36%).
    • Step 3
  • tert-Butyl ((3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl)(4-methoxybenzyl) carbamate (2.2 g, 5.6 mmol) was dissolved in acetonitrile (40 mL), ammonium cerium(IV) nitrate (9.2 g, 16.8 mmol) was added, and the mixture was stirred at room temperature for 2 h. The mixture was concentrated and purified by silica gel chromatography eluting with a gradient of EtOAc/hexanes (0-80% EtOAc) to afford crude tert-butyl ((3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl)carbamate (1.5 g, 98% yield), which was used to the next step without further purification. MS m/z: 275.2 [M+H]+.
  • Step 4:The crude tert-butyl ((3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl)carbamate (1.5 g, 0.54 mmol) obtained in step 3 was dissolved in CH2Cl2 (20 mL), and then 2 mL of HCl in dioxane (4 mol/L) was added, and the mixture was stirred at room temperature for 16 h. The precipitate was filtered, washed with 5 mL of CH2Cl2 and dried to yield (3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-amine (533 mg, HCl salt, 47% yield) as a white solid.
  • MS m/z: 175.2 [M+H]+; 1H NMR (methanol-d4) δ: 4.91 (d, J=48 Hz, 1H), 4.25 (dd, J=11.6 Hz, 30 Hz, 1H), 2.14-2.00 (m, 2H).1.62-1.57 (m, 12H); 3NHs not observed.
  • Using the procedure described, additional compounds described herein may be prepared by substituting the appropriate starting material, suitable reagents and reaction conditions, obtaining compounds such as those selected from:
  • Structure Data
    Figure US20230331725A1-20231019-C00122
         		MS m/z 175.2 [M + H]+; 1H NMR (methanol-d4) δ: 4.90 (d, J = 48 Hz, 1H), 4.25 (dd, J1 = 10.8 Hz, J2 = 28.8 Hz, 1H), 2.14-2.00 (m, 2H). 1.64-1.50 (m, 12H), 3 NHs not observed.
    • Preparation of Starting Material: Racemic (3R,4R)-4-amino-2,2,6,6-tetramethyl-piperidin-3-ol dihydrochloride
  • Figure US20230331725A1-20231019-C00123
    • Step 1:
  • 2,2,6,6-Tetramethylpiperidine-3,4-dione (2.98 g, 17.6 mmol) was dissolved in ethanol (15 mL), followed by the addition of aqueous hydroxylamine (1.2 mL, 20 mmol, 50 wt % in H2O). The reaction was sealed and heated to 70° C. for 10 minutes, and then cooled to room temperature and concentrated providing crude (E)-4-(hydroxyimino)-2,2,6,6-tetramethylpiperidin-3-one (2.1 g, 63% yield) which was used directly in the next step. MS m/z 185.3 [M+H]+.
    • Step 2:
  • (E)-4-(hydroxyimino)-2,2,6,6-tetramethylpiperidin-3-one (2.1 g, 11 mmol), zinc (4.5 g, 69 mmol), and aqueous sodium hydroxide (16 mL, 6.0 M) were combined and heated at 70° C. for 30 min and then cooled to room temperature. The reaction was filtered through a frit, rinsing with CH2Cl2/MeOH. The aqueous layer was extracted twice with CH2Cl2/MeOH (9:1) and three times with CHCl3/iPrOH (7:3). The combined organic layers were dried over sodium sulfate, filtered and then concentrated to yield crude 4-amino-2,2,6,6-tetramethyl-piperidin-3-one (1.75 g, 90%) as an orange oil which was used directly in the next step without purification.
    • Step 3:
  • 4-Amino-2,2,6,6-tetramethyl-piperidin-3-one (1.75 g, 10.3 mmol), DMF (6 mL), and N,N-diisopropylethylamine (2.70 mL, 15.5 mmol) were stirred at room temperature and then cooled to 0° C. Benzyl chloroformate (2.20 mL, 15.5 mmol) was added dropwise. Stirring was continued at 0° C. for 25 min. The reaction was then partitioned between EtOAc and brine and the layers were separated. The aqueous layer was extracted twice with EtOAc and the combined organic layers were washed three times with brine. The organic layer was dried over sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography eluting with a EtOAc/hexanes gradient (0-100% EtOAc) to yield benzyl N-(2,2,6,6-tetramethyl-3-oxo-4-piperidyl)carbamate (1.45 g, 46%) as an orange solid.
  • MS m/z 305.6 [M+H]+; 1H NMR (DMSO-d6) δ: 7.55 (br d, J=8.5 Hz, 1H), 7.29-7.41 (m, 5H), 5.06 (s, 2H), 4.86-4.96 (m, 1H), 4.69 (s, 1H), 2.13 (dd, J=12.8, 8.9 Hz, 1H), 1.58 (dd, J=12.8, 7.3 Hz, 1H), 1.28 (d, J=1.8 Hz, 6H), 1.24 (s, 3H), 1.09 (s, 3H).
    • Step 4
  • Benzyl N-(2,2,6,6-tetramethyl-3-oxo-4-piperidyl)carbamate (1.20 g, 3.95 mmol) was dissolved in MeOH (5 mL), followed by the addition of sodium borohydride (247 mg, 6.54 mmol). The reaction was stirred at room temperature for 1 h, then acetone (3 mL) was added slowly and the reaction was concentrated. The residue was partitioned between EtOAc and H2O and the layers were separated. The aqueous layer was extracted four times with EtOAc. The combined organic layers were dried over sodium sulfate, filtered and concentrated to yield crude racemic benzyl N-[(3R,4R)-3-hydroxy-2,2,6,6-tetramethyl-4-piperidyl]carbamate that was used directly in the next step.
  • MS m/z 307.5 [M+H]+; 1H NMR (DMSO-d6) δ 7.30-7.40 (m, 6H), 5.01 (d, J=5.8 Hz, 2H), 4.94-4.95 (m, 1H), 3.91-4.00 (m, 1H), 2.93 (br d, J=7.3 Hz, 1H), 1.76 (dd, J=12.2, 9.8 Hz, 1H), 1.46 (br dd, J=12.8, 5.5 Hz, 1H), 1.14 (s, 3H), 1.08 (s, 3H), 1.06 (s, 3H), 1.05 (s, 3H); 1H not observed (NH).
    • Step 5
  • The residue from Step 4 containing racemic benzyl N-[(3R,4R)-3-hydroxy-2,2,6,6-tetramethyl-4-piperidyl]carbamate was dissolved in methanol (5 mL), followed by the addition of 10% palladium on carbon (293 mg, 0.275 mmol). The reaction was stirred at room temperature while hydrogen gas was used to sparge the solution for 3 minutes. Stirring was continued under a hydrogen atmosphere at room temperature for 72 h. The reaction was filtered through celite and rinsed with methanol. Methanolic HCl (5 mL, 1.25 M) was added to the filtrate and the filtrate was concentrated to yield racemic (3R,4R)-4-amino-2,2,6,6-tetramethyl-piperidin-3-ol dihydrochloride (251 mg, 26% yield).
  • MS m/z 173.0 [M+H]+; 1H NMR (1:1 chloroform-d: methanol-d4) δ: 3.48 (q, J=7.6 Hz, 1H), 2.86 (d, J=7.6 Hz, 1H), 2.00 (dd, J=12.8, 8.5 Hz, 1H), 1.57 (dd, J=12.8, 7.3 Hz, 1H), 1.30 (d, J=2.1 Hz, 6H), 1.23 (s, 3H), 1.23 (s, 3H); 4Hs not observed (3NHs and OH).
    • Preparation of Starting Material: Racemic (3aR,4R,6aS)-N,N-dimethyl-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrol-4-amine
  • Figure US20230331725A1-20231019-C00124
    • Step 1
  • Racemic tert-butyl 4-oxo-1,3,3a,5,6,6a-hexahydrocyclopenta[c]pyrrole-2-carboxylate (523.8 mg, 2.325 mmol), dichloromethane (5 mL), aqueous dimethylamine (2.0 mL, 40 wt. %, 6.8 equiv), and sodium triacetoxyborohydride (2.06 g, 9.72 mmol, 4.18 equiv) were combined and stirred at room temperature for 20 h. The reaction was partitioned between CH2Cl2 and aqueous sodium hydroxide (1.0 M) and the layers were separated. The aqueous layer was extracted twice with CH2Cl2/MeOH (9:1) and once with CHCl3/iPrOH (7:3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography eluting with a gradient of MeOH/CH2Cl2 (0-30% MeOH/NH4OH, 2.5% NH4OH v/v) to yield racemic tert-butyl (3aR,4R,6aS)-4-(dimethylamino)-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxylate (452.4 mg, 76% yield).
  • MS m/z 255.3 [M+H]+; 1H NMR (methanol-d4) δ: 3.42-3.51 (m, 1H), 3.39 (dd, J=8.7, 4.1 Hz, 2H), 3.20 (br d, J=10.4 Hz, 1H), 2.80 (br s, 1H), 2.62-2.73 (m, 1H), 2.42-2.51 (m, 1H), 2.22 (s, 6H), 1.91-2.01 (m, 1H), 1.83-1.90 (m, 1H), 1.57 (quin, J=10.6 Hz, 1H), 1.45-1.50 (m, 1H), 1.43 (s, 9H).
    • Step 2
  • Racemic tert-butyl (3aR,4R,6aS)-4-(dimethylamino)-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxylate (43.1 mg, 0.169 mmol) was dissolved in TFA (2 mL) and stirred at room temperature for 4 h. The reaction was concentrated and the residue used directly in subsequent reactions, assuming a quantitative yield of racemic (3aR,4R,6aS)-N,N-dimethyl-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrol-4-amine 2,2,2-trifluoroacetic acid. MS m/z 155.3 [M+H]+.
    • Preparation of Starting Material: N-(tert-Butyl)pyrrolidin-3-amine
  • Figure US20230331725A1-20231019-C00125
    • Step 1
  • A dry vial was charged with 1-benzylpyrrolidin-3-one (4.0 g, 22.8 mmol), 2-methylpropan-2-amine (3.8 g, 52.0 mmol) and Ti(OiPr)4 (6.0 mL, 20.2 mmol). The mixture was purged with N2 for 15 min and then allowed to stir at room temperature for 2 h. The resulting (E)-1-benzyl-N-(tert-butyl)pyrrolidin-3-imine was used without further purification.
    • Step 2:
  • To the mixture from step 1 was added dry methanol (40 mL) and the reaction was cooled to 0° C. in an ice bath. NaBH4 (1.6 g, 42.3 mmol) was added slowly in portions (caution: very exothermic reaction). Once evolution of the gas subsided, the mixture was warmed to room temperature and stirred for 2h at room temperature. Upon completion, 0.1M NaOH solution (20 mL) was added to precipitate the titanium salts. The biphasic mixture was filtered through celite and washed with methanol. The solvent was removed under vacuum and the crude oil was purified by reverse phase chromatography using a acetonitrile/H2O gradient (10%-100% acetonitrile) to afford 1-benzyl-N-(tert-butyl)pyrrolidine-3-amine (3.2 g, 60% yield) as a colorless oil.
    • Step 3
  • To an oven-dry round bottom flask containing palladium hydroxide on activated carbon (320 mg) was added 1-benzyl-N-(tert-butyl)pyrrolidine-3-amine (3.2 g, 13.8 mmol) dissolved in MeOH (20 mL). The mixture was sparged with H2 for 5 minutes and a balloon of H2 was placed on top of the flask and the reaction was stirred for 2 h at room temperature. The reaction mixture was filtered through celite, washed with MeOH and concentrated to afford N-(tert-butyl)pyrrolidin-3-amine (1.89 g, 96% yield) as a colorless oil which solidified upon standing.
  • 1H NMR (methanol-d4) δ: 4.21 (dq, J=14.4, 7.0 Hz, 1H), 3.80 (dd, J=12.7, 8.0 Hz, 1H), 3.58-3.50 (m, 2H), 3.38-3.32 (m, 1H), 2.62-2.56 (m, 1H), 2.28-2.20 (m, 1H), 1.42 (s, 9H); 2NHs not observed.
  • Using the procedure described, additional compounds described herein may be prepared by substituting the appropriate starting material, suitable reagents and reaction conditions, obtaining compounds such as those selected from:
  • Structure Data
    Figure US20230331725A1-20231019-C00126
         		1H NMR (chloroform-d) δ: 0.93 (d, J = 6.71 Hz, 6H) 1.74 (dq, J = 13.28, 6.66 Hz, 2H) 1.98-2.15 (m, 1H) 2.42 (d, J = 6.71 Hz, 2H) 2.98 (dd, J = 11.60, 3.66 Hz, 1H) 3.06-3.21 (m, 2H) 3.29 (dt, J = 11.14, 7.40 Hz, 1H) 3.35-3.46 (m, 3H)
    Figure US20230331725A1-20231019-C00127
         		1H NMR (chloroform-d) δ: 1.57 (br d, J = 5.49 Hz, 1H) 2.02 (br dd, J = 13.12, 6.71 Hz, 1H) 2.38 (br s, 2H) 2.70-2.86 (m, 3H) 2.92 (br d, J = 8.09 Hz, 1H) 3.00 (br dd, J = 11.14, 5.80 Hz, 1H) 3.07- 3.16 (m, 1H) 3.31 (br s, 1H) 3.49 (s, 1H) 3.67 (br t, J = 4.73 Hz, 2H)
    Figure US20230331725A1-20231019-C00128
         		MS m/z 155 [M + H]+; 1H NMR (methanol-d4) δ: 3.35-3.41 (m, 1H), 3.03-3.16 (m, 3H), 2.86-2.97 (m, 1H), 2.67-2.75 (m, 1H), 2.03-2.15 (m, 1H), 1.88-2.00 (m, 2H), 1.68-1.79 (m, 2H), 1.54-1.68 (m, 3H), 1.30-1.44 (m, 2H); 2NHs not observed
    Figure US20230331725A1-20231019-C00129
         		MS m/z 159.2 [M + H]+
    Figure US20230331725A1-20231019-C00130
         		MS m/z 173.3 [M + H]+; 1H NMR (chloroform-d) δ: 3.46-3.39 (m, 1H), 3.36 (s, 3H), 3.27-3.17 (m, 3H), 3.09-3.01 (m, 2H), 2.75-2.65 (m, 1H), 2.18-2.07 (m, 1H), 1.65-1.53 (m, 1H), 1.65- 1.53 (m, 1H), 1.08 (s, 3H), 1.07 (s, 3H); 1NH not observed
    Figure US20230331725A1-20231019-C00131
         		1H NMR (chloroform-d) δ: 4.45-4.20 (m, 2H), 3.81-3.68 (m, 1H), 3.31-3.15 (m, 2H), 3.12- 2.88 (m, 3H), 2.40-2.23 (m, 1H), 1.95-1.80 (m, 1H), 1.12 (t, J = 7.9 Hz, 3H); 2NHs not observed
    Figure US20230331725A1-20231019-C00132
         		1H NMR (chloroform-d) δ: 4.57-4.44 (m, 2H), 4.43-4.28 (m, 2H), 3.54-3.41 (m, 1H), 2.81- 2.64 (m, 2H), 2.62-2.50 (m, 1H), 2.34-2.13 (m, 2H), 1.60-1.41 (m, 4H); 2NHs not observed
    Figure US20230331725A1-20231019-C00133
         		MS m/z 143.3 [M + H]+
    Figure US20230331725A1-20231019-C00134
         		1H NMR (methanol-d4) δ: 1.87-2.03 (m, 2H) 2.12-2.31 (m, 3H) 2.32-2.45 (m, 2H) 2.47- 2.59 (m, 1H) 3.38-3.49 (m, 2H) 3.56 (br dd, J = 12.21, 6.41 Hz, 1H) 3.73 (br dd, J = 12.21, 8.24 Hz, 1H) 3.83-3.92 (m, 1H) 3.94-4.06 (m, 1H); 2NHs not observed
    Figure US20230331725A1-20231019-C00135
         		1H NMR (methanol-d4) δ: 1.87-2.03 (m, 2H) 2.14-2.31 (m, 3H) 2.38 (br d, J = 3.66 Hz, 2H) 2.52 (br dd, J = 14.04, 7.02 Hz, 1H) 3.36-3.51 (m, 2H) 3.53-3.64 (m, 1H) 3.73 (br dd, J = 12.66, 8.09 Hz, 1H) 3.88 (br t, J = 8.09 Hz, 1H) 3.94- 4.06 (m, 1H); 2NHs not observed
    Figure US20230331725A1-20231019-C00136
         		MS m/z 141.1 [M + H]+
    Figure US20230331725A1-20231019-C00137
         		MS m/z 185.3 [M + H]+
    • Preparation of Starting Material: N-(Pyrrolidin-3-ylmethyl)propan-2-amine hydrochloride
  • Figure US20230331725A1-20231019-C00138
    • Step 1
  • To a round bottom flask were added 1-Boc-3-formylpyrrolidine (300 mg, 1.5 mmol), isopropyl amine (0.2 mL, 2.54 mmol) and methylene chloride (5 mL). The mixture was stirred for 30 min at room temperature followed by the portion-wise addition of sodium triacetoxyborohydride (636 mg, 3 mmol) and the mixture continued to stir for 16 h at room temperature. The reaction was quenched by the addition of 1.0 M NaOH and washed with water. The aqueous phase was extracted with CH2Cl2 (2 times) and the combined organic layers were dried over Mg2SO4. The solvent volume was reduced in vacuo and an HCl solution (2.0M in ether, 2 mL) was added. The mixture was stirred for 5 h at room temperature, and the solids were collected by filtration, and dried to provide N-(pyrrolidin-3-ylmethyl)propan-2-amine bishydrochloride salt (160 mg, 50% yield) as an off white solid.
  • 1H NMR (DMSO-d6) δ: 9.70-9.45 (m, 2H), 9.19 (br s, 2H), 3.39-3.30 (m, 1H), 3.25 (dd, J=6.1, 11.9 Hz, 2H), 3.17-3.07 (m, 1H), 3.06-2.94 (m, 3H), 2.75-2.64 (m, 1H), 2.20-2.06 (m, 1H), 1.81-1.66 (m, 1H), 1.27 (d, J=6.3 Hz, 6H).
  • Using the procedure described, additional compounds described herein may be prepared by substituting the appropriate starting material, suitable reagents and reaction conditions, obtaining compounds such as those selected from: Structure Data
  • Structure Data
    Figure US20230331725A1-20231019-C00139
         		1H NMR (methanol-d4) δ: 3.66-3.55 (m, 1H), 3.53-3.43 (m, 1H), 3.38-3.29 (m, 2H), 3.25- 3.13 (m, 2H), 3.13-3.02 (m, 1H), 2.77-2.63 (m, 1H), 2.42-2.30 (m, 1H), 1.92-1.77 (m, 1H), 1.41 (s, 9H); 1NH not observed.
    Figure US20230331725A1-20231019-C00140
         		1H NMR (DMSO-d6) δ: 9.25-8.98 (m, 2H), 8.96- 8.74 (m, 2H), 4.00-3.87 (m, 2H), 3.45-3.36 (m, 1H), 3.35-3.23 (m, 4H), 3.23-3.12 (m, 1H), 3.12-3.02 (m, 2H), 2.93 (br s, 1H), 2.64-2.53 (m, 1H), 2.20-2.07 (m, 1H), 1.99-1.87 (m, 2H), 1.74-1.62 (m, 1H), 1.62-1.50 (m, 2H)
    Figure US20230331725A1-20231019-C00141
         		1H NMR (methanol-d4) δ: 1.76-1.87 (m, 1H) 1.95 (br d, J = 9.77 Hz, 2H) 2.17-2.29 (m, 2H) 2.29-2.44 (br s, 3H) 2.64-2.79 (m, 1H) 2.99- 3.15 (m, 3H) 3.33 (br s, 1H) 3.46 (br d, J = 4.27 Hz, 1H) 3.53-3.65 (m, 1H) 3.80 (br t, J = 8.09 Hz, 1H); 2NHs not observed
    • Preparation of Starting Material: N-(Pyrrolidin-3-ylmethyl)tetrahydrofuran-3-amine
  • Figure US20230331725A1-20231019-C00142
    • Step 1
  • To a solution of tert-butyl 3-(aminomethyl)pyrrolidine-1-carboxylate (50 mg, 0.25 mmol) and dihydrofuran-3(2H)-one (43 mg, 0.50 mmol) in CH2Cl2 (1.3 mL) was added sodium triacetoxyborohydride (110 mg, 0.050 mmol). The reaction was stirred at room temperature for 2 hours and then partitioned between EtOAc and aq. NaHCO3. The organic phase was collected, and the aqueous layer was extracted once more with EtOAc. The organic phases were combined, washed with water, then brine, dried over Na2SO4 and then concentrated to afford tert-butyl 3-(((tetrahydrofuran-3-yl)amino)methyl)pyrrolidine-1-carboxylate which was used without further purification. MS m/z 271.4 [M+H]+.
    • Step 2:
  • 3-(((Tetrahydrofuran-3-yl)amino)methyl)pyrrolidine-1-carboxylate from step 1 was dissolved in CH2Cl2 (2 mL) and then trifluoroacetic acid (0.5 mL) was added. The reaction was stirred at room temperature for 1 hour and then concentrated under high vacuum to afford N-(pyrrolidin-3-ylmethyl)tetrahydrofuran-3-amine which was used without further purification. MS m/z 171.3 [M+H]+.
  • Using the procedure described, additional compounds described herein may be prepared by substituting the appropriate starting material, suitable reagents and reaction conditions, obtaining compounds such as those selected from:
  • Structure Data
    Figure US20230331725A1-20231019-C00143
         		MS m/z 211.2 [M + H]+
    • Preparation of Starting Material (R)-N-(tert-Butyl)pyrrolidin-3-amine
  • Figure US20230331725A1-20231019-C00144
    • Step 1
  • (R)-1-Benzylpyrrolidin-3-amine (2.0 g, 11.3 mmol), molecular sieves (2.0 g), and acetone (4.2 mL, 57.0 mmol) were mixed in a microwave vial and the mixture was heated in a microwave at 60° C. for 4 h. The molecular sieves were filtered off and the red solution was concentrated. The crude red oil was diluted with THE (4.0 mL) and 1.6 M solution of methyl lithium (8.7 mL, 14.0 mmol) was added slowly at room temperature. The reaction was stirred at room temperature for 4 h. The reaction mixture was then quenched with water and extracted with EtOAc, and the organic layer was dried over Na2SO4 and concentrated. The residue was purified by silica gel chromatography using a MeOH/CH2Cl2 gradient (0-30%), followed by reverse phase purification using a gradient from 10% ACN/H2O up to 100% ACN to afford (R)-1-benzyl-N-(tert-butyl)pyrrolidin-3-amine (0.2 g, 9% yield) as a colorless oil.
    • Step 2
  • To a round bottom flask containing Pd(OH)2/C was added MeOH (10 mL) followed by (R)-1-benzyl-N-(tert-butyl)pyrrolidin-3-amine (0.2 g, 0.9 mmol) and the solvent was bubbled with H2 for 5 min. A balloon containing H2 was then placed on top of the flask and the reaction was allowed to stir for 2 h at room temperature. The solution was filtered over Celite and then concentrated to afford (R)-N-(tert-butyl)pyrrolidin-3-amine (0.12 g, 94% yield) as a colorless oil.
  • 1H NMR (methanol-d4) δ: 4.23 (dq, J=14.0, 7.2 Hz, 1H), 3.83 (dd, J=12.5, 9.0 Hz, 1H), 3.62-3.50 (m, 2H), 3.40-3.33 (m, 1H), 2.66-2.58 (m, 1H), 2.30-2.23 (m, 1H), 1.46 (s, 9H).
  • Using the procedure described, additional compounds described herein may be prepared by substituting the appropriate starting material, suitable reagents and reaction conditions, obtaining compounds such as those selected from:
  • Structure Data
    Figure US20230331725A1-20231019-C00145
         		1H NMR (methanol-d4) δ: 4.23 (dq, J = 15.0, 8.0 Hz, 1H), 3.83 (dd, J = 12.9, 8.3 Hz, 1H), 3.62-3.52 (m, 2H), 3.40-3.33 (m, 1H), 2.65-2.59 (m, 1H), 2.26 (dq, J = 16.3, 8.4 Hz, 1H), 1.46 (s, 9H)
    • Example 1 Preparation of Compound 15
  • Figure US20230331725A1-20231019-C00146
    • Step 1
  • A solution of 3-(methylthio)-1,2,4-triazine (500 mg, 3.9 mmol) in 10 mL of CH2Cl2 was cooled in an ice-water batch, and m-CPBA (958 mg, 3.9 mmol) was added. The reaction mixture was stirred at 0° C. for 1 h until UPLC showed complete consumption of the starting material. The solvent was removed under reduced pressure without heating. The residue was redissolved in 5 mL of n-BuOH, N,2,2,6,6-pentamethylpiperidin-4-amine (1.0 g, 5.9 mmol) was added, and the reaction mixture was heated to 100° C. for 16 h. The reaction mixture was cooled to room temperature, the solvent was removed under reduced pressure. The crude product, N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,2,4-triazin-3-amine, was used as is in the next step.
    • Step 2:
  • N-Methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,2,4-triazin-3-amine prepared in step 1 was dissolved in 10 mL of MeOH and 5 mL of water. Bromine (200 μL, 3.9 mmol) was added, and the reaction mixture was stirred for 30 min at room temperature until UPLC showed full conversion. The solvents were removed under reduced pressure. The residue was dissolved in EtOAc (20 mL) and washed with water followed by brine. The organic layer was dried over Na2SO4, concentrated, and purified using silica gel chromatography eluting with a MeOH/CH2Cl2 gradient (0 to 30% MeOH) to yield 6-bromo-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,2,4-triazin-3-amine (367 mg, 29%) as brownish solid.
  • MS m/z 328.2, 330.3 [M+H]+; 1H NMR (methanol-d4) S: 8.46 (s, 1H), 5.15-5.32 (m, 1H), 3.10 (s, 3H), 2.04-2.09 (m, 2H), 1.96-1.99 (m, 2H), 1.58 (s, 6H), 1.54 (s, 6H), NH not observed.
    • Step 3:
  • An oven-dried flask was equipped with a magnetic stir bar and charged with 6-bromo-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,2,4-triazin-3-amine (40 mg, 0.12 mmol), 4-[3-(methoxymethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1-tetrahydropyran-2-yl-pyrazole (61 mg, 0.15 mmol), [1,1′-bis(diphenylphosphino)ferrocene] dichloropalladium(II) (9 mg, 0.012 mmol), and K2CO3 (51 mg, 0.37 mmol). The flask was sealed with a rubber septum and then evacuated and backfilled with argon. Dioxane (2 mL) and water (0.5 mL) were added, and the reaction was heated to 90° C. for 16 h. The reaction was cooled to room temperature, diluted with water, and extracted with EtOAc. The combined organic layers were dried over Na2SO4, concentrated under reduced pressure, and purified by column chromatography eluting with a MeOH/CH2Cl2 gradient (0 to 30% MeOH) to provide 6-(2-(methoxymethoxy)-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,2,4-triazin-3-amine (41 mg, 63%) as a brownish solid. MS m/z 536.5 [M+H]+.
    • Step 4:
  • To a solution of 6-[2-(methoxymethoxy)-4-(1-tetrahydropyran-2-ylpyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidyl)-1,2,4-triazin-3-amine (41 mg, 0.077 mmol) in CH2Cl2 (1 mL) and 2 drops of MeOH was added HCl (4 mol/L) in 1,4-dioxane (38 μL, 0.15 mmol). The reaction was stirred for 5 h until UPLC showed complete consumption of the starting material. The solvents were removed under reduced pressure, and the product was purified by column chromatography eluting with a gradient CH2Cl2/MeOH (5 to 3000 MeOH). Provided 2-[3-[methyl-(2,2,6,6-tetramethyl-4-piperidyl)amino]-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol; dihydrochloride (24 mg, 65H) as brownish solid.
  • MS m/z 48.5 [M+H]; 1H NMR (methanol-d4) δ: 9.11 (s, 1H), 8.03 (br. s., 2H), 7.84 (d, J=7.9 Hz, 1H), 7.25 (dd, J=8.2, 1.9 Hz, 1H), 7.21 (d, J=1.9 Hz, 1H), 5.32-5.46 (m, 1H), 3.23 (s, 3H), 1.93-2.10 (m, 3H), 1.65 (s, 6H), 1.54 (s, 6H); 3Hs not observed (2N1s and OH).
  • Using the procedure described for Example 1, additional compounds described herein may be prepared by substituting the appropriate starting material, suitable reagents and reaction conditions, obtaining compounds such as those selected from:
  • Cpd Data
    10 MS m/z 422.5 [M + H]+; 1H NMR (DMSO-d6) δ: 11.78 (br s, 1H), 9.65 (s, 1H), 9.43 (s,
    br, 1H), 9.09 (s, 1H), 8.08 (d, J = 8.5 Hz, 1H), 8.03 (s, 1H), 7.38-7.35 (m, 2H), 5.21-
    5.29 (m, 1H), 3.13 (s, 3H), 2.38 (s, 3H), 2.09 (t, J = 12.0 Hz, 2H), 1.78 (d, J = 12.0 Hz,
    2H), 1.52 (s, 6H), 1.51 (s, 6H)
    50 MS m/z 426.6 [M + H]+; 1H NMR (DMSO-d6) δ: 11.64 (br s, 1H), 9.28 (br s, 1H), 9.10
    (s, 1H), 8.22 (br s, 1H), 8.06 (s, 1H), 8.00 (d, J = 8.0 Hz, 1H), 7.56 (d, J = 8.0 Hz,
    1H), 7.26 (d, J = 8.5 Hz, 1H), 7.24 (s, 1H), 5.22 (t, J = 13.0 Hz, 1H), 3.11 (s, 3H), 1.94-
    2.07 (m, 2H), 1.77 (d, J = 10.0 Hz, 2H), 1.49 (s, 6H), 1.46 (s, 6H); 1H is from HCl
    salt
    87 MS m/z 406.5 [M + H]+. 1H NMR (methanol-d4) δ: 9.10 (s, 1H), 8.02 (s, 2H), 7.84, (d,
    J = 8.09 Hz, 1H), 7.24 (d, J = 8.00 Hz, 1H), 7.21 (s, 1H), 6.00-5.56 (m, 1H) 3.74 (s,
    3H), 3.12 (s, 3H), 2.75-2.60 (m, 2H), 2.42-2.30 (m, 2H), 2.29-2.17 (m, 2H), 2.16-1.97
    (m, 4H), 1.96-1.87 (m, 2H); 2NHs not observed (NH and OH)
    105 MS m/z 393.5 [M + H]+; 1H NMR (methanol-d4) δ: 9.13 (s, 1H), 8.77 (dd, J = 4.6, 1.5
    Hz, 1H), 8.41 (s, 1H), 8.37 (d, J = 7.3 Hz, 1H), 7.47 (s, 1H), 7.40 (dd, J = 8.2, 4.6 Hz,
    1H), 5.36-5.48 (m, 1H), 3.26 (s, 3H), 1.95-2.09 (m, 4H), 1.65 (s, 6H), 1.55 (s, 6H);
    2Hs not observed (NH and OH)
    125 MS m/z 426.6 [M + H]+; 1H NMR (methanol-d4) δ: 9.11 (s, 1H), 7.66-7.83 (m, 2H),
    7.50 (br s, 1H), 6.77 (t, J = 2.7 Hz, 1H), 5.32-5.45 (m, 1H), 3.23 (s, 3H), 1.92-2.01 (m,
    4H), 1.62 (s, 6H), 1.51 (s, 6H); 3Hs not observed (2 NHs and OH)
    • Example 2 Preparation of Compound 1
  • Figure US20230331725A1-20231019-C00147
    • Step 1
  • An oven-dried flask was equipped with a magnetic stir bar and charged with 6-bromo-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidyl)-1,2,4-triazin-3-amine (80 mg, 0.24 mmol), 2-[3-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-methyl-oxazole (92 mg, 0.29 mmol), tetrakis(triphenylphosphine)palladium(0) (28 mg, 0.024 mmol), and Na2CO3 (77.5 mg, 0.73 mmol). The flask was sealed with a rubber septum, and then evacuated and backfilled with argon. Dioxane (2 mL) and water (0.5 mL) were added, and the reaction was heated to 90° C. for 16 h. The reaction was cooled to room temperature, diluted with water, and extracted with EtOAc. The combined organic layers were dried over Na2SO4, concentrated under reduced pressure, and purified by column chromatography eluting with a MeOH/CH2Cl2 gradient (0 to 30% MeOH) to provide 6-(2-methoxy-4-(5-methyloxazol-2-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,2,4-triazin-3-amine (38 mg, 36%) as a brownish solid. MS m/z 437.5 [M+H]+.
    • Step 2:
  • 6-[2-Methoxy-4-(5-methyloxazol-2-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidyl)-1,2,4-triazin-3-amine (38 mg, 0.09 mmol) in CH2Cl2 (2 mL) was treated with BBr3 in CH2Cl2 (1 mol/L, 0.87 mL). The reaction was stirred at room temperature for 4 h until UPLC showed complete consumption of the starting material. The precipitate was filtered and dried to give 2-(3-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,2,4-triazin-6-yl)-5-(5-methyloxazol-2-yl)phenol hydrobromide (13 mg, 35%) as an orange solid.
  • MS m/z 423.5 [M+H]+; 1H NMR (methanol-d4) δ: 9.14 (s, 1H), 7.98 (d, J=8.2 Hz, 1H), 7.61 (dd, J=8.2, 1.6 Hz, 1H), 7.58 (d, J=1.6 Hz, 1H), 6.96 (d, J=1.3 Hz, 1H), 5.37-5.45 (m, 1H), 3.25 (s, 3H), 2.46 (s, 3H), 1.98-2.05 (m, 4H), 1.66 (s, 6H), 1.55 (s, 6H); 2Hs not observed (NH and OH).
  • Using the procedure described for Example 2, additional compounds described herein may be prepared by substituting the appropriate starting material, suitable reagents and reaction conditions, obtaining compounds such as those selected from:
  • Cpd Data
    17 MS m/z 408.3 [M + H]+; 1H NMR (methanol-d4) δ: 8.33 (d, J = 2.1 Hz, 1H), 7.74-7.81
    (m, 2H), 7.37-7.48 (m, 2H), 6.57 (s, 1H), 6.03 (s, 1H), 4.46-4.59 (m, 1H), 3.21 (s,
    3H), 2.06-2.30 (m, 4H), 1.66 (s, 6H), 1.62 (s, 6H); 2Hs not observed (NH and OH).
    368 MS m/z 438.5 [M + H]+. 1H NMR (methanol-d4): 9.11 (s, 1H), 7.71 (s, 1H), 7.40 (d,
    J = 8.00 Hz, 2H), 7.32 (d, J = 8.50 Hz, 2H), 7.31 (s, 1H), 6.80 (s, 1H), 5.51 (s, 3H),
    5.36-5.39 (m, 1H), 4.01 (s, 3H), 1.96-2.05 (m, 4H), 1.66 (s, 6H), 1.54 (s, 6H)
    376 MS m/z 410.5 [M + H]+. 1H NMR (methanol-d4): 8.89 (s, 1H), 8.06 (s, 2H), 6.85-6.91
    (m, 2H), 4.31-4.26 (m, 1H), 4.25-4.17 (m, 1H), 4.02-3.96 (m, 1H), 3.93 (s, 3H), 3.81-
    3.75 (m, 2H), 2.71-2.60 (m, 1H), 2.33-2.24 (m, 1H), 1.50 (s, 9H); 3Hs not observed
    (2NHs and OH)
    • Example 3 Preparation of Compound 16
  • Figure US20230331725A1-20231019-C00148
    Figure US20230331725A1-20231019-C00149
    • Step 1:
  • An oven-dried flask was equipped with a magnetic stir bar and charged with 6-bromo-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidyl)-1,2,4-triazin-3-amine (450 mg, 1.37 mmol), triisopropyl-[3-(methoxymethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]silane (658 mg, 1.51 mmol), [1,1′-bis(diphenylphosphino)ferrocene] dichloropalladium(II) (102 mg, 0.14 mmol) and K2CO3 (383 mg, 2.74 mmol). The flask was sealed with a rubber septum, and then evacuated and backfilled with argon. Dioxane (4 mL) and water (1 mL) were added and the reaction was heated to 90° C. for 16 h. The reaction was cooled to room temperature, diluted with water (5 mL), and extracted with EtOAc. The combined organic layers were dried over Na2SO4, concentrated under reduced pressure, and purified by column chromatography eluting with a MeOH/CH2Cl2 gradient (0 to 30% MeOH) to provide crude 6-(2-(methoxymethoxy)-4-((triisopropylsilyl)oxy)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,2,4-triazin-3-amine (316 mg, 41%) as a brownish solid. MS m/z 558.6 [M+H]+.
    • Step 2
  • To a solution of 6-[2-(methoxymethoxy)-4-triisopropylsilyloxy-phenyl]-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidyl)-1,2,4-triazin-3-amine (316 mg, 0.57 mmol) in dry THE (2 mL) was added a 1.0 M solution of TBAF in THF (1.1 mL, 1.1 mmol). The reaction mixture was stirred at room temperature for 10 min until TLC showed complete consumption of the starting material. The solvent was removed under reduced pressure, and the residue was purified by column chromatography eluting with a MeOH/CH2Cl2 gradient (0 to 30% MeOH) to yield 3-(methoxymethoxy)-4-(3-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,2,4-triazin-6-yl)phenol (156 mg, 69%) as a tan oil.
    • Step 3
  • To a solution of 3-(methoxymethoxy)-4-(3-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,2,4-triazin-6-yl)phenol in CH2Cl2 (3 mL) were added N,N-bis(trifluoromethylsulfonyl)aniline (280 mg, 0.78 mmol) and Et3N (0.16 mL, 1.2 mmol). The reaction was stirred for 16 h until UPLC showed complete conversion. The solvent was removed under reduced pressure, the residue was purified by column chromatography on silica gel eluting with a EtOAc/hexanes gradient (30-100% EtOAc) to give 3-(methoxymethoxy)-4-(3-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,2,4-triazin-6-yl)phenyl trifluoromethanesulfonate (154 mg, 74%). MS m/z 534.4 [M+H]+.
    • Step 4
  • An oven-dried flask was equipped with a magnetic stir bar and charged with 3-(methoxymethoxy)-4-(3-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,2,4-triazin-6-yl)phenyl trifluoromethanesulfonate (51 mg, 0.096 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (24 mg, 0.12 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (7 mg, 0.01 mmol), and K2CO3 (40 mg, 029 mmol). The flask was sealed with a rubber septum and then evacuated and backfilled with argon. Dioxane (2 mL) and water (0.5 mL) were added and the reaction was heated to 90° C. for 16 h. The reaction was cooled to room temperature, diluted with water, and extracted with EtOAc. The combined organic layers were dried over Na2SO4, concentrated under reduced pressure, and purified by column chromatography eluting with a MeOH/CH2Cl2 gradient (0 to 30% MeOH) to provide 6-(2-(methoxymethoxy)-4-(1-methyl-1H-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,2,4-triazin-3-amine (40 mg, 90%). MS m/z 466.6 [M+H]+.
    • Step 5:
  • To a solution of 6-(2-(methoxymethoxy)-4-(1-methyl-1H-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,2,4-triazin-3-amine (40 mg, 0.086 mmol) in CH2Cl2 (1 mL), were added 2 drops of MeOH and HCl (4 mol/L) in 1,4-dioxane (43 μL, 0.17 mmol). The reaction was stirred for 16 h at room temperature. The solvents were removed under reduced pressure, and the product was purified by column chromatography eluting with a MeOH/CH2Cl2 gradient (5 to 30% MeOH) to provide 2-(3-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,2,4-triazin-6-yl)-5-(1-methyl-1H-pyrazol-4-yl)phenol.
  • MS m/z 422.5 [M+H]+; 1H NMR (methanol-d4) δ: 9.37-9.43 (m, 1H), 8.10 (s, 1H), 7.94 (s, 1H), 7.64 (d, J=8.2 Hz, 1H), 7.24 (dd, J=8.5, 1.8 Hz, 1H), 7.19 (d, J=1.8 Hz, 1H), 5.36-5.48 (m, 1H), 3.97 (s, 3H), 3.16 (s, 3H), 2.00-2.15 (m, 4H), 1.64 (s, 6H), 1.58 (s, 6H); 2Hs not observed (OH and NH).
  • Using the procedure described for Example 3, additional compounds described herein may be prepared by substituting the appropriate starting material, suitable reagents and reaction conditions, obtaining compounds such as those selected from:
  • Cpd Data
    8 MS m/z 419.2 [M + H]+; 1H NMR (DMSO-d6) δ: 11.25 (br s, 1H), 9.09 (s, 1H), 8.58-
    8.71 (m, 2H), 8.00 (d, J = 8.3 Hz, 1H), 7.65-7.76 (m, 2H), 7.41-7.43 (m, 1H), 7.40 (s,
    1H), 5.10-5.32 (m, 1H), 3.13 (s, 3H), 1.98 (t, J = 13.0 Hz, 2H), 1.82 (dd, J = 13.0, 3.7
    Hz, 2H), 1.50 (s, 6H), 1.45 (s, 6H); 1H not observed (NH or OH).
    9 MS m/z 433.3 [M + H]+; 1H NMR (DMSO-d6) δ: 9.08 (s, 1H), 8.51 (d, J = 5.1 Hz, 1H),
    7.99 (d, J = 8.1 Hz, 1H), 7.54-7.63 (m, 1H), 7.49 (dd, J = 5.1, 1.5 Hz, 1H), 7.38 (dd,
    J = 8.1, 1.5 Hz, 1H), 7.35-7.36 (m, 1H), 5.11-5.32 (m, 1H), 3.08 (s, 3H), 2.54 (s, 3H),
    1.54 (dd, J = 12.1, 3.4 Hz, 2H), 1.47 (t, J = 12.1 Hz, 2H), 1.24 (s, 6H), 1.10 (s, 6H); 2Hs
    not observed (NH and OH).
    60 MS m/z 420.6 [M + H]+; 1H NMR (methanol-d4) δ: 9.61 (s, 1H), 9.28 (br d, J = 5.2 Hz,
    1H), 9.16 (s, 1H), 8.10 (br dd, J = 5.6, 2.5 Hz, 1H), 8.07 (d, J = 7.9 Hz, 1H), 7.52 (dd,
    J = 8.4, 1.7 Hz, 1H), 7.49 (d, J = 1.8 Hz, 1H), 5.35-5.48 (m, 1H), 3.25 (s, 3H), 1.95-
    2.09 (m, 4H), 1.66 (s, 6H), 1.56 (s, 6H); 2Hs not observed (NH and OH)
    61 MS m/z 434.6 [M + H]+; 1H NMR (methanol-d4) δ: 9.39 (s, 1H), 9.13 (s, 1H), 8.04 (br
    d, J = 7.9 Hz, 1H), 7.95 (s, 1H), 7.37-7.53 (m, 2H), 5.29-5.46 (m, 1H), 3.21 (s, 3H),
    2.78 (s, 3H), 1.67-1.85 (m, 4H), 1.47 (s, 6H), 1.35 (s, 6H); 2Hs not observed (NH and
    OH)
    70 MS m/z 419.1 [M + H]+; 1H NMR (DMSO-d6) δ: 9.08 (s, 1H), 8.91 (s, 1H), 8.59 (d, J =
    4.0 Hz, 1H), 8.09 (d, J = 8.0 Hz, 1H), 7.98 (d, J = 8.0 Hz, 1H), 7.48-7.52 (m, 1H),
    7.30-7.33 (m, 2H), 5.19 (br s, 1H), 3.08 (s, 3H), 1.45-1.55 (m, 4H), 1.11 (s, 6H), 1.24
    (s, 6H); 2Hs not observed (OH and NH)
    74 MS m/z 423.5 [M + H]+; 1H NMR (methanol-d4) δ: 9.11 (s, 1H), 7.82 (d, J = 8.4 Hz,
    1H), 7.69 (s, 1H), 7.54 (d, J = 1.1 Hz, 1H), 7.34-7.39 (m, 2H), 5.33-5.42 (m, 1H), 3.77-
    3.83 (m, 3H), 3.21 (s, 3H), 1.84-1.99 (m, 4H), 1.59 (br s, 6H), 1.47 (br s, 6H); 1H not
    observed
    77 MS m/z 392.5 [M + H]+. 1H NMR (methanol-d4): 8.41 (s, 2H), 7.66 (dd, J = 8.32, 1.60
    Hz, 1H), 7.31 (d, J = 8.33 Hz, 1H), 7.28 (s, 1H), 6.00 (s, 1H), 5.98 (s, 1H), 3.1 (s,
    3H), 2.58-2.51 (m, 1H), 2.39-2.06 (m, 9H), 2.07-1.88 (m, 1H), 1.89-1.76 (m, 1H);
    3Hs not observed (2NHs and OH)
    78 MS m/z 364.4 [M + H]+. 1H NMR (methanol-d4): 8.91 (s, 1H), 7.90 (s, 2H), 7.72, (d,
    J = 8.09 Hz, 1H), 7.12 (d, J = 8.00 Hz, 1H), 7.09, (s, 1H), 4.11-4.07 (m, 1H), 4.00-3.96
    (m, 2H), 2.39-2.35 (m, 2H), 2.29-2.25 (m, 4H), 2.17-2.01 (m, 4H); 2Hs not observed
    (OH and NH)
    86 MS m/z 420.2 [M + H]+; 1H NMR (DMSO-d6) δ: 9.21 (s, 1H), 9.15 (s, 2H), 9.10 (s,
    1H), 8.36 (br s, 1H), 8.00 (d, J = 8.4 Hz, 1H), 7.38-7.42 (m, 2H), 5.23 (br s, 1H), 3.11
    (s, 3H), 1.81-1.89 (m, 2H), 1.67-1.71 (m, 2H), 1.41 (s, 6H), 1.33 (s, 6H); 1H not
    observed (OH or NH)
    103 MS m/z 434.3 [M + H]+; 1H NMR (DMSO-d6) δ: 9.07 (s, 1H), 8.35 (s, 1H), 7.87-7.90
    (m, 1H), 7.50 (d, J = 8.8 Hz, 2H), 7.17-7.19 (m, 2H), 6.86 (d, J = 8.4 Hz, 2H), 5.21 (br
    s, 1H), 3.10 (s, 3H), 1.66-1.82 (m, 4H), 1.39 (s, 6H), 1.30 (s, 6H); 2Hs not observed
    (OH and NH)
    104 MS m/z 435.1 [M + H]+; 1H NMR (DMSO-d6) δ: 9.07 (s, 1H), 7.89 (d, J = 8.4 Hz, 1H),
    7.84 (dd, J = 9.6, 2.8 Hz, 1H), 7.75 (d, J = 2.8 Hz, 1H), 7.17 (dd, J = 8.0, 1.6 Hz, 2H),
    7.13 (d, J = 1.6 Hz, 2H), 6.44 (d, J = 9.2 Hz, 1H), 5.19 (br s, 1H), 3.17 (s, 3H), 1.48-
    1.58 (m, 4H), 1.27 (s, 6H), 1.14 (s, 6H); 1H not observed (OH or NH)
    124 MS m/z 422.4 [M + H]+; 1H NMR (methanol-d4) δ: 9.11 (br s, 1H), 7.88 (br d, J = 5.8
    Hz, 1H), 7.52 (d, J = 1.5 Hz, 1H), 6.94-7.09 (m, 2H), 6.42 (d, J = 1.5 Hz, 1H), 5.24-5.42
    (m, 1H), 3.94 (s, 3H), 3.16 (s, 3H), 1.70 (dd, J = 12.5, 3.4 Hz, 2H), 1.62 (t, J = 12.5 Hz,
    2H), 1.38 (s, 6H), 1.26 (s, 6H); 2Hs not observed (NH and OH)
    131 MS m/z 458.7 [M + H]+; 1H NMR (DMSO- d6) δ: 12.60 (br s, 1H), 11.30 (br s, 1H),
    9.08 (s, 1H), 8.28 (s, 1H), 7.60-8.00 (m, 3H), 7.52 (br s, 1H), 7.28-7.31 (m, 2H), 5.21
    (br s, 1H), 3.15 (s, 3H), 1.35-1.55 (m, 4H), 1.24 (s, 6H), 1.00 (s, 6H)
    176 MS m/z 473.3 [M + H]+; 1H NMR (DMSO-d6) δ: 9.09 (s, 1H), 8.90 (d, J = 2.0 Hz, 1H),
    8.51 (d, J = 2.0 Hz, 1H), 8.38 (br s, 2H), 8.23 (s, 1H), 7.98 (d, J = 6.0 Hz, 1H), 7.34-
    7.36 (m, 2H), 5.21 (m, 1H), 4.11 (s, 3H), 3.17 (s, 3H), 1.60-1.70 (m, 4H), 1.33 (s, 6H),
    1.15 (s, 6H)
    177 MS m/z 472.3 [M + H]+; 1H NMR (DMSO-d6) δ: 9.09 (s, 1H), 8.40 (s, 1H), 8.12 (s,
    1H), 8.05 (s, 1H), 7.95 (d, J = 8.8 Hz, 1H), 7.74 (s, 2H), 7.30-7.32 (m, 2H), 5.21 (m,
    1H), 4.08 (s, 3H), 3.10 (s, 3H), 1.63-1.78 (m, 4H), 1.37 (s, 6H), 1.27 (s, 6H); 1H not
    observed (OH or NH)
    188 MS m/z 462.5 [M + H]+; 1H NMR (methanol-d4) δ: 9.09 (s, 1H), 7.82-7.87 (m, 1H),
    7.18 (d, J = 7.9 Hz, 1H), 7.15 (d, J = 7.6 Hz, 3H), 6.90 (d, J = 7.9 Hz, 1H), 6.00 (s, 2H),
    5.29-5.44 (m, 1H), 3.19 (s, 3H), 1.84-1.96 (m, 4H), 1.56 (s, 6H), 1.44 (s, 6H); 2Hs not
    observed (NH and OH)
    352 MS m/z 395.2 [M + H]+; 1H NMR (DMSO-d6) δ: 8.98 (s, 1H), 8.41 (br s, 1H), 8.25 (s,
    1H), 7.96 (d, J = 8.0 Hz, 1H), 7.62 (d, J = 1.6 Hz, 1H), 7.54 (dd, J = 8.0, 1.6 Hz, 1H),
    7.41 (s, 1H), 4.38 (br s, 1H), 1.98 (d, J = 1.6 Hz, 2H), 1.39-1.54 (m, 2H), 1.27 (s, 6H),
    1.02 (s, 6H); 2Hs not observed (OH and NH)
    • Example 4 Preparation of Compound 23
  • Figure US20230331725A1-20231019-C00150
    Figure US20230331725A1-20231019-C00151
    • Step 1
  • A suspension of 3-(methoxymethoxy)-4-(3-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,2,4-triazin-6-yl)phenyl trifluoromethanesulfonate (30 mg, 0.056 mmol, 1.0 equiv), B2Pin2 (20 mg, 0.078 mmol, 1.4 equiv), Pd(dppf)Cl2 (4.6 mg, 0.0056 mmol, 0.1 equiv), and dry KOAc (16 mg, 0.168 mmol, 3.0 equiv) in dioxane (0.9 mL) was sparged with argon for 10 minutes, then heated to 90° C. under argon atmosphere for 2 h, after which complete conversion to 6-(2-(methoxymethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,2,4-triazin-3-amine was observed. The reaction mixture was then cooled to room temperature and used directly in the next step.
  • Alternatively, 6-(4-chloro-2-(methoxymethoxy)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,2,4-triazin-3-amine could be used as a starting material for step 1. XPhos Pd G3 (10 mol %) could be used as catalyst in this case, otherwise following the above procedure.
    • Step 2
  • To the mixture from Step 1 was added aq. K2CO3 (85 μL, 2M, 3.0 equiv), 4-bromo-2-methyl-2H-1,2,3-triazole (13.6 mg, 0.084 mmol, 1.5 equiv), and Pd(dppf)Cl2 (4.6 mg, 0.0056 mmol, 0.1 equiv). The mixture was then heated to 95° C. under argon for 12 h. The reaction was cooled to room temperature, filtered over Celite (washed with 10% MeOH/CH2Cl2), concentrated, and purified by column chromatography eluting with MeOH/CH2Cl2 (5-15% MeOH) to afford 6-(2-(methoxymethoxy)-4-(2-methyl-2H-1,2,3-triazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,2,4-triazin-3-amine which was used in the next step without further purification.
    • Step 3:
  • 6-(2-(Methoxymethoxy)-4-(2-methyl-2H-1,2,3-triazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,2,4-triazin-3-amine from Step 2 was dissolved in MeOH (0.5 mL), then HCl (0.5 mL, 4M in dioxane) was added. The solution was stirred at room temperature for 30 minutes. The reaction mixture was concentrated and purified by column chromatography eluting with MeOH/CH2Cl2 (10-30% MeOH) to afford 2-(3-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,2,4-triazin-6-yl)-5-(2-methyl-2H-1,2,3-triazol-4-yl)phenol (11.5 mg, 50% over 3 steps).
  • MS m/z 423.3 [M+H]+ 1H NMR (methanol-d) δ: 9.12 (s, 1H), 8.04 (s, 1H), 7.87-7.96 (m, 1H), 7.42-7.51 (m, 2H), 5.36-5.45 (m, 1H), 4.25 (s, 3H), 3.23 (s, 3H), 1.90-2.07 (m, 4H), 1.65 (s, 6H), 1.53 (s, 6H); 2Hs not observed (NH and OH).
  • Using the procedure described for Example 4, additional compounds described herein may be prepared by substituting the appropriate starting material, suitable reagents and reaction conditions, obtaining compounds such as those selected from:
  • Cpd Data
    2 MS m/z 450.2 [M + H]+; 1H NMR (DMSO-d6) δ: 9.07 (s, 1H),
    8.87 (d, J = 1.0 Hz, 1H), 8.35 (s, 1H), 7.99 (d, J = 8.3 Hz,
    1H), 7.84 (d, J = 1.7 Hz, 1H), 7.75 (dd, J = 8.3, 1.7 Hz, 1H),
    7.48 (d, J = 1.0 Hz, 1H), 5.13-5.30 (m, 1H), 3.99 (s, 3H), 3.09 (s,
    3H), 1.59 (d, J = 7.8 Hz, 4H), 1.29 (s, 6H), 1.17 (s, 6H); 1H
    not observed (NH or OH).
    3 MS m/z 449.2 [M + H]+; 1H NMR (DMSO-d6) δ: 9.07
    (s, 1H), 8.33 (s, 1H), 8.25 (d, J = 5.4 Hz, 1H), 7.97 (d,
    J = 8.1 Hz, 1H), 7.33-7.40 (m, 2H), 7.30 (dd, J = 5.4,
    1.5 Hz, 1H), 7.09 (d, J = 0.9 Hz, 1H), 5.11-5.32 (m, 1H),
    3.90 (s, 4H), 3.10 (s, 3H), 1.60-1.79 (m, 3H), 1.35 (s, 6H), 1.25
    (s, 6H); 1H not observed (NH or OH).
    4 MS m/z 409.1 [M + H]+; 1H NMR (DMSO-d6) δ:
    11.33 (br. s., 2H), 9.06 (s, 1H), 8.37 (s, 1H), 7.94 (d, J = 8.2
    Hz, 1H), 7.50 (d, J = 1.6 Hz, 1H), 7.45 (dd, J = 8.2,
    1.6 Hz, 1H), 5.05-5.34 (m, 1H), 3.08 (s, 3H), 1.54 (dd, J =
    12.0, 3.7 Hz, 2H), 1.48 (t, J = 12.0 Hz, 2H), 1.24 (s, 6H),
    1.11 (s, 6H); 1H not observed (NH or OH).
    5 MS m/z 435.2 [M + H]+; 1H NMR (DMSO-d6) δ:
    11.65 (br. s., 1H), 11.12 (br. s., 1H), 9.06 (s, 1H), 8.80 (br. s., 1H),
    7.94 (d, J = 8.3 Hz, 1H), 7.47 (d, J = 6.8 Hz, 1H), 7.28
    (dd, J = 8.3, 1.7 Hz, 1H), 7.25 (d, J = 1.6 Hz, 1H), 6.56
    (d, J = 1.6 Hz, 1H), 6.48 (dd, J = 6.8, 1.6 Hz, 1H), 5.06-
    5.35 (m, 1H), 3.34 (s, 3H), 1.75-2.02 (m, 4H), 1.48 (s, 6H), 1.40
    (s, 6H).
    6 MS m/z 422.2 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.06 (s, 1H), 8.38 (br. s., 1H), 7.86 (d, J = 8.2 Hz, 1H), 7.82 (s,
    1H), 7.10 (d, J = 1.6 Hz, 1H), 7.07 (dd, J = 8.2, 1.6 Hz,
    1H), 5.07-5.28 (m, 1H), 3.10 (s, 3H), 2.41 (s, 3H), 1.85 (t, J =
    12.5 Hz, 2H), 1.69 (dd, J = 12.5, 3.5 Hz, 2H), 1.41 (s, 6H),
    1.33 (s, 6H); 2Hs not observed (NH and OH).
    7 MS m/z 409.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.02 (s, 1H), 8.25 (s, 1H), 8.00 (d, J = 8.2 Hz, 1H), 7.60 (s, 1H),
    7.56 (d, J = 8.2 Hz, 1H), 7.41 (s, 1H), 5.09-5.37 (m, 1H), 3.08
    (s, 3H), 1.41-1.61 (m, 4H), 1.24 (s, 6H), 1.11 (s, 6H); 2Hs not
    observed (NH and OH).
    12 MS m/z 426.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.09 (s, 1H), 7.97 (d, J = 2.0 Hz, 1H), 7.84 (d, J = 8.5 Hz,
    1H), 7.22-7.20 (m, 2H), 5.36 (dt, J = 17.0, 9.0 Hz, 1H), 3.20
    (s, 3H), 1.96 (d, J = 8.0 Hz, 4H), 1.61 (s, 6H), 1.50 (s, 6H); 3Hs
    not observed (2NHs and OH).
    18 MS m/z 440.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.10 (s, 1H), 7.93 (d, J = 2.3 Hz, 1H), 7.85 (d, J = 8.9 Hz,
    1H), 7.14-7.23 (m, 2H), 5.32-5.39 (m, 1H), 3.83 (s, 3H), 3.20 (s,
    3H), 1.91-2.00 (m, 4H), 1.61 (s, 6H), 1.50 (s, 6H); 2H not
    observed (NH and OH).
    53 MS m/z 424.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    8.97 (s, 1H), 7.82 (d, J = 8.09 Hz, 1H), 7.52 (dd, J =
    5.04, 0.92 Hz, 1H), 7.47 (dd, J = 3.51, 0.91 Hz, 1H), 7.22-7.17
    (m, 2H), 7.09-7.07 (m, 1H), 5.21-5.08 (m, 1H), 3.03 (s, 3H), 2.00-
    1.66 (m, 4H), 1.38, (s, 12H); 2Hs not observed (NH and OH)
    54 MS m/z 438.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.05 (s, 1H), 7.89 (d, J = 8.09 Hz, 1H), 7.37 (s, 1H), 7.25 (dd,
    J = 8.24, 1.53 Hz, 1H), 7.22 (s, 1H), 7.17 (s, 1H), 5.28-
    5.17 (m, 1H), 3.12 (s, 3H), 2.27 (s, 3H), 2.04-1.74 (m, 4H), 1.38,
    (s, 12H); 2Hs not observed (NH and OH).
    56 MS m/z 449.2 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.06 (s, 1H), 7.94 (d, J = 8.0 Hz, 1H), 7.82 (d, J =
    6.8 Hz, 1H), 7.28-7.31 (m, 2H), 6.64 (d, J = 2.0 Hz, 1H), 6.55
    (dd, J = 7.2, 2.0 Hz, 1H), 5.23 (br s, 1H), 3.92 (s, 3H), 3.11
    (s, 3H), 1.83-1.91 (m, 2H), 1.68-1.73 (m, 2H), 1.43 (s, 6H), 1.37
    (s, 6H); 2Hs not observed (OH and NH)
    57 MS m/z 442.5 [M + H]+, 444.5 [M + 2 + H]+;
    1H NMR (methanol-d4) δ: 9.09 (s, 1H), 8.29 (s, 1H), 7.92 (d, J =
    11.0 Hz, 1H), 7.55-7.64 (m, 1H), 7.27-7.40 (m, 1H), 5.25-5.42 (m,
    1H), 3.17 (s, 3H), 1.70 (ddd, J = 8.7, 5.3, 3.8 Hz, 2H), 1.60
    (dd, J = 14.6, 12.5 Hz, 2H), 1.40 (s, 6H), 1.27 (s, 6H); 3Hs not
    observed (2 NHs and OH)
    58 MS m/z 425.5 [M + H]+; 1H NMR (methanol-d4) δ:
    9.14 (s, 1H), 7.98 (d, J = 8.9 Hz, 1H), 7.95-8.00 (m, 1H), 7.92
    (d, J = 3.4 Hz, 1H), 7.67 (d, J = 3.2 Hz, 1H), 7.57-7.61
    (m, 2H), 5.35-5.46 (m, 1H), 3.25 (s, 3H), 2.01 (s, 4H), 1.66 (s,
    6H), 1.55 (s, 6H); 1H not observed (NH or OH)
    62 MS m/z 423.6 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.04 (s, 1H), 8.55 (s, 1H), 7.92 (d, J = 8.2 Hz, 1H), 7.66 (d,
    J = 1.5 Hz, 1H), 7.59 (dd, J = 7.9, 1.5 Hz, 1H), 5.18-
    5.29 (m, 1H), 3.94 (s, 3H), 3.13 (s, 3H), 1.94-2.06 (m, 2H), 1.75-
    1.87 (m, 2H), 1.52 (s, 6H), 1.48 (s, 6H); 2Hs not observed (OH
    and NH)
    64 MS m/z 439.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    8.78 (s, 1H), 8.20 (s, 1H), 7.82 (d, J = 7.93 Hz, 1H), 7.40 (s,
    1H), 7.31 (d, J = 8.01, 1.60 Hz, 1H), 5.31-5.15 (m, 1H),
    3.94 (s, 3H), 3.11 (s, 3H), 2.09-1.7 (m, 4H), 1.46 (s, 12H); 2Hs
    not observed (NH and OH)
    65 MS m/z 426.5 [M + H]+; 1H NMR (methanol-d4) δ:
    9.15 (s, 1H), 8.81 (s, 1H), 8.02 (d, J = 7.9 Hz, 1H), 7.65-7.70
    (m, 2H), 5.34-5.47 (m, 1H), 3.25 (s, 3H), 1.96-2.03 (m,
    4H), 1.64 (s, 6H), 1.53 (s, 6H); 2Hs not observed (NH and OH).
    66 MS m/z 440.5 [M + H]+; 1H NMR (chloroform-d) δ:
    9.12 (s, 1H), 8.00 (d, J = 8.1 Hz, 1H), 7.96-8.04 (m, 1H), 7.57-
    7.62 (m, 2H), 5.29-5.46 (m, 1H), 3.22 (s, 3H), 2.69 (s, 3H),
    1.93-2.01 (m, 4H), 1.61 (s, 6H), 1.50 (s, 6H); 1H not observed
    (NH or OH)
    71 MS m/z 419.1 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.07 (s, 1H), 8.69 (d, J = 4.4 Hz, 1H), 8.38 (br s, 1H), 7.94-7.98
    (m, 2H), 7.87-7.92 (m, 1H), 7.78 (d, J = 1.6 Hz, 1H),
    7.66 (dd, J = 6.4, 1.6 Hz, 1H), 7.36-7.40 (m, 1H), 5.23 (br s,
    1H), 3.10 (s, 3H), 1.75-1.82 (m, 2H), 1.64-1.68 (m, 2H), 1.38 (s,
    6H), 1.29 (s, 6H); 1H not observed (OH or NH)
    75 MS m/z 422.5 [M + H]+; 1H NMR (methanol-d4) δ:
    9.10 (s, 1H), 7.84 (d, J = 8.9 Hz, 1H), 7.69 (s, 1H), 7.54 (d, J =
    1.1 Hz, 1H), 7.34-7.38 (m, 2H), 5.32-5.46 (m, 1H), 3.80 (s, 3H),
    3.21 (s, 3H), 1.87-1.98 (m, 4H), 1.59 (s, 6H), 1.47 (s, 6H); 2Hs
    not observed (NH and OH)
    76 MS m/z 422.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.00 (s, 1H), 7.75 (d, J = 7.78 Hz, 1H), 7.52 (d, J = 2.29 Hz,
    1H), 7.31 (s, 1H), 7.29 (s, 1H), 6.55 (d, J = 2.29 Hz, 1H),
    5.37-5.18 (m, 1H), 3.84 (s, 3H), 3.11 (s, 3H), 1.91-1.83 (m, 4H),
    1.53 (s, 6H), 1.42 (s, 6H); 2Hs not observed (NH and OH)
    80 MS m/z 459.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.15-9.18 (m, 1H), 9.10 (br d, J = 13.3 Hz, 2H), 8.10-8.15 (m,
    1H), 7.96 (d, J = 9.0 Hz, 1H), 7.86 (s, 1H), 7.69-7.72
    (m, 1H), 7.63 (d, J = 7.0 Hz, 1H), 5.35-5.46 (m, 1H), 3.25
    (s, 3H), 1.99-2.09 (m, 4H), 1.66 (s, 6H), 1.56 (s, 6H); 2Hs not
    observed (NH and OH)
    81 MS m/z 424.6 [M + H]+; 1H NMR (methanol-d4) δ
    9.13 (s, 1H), 7.98-8.12 (m, 1H), 7.55-7.72 (m, 2H), 5.34-5.47 (m,
    1H), 3.24 (s, 3H), 2.66 (s, 3H), 1.86-2.01 (m, 4H), 1.62 (s, 6H),
    1.51 (s, 6H); 2Hs not observed (OH and NH)
    83 MS m/z 420.1 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.27 (d, J = 1.2 Hz, 1H), 9.07 (s, 1H), 8.74 (dd, J = 2.4,
    1.6 Hz, 1H), 8.63 (d, J = 2.4 Hz, 1H), 8.01 (d, J = 8.0
    Hz, 1H), 7.78 (d, J = 1.6 Hz, 1H), 7.74 (dd, J = 8.4,
    1.6 Hz, 1H), 5.21 (br s, 1H), 3.09 (s, 3H), 1.45-1.58 (m, 4H),
    1.25 (s, 6H), 1.06 (s, 6H); 2Hs not observed (OH and NH)
    84 MS m/z 420.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.23 (dd, J = 4.8, 1.2 Hz, 1H), 9.09 (s, 1H), 8.36 (br s, 1H),
    8.23 (d, J = 8.0 Hz, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.86
    (d, J = 8.4 Hz, 1H), 7.70-7.82 (m, 1H), 7.72 (dd, J =
    8.4, 1.6 Hz, 1H), 5.23 (br s, 1H), 3.07 (s, 3H), 1.78-1.85 (m, 2H),
    1.67-1.71 (m, 2H), 1.40 (s, 6H), 1.24 (s, 6H); 1H not observed
    (OH or NH)
    85 MS m/z 420.2 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.05 (s, 1H), 8.93 (d, J = 4.8 Hz, 2H), 8.06 (s, 1H), 7.99 (s,
    2H), 7.47 (t, J = 4.8 Hz, 1H), 5.23 (br s, 1H), 3.08 (s, 3H),
    1.44-1.56 (m, 4H), 1.25 (s, 6H), 1.11 (s, 6H); 2Hs not observed
    (OH and NH)
    88 MS m/z 451.6 [M + H]+; 1H NMR (methanol-
    d4) δ: 9.08-9.24 (m, 1H), 8.95 (s, 1H), 8.00 (s, 1H), 7.78-7.92
    (m, 2H), 5.27-5.42 (m, 1H), 3.37 (s, 3H), 3.16 (s, 3H), 1.53-
    1.76 (m, 4H), 1.36 (s, 6H), 1.24 (s, 6H); 2Hs not observed (NH
    and OH)
    91 MS m/z 409.5 [M + H]+; 1H NMR (methanol-d4) δ:
    9.09 (s, 1H), 8.29 (s, 1H), 7.90 (d, J = 7.2 Hz, 1H), 7.59 (s, 1H),
    7.29-7.41 (m, 2H), 5.29-5.40 (m, 1H), 3.18 (s, 3H), 1.64-1.80
    (m, 4H), 1.42 (s, 6H), 1.30 (s, 6H); 2Hs not observed (NH
    and OH)
    92 MS m/z 459.6 [M + H]+; 1H NMR (methanol-d4) δ:
    9.17 (s, 1H), 8.22 (s, 1H), 8.11 (d, J = 9.6 Hz, 1H), 8.03 (d,
    J = 7.9 Hz, 1H), 7.79-7.85 (m, 2H), 7.69-7.74 (m, 2H), 5.41
    (br s, 1H), 3.25 (s, 3H), 1.96-2.03 (m, 4H), 1.65 (s, 6H), 1.53
    (s, 6H); 2Hs not observed (NH and OH)
    97 MS m/z 458.6 [M + H]+; 1H NMR (DMSO-d6) δ 9.37
    (br d, J = 10.38 Hz, 1H), 9.09 (s, 1H), 8.29 (br d, J = 10.83 Hz,
    1H), 8.15 (s, 1H), 8.05 (s, 1H), 7.94 (d, J = 7.93 Hz, 1H), 7.62-
    7.70 (m, 2H), 7.28-7.33 (m, 2H), 5.23 (br s, 1H), 3.12 (s, 3H),
    2.06 (br t, J = 12.82 Hz, 2H), 1.74-1.82 (m, 2H), 1.52 (s, 6H),
    1.50 (s, 6H); 1H not observed (NH or OH)
    98 MS m/z 437.3 [M + H]+; 1H NMR (DMSO-d6) δ: 9.08
    (s, 1H), 8.68-8.73 (m, 1H), 7.91-8.00 (m, 2H), 7.80 (s, 1H), 7.70
    (d, J = 7.6 Hz, 1H), 7.32 (br s, 1H), 5.21 (br s, 1H), 3.08 (s, 3H),
    1.44-1.55 (m, 4H), 1.24 (s, 6H), 1.03 (s, 6H); 2Hs not observed
    (OH and NH)
    101 MS m/z 448.6 [M + H]+; 1H NMR (methanol-d4) δ: 9.09-
    9.11 (m, 1H), 8.09-8.13 (m, 1H), 7.86 (s, 1H), 7.82 (d, J = 8.2
    Hz, 1H), 7.19 (dd, J = 6.6, 1.5 Hz, 1H), 7.17 (d, J = 1.7 Hz,
    1H), 5.32-5.43 (m, 1H), 3.72 (tt, J = 7.3, 3.8 Hz, 1H), 3.22 (s,
    3H), 1.97-2.00 (m, 4H), 1.63 (s, 6H), 1.52 (s, 6H), 1.14-1.18 (m,
    2H), 1.07-1.13 (m, 2H); 2Hs not observed (NH and OH)
    102 MS m/z 420.2 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.27 (s, 1H), 9.07 (s, 1H), 8.87 (d, J = 5.2 Hz, 1H), 8.36 (br s,
    1H), 8.08 (d, J = 5.2 Hz, 1H), 8.02 (d, J = 8.4 Hz, 1H),
    7.89 (s, 1H), 7.78 (d, J = 8.0 Hz, 1H), 5.23 (br s, 1H), 3.17 (s,
    3H), 1.63-1.75 (m, 4H), 1.35 (s, 6H), 1.25 (s, 6H); 1H not
    observed (OH or NH)
    106 MS m/z 410.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.14 (s, 1H), 9.06 (s, 1H), 8.06 (d, J = 7.3 Hz, 1H), 7.63-7.75
    (m, 2H), 5.31-5.48 (m, 1H), 3.22 (s, 3H), 1.74-1.96 (m, 4H),
    1.54 (s, 6H), 1.42 (s, 6H); 2Hs not observed (OH and NH)
    107 MS m/z 395.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.27 (s, 1H), 8.82 (d, J = 12.0 Hz, 1H), 8.10 (d, J = 12.0 Hz,
    1H), 7.91 (d, J = 8.0 Hz, 1H), 7.77 (s, 1H), 7.51 (s, 1H),
    7.44 (dd, J = 8.0, 1.5 Hz, 1H), 6.72 (d, J = 2.0 Hz,
    1H), 5.67-5.61 (m, 1H), 2.37 (dd, J = 13.5, 4.0 Hz, 2H), 1.82
    (t, J = 12.0 Hz, 2H), 1.51 (s, 6H), 1.47 (s, 6H)
    108 MS m/z 409.4 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.27 (s, 1H), 9.02 (d, J = 11.5 Hz, 1H), 8.25 (d, J = 11.5
    Hz, 1H), 7.90 (d, J = 8.0 Hz, 1H), 7.77 (d, J = 2.0, 1H),
    7.50 (d, J = 1.5 Hz, 1H), 7.41 (dd, J = 8.0, 1.5 Hz, 1H),
    6.70 (d, J = 2.0 Hz, 1H), 5.65-5.60 (m, 1H), 3.90 (s, 3H), 2.35
    (dd, J = 13.0, 3.5 Hz, 2H), 1.84 (t, J = 12.5 Hz, 2H), 1.52
    (s, 6H), 1.49 (s, 6H)
    111 MS m/z 408.5 [M + H]+; 1H NMR (methanol-d4) δ:
    9.13 (s, 1H), 7.91 (d, J = 8.09 Hz, 1H), 7.71 (s, 1H), 7.43 (s, 2H),
    6.73 (s, 1H), 5.42-5.35 (m, 1H), 3.23 (s, 3H), 2.04-1.97 (m, 4H),
    1.66 (s, 6H), 1.54 (s, 6H); 3Hs not observed (2 NHs and OH)
    112 MS m/z 438.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.12-9.13 (m, 1H), 8.81 (s, 2H), 8.00-8.03 (m, 2H), 7.95 (d, J = 8.5
    Hz, 1H), 5.32-5.43 (m, 1H), 3.21 (s, 3H), 1.77-1.88 (m, 4H), 1.50
    (s, 6H), 1.38 (s, 6H); 2Hs not observed (NH and OH)
    123 MS m/z 454.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.15 (s, 1H), 8.22 (d, J = 8.9 Hz, 1H), 8.02 (d, J = 7.5
    Hz, 1H), 7.84 (d, J = 9.0 Hz, 1H), 7.76 (s, 1H), 7.71 (br d,
    J = 8.2 Hz, 1H), 5.32-5.45 (m, 1H), 3.22 (s, 3H), 1.85-1.92
    (m, 4H), 1.55 (s, 6H), 1.43 (s, 6H); 2Hs not observed
    (NH and OH)
    128 MS m/z 434.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.14 (s, 1H), 8.73 (s, 2H), 7.98-8.01 (m, 2H), 7.97 (s, 1H), 5.34-
    5.46 (m, 1H), 3.23 (s, 3H), 2.40 (s, 3H), 1.96-2.00 (m, 4H),
    1.62 (s, 6H), 1.51 (s, 6H); 2Hs not observed (NH and OH)
    129 MS m/z 434.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.17 (s, 1H), 8.69 (d, J = 4.9 Hz, 1H), 8.01-8.07 (m, 2H),
    7.98 (s, 1H), 7.28-7.31 (m, 1H), 5.36-5.45 (m, 1H), 3.24 (s,
    3H), 2.62 (s, 3H), 1.99-2.05 (m, 4H), 1.66 (s, 6H), 1.55 (s, 6H);
    2Hs not observed (NH and OH)
    130 MS m/z 454.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.15 (s, 1H), 8.70 (d, J = 5.0 Hz, 1H), 8.01 (d, J = 9.6
    Hz, 1H), 7.97 (d, J = 5.2 Hz, 1H), 7.78-7.85 (m, 2H), 5.34-
    5.46 (m, 1H), 3.24 (s, 3H), 1.92-1.98 (m, 4H), 1.60 (s, 6H),
    1.49 (s, 6H); 2Hs not observed (NH and OH)
    132 MS m/z 459.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.10 (s, 1H), 8.85 (d, J = 2.0 Hz, 1H), 8.49 (d, J = 2.0 Hz,
    1H), 8.39 (br s, 1H), 8.22 (s, 1H), 7.97 (d, J = 8.0 Hz, 1H),
    7.33-7.36 (m, 2H), 5.23 (br s, 1H), 3.11 (s, 3H), 1.74-1.82
    (m, 2H), 1.64-1.67 (m, 2H), 1.38 (s, 6H), 1.29 (s, 6H); 2Hs not
    observed (OH and NH)
    134 MS m/z 436.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.19-9.38 (m, 1H), 8.05 (d, J = 10.1 Hz, 1H), 7.82 (d,
    J = 7.9 Hz, 1H), 7.32 (s, 1H), 7.20 (dd, J = 7.9,
    1.2 Hz, 1H), 7.07 (d, J = 10.1 Hz, 1H), 5.28-5.38 (m,
    1H), 3.16 (s, 3H), 1.68 (br dd, J = 12.8, 2.2 Hz, 2H),
    1.61 (t, J = 12.8 Hz, 2H), 1.37 (s, 6H), 1.25 (s, 6H); 3Hs
    not observed (NH and 2 OHs)
    136 MS m/z 459.1 [M + H]+; 1H NMR (DMSO-d6) δ:
    13.40 (br s, 1H), 11.30 (br s, 1H), 9.07 (s, 1H), 8.37 (s, 1H),
    8.11 (d, J = 8.8 Hz, 1H), 7.97-8.00 (m, 2H), 7.82 (d, J = 1.2
    Hz, 1H), 7.72 (d, J = 8.0 Hz, 1H), 5.19-5.22 (m, 1H), 3.08
    (s, 3H), 1.44-1.55 (m, 4H), 1.25 (s, 6H), 1.11 (s, 6H); 1H not
    observed (OH or NH)
    141 MS m/z 487.5 [M + H]+; 1H NMR (methanol-d4) δ:
    9.14 (s, 1H), 7.97 (d, J = 8.4 Hz, 1H), 7.92 (s, 1H), 7.62-
    7.67 (m, 2H), 7.57 (s, 1H), 5.34-5.46 (m, 1H), 3.24 (s, 3H),
    2.68 (s, 3H), 2.50 (s, 3H), 1.98-2.05 (m, 4H), 1.66 (s, 6H),
    1.56 (s, 6H); 2Hs not observed (NH and OH)
    142 MS m/z 473.5 [M + H]+; 1H NMR (methanol-d4) δ:
    9.16 (s, 1H), 7.93-8.04 (m, 3H), 7.72 (d, J = 10.2 Hz, 1H),
    7.65-7.70 (m, 2H), 5.34-5.47 (m, 1H), 3.25 (s, 3H), 2.51 (s,
    3H), 2.01 (br d, J = 7.8 Hz, 4H), 1.65 (s, 6H), 1.55 (s,
    6H); 2Hs not observed (NH and OH)
    143 MS m/z 424.6 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.01-9.14 (m, 2H), 7.99-8.11 (m, 2H), 7.72 (d, J = 1.5
    Hz, 1H), 7.65 (dd, J = 8.2, 1.5 Hz, 1H), 5.18-5.30 (m,
    1H), 4.45 (s, 3H), 3.14 (s, 3H), 2.01 (t, J = 13.0 Hz,
    2H), 1.78-1.87 (m, 2H), 1.52 (s, 6H), 1.48 (s, 6H)
    144 MS m/z 451.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.16 (s, 1H), 8.04 (d, J = 8.2 Hz, 2H), 7.74 (d, J =
    1.5 Hz, 1H), 7.70 (dd, J = 8.2, 1.5 Hz, 1H), 5.36-5.46 (m,
    1H), 4.23 (s, 3H), 3.25 (s, 3H), 1.94-2.08 (m, 4H), 1.65 (s, 6H),
    1.54 (s, 6H); 2Hs not observed (NH and OH)
    145 MS m/z 459.0 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.09 (s, 1H), 8.80 (s, 1H), 8.10 (d, J = 1.6 Hz, 1H), 7.97
    (d, J = 8.0 Hz, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.73
    (dd, J = 8.4, 1.6 Hz, 1H), 7.33-7.37 (m, 2H), 5.20 (br s,
    1H), 3.09 (s, 3H), 1.44-1.56 (m, 4H), 1.24 (s, 6H), 1.09 (s, 6H);
    2Hs not observed (OH and NH)
    146 MS m/z 450.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.20-9.27 (m, 1H), 9.07 (s, 1H), 8.58 (s, 1H), 8.14-8.22 (m, 1H),
    7.95 (d, J = 8.2 Hz, 1H), 7.73 (d, J = 1.8 Hz, 1H),
    7.63 (dd, J = 8.2, 1.8 Hz, 1H), 6.93 (s, 1H), 5.18-5.30
    (m, 1H), 3.45 (s, 3H), 3.13 (s, 3H), 2.04 (t, J = 12.8 Hz,
    2H), 1.79-1.84 (m, 2H), 1.52 (s, 6H), 1.49 (s, 6H)
    147 MS m/z 450.6 [M + H]+; 1H NMR (DMSO-
    d6) δ: 9.17-9.27 (m, 1H), 9.10 (s, 1H), 8.32 (d, J =
    2.4 Hz, 1H), 8.12-8.21 (m, 1H), 8.00 (d, J = 8.2 Hz, 1H),
    7.43 (dd, J = 8.1, 1.7 Hz, 1H), 7.39 (d, J = 1.5 Hz,
    1H), 7.18 (d, J = 2.1 Hz, 1H), 5.18-5.30 (m, 1H), 3.70
    (s, 3H), 3.13 (s, 3H), 2.04 (t, J = 12.8 Hz, 2H), 1.78-1.84
    (m, 2H), 1.52 (s, 6H), 1.49 (s, 6H)
    152 MS m/z 459.4 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.16 (d, J = 7.6 Hz, 1H), 9.12 (s, 1H), 8.90-8.98 (m, 1H), 8.28
    (s, 1H), 8.27 (s, 1H), 8.02 (d, J = 8.2 Hz, 1H), 7.90-7.98
    (m, 1H), 7.52 (d, J = 7.6 Hz, 1H), 7.46 (d, J = 8.2
    Hz, 1H), 7.42 (s, 1H), 5.17-5.30 (m, 1H), 3.14 (s, 3H), 1.95-2.05
    (m, 2H), 1.80-1.89 (m, 2H), 1.52 (s, 6H), 1.47 (s, 6H)
    155 MS m/z 460.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.40 (d, J = 7.0 Hz, 1H), 9.09-9.15 (m, 2H), 8.53 (s, 1H), 8.03-
    8.12 (m, 2H), 7.80 (d, J = 7.3 Hz, 1H), 7.56 (d, J = 8.2 Hz,
    1H), 7.52 (s, 1H), 5.19-5.30 (m, 1H), 3.14 (s, 3H), 2.03 (t, J =
    13.0 Hz, 2H), 1.83 (d, J = 12.5 Hz, 2H), 1.53 (s, 6H), 1.49 (s, 6H)
    156 MS m/z 426.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.10 (s, 1H), 7.92 (d, J = 8.00 Hz, 1H), 7.68 (d, J = 4.00 Hz,
    1H), 7.44 (s, 2H), 5.44-5.34, (m, 1H), 3.23 (s, 3H), 2.01 (d, J =
    7.5 Hz, 4H), 1.65 (s, 6H), 1.54, (s, 6H); 3Hs not observed (2
    NHs and OH)
    158 MS m/z 459.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    12.16 (s, 1H), 9.07 (s, 1H), 8.86 (s, 1H), 8.38 (s, 1H), 7.97-7.99
    (m, 1H), 7.92-7.93 (m, 1H), 7.80 (d, J = 1.2 Hz, 1H),
    7.71-7.73 (m, 1H), 6.69 (d, J = 3.2 Hz, 1H), 5.21 (br s,
    1H), 3.13 (s, 3H), 1.54-1.60 (m, 4H), 1.33 (s, 6H), 1.21 (s, 6H);
    1H not observed (OH or NH)
    163 MS m/z 473.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.65 (s, 1H), 9.11 (s, 1H), 8.41 (d, J = 8.54 Hz, 1H), 8.20 (d,
    J = 8.54 Hz, 1H), 8.03 (d, J = 8.09 Hz, 1H), 7.93 (s, 1H),
    7.80 (d, J = 7.93 Hz, 1H), 5.26 (br s, 1H), 4.08 (s, 3H), 3.13
    (s, 3H), 2.15 (t, J = 12.82 Hz, 2H) 1.75 (d, J = 12.36
    Hz, 2H) 1.54 (s, 12H); 2Hs not observed (NH and OH)
    164 MS m/z 473.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.09 (s, 1H), 8.48 (s, 1H), 8.14 (d, J = 8.09 Hz, 1H), 7.98 (d,
    J = 8.39 Hz, 1H), 7.92 (d, J = 8.39 Hz, 1H), 7.84-7.89
    (m, 1H), 7.72 (d, J = 8.24 Hz, 1H), 5.26 (br s, 1H) 3.91 (s,
    3 H), 3.13 (s, 3H), 2.11 (t, J = 12.82 Hz, 2H), 1.77 (d, J =
    11.60 Hz, 2H), 1.54 (s, 6H), 1.53 (s, 6H); 2Hs not observed (NH
    and OH)
    168 MS m/z 464.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.10-9.13 (m, 1H), 7.87 (d, J = 7.9 Hz, 1H), 7.18-7.26 (m,
    2H), 6.58 (s, 1H), 5.34-5.44 (m, 1H), 3.23 (s, 3H), 2.21 (s,
    3H), 1.98-2.05 (m, 4H), 1.65 (s, 6H), 1.56 (s, 6H); 5Hs not
    observed (3 NHs and 2 OHs)
    169 MS m/z 488.5 [M + H]+; 1H NMR (methanol-d4) δ:
    9.13 (s, 1H), 7.95 (d, J = 7.8 Hz, 1H), 7.80 (s, 1H), 7.66-
    7.71 (m, 2H), 5.33-5.45 (m, 1H), 3.22 (s, 3H), 2.71 (s, 3H),
    2.66-2.70 (m, 3H), 1.93 (t, J = 10.8 Hz, 4H), 1.59 (s,
    6H), 1.47 (s, 6H); 2Hs not observed (NH and OH)
    173 MS m/z 474.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.11 (s, 1H), 8.63 (d, J = 8.7 Hz, 1H), 8.09 (d, J =
    8.7 Hz, 1H), 8.06-8.01 (m, 1H), 7.93 (s, 1H), 7.84 (d, J =
    8.1 Hz, 1H), 5.33-5.17 (m, 1H), 4.37 (s, 3H), 3.14 (s, 3H),
    2.14-2.01 (m, 2H), 1.84-1.72 (m, 2H), 1.53 (s, 6H), 1.51 (s,
    6H); 2Hs not observed (NH and OH)
    178 MS m/z 461.2 [M + H]+; 1H NMR (DMSO-d6) δ:
    11.24 (br s, 1H), 9.11 (s, 1H), 8.97-9.07 (m, 1H), 8.90 (d, J =
    9.5 Hz, 1H), 8.45 (d, J = 9.5 Hz, 1H), 8.10 (d, J = 7.9 Hz,
    1H), 7.93-8.07 (m, 1H), 7.87 (s, 1H), 7.82 (d, J = 8.2 Hz, 1H),
    5.15-5.35 (m, 1H), 3.15 (s, 3H), 1.97-2.06 (m, 2H), 1.80-1.88 (m,
    2H), 1.53 (s, 6H), 1.48 (s, 6H); 1H from HCl salt
    179 MS m/z 450.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    11.05 (br s, 1H), 9.15 (s, 1H), 9.07 (s, 1H), 8.00-8.08 (m, 2H),
    7.87 (s, 1H), 7.78 (d, J = 8.2 Hz, 1H), 5.74 (t, J =
    5.8 Hz, 1H), 5.14-5.32 (m, 1H), 4.64 (d, J = 5.8 Hz, 2H),
    3.13 (s, 2H), 1.88-2.03 (m, 2H), 1.73-1.85 (m, 2H), 1.48 (s, 6H),
    1.43 (s, 6H); 2Hs not observed (OH and NH)
    184 MS m/z 459.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    13.75 (br s, 1H), 11.24 (br s, 1H), 9.15 (s, 1H), 9.08 (s, 1H), 8.33
    (d, J = 0.8 Hz, 1H), 8.31 (m, 1H), 8.28 (s, 1H), 7.96
    (d, J = 8.4 Hz, 1H), 7.80 (d, J = 1.6 Hz, 1H), 7.69-
    7.71 (m, 1H), 5.22 (br s, 1H), 3.42 (s, 3H), 1.63-1.64 (m, 4H),
    1.33 (s, 6H), 1.21 (s, 6H)
    185 MS m/z 469.5 [M + H]+; 1H NMR (methanol-d4) δ:
    9.31 (d, J = 8.00 Hz, 1H), 9.27-9.23 (m, 2H), 8.69
    (s, 1H), 8.61-8.55 (m, 1H), 8.37 (d, J = 9.00 Hz, 1H),
    8.20-8.16 (m, 1H), 8.06 (d, J = 8.00 Hz, 1H), 7.54 (d,
    J = 10 Hz, 1H), 7.52 (s, 1H), 5.47-5.37 (m, 1H), 3.19,
    (s, 3H), 2.19-2.01 (m, 4H), 1.65, (s, 6H), 1.57 (s, 6H);
    2Hs not observed (NH and OH)
    186 MS m/z 474.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.02 (s, 1H), 8.41 (d, J = 8.70 Hz, 1H), 8.15 (d, J =
    8.70 Hz, 1H), 7.94 (d, J = 8.09 Hz, 1H), 7.84 (s, 1H), 7.72
    (d, J = 8.09 Hz, 1H), 5.17 (br s, 1H), 4.30 (s, 3H), 3.05
    (s, 3H), 1.99 (t, J = 12.89 Hz, 2H) 1.71 (d, J = 12.51 Hz,
    2H), 1.45 (s, 6H), 1.42 (m, 6H); 2Hs not observed (NH and OH)
    192 MS m/z 459.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.57 (br s, 1H), 9.42 (s, 1H), 9.12 (s, 1H), 8.45 (br s, 1H), 8.25
    (s, 1H), 8.08 (d, J = 10.1 Hz, 1H), 8.01 (d, J = 8.5
    Hz, 1H), 7.76 (dd, J = 9.3, 1.4 Hz, 1H), 7.42-7.49
    (m, 2H), 5.17-5.31 (m, 1H), 3.13 (s, 3H), 2.13 (t, J =
    12.8 Hz, 2H), 1.73-1.80 (m, 2H), 1.54 (s, 6H), 1.53 (s, 6H)
    194 MS m/z 460.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.22 (s, 1H), 9.08 (s, 1H), 8.52 (s, 1H), 8.34 (br s, 1H), 8.02
    (d, J = 8.4 Hz, 1H), 7.84 (d, J = 2.0 Hz, 1H), 7.78
    (dd, J = 8.0, 2.0 Hz, 1H), 5.22 (br s, 1H), 3.14 (s, 3H),
    1.60-1.69 (m, 4H), 1.32 (s, 6H), 1.21 (s, 6H); 2Hs not observed
    (OH and NH)
    195 MS m/z 460.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.46 (s, 1H), 9.07 (s, 1H), 8.50 (s, 1H), 8.42 (s, 1H), 8.14 (d, J =
    1.6 Hz, 1H), 8.05 (dd, J = 8.0, 1.2 Hz, 1H), 8.00 (d, J = 8.4
    Hz, 1H), 5.24 (br s, 1H), 3.11 (s, 3H), 1.64-1.80 (m, 4H), 1.38
    (s, 6H), 1.28 (s, 6H); 2Hs not observed (OH and NH)
    198 MS m/z 473.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.07 (s, 1H), 8.37 (br s, 1H), 8.33 (s, 1H), 8.25 (d, J = 8.8 Hz,
    1H), 8.04 (d, J = 8.8 Hz, 1H), 7.98 (d, J = 8.0 Hz,
    1H), 7.83 (d, J = 1.6 Hz, 1H), 7.73 (dd, J = 8.4, 1.6 Hz,
    1H), 5.22 (br, 1H), 4.11 (s, 3H), 3.10 (s, 3H), 1.64-1.74 (m, 4H),
    1.35 (s, 6H), 1.25 (s, 6H); 1H not observed (OH or NH)
    200 MS m/z 473.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    11.20 (br s, 1H), 9.11 (s, 1H), 8.30 (s, 1H), 7.93-8.03 (m, 2H),
    7.87-7.93 (m, 1H), 7.40 (d, J = 8.2 Hz, 1H), 7.37 (s, 1H),
    5.18-5.28 (m, 1H), 4.36 (s, 3H), 3.13 (s, 3H), 1.81-1.90 (m, 2H),
    1.69-1.81 (m, 2H), 1.46 (s, 6H), 1.38 (s, 6H); 1H not
    observed (OH or NH)
    207 MS m/z 431.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.24-9.38 (m, 2H), 9.11-9.18 (m, 2H), 8.27 (d, J = 7.3
    Hz, 2H), 8.01 (d, J = 8.5 Hz, 1H), 7.52 (d, J = 7.3
    Hz, 1H), 7.42-7.49 (m, 2H), 4.05-4.21 (m, 3H), 3.80-3.93
    (m, 4H), 1.41 (s, 9H)
    208 MS m/z 444.6 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.04-9.25 (m, 3H), 8.13 (s, 1H), 8.05 (s, 1H), 7.95 (d, J =
    7.6 Hz, 1H), 7.74 (s, 2H), 7.29-7.38 (m, 2H), 4.13-4.25 (m, 3H),
    4.09 (s, 3H), 3.76-3.97 (m, 4H), 1.40 (s, 9H)
    209 MS m/z 392.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.29 (br s, 2H), 9.10 (s, 1H), 8.93 (dd, J = 4.7, 1.1
    Hz, 2H), 8.09 (s, 1H), 7.96-8.03 (m, 2H), 7.44-7.51 (m,
    1H), 4.05-4.22 (m, 3H), 3.77-3.98 (m, 4H), 1.41 (s, 9H)
    210 MS m/z 395.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.17 (br s, 2H), 9.10 (s, 1H), 8.24 (s, 1H), 7.93 (d, J =
    7.9 Hz, 1H), 7.48 (s, 1H), 7.44 (d, J = 8.2 Hz, 1H), 4.22
    (s, 3H), 3.79-3.92 (m, 3H), 3.55-3.66 (m, 4H), 1.40 (s, 9H)
    211 MS m/z 396.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.17 (br s, 2H), 9.10 (s, 1H), 8.24 (s, 1H), 7.93 (d, J =
    7.9 Hz, 1H), 7.48 (s, 1H), 7.44 (d, J = 8.2 Hz, 1H), 4.22
    (s, 3H), 3.79-3.92 (m, 3H), 3.55-3.66 (m, 4H), 1.40 (s, 9H);
    1H from HCl salt
    214 MS m/z 421.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    8.10 (d, J = 5.80 Hz, 1H), 7.79 (d, J = 7.78 Hz, 1H),
    7.38 (d, J = 7.93 Hz, 1H), 7.35 (s, 1H), 7.23-7.21 (m, 1H),
    7.16 (s, 1H), 6.01 (s, 1H), 4.36-4.32 (m, 1H), 4.12-4.17 (m,
    1H), 3.99-3.88 (m, 2H), 3.84 (s, 3H), 3.79-3.71 (m, 1H),
    2.66-2.69 (m, 1H), 2.41-2.48 (m, 1H), 1.51 (s, 9H); 2Hs
    not observed (NH and OH)
    215 MS m/z 446.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.14 (s, 1H), 8.55-8.45 (m, 1H), 8.28-8.18 (m, 1H), 8.03-
    7.97 (m, 1H), 7.93 (br s, 1H), 7.85-7.77 (m, 1H), 4.38 (s,
    3H), 3.93-3.81 (m, 4H), 3.72-3.55 (m, 1H), 1.41 (s, 9H);
    (4Hs overlapped with residual solvent peaks)
    216 MS m/z 422.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.13 (s, 1H), 7.83 (d, J = 8.09 Hz, 1H), 7.5-7.50 (m, 2H),
    7.02 (s, 1H), 6.03 (s, 1H), 4.42-4.32 (m, 1H), 4.22-4.18
    (m, 1H), 4.03-3.91 (m, 2H), 3.82-3.74 (m, 1H), 3.63-3.69
    (m, 3H), 2.73-2.65 (m, 1H), 2.54-2.42 (m, 1H), 1.53 (s, 9H);
    2Hs not observed (NH and OH)
    217 MS m/z 422.5 [M + H]+; 1H NMR (methanol-d4) δ:
    9.16 (s, 1H), 8.81 (s, 1H), 7.99 (d, J = 8.5 Hz, 1H), 7.70
    (s, 1H), 7.67 (d, J = 8.0 Hz, 1H), 7.33 (s, 1H), 4.31-4.21
    (m, 2H), 4.06 (s, 3H), 4.01-3.97 (m,1H), 3.80-3.76 (m, 2H),
    2.68-2.62 (m, 1H), 2.31-2.24 (m, 1H), 1.49 (s, 9H); 2Hs not
    observed (NH and OH)
    221 MS m/z 445.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.16 (s, 1H), 8.89 (s, 1H), 8.49 (s, 1H), 8.17 (s, 1H), 7.96 (d, J =
    8.9 Hz, 1H), 7.29-7.38 (m, 2H), 4.18 (s, 4H), 3.99-4.07 (m, 1H),
    3.92-3.99 (m, 1H), 3.67-3.77 (m, 1H), 3.54-3.63 (m, 1H), 2.47-
    2.60 (m, 1H), 2.08-2.19 (m, 1H), 1.36-1.40 (m, 9H); 2Hs not
    observed (NH and OH)
    222 MS m/z 473.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.19 (s, 1H), 9.13 (s, 1H), 8.41 (s,
    1H), 8.15 (s, 1H), 7.94 (d, J = 7.9 Hz, 1H), 7.58-7.66 (m,
    2H), 5.36 (br d, J = 1.7 Hz, 1H), 4.35 (s, 3H), 3.19 (s, 3H),
    1.66-1.83 (m, 4H), 1.45 (s, 6H), 1.32 (s, 6H); 2Hs not
    observed (NH and OH)
    225 MS m/z 381.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.13 (s, 1H), 8.20 (s, 1H), 7.92 (d, J = 8.5 Hz, 1H), 7.47-
    7.46 (m, 2H), 4.26-4.18 (m, 2H), 3.99-3.95 (m, 1H), 3.75-3.72
    (m, 2H), 2.65-2.59 (m, 1H), 2.30-2.23 (m, 1H), 1.47 (s, 9H);
    1H not observed (NH or OH)
    227 MS m/z 407.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    8.08 (d, J = 6.87 Hz, 1H), 7.80 (d, J = 8.24 Hz, 1H),
    7.39 (d, J = 8.24 Hz, 1H), 7.36 (s, 1H), 7.18 (d, J =
    6.71 Hz, 1H), 7.14 (s, 1H), 6.02 (d, J = 2.6 Hz, 1H), 4.38-
    4.24 (m, 1H), 4.19-4.09 (m, 1H), 4.06-3.88 (m, 2H),
    3.83-3.79 (m, 4H), 3.64-3.53 (m, 1H), 2.73-2.59 (m, 1H),
    2.55-2.38 (m, 1H), 1.41-1.53 (m, 6H); 2Hs not observed
    (NH and OH)
    234 MS m/z 408.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    8.76 (s, 1H), 7.70 (d, J = 8.09 Hz, 1H), 7.54-7.50 (m,
    2H), 6.92 (s, 1H), 5.94 (m, 1H), 4.29-4.20 (m, 1H), 4.17-4.08
    (m, 1H), 4.06-3.90 (m, 2H), 3.82-3.72 (m, 1H), 3.68-3.59
    (m, 3H), 3.59-3.45 (m, 1H), 2.69-2.39 (m, 2H), 1.47 (br s,
    6H); 2Hs not observed (NH and OH)
    241 MS m/z 419.4 [M + H]+; 1H NMR (DMSO-d6) δ:
    10.18 (br s, 1H), 9.04 (s, 1H), 7.91 (d, J = 7.9 Hz, 1H),
    7.79 (d, J = 7.2 Hz, 1H), 7.30 (d, J = 8.2 Hz, 1H),
    7.28 (s, 1H), 6.64 (s, 1H), 6.54 (d, J = 7.0 Hz, 1H), 4.06
    (br s, 2H), 3.98 (br s, 2H), 3.46 (s, 3H), 3.37 (m, 2H), 3.00 (dd,
    J = 22.1, 10.5 Hz, 2H), 2.74 (d, J = 4.43 Hz, 3H), 2.17
    (d, 13.7 Hz, 2H), 2.00 (td, J = 13.7, 13.7, 3.5 Hz, 2H)
    242 MS m/z 393.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    11.13 (br s, 1H), 9.29 (br s, 1H), 9.04 (s, 1H), 8.24 (s, 1H), 7.91
    (d, J = 8.1 Hz, 1H), 7.46 (s, 1H), 7.44 (d, J = 8.1 Hz,
    1H), 4.22 (s, 3H), 4.06 (br s, 2H), 3.97 (br s, 2H), 3.42 (d, J =
    12.05 Hz, 2H), 3.03 (dd, J = 22.3, 11.4 Hz, 2H), 2.79 (d,
    J = 4.0 Hz, 3H), 2.20 (d, J = 13.7 Hz, 2H), 1.90
    (ddd, J = 14.8, 8.9, 3.4 Hz, 2H); 1H from TFA salt
    243 MS m/z 420.4 [M + H]+; 1H NMR (DMSO-d6) δ:
    11.10 (br s, 1H), 9.26 (br dd, J = 3.5, 2.0 Hz, 1H), 9.06 (s, 1H),
    8.88 (s, 1H), 7.96 (br d, J = 8.1 Hz, 1H), 7.84 (s, 1H), 7.76
    (br d, J = 8.2 Hz, 1H), 7.47 (s, 1H), 4.07 (br s, 2H), 3.96-
    4.01 (m, 5H), 2.99-3.07 (m, 2H), 2.77-2.82 (m, 3H), 2.18-2.25
    (m, 2H), 1.84-1.95 (m, 2H); 2Hs not observed (CH2 obscured
    by solvent peak); 1H from TFA salt
    244 MS m/z 390.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    10.88 (br s, 1H), 9.25 (br s, 1H), 8.97 (s, 1H), 8.87 (d, J =
    4.9 Hz, 2H), 8.00 (s, 1H), 7.93 (d, J = 8.4 Hz, 1H), 7.89 (d,
    J = 8.4 Hz, 1H), 7.40 (t, J = 4.7 Hz, 1H), 4.00 (br s,
    2H), 3.91 (br s, 2H), 2.96 (dd, J = 22.1, 11.6 Hz, 2H), 2.73
    (d, J = 4.1 Hz, 3H), 2.13 (d, J = 14.0 Hz, 2H) 1.83
    (ddd, J = 14.2, 12.5, 3.4 Hz, 2H); 2Hs not observed
    (CH2 obscured by solvent peak); 1H from TFA salt
    245 MS m/z 379.2 [M + H]+; 1H NMR (DMSO-d6) δ:
    15.02 (br s, 1H), 11.12 (br s, 1H), 9.21 (br s, 1H), 9.05 (s, 1H),
    8.27 (br s, 1H), 7.91 (d, J = 8.5 Hz, 1H), 7.51 (br s, 1H), 7.46
    (d, J = 7.4 Hz, 1H), 4.06 (br s, 2H), 3.97 (br s, 2H), 3.03
    (dd, J = 22.4, 10.8 Hz, 2H), 2.79 (d, J = 4.6 Hz, 3H),
    2.20 (d, J = 13.6 Hz, 2H), 1.90 (ddd, J = 14.0, 12.8,
    4.3 Hz, 2H); 2Hs not observed (CH2 obscured by solvent peak);
    1H from TFA salt
    246 MS m/z 454.5 [M + H]+; 1H NMR (methanol-d4) δ:
    8.88 (s, 1H), 7.77 (d, J = 8.2 Hz, 1H), 7.63-7.46 (m,
    2H), 6.97 (s, 1H), 6.04 (d, J = 8.9 Hz, 1H), 3.64 (s, 3H),
    2.22-2.01 (m, 2H), 1.76-1.65 (m, 6H), 1.64-1.51 (m, 6H);
    4Hs not observed (2 NHs, OH and 1 CH obscured by solvent
    peak)
    250 MS m/z 381.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.09 (s, 1H), 8.01 (s, 1H), 7.97 (d, J = 8.0 Hz, 1H), 7.63
    (d, J = 9.0 Hz, 2H), 7.33 (s, 1H), 4.09-4.05 (m, 1H), 3.91-
    3.88 (m, 1H), 3.81-3.74 (m, 1H), 3.66-3.60 (m, 1H), 3.42-3.36
    (m, 1H), 2.44-2.37 (m, 1H), 2.02-1.94 (m, 1H), 1.25 (s, 9H);
    2Hs not observed (NH and OH)
    251 MS m/z 394.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    11.06 (br s, 1H), 9.28 (br s, 1H), 9.01 (s, 1H), 7.98 (d,
    J = 8.1 Hz, 1H), 7.70 (s, 1H), 7.65 (d, J =
    8.1 Hz, 1H), 4.45 (s, 3H), 4.07 (br s, 2H), 3.98 (br s, 2H),
    3.03 (dd, J = 22.1, 11.0 Hz, 2H), 2.79 (d, J = 4.1
    Hz, 3H), 2.20 (d, J = 14.0 Hz, 2H), 1.90 (ddd, J =
    14.6, 12.4, 2.6 Hz, 2H); 2Hs not observed (CH2 obscured
    by solvent peak); 1H from TFA salt
    252 MS m/z 379.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    11.08 (br s, 1H), 9.35 (br s, 1H), 9.00 (s, 1H), 8.24 (s, 1H),
    7.95 (d, J = 8.1 Hz, 1H), 7.61 (s, 1H), 7.56 (d, J =
    8.1 Hz, 1H), 7.41 (s, 1H), 4.06 (s, 2H), 3.96 (s, 2H), 3.02
    (dd, J = 22.7, 10.8 Hz, 2H), 2.79 (d, J = 4.1
    Hz, 3H), 2.20 (d, J = 14.0 Hz, 2H), 1.90 (ddd, J =
    13.9, 13.0, 2.9 Hz, 2H); 2Hs not observed (CH2 obscured
    by solvent peak); 1H from TFA salt
    253 MS m/z 408.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.01 (s, 1H), 8.22 (m, 1H), 7.86 (d, J = 8.4 Hz, 1H),
    7.75 (d, J = 2.0 Hz, 1H), 7.42 (d, J = 2.0 Hz, 1H),
    7.35-7.38 (m, 1H), 6.70 (d, J = 2.4 Hz, 1H), 4.40 (br s,
    1H), 3.89 (s, 3H), 2.02-2.09 (m, 2H), 1.46-1.54 (m, 2H), 1.44
    (s, 6H), 1.35 (s, 6H); 2Hs not observed (OH and NH)
    254 MS m/z 436.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.02 (s, 1H), 8.87 (s, 1H), 8.38 (s, 1H), 7.97 (d, J =
    8.4 Hz, 1H), 7.84 (d, J = 1.2 Hz ,1H), 7.73-7.76 (m,
    1H), 7.48 (s, 1H), 4.35 (br s, 1H), 3.98 (s, 3H), 1.93-1.96
    (m, 2H), 1.35-1.40 (m, 2H), 1.34 (s, 6H), 1.23 (s, 6H);
    2Hs not observed (OH and NH)
    258 MS m/z 367.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.17 (s, 1H), 8.01 (d, J = 8.5 Hz, 1H), 7.84-7.77 (m,
    1H), 7.74-7.72 (m, 2H), 4.25 (q, J = 6.3 Hz, 1H),
    4.19 (dd, J = 12.1, 7.0 Hz, 1H), 4.03-3.99 (m, 1H),
    3.86-3.78 (m, 2H), 3.63-3.57 (m, 1H), 2.63 (tt, J =
    13.2, 6.3 Hz, 1H), 2.31 (dq, J = 14.2, 7.3 Hz, 1H),
    1.45 (dd, J = 6.6, 4.0 Hz, 6H); 3Hs not observed
    (2NHs and OH)
    259 MS m/z 382.2 [M + H]+; 1H NMR (methanol-d4) δ:
    9.14 (s, 1H), 8.20 (s, 1H), 7.92 (d, J = 9.0 Hz, 1H),
    7.48-7.46 (m, 2H), 4.23 (dt, J = 13.0, 7.0 Hz, 1H),
    4.15 (dd, J = 12.5, 7.5 Hz, 1H), 3.98 (ddd, J = 11.5,
    8.5, 5.5 Hz, 1H), 3.83-3.76 (m, 2H), 3.58 (quin, J =
    6.5 Hz, 1H), 3.31 (s, 3H), 2.60 (td, J = 13.0, 7.5 Hz,
    1H), 2.31-2.24 (m, 1H), 1.42 (dd, J = 6.5, 4.0 Hz,
    6H); 1H not observed (NH or OH)
    265 MS m/z 408.6 [M + H]+; 1H NMR (methanol-d4) δ:
    9.02-9.22 (m, 1H), 8.70-8.83 (m, 1H), 7.84-7.97 (m, 1H), 7.50-
    7.67 (m, 2H), 7.22-7.38 (m, 1H), 4.05 (s, 3H), 3.93-4.01 (m, 1H),
    3.82-3.91 (m, 1H), 3.61-3.70 (m, 2H), 3.36-3.46 (m, 1H), 2.94-
    3.03 (m, 1H), 2.30-2.39 (m, 1H), 1.85-1.99 (m, 1H), 1.14 (t,
    J = 6.7 Hz, 6H); 2Hs not observed (NH and OH)
    266 MS m/z 409.6 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.06-9.13 (m, 1H), 9.04 (s, 1H), 8.25 (s, 1H), 8.12 (br s, 1H),
    7.94-8.01 (m, 1H), 7.93 (d, J = 8.2 Hz, 1H), 7.47 (d,
    J = 1.2 Hz, 1H), 7.43 (dd, J = 8.2, 1.5 Hz, 1H),
    4.36-4.46 (m, 1H), 4.22 (s, 3H), 2.05-2.12 (m, 2H), 1.62 (t,
    J = 12.7 Hz, 2H), 1.50 (s, 6H), 1.44 (s, 6H)
    267 MS m/z 410.1 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.05-9.15 (m, 1H), 9.00 (s, 1H), 8.15 (br s, 1H), 7.92-8.03 (m,
    2H), 7.72 (d, J = 1.5 Hz, 1H), 7.64 (dd, J = 8.2,
    1.5 Hz, 1H), 4.33-4.50 (m, 4H), 2.02-2.16 (m, 2H), 1.62 (t,
    J = 12.8 Hz, 2H), 1.50 (s, 6H), 1.44 (s, 6H)
    268 MS m/z 380.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.10 (s, 1H), 8.80 (s, 1H), 7.97 (d, J = 8 Hz, 1H), 7.65-
    7.70 (m, 2H), 7.33 (s, 1H), 4.06 (s, 3H), 3.80-3.95 (m, 2H), 3.70-
    3.78 (m, 1H), 3.52-3.59 (m, 1H), 3.43-3.48 (m, 1H), 2.47 (s, 3H),
    2.29-2.35 (m, 1H), 2.00-2.04 (m, 1H); 2Hs not observed (NH
    and OH)
    269 MS m/z 356.3 [M + H]+; 1H NMR (methanol-d4) δ:
    8.83 (s, 1H), 7.99 (d, J = 8 Hz, 1H), 7.61-7.72 (m, 2H),
    6.04 (s, 1H), 4.03-4.15 (m, 2H), 3.78-3.95 (m, 2H), 3.50-3.54
    (m, 1H), 2.65 (s, 3H), 2.58-2.66 (m, 1H), 2.42-2.53 (m, 1H);
    2Hs not observed (NH and OH)
    270 MS m/z 350.2 [M + H]+; 1H NMR (methanol-d4) δ:
    8.93 (d, J = 5.0 Hz, 2H), 8.02-8.05 (m, 1H), 7.79 (d,
    J = 8.5 Hz, 2H), 7.48 (t, J = 5.0 Hz, 1H), 6.05
    (s, 1H), 4.06-4.16 (m, 2H), 3.75-3.85 (m, 2H), 3.60-3.70 (m,
    1H), 2.85 (s, 3H), 2.61-2.69 (m, 1H), 2.40-2.57 (m, 1H);
    2Hs not observed (NH and OH)
    271 MS m/z 403.3 [M + H]+; 1H NMR (methanol-d4) δ:
    8.87 (d, J = 2 Hz, 1H), 8.53 (d, J = 2 Hz, 1H),
    8.18 (d, J = 3.5 Hz, 1H), 7.76 (d, J = 8.5 Hz,
    1H), 7.35 (dd, J = 8 Hz, 2 Hz, 1H), 7.32 (s, 1H), 6.01
    (s, 1H), 4.16 (s, 3H), 4.00-4.15 (m, 2H), 3.88-3.95 (m, 2H),
    3.80 (m, 1H), 2.84 (s, 3H), 2.60-2.70 (m, 1H), 2.35-2.50 (m,
    1H); 2Hs not observed (NH and OH)
    277 MS m/z 409.5 [M + H]+; 1H NMR (methanol-d4) δ:
    7.76 (s, 1H), 7.72 (d, J = 8.2 Hz, 1H), 7.35 (d, J =
    8.3 Hz, 1H), 7.31 (s, 1H), 5.98 (s, 1H), 4.42-4.32 (m, 1H),
    2.67 (s, 3H), 2.30-2.17 (m, 2H), 1.86-1.73 (m,
    2H), 1.63 (s, 3H), 1.62 (s, 3H), 1.55 (s, 3H), 1.53 (s, 3H);
    2Hs not observed (NH and OH)
    279 MS m/z 406.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.01 (s, 1H), 8.92 (d, J = 5.2 Hz, 2H), 8.06 (s, 1H),
    7.98 (s, 2H), 7.47 (t, J = 5.0 Hz, 1H), 4.41 (br s,
    1H), 2.02-2.12 (m, 2H), 1.48-1.56 (m, 2H), 1.44 (s, 6H),
    1.35 (s, 6H); 3Hs not observed (OH and 2NHs)
    280 MS m/z 475.8 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.08 (s, 1H), 8.33 (s, 1H), 7.95 (d, J = 8.0 Hz, 1H),
    7.66 (br s, 1H), 7.29-7.37 (m, 3H), 6.56 (s, 1H), 6.32 (s,
    1H), 5.20 (br s, 1H), 3.09 (s, 3H), 1.54-1.60 (m, 4H),
    1.30 (s, 6H), 1.17 (s, 6H); 1H not observed (OH or NH)
    281 MS m/z 474.2 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.58 (s, 1H), 9.05 (s, 1H), 8.45 (s, 1H), 8.12 (d, J =
    1.6 Hz, 1H), 8.05 (dd, J = 8.0, 1.2 Hz, 1H), 8.00 (d,
    J = 8.0 Hz, 1H), 5.22 (br s, 1H), 4.23 (s, 3H), 3.05
    (s, 3H), 1.47-1.58 (m, 4H), 1.26 (s, 6H), 1.06 (s, 6H); 2Hs
    not observed (OH and NH)
    283 MS m/z 417.4 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.26 (s, 1H), 9.17 (s, 1H), 9.07 (s, 1H), 8.17 (s, 1H), 7.97
    (d, J = 7.9 Hz, 1H), 7.86 (d, J = 0.9 Hz, 1H), 7.71
    (s, 1H), 7.61 (dd, J = 8.5, 1.5 Hz, 1H), 3.67-3.86 (m,
    2H), 3.47-3.54 (m, 1H), 3.18-3.38 (m, 2H), 2.84 (dt, J =
    12.4, 6.3 Hz, 1H), 2.10-2.23 (m, 1H), 1.74-1.89 (m, 1H),
    1.02 (t, J = 6.4 Hz, 6H); 2Hs not observed (NH and OH)
    284 MS m/z 477.4 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.82-9.94 (m, 1H), 9.11 (s, 1H), 8.90 (d, J = 2.1 Hz,
    1H), 8.52 (d, J = 2.1 Hz, 1H), 8.29 (br s, 1H), 8.23 (s,
    1H), 8.08-8.17 (m, 1H), 7.99 (d, J = 8.9 Hz, 1H),
    7.34-7.40 (m, 2H), 4.70-4.87 (m, 2H), 4.11 (s, 3H), 1.95-
    2.06 (m, 1H), 1.84-1.95 (m, 1H), 1.57 (d, J = 18.5 Hz,
    6H), 1.48 (d, J = 6.4 Hz, 6H)
    285 MS m/z 472.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.07 (s, 1H), 8.37 (br s, 2H), 8.25 (s, 1H), 7.93 (d, J =
    7.2 Hz, 2H), 7.67 (d, J = 8.4 Hz, 1H), 7.61 (d, J =
    8.40 Hz, 1H), 7.31 (d, J = 7.6 Hz, 2H), 5.22 (br s, 1H),
    4.03 (s, 3H), 3.10 (s, 3H), 1.64-1.77 (m, 4H), 1.33 (s, 6H),
    1.06 (s, 6H)
    287 MS m/z 427.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.07 (s, 1H), 8.97 (d, J = 10.7 Hz, 1H), 8.25 (s, 1H),
    8.20 (br d, J = 12.7 Hz, 1H), 7.94 (d, J = 8.1 Hz,
    1H), 7.47 (d, J = 1.5 Hz, 1H), 7.44 (dd, J = 8.0,
    1.6 Hz, 1H), 4.83 (d, J = 49.0 Hz, 1H), 4.22 (s, 3H),
    2.00 (br d, J = 13.3 Hz, 1H), 1.90-1.96 (m, 1H), 1.53
    (br d, J = 19.2 Hz, 6H), 1.45 (br d, J = 5.5 Hz, 6H);
    2Hs not observed (1 NH and 1 CH obscured by solvent peak)
    288 MS m/z 413.4 [M + H]+; 1H NMR (DMSO-d6) δ:
    10.95-11.09 (m, 1H), 8.91-8.99 (m, 2H), 8.19 (d, J =
    0.6 Hz, 1H), 8.12 (br dd, J = 11.7, 1.4 Hz, 1H), 7.92
    (d, J = 8.2 Hz, 1H), 7.56 (d, J = 1.5 Hz, 1H),
    7.51 (dd, J = 8.2, 1.7 Hz, 1H), 7.35 (d, J = 0.8
    Hz, 1H), 4.71-4.86 (m, 1H), 1.90-1.98 (m, 1H), 1.83-1.90
    (m, 1H), 1.46 (br d, J = 18.9 Hz, 6H), 1.38 (br d,
    J = 5.3 Hz, 6H); 1H not observed (1 CH obscured by
    solvent peak).
    290 MS m/z 454.4 [M + H]+; 1H NMR (DMSO-d6) δ:
    11.14 (bs, 1H), 9.08 (m, 2H), 8.88 (s, 1H), 8.20 (d, 12.5 Hz,
    1H), 7.98 (d, J = 8.2 Hz, 1H), 7.84 (d, J = 1.7
    Hz, 1H), 7.76 (dd, J = 8.2, 1.7 Hz, 1H), 7.47 (s, 1H),
    4.85 (bd, J = 47.3 Hz, 1H), 3.99 (s, 3H), 2.01
    (t, J = 13.4 Hz, 1H), 1.93 (dd, J = 13.7, 3.6 Hz,
    1H), 1.55 (s, 3H), 1.51 (s, 3H), 1.46 (d, J = 1.4 Hz,
    3H), 1.44 (s, 3H); 1H not observed (1 CH obscured by
    solvent peak)
    291 MS m/z 428.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.03 (s, 2H), 8.98 (d, J = 10.8 Hz, 1H), 8.20 (br d,
    J = 11.3 Hz, 1H), 8.01 (d, J = 8.1 Hz, 1H), 7.72
    (d, J = 1.4 Hz, 1H), 7.66 (dd, J = 8.1, 1.7 Hz,
    1H), 4.86 (d, J = 47.9 Hz, 1H), 4.45 (s, 3H), 2.02 (d,
    J = 13.6 Hz, 1H), 1.91-1.98 (m, 1H), 1.55 (s, 3H),
    1.51 (s, 3H), 1.46 (br d, J = 0.9 Hz, 3H), 1.45 (s,
    3H); 1H not observed (1 CH obscured by solvent peak)
    292 MS m/z 430.4 [M + H]+; 1H NMR (DMSO-d6) δ:
    10.96-11.45 (m, 1H), 9.02-9.10 (m, 2H), 9.00 (s, 1H), 8.20 (br
    d, J = 13.1 Hz, 1H), 8.04 (d, J = 8.1 Hz, 1H), 7.69
    (d, J = 1.7 Hz, 1H), 7.65 (dd, J = 8.1, 1.7 Hz, 1H),
    4.86 (d, J = 47.5 Hz, 1H), 2.02 (br t, J = 13.4
    Hz, 1H), 1.94 (br dd, J = 13.7, 4.0 Hz, 1H), 1.55 (s, 3H),
    1.51 (s, 3H), 1.46 (br s, 3H), 1.45 (s, 3H); 1H not observed
    (1 CH obscured by solvent peak)
    294 MS m/z 417.4 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.13 (br s, 1H), 8.32 (br s, 1H), 8.10-8.24 (m, 1H), 7.92-8.00
    (m, 1H), 7.73-7.83 (m, 2H), 7.43-7.57 (m, 2H), 3.69-3.84 (m,
    2H), 3.45-3.60 (m, 3H), 2.79-2.89 (m, 1H), 2.10-2.25 (m, 1H),
    1.74-1.88 (m, 1H), 1.34 (t, J = 6.1 Hz, 6H); 2Hs not
    observed (NH and OH)
    295 MS m/z 353.2 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.07 (s, 1H), 8.23 (s, 1H), 7.91 (d, J = 8 Hz, 1H), 7.42-
    7.48 (m, 2H), 4.20 (s, 3H), 3.75-4.00 (m, 4H), 3.65-3.75 (m,
    1H), 2.66 (s, 3H), 2.40-2.50 (m, 1H), 2.29-2.35 (m, 1H); 2Hs
    not observed (NH and OH)
    300 MS m/z 490.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.10 (s, 1H), 8.81 (d, J = 11.6 Hz, 1H), 8.41 (s, 1H),
    7.89-7.96 (m, 2H), 7.80 (s, 1H), 7.47 (d, J = 12.8 Hz,
    1H), 7.31-7.36 (m, 2H), 5.22 (br s, 1H), 4.03 (s, 3H), 3.13
    (s, 3H), 1.93-2.00 (m, 2H), 1.83-1.87 (m, 2H), 1.51 (s,
    6H), 1.44 (s, 6H
    301 MS m/z 494.2 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.06 (s, 1H), 8.38 (s, 1H), 8.29 (s, 1H), 7.95 (d, J =
    8.4 Hz, 1H), 7.49 (s, 1H), 7.16-7.20 (m, 2H), 5.22 (br s,
    1H), 3.10 (s, 3H), 1.63-1.66 (m, 4H), 1.33 (s, 6H), 1.21
    (s, 6H); 2Hs not observed (OH and NH)
    302 MS m/z 508.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.06 (s, 1H), 8.35 (br s, 1H), 8.29 (s, 1H), 7.94 (d, J =
    8.0 Hz, 1H), 7.59 (d, J = 5.2 Hz, 1H), 7.20 (s, 1H),
    7.17 (d, J = 8.0 Hz, 1H), 5.20 (br s, 1H), 4.00 (s,
    3H), 3.11 (s, 3H), 1.69-1.86 (m, 4H), 1.41 (s, 6H),
    1.25 (s, 6H); 1H not observed (OH or NH)
    303 MS m/z 473.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.16 (s, 1H), 8.54 (br s, 2H), 8.18 (s, 1H), 8.01 (d, J =
    8.8 Hz, 1H), 7.75 (d, J = 0.6 Hz, 1H), 7.66-7.70 (m,
    3H), 5.38-5.42 (m, 1H), 3.24 (s, 3H), 2.72 (s, 3H), 1.92-
    1.99 (m, 4H), 1.63 (s, 6H), 1.51 (s, 6H)
    304 MS m/z 489.2 [M + H]+; 1H NMR (methanol-d4) δ:
    9.19 (s, 1H), 8.38 (d, J = 1.6 Hz, 1H), 8.06 (d, J =
    8.8 Hz, 1H), 8.01 (s, 1H), 7.75-7.77 (m, 2H), 7.58 (s, 1H),
    5.38-5.45 (m, 1H), 4.36 (s, 3H), 3.25 (s, 3H), 2.02 (d,
    J = 8.0 Hz, 4H), 1.66 (s, 6H), 1.54 (s, 6H); 2Hs not
    observed (OH and NH)
    305 MS m/z 407.4 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.79 (s, 1H), 9.44 (s, 1H), 9.07 (s, 1H), 8.68 (br d, J =
    12.8 Hz, 1H), 8.07 (d, J = 8.2 Hz, 1H), 7.89 (d,
    J = 1.7 Hz, 1H), 7.80-7.82 (m, 1H), 2.10-2.15 (m,
    2H), 1.60 (br t, J = 12.7 Hz, 2H), 1.49 (s, 6H), 1.41
    (s, 6H); 3Hs not observed (2 NHs, 1CH obscured by solvent
    peak)
    307 MS m/z 431.4 [M + H]+; 1H NMR (methanol-d4) δ:
    8.85 (d, J = 1.8 Hz, 1H), 8.80 (s, 1H), 8.47 (d, J =
    1.8 Hz, 1H), 8.15 (s, 1H), 7.87 (d, J = 7.9 Hz, 1H), 7.56
    (d, J = 0.9 Hz, 1H), 7.47 (d, J = 7.9 Hz, 1H),
    4.15 (s, 3H), 3.80-4.03 (m, 2H), 3.55-3.72 (m, 2H), 3.36-
    3.43 (m, 1H), 2.94-3.03 (m, 1H), 2.28-2.43 (m, 1H), 1.86-
    1.99 (m, 1H), 1.14 (t, J = 5.8 Hz, 6H); 2Hs not
    observed (NH and OH)
    314 MS m/z 406.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.54 (s, 1H), 9.24 (d, J = 5.3 Hz, 1H), 9.06 (s, 1H),
    8.52 (br s, 1H), 8.06 (dd, J = 5.3, 2.1 Hz, 1H), 7.99
    (d, J = 8.2 Hz, 1H), 7.48 (br d, J = 8.1 Hz, 1H),
    7.44 (s, 1H), 4.52 (br s, 1H), 2.19-2.29 (m, 2H), 1.67
    (br t, J = 13.0 Hz, 2H), 1.61 (s, 6H), 1.50 (s, 6H);
    2Hs not observed (NH and OH)
    320 MS m/z 354.2 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.05 (s, 1H), 7.99 (d, J = 8 Hz, 1H), 7.73 (s, 1H),
    7.66 (d, J = 8 Hz, 1H), 4.44 (s, 3H), 3.75-4.00 (m,
    4H), 3.65-3.75 (m, 1H), 2.67 (s, 3H), 2.40-2.48 (m, 1H),
    2.31 (m, 1H); 2Hs not observed (NH and OH)
    321 MS m/z 459.4 [M + H]+; 1H NMR (methanol-d4) δ:
    8.87 (s, 1H), 8.52 (s, 1H), 8.21 (s, 1H), 7.73 (d, J =
    8 Hz, 1H), 7.35 (d, J = 8 Hz, 1H), 7.30 (s, 1H), 6.01
    (s, 1H), 4.33 (m, 1H), 4.16 (s, 3H), 2.25 (t, J = 16
    Hz, 2H), 1.7-1.82 (m, 2H), 1.62 (d, J = 8.5 Hz,
    6H), 1.53 (d, J = 5.5 Hz, 6H); 2Hs not observed
    (NH and OH)
    344 MS m/z 484.2 [M + H]+; 1H NMR (methanol-d4), δ:
    9.15 (s, 1H), 8.39 (d, J = 1.2 Hz, 1H), 8.38 (s, 1H), 8.03
    (d, J = 8.4 Hz, 1H), 7.94 (d, J = 1.2 Hz, 1H), 7.70-
    7.72 (m, 2H), 5.40-5.42 (m, 1H), 3.24 (s, 3H), 1.97-2.05 (m,
    4H), 1.66 (s, 6H), 1.54 (s, 6H); 2Hs not observed (OH and NH)
    351 MS m/z 488.3 [M + H]+; 1H NMR (methanol-d4), δ:
    9.17 (s, 1H), 8.54 (br s, 2H), 8.25 (s, 1H), 8.03 (d, J =
    8.0 Hz, 1H), 7.86 (s, 1H), 7.81 (s, 1H), 7.71-7.74 (m, 2H),
    5.39-5.43 (m, 1H), 4.46 (s, 2H), 3.25 (s, 3H), 2.01 (d,
    J = 7.6 Hz, 4H), 1.65 (s, 6H), 1.54 (s, 6H); 2Hs
    not observed (OH and NH)
    359 MS m/z 445.6 [M + H]+; 1H NMR (methanol-d4) δ:
    9.48 (s, 1H), 8.87 (d, J = 4.0 Hz, 1H), 8.48 (s, 1H), 8.24-
    8.40 (m, 1H), 7.81 (d, J = 8.2 Hz, 1H), 7.27-7.39 (m, 2H),
    5.96 (s, 1H), 4.29-4.49 (m, 1H), 2.15 (dd, J = 22.0, 13.7
    Hz, 2H), 1.63-1.81 (m, 2H), 1.56 (d, J = 8.9 Hz, 6H),
    1.46 (d, J = 5.2 Hz, 6H); 3Hs not observed (2NHs and OH)
    360 MS m/z 444.7 [M + H]+; 1H NMR (methanol-d4) δ:
    8.85 (d, J = 6.1 Hz, 1H), 8.71 (s, 1H), 8.02-8.11 (m, 1H),
    7.95-8.00 (m, 1H), 7.83-7.92 (m, 1H), 7.52-7.61 (m, 3H),
    5.80-6.24 (m, 1H), 4.24-4.57 (m, 1H), 2.28 (dd, J =
    19.5, 15.0 Hz, 2H), 1.68-1.89 (m, 2H), 1.65 (d, J =
    8.2 Hz, 6H), 1.56 (d, J = 5.2 Hz, 6H); 3Hs not observed
    (2NHs and OH)
    365 MS m/z 414.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.12 (s, 1H), 8.00 (s, 1H), 7.86 (d, J = 8.0 Hz, 1H),
    7.30 (s, 1H), 7.26 (d, J = 7.5 Hz, 1H), 4.30-4.19 (m,
    2H), 4.00-3.95 (m, 1H), 3.77-3.73 (m, 2H), 2.67-2.61 (m,
    1H), 2.32-2.24 (m, 1H), 1.49 (s, 9H); 3Hs not observed
    (2NHs and OH)
    366 MS m/z 405.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.14 (s, 1H), 8.20 (s, 1H), 7.92 (d, J = 9.0 Hz, 1H),
    7.34 (br s, 2H), 4.31-4.20 (m, 2H), 4.01-3.96 (m, 1H),
    3.79-3.73 (m, 2H), 2.68-2.62 (m, 1H), 2.32-2.24 (m, 1H),
    1.49 (s, 9H); 3Hs not observed (2NHs and OH)
    374 MS m/z 398.4 [M + H]+; 1H NMR (methanol-d4) δ:
    8.50 (s, 1H), 8.24 (d, J = 10.2 Hz, 1H), 7.99 (s, 1H),
    7.21 (m, 2H), 3.96-4.04 (m, 1H), 3.77-3.88 (m, 2H), 3.62
    (br d, J = 7.6 Hz, 1H), 3.44-3.50 (m, 1H), 2.39-2.52
    (m, 1H), 1.93-2.10 (m, 1H), 1.27 (s, 9H); 3Hs not observed
    (2 NHs and OH)
    375 MS m/z 394.3 [M + H]+; 1H NMR (methanol-d4) δ:
    8.01 (br s, 1H), 7.67 (d, J = 8.0 Hz, 1H), 7.15 (d,
    J = 8.5 Hz, 1H), 7.12 (s, 1H), 5.99 (s, 1H), 4.41-
    4.33 (m, 1H), 4.22-4.18 (m, 1H), 4.02-3.91 (m, 2H), 3.80-
    3.76 (m, 1H), 2.73-2.66 (m, 1H), 2.53 (s, 3H), 2.50-
    2.46 (m, 1H), 1.54 (s, 9H); 3Hs not observed (2NHs
    and OH)
    383 MS m/z 476.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.10 (s, 1H), 8.27 (d, J = 3.4 Hz, 1H), 7.84-8.02
    (m, 2H), 7.55 (dd, J = 12.6, 0.9 Hz, 1H), 7.28-7.38
    (m, 2H), 5.10-5.32 (m, 1H), 3.11 (s, 3H), 1.77-1.94
    (m, 2H), 1.66-1.77 (m, 2H), 1.43 (s, 6H), 1.34 (s,
    6H); 3Hs not observed (OH and 2 NHs)
    • Example 5 Preparation of Compound 63
  • Figure US20230331725A1-20231019-C00152
    • Step 1.
  • Tris(dibenzylideneacetone)dipalladium(0) (4.5 mg, 0.005 mmol) and 2-di-tert-butylphosphino-3,4,5,6-tetramethyl-2′,4′,6′-triisopropyl-1,1′-biphenyl (6.0 mg, 0.0125 mmol) were suspended in 5:1 toluene/dioxane (1 mL). The purple solution was sparged with argon for 5 minutes, then heated to 120° C. for 5 minutes. The solution was cooled to room temperature and 3-(methoxymethoxy)-4-(3-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,2,4-triazin-6-yl)phenyl trifluoromethanesulfonate (53 mg, 0.10 mmol), K3PO4 (64 mg, 0.30 mmol), and 1,2,3-triazole (9.0 mg, 0.013 mmol) were added. The suspension was sparged once more with argon, then heated to 120° C. for 1 h until complete consumption of aryl triflate or chloride occurred, as monitored by UPLC. The reaction was cooled to room temperature and the product was purified by chromatography on silica gel (ISCO), eluting with 5-30% MeOH in CH2Cl2 to afford 6-(2-(methoxymethoxy)-4-(2H-1,2,3-triazol-2-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,2,4-triazin-3-amine (34 mg, 75% yield) as a dark solid. MS m/z 453.6 [M+H]+.
  • Alternatively, 6-(4-chloro-2-(methoxymethoxy)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,2,4-triazin-3-amine could be used as a starting material for step 1.
    • Step 2.
  • 6-(2-(methoxymethoxy)-4-(2H-1,2,3-triazol-2-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,2,4-triazin-3-amine (34 mg, 0.075 mmol) was suspended in MeOH (1 mL), then HCl (4 M in dioxane, 1 mL) was added. The solution was stirred at room temperature for 1 h. The reaction mixture was concentrated, and the product was purified by chromatography on silica gel (ISCO), eluting with 530 MeOH in CH2Cl2 to afford 2-(3-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,2,4-triazin-6-yl)-5-(2H-1,2,3-triazol-2-yl)phenol (25 mg, 8000 yield) as an orange solid.
  • MS m/z 409.5 [M+H]; 1H NMR (DMSO-d6) δ: 9.03-9.15 (m, 2H), 8.16 (s, 2H), 7.99-8.13 (s, 2H), 7.72 (d, J=2.1 Hz, 1H), 7.64 (dd, J=8.5, 2.1 Hz, 1H), 5.14-5.32 (m, 1H), 3.13 (s, 3H), 1.98-2.04 (4, 2H), 1.80-1.85 (m, 2H), 1.52 (s, 6H), 1.48 (s, 6H).
  • Using the procedure described for Example 5, additional compounds described herein may be prepared by substituting the appropriate starting material, suitable reagents and reaction conditions, obtaining compounds such as those selected from:
  • Cpd Data
    51 MS m/z 423.6 [M + H]+; 1H NMR (methanol-d4) δ:
    9.12 (s, 1H), 9.02 (s, 1H), 8.01 (d, J = 8.5 Hz, 1H),
    7.38-7.47 (m, 2H), 5.35-5.45 (m, 1H), 3.24 (s, 3H), 2.47
    (s, 3H), 1.96-2.04 (m, 4H), 1.64 (s, 6H), 1.53 (s, 6H);
    2Hs not observed (OH and NH)
    55 MS m/z 438.6 [M + H]+; 1H NMR (methanol-d4) δ:
    9.24 (s, 1H), 8.02 (s, 1H), 8.05 (s, 1H), 7.92 (d, J =
    8.5 Hz, 1H), 7.71-7.78 (m, 1H), 7.49-7.57 (m, 2H), 7.32-
    7.42 (m, 4H), 5.99 (s, 1H), 5.36-5.46 (m, 1H), 4.41-4.52
    (m, 1H), 3.85 (s, 6H), 3.25 (s, 3H), 3.16 (s, 3H), 1.98-
    2.19 (m, 8H); 1.56-1.70 (m, 24H); 2 rotamers (1:1), 2Hs
    not observed (NHs)
    59 MS m/z 442.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.10 (s, 1H), 8.30 (s, 1H), 8.00 (d, J = 8.0 Hz, 1H),
    7.94 (s, 1H), 7.27 (d, J = 8.5 Hz, 1H), 7.24 (s, 1H),
    5.13-5.28 (m, 1H), 3.11 (s, 3H), 1.85-2.06 (m, 2H), 1.70-
    1.81 (m, 2H), 1.46 (s, 6H), 1.42 (s, 6H); 2Hs not
    observed (NH and OH)
    68 MS m/z 450.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    11.42 (br s, 1H), 9.24 (s, 1H), 9.08-9.15 (m, 2H), 8.21
    (s, 1H), 8.05-8.13 (m, 1H), 8.01 (d, J = 8.5 Hz,
    1H), 7.59 (d, J = 2.1 Hz, 1H), 7.55 (dd, J =
    8.5, 2.1 Hz, 1H), 5.16-5.29 (m, 1H), 3.90 (s, 3H), 3.13 (s,
    3H), 2.01 (t, J = 13.0 Hz, 2H), 1.75-1.86 (m, 2H),
    1.52 (s, 6H), 1.48 (s, 6H)
    69 MS m/z 423.6 [M + H]+; 1H NMR (DMSO-d6) δ:
    11.17 (br s, 1H), 9.04-9.13 (m, 1H), 9.02 (s, 1H), 8.01-
    8.09 (m, 1H), 7.99 (d, J = 8.5 Hz, 1H), 7.92 (s, 1H),
    7.65 (d, J = 2.1 Hz, 1H), 7.57 (dd, J = 8.5,
    2.1 Hz, 1H), 5.13-5.31 (m, 1H), 3.13 (s, 3H), 2.38 (s, 3H),
    1.95-2.05 (m, 2H), 1.80-1.86 (m, 2H), 1.52 (s, 6H), 1.48
    (s, 6H)
    79 MS m/z 409.4 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.35 (s, 1H), 9.15-9.18 (m, 1H), 9.06 (s, 1H), 8.27 (s, 1H),
    8.08-8.17 (m, 1H), 8.02 (d, J = 8.2 Hz, 1H), 7.47-
    7.55 (m, 2H), 5.16-5.30 (m, 1H), 3.13 (s, 3H), 2.03 (t,
    J = 13.0 Hz, 2H), 1.77-1.85 (m, 2H), 1.52 (s, 6H),
    1.49 (s, 6H)
    89 MS m/z 408.5 [M + H]+; 1H NMR (methanol-d4) δ:
    9.12 (s, 1H), 8.23 (s, 1H), 8.01 (d, J = 8.0 Hz, 1H),
    7.65 (s, 1H), 7.23 (d, J = 8.5 Hz, 1H), 7.21 (s, 2H),
    5.39-5.43 (m, 1H), 3.24 (s, 3H), 2.00-2.01 (m, 4H), 1.65
    (s, 6H), 1.54 (s, 6H); 2Hs not observed (NH and OH)
    90 MS m/z 424.2 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.27-9.38 (m, 1H), 9.06 (s, 1H), 8.18-8.31 (m, 1H), 7.87-7.96
    (m, 2H), 7.38-7.44 (m, 2H), 7.32 (d, J = 8.2 Hz, 1H),
    3.12 (s, 3H), 2.05 (t, J = 13.0 Hz, 2H), 1.72-1.83 (m,
    2H), 1.52 (s, 6H), 1.50 (s, 6H); 1H not observed
    93 MS m/z 426.6 [M + H]+; 1H NMR (DMSO-d6) δ
    9.13-9.27 (m, 1H), 9.06 (s, 1H), 8.73 (d, J = 4.3 Hz,
    1H), 8.09-8.20 (m, 1H), 7.97 (d, J = 8.5 Hz, 1H), 7.88
    (d, J = 4.0 Hz, 1H), 7.49 (s, 1H), 7.39 (d, J =
    8.5 Hz, 1H), 5.18-5.26 (m, 1H), 3.12 (s, 3H), 2.03 (t, J =
    13.0 Hz, 2H), 1.74-1.85 (m, 2H), 1.52 (s, 6H), 1.49 (s, 6H)
    94 MS m/z 422.6 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.10-9.21 (m, 1H), 9.06 (s, 1H), 8.28 (s, 1H), 8.06-8.17 (m,
    1H), 7.94 (d, J = 8.9 Hz, 1H), 7.59 (s, 1H), 7.46 (s,
    1H), 7.38 (d, J = 8.2 Hz, 1H), 5.16-5.29 (m, 1H), 3.12
    (s, 3H), 2.11 (s, 3H), 2.02 (t, J = 13.0 Hz, 2H), 1.77-
    1.84 (m, 2H), 1.52 (s, 6H), 1.48 (s, 6H)
    99 MS m/z 454.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.15-9.26 (m, 1H), 9.05 (s, 1H), 9.03 (s, 1H), 8.12-8.21 (m,
    1H), 8.09 (d, J = 8.5 Hz, 1H), 7.77 (d, J = 2.1
    Hz, 1H), 7.69 (dd, J = 8.5, 2.1 Hz, 1H), 5.17-5.32
    (m, 1H), 3.14 (s, 3H), 1.98-2.09 (m, 2H), 1.76-1.85 (m,
    2H), 1.52 (s, 6H), 1.49 (s, 6H)
    119 MS m/z 424.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.11-9.23 (m, 1H), 9.03 (s, 1H), 8.10-8.20 (m, 1H), 8.08
    (d, J = 8.5 Hz, 1H), 7.73 (d, J = 1.8 Hz, 1H),
    7.67 (dd, J = 8.5, 2.1 Hz, 1H), 5.16-5.33 (m, 1H),
    3.14 (s, 3H), 2.61 (s, 3H), 2.03 (t, J = 12.8 Hz, 2H),
    1.76-1.87 (m, 2H), 1.52 (s, 6H), 1.49 (s, 6H)
    121 MS m/z 395.2 [M + H]+; 1H NMR (DMSO-d6) δ:
    11.33 (br s, 1H), 9.35 (br s, 1H), 8.97 (s, 1H), 8.15 (s,
    2H), 8.07 (br s, 1H), 8.00 (d, J = 8.5 Hz, 1H),
    7.71 (d, J = 1.5 Hz, 1H), 7.62 (dd, J = 8.5,
    2.0 Hz, 1H), 4.40 (br s, 1H), 2.06 (d, J = 12.5 Hz,
    2H), 1.63 (t, J = 12.5 Hz, 2H), 1.50 (s, 6H), 1.45
    (s, 6H)
    122 MS m/z 396.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    11.18 (s, 1H), 9.24 (s, 1H), 9.18-9.13 (m, 1H), 8.37-8.30
    (m, 1H), 8.17 (s, 2H), 8.03 (d, J = 8.5 Hz, 1H), 7.78
    (d, J = 2.0 Hz, 1H), 7.68 (dd, J = 8.5, 2.0 Hz,
    1H), 5.66-5.61 (m, 1H), 2.35 (dd, J = 13.0, 3.0 Hz,
    2H), 1.86 (t, J = 12.5 Hz, 2H), 1.52 (s, 6H), 1.51 (s,
    6H)
    133 MS m/z 443.4 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.40 (s, 1H), 9.15-9.23 (m, 1H), 9.05 (s, 1H), 8.10-8.18
    (m, 1H), 8.03 (d, J = 9.2 Hz, 1H), 7.43-7.49 (m,
    2H), 5.18-5.29 (m, 1H), 3.13 (s, 3H), 2.03 (t, J =
    12.8 Hz, 2H), 1.78-1.84 (m, 2H), 1.52 (s, 6H), 1.49 (s,
    6H)
    135 MS m/z 433.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.42 (s, 1H), 9.17 (s, 1H), 8.44 (s, 1H), 8.07 (d, J =
    8.5 Hz, 1H), 7.56 (s, 1H), 7.40-7.47 (m, 1H), 5.20-5.36 (m,
    1H), 3.16 (s, 3H), 1.64-1.72 (m, 2H), 1.51-1.58 (m, 2H),
    1.32 (s, 6H), 1.18 (s, 6H); 2Hs not observed (OH and NH)
    139 MS m/z 433.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.20 (s, 1H), 8.87 (s, 1H), 8.65 (s, 1H), 8.13 (d, J =
    8.5 Hz, 1H), 7.32-7.42 (m, 2H), 5.22-5.40 (m, 1H), 3.18
    (s, 3H), 1.52-1.69 (m, 4H), 1.34 (s, 6H), 1.20 (s, 6H); 2Hs
    not observed (OH and NH)
    140 MS m/z 450.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.40 (s, 1H), 9.14-9.23 (m, 1H), 9.05 (s, 1H), 8.09-8.21
    (m, 1H), 8.03 (d, J = 9.2 Hz, 1H), 7.41-7.51 (m,
    2H), 5.17-5.31 (m, 1H), 3.17 (s, 3H), 3.13 (s, 3H), 2.03
    (t, J = 12.8 Hz, 2H), 1.75-1.86 (m, 2H), 1.52 (s,
    6H), 1.49 (s, 6H); 1H not observed (OH or NH)
    161 MS m/z 438.6 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.31-9.44 (m, 1H), 9.06 (s, 1H), 8.38 (s, 1H), 8.24-8.34 (m,
    1H), 7.95 (d, J = 8.5 Hz, 1H), 7.70 (s, 1H), 7.49 (s, 1H),
    7.41 (d, J = 8.5 Hz, 1H), 5.16-5.30 (m, 1H), 4.45 (s, 2H),
    3.12 (s, 3H), 2.07 (t, J = 12.8 Hz, 2H), 1.72-1.84 (m,
    2H), 1.52 (s, 6H), 1.51 (s, 6H); 1H not observed (OH)
    172 MS m/z 439.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.02 (s, 1H), 8.04 (s, 1H), 8.01 (d, J = 8.5 Hz, 1H), 7.65
    (s, 1H), 7.59 (d, J = 8.9 Hz, 1H), 5.45 (t, J = 5.5 Hz,
    1H), 5.15-5.29 (m, 1H), 4.66 (d, J = 5.8 Hz, 2H), 3.12
    (s, 3H), 1.67-1.89 (m, 4H), 1.43 (s, 6H), 1.33 (s, 6H); 2Hs not
    observed (OH and NH)
    187 MS m/z 380.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.38 (br s, 1H), 9.16 (s, 1H), 8.11 (d, J = 9.0 Hz, 1H),
    8.07 (s, 1H), 7.73 (s, 1H), 7.35-7.33 (m, 2H), 4.31-4.22 (m,
    2H), 4.02-3.98 (m, 1H), 3.80-3.75 (m, 2H), 2.68-2.62 (m,
    1H), 2.33-2.25 (m, 1H), 1.49 (s, 9H); 2Hs not observed
    (NH and OH)
    197 MS m/z 394.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.37 (s, 1H), 9.16 (s, 1H), 8.10 (d, J = 8.0 Hz, 1H),
    7.83 (s, 1H), 7.32-7.30 (m, 2H), 4.31-4.22 (m, 2H), 4.02-
    3.98 (m,1H), 3.81-3.75 (m, 2H), 2.68-2.62 (m, 1H), 2.45
    (s, 3H), 2.33-2.26 (m, 1H), 1.49 (s, 9H); 2Hs not observed
    (NH and OH)
    204 MS m/z 381.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    11.37 (br s, 1H), 9.02 (s, 1H), 8.15 (s, 2H), 8.00 (d, J =
    8.2 Hz, 1H), 7.72 (s, 1H), 7.63 (d, J = 8.2 Hz, 1H), 3.92-
    4.02 (m, 2H), 3.72-3.85 (m, 2H), 3.50-3.62 (m, 3H), 1.24 (s,
    9H); 1 H not observed (OH or NH)
    218 MS m/z 339.2 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.03 (s, 1H), 8.14 (s, 2H), 7.99 (d, J = 8.5 Hz, 1H), 7.71
    (s, 1H), 7.64 (d, J = 8.5 Hz, 1H), 3.75-3.98 (m, 4H), 3.62-
    3.70 (br s, 1H), 2.66 (s, 3H), 2.40-2.48 (m, 1H), 2.25-2.35 (m,
    1H); 2Hs not observed (NH and OH)
    219 MS m/z 356.2 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.05 (s, 1H), 8.69 (d, J = 4 Hz, 1H), 7.94 (d, J = 8.5
    Hz, 1H), 7.86 (d, J = 4 Hz, 1H), 7.47 (s, 1H), 7.39 (d,
    J = 8.5 Hz, 1H), 3.70-4.00 (m, 4H), 3.60-3.70 (m, 1H),
    2.66 (s, 3H), 2.40-2.50 (m, 1H), 2.25-2.35 (m, 1H); 2Hs not
    observed (NH and OH)
    220 MS m/z 338.2 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.76 (s, 1H), 9.10 (s, 1H), 8.31 (s, 1H), 8.08 (d, J = 5
    Hz, 1H), 7.95 (s, 1H), 7.42 (m, 2H), 3.80-4.00 (m, 4H), 3.72
    (m, 1H), 2.65 (s, 3H), 2.43 (m, 1H), 2.31 (m, 1H); 2Hs not
    observed (NH and OH)
    228 MS m/z 392.5 [M + H]+; 1H NMR (methanol-d4) δ:
    9.42 (s, 1H), 7.85 (s, 2H), 7.34-7.31 (m, 2H), 5.98 (s, 1H),
    4.27 (s, 2H), 4.16 (s, 2H), 3.53 (d, J = 12.8 Hz, 3H), 3.20-
    3.12 (m, 2H), 2.91 (s, 3H), 2.45 (s, 3H), 2.37 (d, J =
    14.5 Hz, 2H), 2.13 (t, J = 11.9 Hz, 2H); 1H not
    observed (OH)
    229 MS m/z 396.5 [M + H]+; 1H NMR (methanol-d4) δ:
    8.34 (d, J = 4.4 Hz, 1H), 7.73-7.64 (m, 2H), 7.41-7.33
    (m, 2H), 5.94 (s, 1H), 4.26 (s, 2H), 4.14 (s, 2H), 3.53 (d, J =
    12.7 Hz, 2H), 3.14 (t, J = 12.7 Hz, 2H), 2.90 (s, 3H), 2.37
    (d, J = 14.6 Hz, 2H), 2.13 (t, J = 13.8 Hz, 2H);
    1H not observed (OH)
    230 MS m/z 396.4 [M + H]+; 1H NMR (methanol-d4) δ:
    8.13 (s, 1H), 7.76 (d, J = 8.5 Hz, 1H), 7.41 (d, J =
    7.5 Hz, 1H), 7.22 (d, J = 9.1 Hz, 1H), 7.20 (s, 1H), 5.95
    (s, 1H), 4.26 (s, 2H), 4.15 (s, 2H), 3.53 (d, J = 12.4 Hz,
    2H), 3.15 (t, J = 12.6 Hz, 2H), 2.90 (s, 3H), 2.37 (d, J =
    14.4 Hz, 2H), 2.13 (t, J = 13.8 Hz, 2H); 1H not observed
    (OH)
    231 MS m/z 378.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.57 (s, 1H), 8.14 (s, 1H), 7.87 (d, J = 8.2 Hz, 1H), 7.80
    (s, 1H), 7.37 (d, J = 8.9 Hz, 2H), 5.99 (s, 1H), 4.28 (s,
    2H), 4.16 (s, 2H), 3.53 (d, J = 12.7 Hz, 2H), 3.15 (t,
    J = 12.6 Hz, 2H), 2.90 (s, 3H), 2.37 (d, J = 14.3
    Hz, 2H), 2.14 (t, J = 13.6 Hz, 2H); 1H not observed (OH)
    232 MS m/z 379.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.06 (s, 1H), 8.00-7.90 (m, 3H), 7.73-7.65 (m, 2H), 4.09
    (br d, J = 20.9 Hz, 4H), 3.51 (br s, 2H), 3.11 (br s, 2H),
    2.90 (s, 3H), 2.30 (br s, 2H), 2.08 (br s, 2H); 1H not
    observed (OH)
    238 MS m/z 381.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    11.37 (br s, 1H), 9.02 (s, 1H), 8.15 (s, 2H), 8.00 (d, J =
    8.2 Hz, 1H), 7.72 (s, 1H), 7.63 (d, J = 8.2 Hz, 1H), 3.92-
    4.02 (m, 2H), 3.72-3.85 (m, 2H), 3.50-3.62 (m, 3H), 1.24 (s,
    9H); 1H not observed (OH or NH)
    239 MS m/z 426.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    10.06-10.18 (m, 1H), 9.66 (s, 1H), 9.08 (s, 1H), 8.36 (br s,
    1H), 8.13 (d, J = 13.4 Hz, 1H), 8.07 (d, J = 8.2
    Hz, 1H), 8.03 (s, 1H), 7.39 (s, 1H), 7.36 (d, J = 8.2 Hz,
    1H), 4.74-4.84 (m, 2H), 2.38 (s, 3H), 1.96-2.07 (m, 1H),
    1.84-1.93 (m, 1H), 1.57 (d, J = 18.5 Hz, 6H), 1.49 (d, J =
    5.8 Hz, 6H)
    240 MS m/z 430.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.94 (br s, 1H), 9.10 (s, 1H), 8.33 (br s, 1H), 8.13 (d, J =
    13.1 Hz, 1H), 8.07 (s, 1H), 8.00 (d, J = 8.2 Hz, 1H), 7.57
    (d, J = 8.2 Hz, 1H), 6.77-7.37 (m, 3H), 4.76-4.85 (m, 2H),
    1.95-2.07 (m, 1H), 1.85-1.94 (m, 1H), 1.57 (d, J = 18.5
    Hz, 6H), 1.48 (d, J = 6.1 Hz, 6H)
    264 MS m/z 367.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.06 (s, 1H), 7.87-7.98 (m, 3H), 7.59-7.68 (m, 2H), 3.96 (dd,
    J = 11.0, 7.0 Hz, 1H), 3.76-3.91 (m, 1H), 3.54-3.70 (m,
    2H), 3.38 (br dd, J = 11.1, 6.6 Hz, 1H), 2.98 (dt, J =
    12.5, 6.3 Hz, 1H), 2.29-2.39 (m, 1H), 1.86-1.97 (m, 1H),
    1.14 (t, J = 6.1 Hz, 6H); 2Hs not observed (NH and OH)
    273 MS m/z 394.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.58 (s, 1H), 8.15 (s, 1H), 7.89 (d, J = 8.1 Hz, 1H), 7.81
    (s, 1H), 7.41-7.36 (m, 2H), 6.01 (s, 1H), 4.49-4.40 (m, 1H),
    2.31-2.18 (m, 2H), 1.87-1.74 (m, 2H), 1.65 (s, 3H), 1.63 (s,
    3H), 1.55 (s, 3H), 1.54 (s, 3H); 3Hs not observed (2 NHs and
    OH)
    274 MS m/z 408.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.44 (s, 1H), 7.89-7.83 (m, 2H), 7.36-7.31 (m, 2H), 6.00 (s,
    1H), 4.48-4.38 (m, 1H), 2.28-2.19 (m, 2H), 1.86-1.75 (m,
    2H), 1.64 (s, 3H), 1.63 (s, 3H), 1.55 (s, 3H), 1.54 (s, 3H);
    3Hs not observed (2NHs and OH)
    275 MS m/z 412.5 [M + H]+; 1H NMR (methanol-d4) δ:
    7.99 (s, 1H), 7.77 (d, J = 8.6 Hz, 1H), 7.35 (d, J =
    9.5 Hz, 1H), 7.22 (d, J = 8.6 Hz, 1H), 7.19 (s, 1H), 5.98
    (s, 1H), 4.37 (m, 1H), 2.29-2.18 (m, 2H), 1.78 (m, 2H), 1.63
    (s, 3H), 1.61 (s, 3H), 1.55 (s, 3H), 1.53 (s, 3H); 2Hs not
    observed (NH and OH)
    276 MS m/z 412.4 [M + H]+; 1H NMR (methanol-d4) δ:
    8.35 (d, J = 4.5 Hz, 1H), 7.71 (d, J = 8.5 Hz,
    1H), 7.69 (d, J = 4.0 Hz, 1H), 7.40-7.35 (m, 2H), 5.97
    (s, 1H), 4.41-4.30 (m, 1H), 2.31-2.19 (m, 2H), 1.84-1.72
    (m, 2H), 1.63 (s, 3H), 1.61 (s, 3H), 1.55 (s, 3H), 1.53 (s, 3H);
    3Hs not observed (2NHs and OH
    315 MS m/z 420.5 [M + H]+; 1H NMR (methanol-d4) δ:
    9.00 (s, 1H), 8.47 (s, 2H), 8.37 (d, J = 2.6 Hz, 1H),
    8.07 (d, J = 4.6 Hz, 1H), 7.73 (d, J = 8.5 Hz,
    1H), 7.66 (d, J = 8.0 Hz, 1H), 7.34 (dd, J =
    8.4, 4.9 Hz, 1H), 6.73 (dd, J = 8.5, 2.1 Hz, 1H),
    6.70 (d, J = 2.1 Hz, 1H), 4.54 (br s, 1H), 2.29 (br
    dd, J = 13.9, 3.4 Hz, 2H), 1.62-1.66 (m, 2H), 1.61
    (s, 6H), 1.49 (s, 6H)
    324 MS m/z 413.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.08 (s, 1H), 7.97 (d, J = 9.2 Hz, 1H), 7.93-7.97 (m,
    2H), 7.69-7.75 (m, 2H), 4.71-4.83 (m, 1H), 4.42-4.65 (m,
    1H), 1.74-1.86 (m, 2H), 1.41 (m, 6H), 1.28-1.31 (m, 6H);
    3Hs not observed (2NHs and OH)
    326 MS m/z 380.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.08 (s, 1H), 8.07 (s, 1H), 7.95 (d, J = 8.5 Hz, 1H),
    7.33 (s, 1H), 7.15 (d, J = 9.0 Hz, 1H), 7.13 (s, 1H),
    4.06 (dd, J = 11.0, 6.5 Hz, 1H), 3.97-3.88 (m, 2H),
    3.73-3.70 (m, 1H), 3.60 (dd, J = 11.5, 6.0 Hz, 1H),
    3.29-3.25 (m, 1H), 2.51-2.42 (m, 1H), 2.26 (s, 3H), 2.15-
    2.06 (m, 1H), 1.28 (t, J = 5.0 Hz, 6H); 2Hs not
    observed (NH and OH)
    331 MS m/z 366.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.16 (s, 1H), 8.75 (br s, 1H), 8.07 (br d, J = 8.5 Hz,
    1H), 7.85 (br s, 1H), 7.44 (br s, 1H), 7.23-7.35 (m, 2H),
    4.13-4.32 (m, 2H), 3.97-4.08 (m, 1H), 3.76-3.91 (m, 2H),
    3.48-3.70 (m, 1H), 2.58-2.69 (m, 1H), 2.24-2.40 (m, 1H),
    1.46 (t, J = 4.6 Hz, 6H); 2Hs not observed (NH and
    OH)
    338 MS m/z 384.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.13 (s, 1H), 8.33 (dd, J = 15.0, 4.0 Hz, 1H), 7.85
    (dd, J = 111.5, 8.5 Hz, 1H), 7.68 (dd, J = 9.0,
    3.5 Hz, 1H), 7.39-7.35 (m, 2H), 4.31-4.22 (m, 1H),
    4.18-4.10 (m, 1H), 4.00-3.75 (m, 3H), 3.60-3.51 (m,
    1H), 2.67-2.58 (m, 1H), 2.48-2.29 (m, 1H), 1.44 (t,
    J = 6.0 Hz, 6H); 2Hs not observed (NH and OH)
    381 MS m/z 459.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.42 (s, 1H), 9.04 (s, 1H), 8.57 (s, 1H), 8.42 (d, J =
    5.6 Hz, 1H), 8.30 (s, 1H), 8.06 (d, J = 9.0 Hz, 1H),
    7.93 (dd, J = 5.5, 1.1 Hz, 1H), 7.47-7.55 (m, 2H),
    5.20-5.27 (m, 1H), 3.11 (s, 3H), 1.57-1.71 (m, 4H),
    1.33 (s, 6H), 1.21 (s, 6H); 1H not observed (OH or NH)
    417 MS m/z 407.5 [M + H]+; 1H NMR (methanol-d4):
    9.13 (s, 1H), 8.01 (d, J = 9.00 Hz, 1H), 7.96 (s, 2H),
    7.73 (s, 2H), 5.41-5.30 (m, 1H), 3.22 (s, 3H), 2.37-2.31 (m,
    2H), 2.15-2.01 (m, 6H), 1.57 (s, 6H); 2Hs not observed
    (NH and OH)
    • Example 6 Preparation of Compound 13
  • Figure US20230331725A1-20231019-C00153
    • Step 1
  • A dry screw cap vial was equipped with a magnetic stir bar and charged with 6-bromo-3-(methylthio)-1,2,4-triazine (0.2 g, 0.9 mmol, 1.0 equiv), 4-(3-(methoxymethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (0.4 g, 1.0 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dicholoropalladium(II) (0.08 g, 0.1 mmol), and K2CO3 (0.4 g, 2.6 mmol) and was purged with argon. Dioxane (4 mL) and water (1 mL) were added, and the reaction was stirred at 90° C. for 1 h. The crude mixture was partitioned between water and EtOAc, washed with water, and the organic layer was dried over MgSO4, filtered, and concentrated. The crude oil was purified by silica gel chromatography eluting with a EtOAc/hexanes gradient (0-75% EtOAc) to afford 6-(2-(methoxymethoxy)-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)phenyl)-3-(methylthio)-1,2,4-triazine (0.2 g, 61% yield) as a yellow solid. MS m/z 414.2 [M+H]+.
    • Step 2:
  • To a solution of 6-(2-(methoxymethoxy)-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)phenyl)-3-(methylthio)-1,2,4-triazine (0.7 g, 1.7 mmol) in CH2Cl2 (15 mL) was added 3-chlorobenzoperoxoic acid (0.6 g, 3.4 mmol). The reaction mixture was stirred at 22° C. for 2 h. The crude mixture was purified by silica gel chromatography eluting with a EtOAc/hexanes gradient (0-100% EtOAc) to afford 6-(2-(methoxymethoxy)-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)phenyl)-3-(methylsulfonyl)-1,2,4-triazine (0.6 g, 1.3 mmol, 78%) as yellow solid. MS m/z 446.2 [M+H]+.
    • Step 3
  • A vial was equipped with a magnetic stir bar and charged with 6-(2-(methoxymethoxy)-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)phenyl)-3-(methylsulfonyl)-1,2,4-triazine (0.06 g, 0.13 mmol), 2,2,6,6-tetramethylpiperidin-4-amine (0.03 g, 0.18 mmol), and dichloroethane (5 mL) and the reaction was stirred at room temperature for 48 h. The solvents were removed, and the crude solid was purified by silica gel chromatography, eluting with a MeOH/CH2Cl2 gradient (0-15% MeOH, containing 2.5% NH4OH) to afford 6-(2-(methoxymethoxy)-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)phenyl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,2,4-triazin-3-amine (0.03 g, 36% yield) as yellow solid. MS m/z 522.3 [M+H]+.
    • Step 4
  • To a solution of 6-(2-(methoxymethoxy)-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)phenyl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,2,4-triazin-3-amine (0.03 g, 0.05 mmol) in MeOH (1 mL) was added 4.0M HCl in dioxane (1 mL), and the mixture was stirred for 1 h at room temperature. The solvents were removed, and the crude residue was purified by silica gel chromatography eluting with a MeOH/CH2Cl2 gradient (0-15% MeOH, containing 2.5% NH4OH) to afford 5-(1H-pyrazol-4-yl)-2-(3-((2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,2,4-triazin-6-yl)phenol hydrochloride (0.02 g, 72% yield) as a yellow solid.
  • MS m/z 394.3 [M+H]+; 1H NMR (methanol-d4) δ: 9.07 (s, 1H), 8.08 (br s, 1H), 7.96 (br s, 1H), 7.83 (d, J=8.5 Hz, 1H), 7.24, (dd, J=8.0, 1.5 Hz, 1H), 7.21 (d, J=2.0 Hz, 1H), 4.58 (t, J=12.5 Hz, 1H), 2.30 (dd, J=13.5, 2.5 Hz, 2H), 1.66-1.60 (m, 2H), 1.62 (s, 6H), 1.50 (s, 6H); 4 Hs not observed (3NHs and OH).
  • Using the procedure described for Example 6, additional compounds described herein may be prepared by substituting the appropriate starting material, suitable reagents and reaction conditions, obtaining compounds such as those selected from:
  • Cpd Data
    11 MS m/z 395.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    13.06 (br s, 1H), 10.96 (br s, 1H), 9.29 (s, 1H), 8.24 (br s,
    1H), 7.94 (s, 1H), 7.90 (d, J = 8.0 Hz, 1H), 7.28 (dd,
    J = 8.0, 1.5 Hz, 1H), 7.25 (d, J = 1.5 Hz, 1H),
    5.61 (t, J = 10.0 Hz, 1H), 2.27 (br s, 2H), 1.01-1.97
    (m, 14H); 1H not observed (NH or OH)
    19 MS m/z 352.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.10 (s, 1H), 8.02 (br. s, 2H), 7.85 (d, J = 8.5 Hz, 1H),
    7.25 (dd, J = 8.0, 1.5 Hz, 1H), 7.21 (d, J = 1.5
    Hz, 1H), 4.98 (dt, J = 12.0, 4.0 Hz, 1H), 3.59 (d,
    J = 13.0 Hz, 2H), 3.26 (d, J = 3.5 Hz, 1H),
    3.24 (s, 3H), 3.21 (d, J = 2.5 Hz, 1H), 2.22 (dd,
    J = 13.0, 3.5 Hz, 2H), 2.07 (d, J = 3.0 Hz,
    2H); 3Hs not observed (2NHs and OH).
    20 MS m/z 352.2 [M + H]+; 1H NMR (methanol-d4) δ:
    9.13 (s, 1H), 8.02 (br. s, 2H), 7.85 (d, J = 8.0 Hz, 1H),
    7.25 (dd, J = 8.5, 2.0 Hz, 1H), 7.21 (d, J = 1.5
    Hz, 1H), 4.22 (dd, J = 15.5, 8.5 Hz, 1H), 4.01-3.95
    (m, 1H), 3.92 (dd, J = 15.0, 3.5 Hz, 1H), 3.45 (dd,
    J = 18.5, 8.0 Hz, 1H), 3.39 (s, 3H), 2.34-2.28 (m, 1H),
    2.22-2.01 (m, 3H), 1.87 (dd, J = 13.0, 9.5 Hz, 1H);
    3Hs not observed (2NHs and OH).
    21 MS m/z 378.3 [M + H]+; 1H NMR (methanol-d4):
    9.09 (s, 1H), 8.01 (br. s, 2H), 7.83 (d, J = 8.5 Hz, 1H),
    7.24 (dd, J = 8.0, 1.5 Hz, 1H), 7.20 (d, J = 1.5
    Hz, 1H), 5.36-5.29 (m, 1H), 4.20 (br. s, 2H), 3.19 (s, 3H),
    2.28 (dt, J = 3.5, 15 Hz, 4H), 2.23 (br. s, 4H), 2.0-
    1.94 (m, 2H); 1H not observed (NH or OH).
    22 MS m/z 392.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.10 (s, 1H), 8.02 (br. s, 2H), 7.84 (d, J = 10 Hz, 1H),
    7.24 (dd, J = 8.0, 1.5 Hz, 1H), 7.21 (d, J = 1.5
    Hz, 1H), 5.98-5.92 (m, 1H), 3.88 (br. s, 2H), 3.18 (s, 3H),
    2.46 (dt, J = 3.6, 14 Hz, 2H), 2.31-2.16 (m, 4H),
    2.13-2.06 (m, 4H), 1.92-1.89 (m, 2H); 1H not observed
    (NH or OH).
    52 MS m/z 352.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.07 (s, 1H), 8.01 (s, 2H), 7.83 (d, J = 8.5 Hz, 1H),
    7.24 (dd, J = 8.5, 2.0 Hz, 1H), 7.21 (d, J = 2.0
    Hz, 1H), 4.18-4.22 (m, 1H), 3.52-3.56 (m, 2H), 3.19-3.27
    (m, 2H), 2.91 (s, 3H), 2.34-2.36 (m, 2H), 1.92-2.00
    (m, 2H); 3Hs not observed (2NHs and OH)
    67 MS m/z 426.6 [M + H]+; 1H NMR (methanol-d4) δ:
    9.19 (s, 1H), 8.52-8.06 (m, 1H), 7.88 (d, J = 7.5 Hz,
    1H), 7.28 (d, J = 8.3 Hz, 2H), 7.24 (s, 1H), 5.60 (dd,
    J = 33.5, 13.3 Hz, 1H), 3.34 (s, 3H), 2.52 (t, J =
    13.5 Hz, 1H), 2.02 (d, J = 12.5 Hz, 1H), 1.72 (s, 3H),
    1.68 (s, 3H), 1.62 (s, 3H), 1.58 (s, 3H), 0.94-0.86 (m, 1H);
    3Hs not observed (2 NHs and OH)
    82 MS m/z 367.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.31 (s, 1H), 8.09 (br s, 1H), 7.94 (br s, 1H), 7.92 (d, J =
    8.5 Hz, 1H), 7.27 (d, J = 9.5 Hz, 1H), 7.22 (s, 1H), 5.40-
    5.46 (m, 1H), 3.44-3.49 (m, 2H), 2.58-2.61 (m, 2H), 1.68 (q,
    J = 12.5 Hz, 2H), 1.43 (s, 3H), 1.42 (s, 3H); 3Hs not
    observed (2 NHs and OH)
    95 MS m/z 364.5 [M + H]+; 1H NMR (methanol-d4) δ:
    9.06 (s, 1H), 7.81 (d, J = 8.0 Hz, 1H), 7.60 (d, J =
    8.0 Hz, 1H), 7.25-7.19 (m, 3H), 4.00-3.93 (m, 6H), 3.70-3.65
    (m, 2H), 2.15-2.09 (m, 2H), 2.00 (t, J = 5.7 Hz, 2H);
    3Hs not observed (2NHs and OH)
    96 MS m/z 364.5 [M + H]+; 1H NMR (methanol-d4) δ:
    8.08 (s, 2H), 7.59 (d, J = 8.5 Hz, 1H), 7.25 (d, J =
    8.5 Hz, 1H), 7.21 (s, 1H), 5.94 (s, 1H), 4.19 (s, 4H), 3.26 (t,
    J = 5.0 Hz, 4H), 2.19 (t, J = 5.0 Hz, 4H); 3Hs
    not observed (2NHs and OH)
    100 MS m/z 336.4 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.07 (s, 1H), 8.27-8.19 (br s, 1H), 7.98-7.92 (br s, 1H), 7.83
    (d, J = 8.0 Hz, 1H), 7.22 (dd, J = 8.0, 2.0 Hz,
    1H), 7.19 (d, J = 1.5 Hz, 1H), 3.88-3.82 (m, 2H),
    3.68-3.62 (m, 2H), 2.64 (t, J = 2.0 Hz, 1H), 1.93
    (s, 2H); 3Hs not observed (2NHs and OH)
    109 MS m/z 364.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    11.33 (br s, 1H), 9.07 (s, 1H), 8.20 (br s, 1H), 7.95 (s, 1H),
    7.83 (d, J = 8.0 Hz, 1H), 7.23-7.20 (m, 2H), 3.98 (d,
    J = 9.0 Hz, 2H), 3.84 (d, J = 8.5, 2H), 3.01
    (s, 2H), 2.75 (s, 2H), 1.81 (t, J = 5.0 Hz, 2H), 1.55 (t,
    J = 5.0 Hz, 2H); 2 H not observed (2 NHs)
    110 MS m/z 350.2 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.14 (br s, 1H), 9.10 (s, 1H), 8.95 (br s, 1H), 8.08 (s, 2H),
    7.84 (d, J = 8.0 Hz, 1H), 7.23-7.20 (m, 2H), 4.08-
    4.05 (m, 2H), 3.97-3.94 (m, 2H), 3.86 (br s, 2H), 3.64
    (br s, 2H), 2.32 (t, J = 7.0 Hz, 2H); 1H not
    observed (NH or OH)
    120 MS m/z 395.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.22 (s, 1H), 7.93 (s, 2H), 7.82 (d, J = 8.5 Hz, 1H),
    7.18 (dd, J = 8.00, 1.5 Hz, 1H), 7.12 (s, 1H), 5.37-
    5.30 (m, 1H), 2.64-2.61 (m, 2H), 1.83-1.75 (m, 2H), 1.63-
    1.49 (m, 4H), 0.98 (t, J = 10 Hz, 6H); 3Hs not
    observed (2NHs and OH); 2Hs (CH2 signal) are obscured
    by the solvent peak at 3.33 ppm
    113 MS m/z 378.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.05 (s, 1H), 8.07 (br s, 1H), 7.92 (s, 1H), 7.82 (d, J =
    8.0 Hz, 1H), 7.22 (dd, J = 8.0, 2.0 Hz, 1H), 7.19 (d,
    J = 2.0 Hz, 1H), 3.93-3.88 (m, 2H), 3.22-3.17 (m,
    3H), 2.67 (s, 3H), 2.53 (t, J = 8.0 Hz, 2H), 2.24
    (d, J = 11.0 Hz, 2H), 2.00 (td, J = 12.0, 4.0
    Hz, 2H); 1H not observed (NH or OH)
    114 MS m/z 338.3 [M + H]+; 1H NMR (methanol-d4) δ:
    8.12 (s, 2H), 7.61 (d, J = 8.0 Hz, 1H), 7.22 (dd,
    J = 8.0, 2.0 Hz, 1H), 7.21 (s, 1H), 5.96 (s, 1H),
    4.16-4.07 (m, 2H), 4.05-3.74 (m, 3H), 2.83 (s, 3H),
    2.65-2.59 (m, 1H), 2.49-2.38 (m, 1H); 3Hs not observed
    (2NHs and OH)
    115 MS m/z 350.2 [M + H]+; 1H NMR (methanol-d4) δ:
    8.25 (br s, 2H), 7.64 (d, J = 8.0 Hz, 1H), 7.27 (d,
    J = 8.0 Hz, 1H), 7.24 (s, 1H), 5.97 (d, J =
    12.5 Hz, 1H), 4.26-4.00 (m, 3H), 3.70 (dd, J =
    20.0, 5.0 Hz, 1H), 3.45 (dd, J = 26.0, 10.5 Hz,
    1H), 1.24 (dt, J = 10.0, 5.0 Hz, 1H), 1.09-1.04
    (m, 2H), 1.00-0.95 (m, 1H); 4Hs not observed (3NHs
    and OH)
    116 MS m/z 364.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.13 (d, J = 5.0 Hz, 1H), 8.03 (br s, 2H), 7.84
    (d, J = 8.0 Hz, 1H), 7.23 (dd, J = 8.0, 1.5
    Hz, 1H), 7.20 (d, J = 1.5 Hz, 1H), 5.34-5.15 (m,
    1H), 4.34 (dd, J = 15.0, 4.0 Hz, 1H), 4.17-3.97
    (m, 2H), 3.86-3.75 (m, 1H), 3.68-3.64 (m, 1H), 3.51-
    3.36 (m, 2H), 3.26-3.09 (m, 2H), 2.43-2.09 (m, 3H),
    2.04-1.83 (m, 1H); 1H not observed (NH or OH)
    117 MS m/z 364.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.14 (s, 1H), 8.02 (br s, 2H), 7.84 (d, J = 8.0 Hz,
    1H), 7.23 (d, J = 8.0, 1H), 7.20 (s, 1H), 4.39 (d,
    J = 13.5 Hz, 1H), 4.26 (t, J = 7.0 Hz, 1H),
    4.03-3.75 (m, 5H), 3.49-3.45 (m, 1H), 3.07 (s, 3H),
    2.67-2.59 (m, 1H), 2.02-1.95 (m, 1H); 2Hs not observed
    (NH and OH)
    118 MS m/z 336.2 [M + H]+; 1H NMR (methanol-d4) δ:
    9.08 (s, 1H), 8.06 (br s, 1H), 7.92 (br s, 1H), 7.82 (d,
    J = 8.0, 1H), 7.22 (dd, J = 8.0, 2.0 Hz, 1H),
    7.18 (d, J = 1.5 Hz, 1H), 4.46 (s, 4H), 4.35 (s,
    4H); 3Hs not observed (2NHs and OH)
    126 MS m/z 412.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    13.00 (br s, 1H), 11.45 (br s, 1H), 9.08 (s, 1H), 8.24 (br s,
    1H), 7.95 (br s, 1H), 7.86 (d, J = 7.9 Hz, 1H),
    7.20-7.25 (m, 2H), 4.30-4.70 (m, 2H), 1.64 (t, J =
    13.1 Hz, 1H), 1.56 (dd, J = 12.2, 3.1 Hz, 1H), 1.33-
    1.47 (m, 1H), 1.22 (br d, J = 14.0 Hz, 6H), 1.09
    (br d, J = 14.0 Hz, 6H); 1H not observed (OH)
    127 MS m/z 392.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.04 (s, 1H), 8.10-7.89 (m, 2H), 7.80 (d, J = 8.5
    Hz, 1H), 7.20 (dd, J = 8.0, 1.5 Hz, 1H), 7.17 (d,
    J = 1.5 Hz, 1H), 3.94 (d, J = 11.4 Hz, 2H),
    3.69 (d, J = 11.4 Hz, 2H), 2.76 (q, J = 7.2
    Hz, 4H), 1.93 (s, 2H), 1.64 (s, 1H), 1.14 (t, J =
    7.2 Hz, 6H); 2Hs not observed (NH and OH)
    137 MS m/z 364.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    13.00 (br s, 1H), 11.42 (s, 1H), 9.10 (s, 1H), 8.35-7.92
    (m, 2H), 7.85 (d, J = 8.0 Hz, 1H), 7.23 (d, J =
    8.5 Hz, 1H), 7.21 (s, 1H), 3.86 (br s, 2H), 3.76 (br s,
    2H), 3.66 (s, 1H), 2.36-2.31 (m, 2H), 2.20-2.17 (m,
    1H), 0.65 (br s, 4H); 1H not observed (NH or OH)
    138 MS m/z 380.3 [M + H]+; 1H NMR (methanol-d4) δ:
    8.44 (s, 2H), 7.67 (d, J = 8.0 Hz, 1H), 7.31 (d,
    J = 8.0 Hz, 1H), 7.29 (s, 1H), 5.98 (s, 1H), 4.29-
    4.40 (m, 1H), 4.14-4.19 (m, 1H), 3.87-3.98 (m, 2H),
    3.71-3.80 (m, 1H), 2.64-2.74 (m, 1H), 2.39-2.51 (m, 1H),
    1.52 (s, 9H); 3Hs not observed (2NHs or OH)
    148 MS m/z 366.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.06 (s, 1H), 7.99 (br s, 2H), 7.80 (d, J = 8.5 Hz,
    1H), 7.20 (dd, J = 8.0, 1.5 Hz, 1H), 7.17 (d,
    J = 1.5 Hz, 1H), 4.03 (dd, J = 11.5, 6.5 Hz,
    1H), 3.92-3.86 (m, 2H), 3.68-3.65 (m, 1H), 3.55 (dd,
    J = 11.5, 6.5 Hz, 1H), 2.47-2.41 (m, 1H), 1.26
    (t, J = 5.5 Hz, 6H), 1.20-1.16 (m, 2H); 3Hs not
    observed (2NHs and OH)
    154 MS m/z 394.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.08 (s, 1H), 8.00 (br s, 2H), 7.82 (d, J = 8.5 Hz,
    1H), 7.22 (d, J = 8.0, 1H), 7.19 (s, 1H), 4.13-4.09
    (m, 1H), 3.99-3.90 (m, 2H), 3.69-3.63 (m, 1H), 3.57-
    3.52 (m, 1H), 2.52-2.49 (m, 1H), 2.14-2.09 (m, 1H),
    1.72-1.64 (m, 2H), 1.30 (s, 6H), 1.00 (t, J = 7.5
    Hz, 3H); 3Hs not observed (2NHs and OH)
    157 MS m/z 458.4 [M + H]+; 1H NMR (DMSO-d6) δ:
    11.29 (s, br, 1H), 9.12 (s, 1H), 8.80-8.69 (m, 2H),
    8.08 (s, br, 2H), 7.85 (d, J = 8.5 Hz, 1H), 7.23
    (d, J = 8.0 Hz, 1H), 7.21 (s, 1H), 4.30-4.22
    (m, 1H), 4.08-4.00 (m, 1H), 3.85-3.79 (m, 1H), 3.74-
    3.69 (m, 1H), 3.66-3.23 (m, 12H), 2.27-2.20 (m, 1H),
    2.17 (s, 1H), 1.93 (q, J = 11.6 Hz, 2H), 1.67
    (q, J = 12.3 Hz, 2H)
    159 MS m/z 458.4 [M + H]+; 1H NMR
    (DMSO-d6) δ:9.13 (s, 1H), 8.62 (br s, 2H), 8.09 (s,
    2H), 7.86 (d, J = 8.0 Hz, 1H), 7.24 (d, J =
    8.0 Hz, 1H), 7.21 (s, 1H), 4.18-4.13 (m, 1H), 4.07-4.04
    (m, 1H), 3.89-3.81 (m, 2H), 3.69-3.57 (m, 1H), 3.52
    (s, 1H), 2.33-2.31 (m, 1H), 2.20 (br s, 2H), 2.04 (d,
    J = 14.0 Hz, 2H), 1.89-1.86 (m, 6H), 1.74 (br s,
    2H), 1.64 (d, J = 12.5 Hz, 3H); 1H not observed
    (NH or OH)
    160 MS m/z 486.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    11.28 (br s, 1H), 9.12 (s, 1H), 9.03-8.96 (m, 2H), 8.08
    (s, 2H), 7.85 (d, J = 7.5 Hz, 1H), 7.23 (d, J =
    8.0 Hz, 1H), 7.21 (s, 1H), 4.23 (br s, 1H), 4.04 (br s,
    1H), 3.82-3.78 (m, 2H), 3.76-3.73 (m, 3H), 2.32-2.28
    (s, 1H), 1.84-1.77 (m, 2H), 1.65-1.56 (m, 4H), 1.38-1.29
    (m, 4H), 1.21-1.15 (m, 2H), 0.90 (s, 6
    162 MS m/z 392.4 [M + H]+; 1H NMR (methanol-d4) δ:
    8.58 (s, 2H), 7.68 (dd, J = 8.1, 4.7 Hz, 1H), 7.38-7.54
    (m, 1H), 7.29-7.36 (m, 2H), 5.97 (d, J = 4.3 Hz, 1H),
    3.83-4.09 (m, 4H), 3.59-3.73 (m, 1H), 3.38-3.42 (m, 1H),
    3.08-3.20 (m, 1H), 3.03 (br d, J = 2.4 Hz, 3H), 2.99
    (s, 3H), 2.30-2.40 (m, 1H), 2.12-2.28 (m, 2H), 1.74-1.86
    (m, 1H); 2H not observed (NH and OH)
    166 MS m/z 378.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.09 (s, 1H), 7.94-8.11 (m, 2H), 7.84 (br d, J = 8.2 Hz,
    1H), 7.61-7.77 (m, 1H), 7.18-7.28 (m, 2H), 3.77-3.88 (m, 2H),
    3.71-3.76 (m, 1H), 3.67 (br dd, J = 10.8, 6.9 Hz, 1H),
    2.96-3.07 (m, 1H), 2.74-2.94 (m, 4H), 2.72 (s, 3H), 2.61-2.66
    (m, 1H), 2.02-2.14 (m, 1H), 1.81-1.91 (m, 1H); 2H not
    observed (NH and OH)
    167 MS m/z 392.3 [M + H]+; 1H NMR (methanol-d4) δ:
    8.32 (s, 2H), 7.63 (br d, J = 7.9 Hz, 1H), 7.29 (br d,
    J = 8.2 Hz, 1H), 7.26 (s, 1H), 5.94 (s, 1H), 4.07 (br s,
    1H), 3.71-3.91 (m, 3H), 3.55-3.64 (m, 1H), 3.13-3.31 (m,
    2H), 3.01 (br s, 3H), 2.89-2.97 (m, 3H), 2.38-2.50 (m,
    1H), 2.18-2.29 (m, 1H), 1.98-2.12 (m, 1H), 1.64-1.79 (m,
    1H); 2Hs not observed (NH and OH)
    170 MS m/z 408.6 [M + H]+; 1H NMR (methanol-d4) δ:
    9.11 (s, 1H), 8.08-7.99 (m, 2H), 7.82 (d, J = 8.0
    Hz, 1H), 7.22 (d, J = 8.0, 1H), 7.19 (s, 1H), 4.29-
    4.21 (m, 2H), 4.01-3.96 (m, 1H), 3.77-3.69 (m, 2H),
    2.67-2.61 (m, 1H), 2.34-2.27 (m, 1H), 1.94-1.75 (m,
    4H), 1.41 (s, 3H), 1.03 (t, J = 7.5 Hz, 6H); 3Hs
    not observed (2 NHs and OH)
    171 MS m/z 394.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.15 (s, 1H), 8.24-7.98 (br s, 2H), 7.91 (d, J = 8.0
    Hz, 1H), 7.30 (d, J = 8.2 Hz, 1H), 7.28 (s, 1H),
    4.43-4.39 (m, 1H), 4.35-4.29 (m, 1H), 3.77-3.69 (m, 1H),
    3.43 (t, J = 9.5 Hz, 1H), 2.76-2.71 (m, 1H), 1.83-
    1.77 (m, 1H), 1.51 (d, J = 6.0 Hz, 3H), 1.32 (s,
    9H); 3Hs not observed (2NHs and OH)
    180 MS m/z 392.4 [M + H]+; 1H NMR (methanol-d4) δ:
    8.11 (br s, 2H), 7.58 (d, J = 8.2 Hz, 1H), 7.16-7.28
    (m, 2H), 5.92 (s, 1H), 3.77-4.06 (m, 1H), 3.61-3.76 (m, 3H),
    3.09-3.22 (m, 4H), 1.67-1.92 (m, 8H); 3Hs not observed (2
    NHs and OH)
    181 MS m/z 378.4 [M + H]+; 1H NMR (methanol-d4) δ:
    8.08 (br s, 2H), 7.59 (d, J = 8.2 Hz, 1H), 7.14-7.28 (m,
    2H), 5.92 (s, 1H), 3.81-4.06 (m, 1H), 3.64-3.80 (m, 3H),
    3.43-3.50 (m, 2H), 3.20-3.27 (m, 2H), 2.06 (q, J = 7.3
    Hz, 2H), 1.81-1.94 (m, 3H), 1.74-1.79 (m, 1H); 3Hs not
    observed (2 NHs and OH)
    182 MS m/z 406.4 [M + H]+; 1H NMR (methanol-d4) δ:
    8.65 (br s, 2H), 7.69 (d, J = 7.9 Hz, 1H), 7.31-7.38
    (m, 2H), 5.96 (s, 1H), 3.80-3.88 (m, 1H), 3.66-3.78 (m, 3H),
    3.61 (br d, J = 9.2 Hz, 1H), 3.53 (br d, J = 10.4
    Hz, 1H), 3.16-3.22 (m, 1H), 2.89-3.01 (m, 4H), 1.95-2.18 (m,
    4H), 1.84-1.95 (m, 2H), 1.73 (br s, 2H); 2Hs not observed (NH
    and OH)
    183 MS m/z 392.5 [M + H]+; 1H NMR (methanol-d4) δ:
    8.75 (br s, 2H), 7.72 (d, J = 8.2 Hz, 1H), 7.32-7.41 (m, 2H),
    5.97 (s, 1H), 3.67-3.86 (m, 5H), 3.67-3.89 (m, 1H), 3.27-3.32
    (m, 1H), 3.09 (br dd, J = 11.0, 8.9 Hz, 1H), 3.00 (s, 3H),
    2.25 (br d, J = 8.2 Hz, 1H), 2.07-2.19 (m, 1H), 1.97 (br s,
    3H), 1.84-2.04 (m, 1H); 2Hs not observed (NH and OH)
    193 MS m/z 420.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.08 (s, 1H), 8.18-7.88 (br s, 2H), 7.82 (d, J = 8.0 Hz,
    1H), 7.22 (dd, J = 8.5, 2.0 Hz, 1H), 7.18 (d, J =
    1.5 Hz, 1H), 3.92-3.86 (m, 2H), 3.79 (d, J = 4.0 Hz,
    2H), 3.71 (dd, J = 12.0, 7.5 Hz, 1H), 3.22-3.16 (m,
    1H), 3.01-2.95 (m, 1H), 2.25-2.11 (m, 2H), 1.98-1.89 (m,
    1H), 1.69-1.64 (m, 1H), 1.44 (s, 9H); 3Hs not observed
    (2NHs and OH)
    199 MS m/z 408.5 [M + H]+; 1H NMR (methanol-d4) δ:
    9.03 (s, 1H), 8.02 (s, 1H), 7.86 (s, 1H), 7.78 (d, J = 7.9
    Hz, 1H), 7.10-7.22 (m, 2H), 4.45 (br t, J = 11.6 Hz, 1H),
    3.96 (s, 3H), 2.03 (br d, J = 11.0 Hz, 2H), 1.35 (s, 6H),
    1.24-1.31 (m, 2H), 1.22 (s, 6H); 3Hs not observed (2 NHs
    and OH)
    201 MS m/z 426.5 [M + H]+; 1H NMR (methanol-d4) δ:
    9.05 (s, 1H), 7.99 (s, 1H), 7.85 (s, 1H), 7.78 (br d, J =
    7.9 Hz, 1H), 7.05-7.26 (m, 2H), 4.65-4.75 (m, 1H), 3.93 (s,
    3H), 1.70-1.80 (m, 2H), 1.35 (br d, J = 6.4 Hz, 6H),
    1.16-1.27 (m, 7H); 3Hs not observed (2NHs and OH)
    202 MS m/z 394.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.07 (s, 1H), 8.02 (s, 1H), 7.86 (s, 1H), 7.79 (d, J = 7.9
    Hz, 1H), 7.13-7.21 (m, 2H), 3.99-4.08 (m, 2H), 3.96 (s, 3H),
    3.83-3.90 (m, 1H), 3.57-3.73 (m, 2H), 2.29-2.45 (m, 1H),
    1.83-2.01 (m, 1H), 1.22 (s, 9H); 2Hs not observed (NH and
    OH)
    203 MS m/z 380.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.06 (s, 1H), 8.01 (s, 1H), 7.85 (s, 1H), 7.81 (d, J = 7.9
    Hz, 1H), 7.18 (d, J = 7.6 Hz, 1H), 7.16 (s, 1H), 3.97-
    4.01 (m, 1H), 3.96 (s, 3H), 3.77-3.94 (m, 1H), 3.57-3.77 (m,
    2H), 3.40 (dd, J = 10.8, 6.9 Hz, 1H), 2.95-3.05 (m,
    1H), 2.28-2.42 (m, 1H), 1.86-2.00 (m, 1H), 1.16 (br t, J =
    5.8 Hz, 6H); 2Hs not observed (NH and OH)
    205 MS m/z 352.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.07 (s, 1H), 8.02 (s, 1H), 7.86 (s, 1H), 7.80 (d, J = 7.9
    Hz, 1H), 7.10-7.26 (m, 2H), 3.96 (s, 3H), 3.79-3.92 (m, 2H),
    3.65-3.74 (m, 1H), 3.49-3.65 (m, 1H), 3.41-3.48 (m, 1H),
    2.46 (s, 3H), 2.22-2.36 (m, 1H), 1.91-2.09 (m, 1H); 2Hs not
    observed (NH and OH)
    206 MS m/z 394.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.07 (s, 1H), 8.01, (s, 2H), 7.82 (d, J = 8.00 Hz, 1H),
    7.23 (d, J = 8.00 Hz, 1H), 7.19 (s, 1H), 4.94 (d, J =
    15 Hz, 2H), 3.79-3.71, (m, 1H), 3.20 (t, J = 14.50 Hz,
    2H), 2.21 (d, J = 12.50 Hz, 2H), 1.78-1.67, (m, 2H),
    1.46, (s, 9H); 3Hs not observed (2 NHs and OH)
    212 MS m/z 394.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.09 (s, 1H), 8.01 (s, 2H), 7.82 (d, J = 8.00 Hz, 1H),
    7.23 (d, J = 8.50 Hz, 1H), 7.19 (s, 1H), 4.91 (d, J =
    13.50 Hz, 1H), 4.58 (d, J = 13.50 Hz, 1H), 3.67-3.65,
    (m, 1H), 3.55-3.52, (m, 1H), 3.46-3.38 (m, 1H), 2.29-2.21,
    (m, 1H), 1.97-1.75, (m, 3H), 1.48 (s, 9H); 3Hs not observed
    (2 NHs and OH)
    226 MS m/z 392.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    11.25 (s, 1H), 9.29 (br s, 1H), 9.07 (s, 1H), 8.17 (s, 1H), 7.87
    (s, 1H), 7.83 (d, J = 8.1 Hz, 1H), 7.18 (d, J = 8.1
    Hz, 1H), 7.15 (s, 1H), 4.04 (br s, 2H), 3.97 (br s, 2H), 3.88 (s,
    3H), 3.40 (m, 2H), 3.02 (m, 2H), 2.78 (s, 3H), 2.18 (m, 2H),
    1.91 (m, 2H)
    262 MS m/z 352.2 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.13 (s, 1H), 8.17 (s, 2H), 7.87 (d, J = 8.5 Hz, 1H),
    7.25 (dd, J = 2.6, 4.1 Hz, 2H), 4.81 (d, J =
    13.3 Hz, 2H), 3.43-3.30 (m, 2H), 3.25-3.12 (m, 2H),
    1.37 (d, J = 6.4 Hz, 6H); 3Hs not observed (2 NH
    and OH)
    278 MS m/z 398.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.97 (br s, 1H), 9.69 (br s, 1H), 9.13(s, 1H), 8.08 (s, 2H),
    7.85 (d, J = 8.0 Hz, 1H), 7.25-7.22 (m, 2H), 5.79
    (d, J = 53.0 Hz, 2H), 4.39-4.26 (m, 2H), 4.13-3.99
    (m, 1H), 3.94-3.80 (m, 2H), 1.44 (s, 9H)
    282 MS m/z 380.4 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.11 (s, 1H), 8.21 (s, 2H), 7.88 (d, J = 8.5 Hz,
    1H), 7.30-7.22 (m, 2H), 4.00 (s, 4H), 1.48 (s, 12H);
    3Hs not observed (2 NHs and OH)
    297 MS m/z 380.5 [M + H]+; 1H NMR (methanol-d4) δ:
    8.30-8.62 (m, 2H), 7.68 (br d, J = 8.2 Hz, 1H),
    7.32 (br d, J = 8.4 Hz, 1H), 7.29 (s, 1H), 5.98 (br
    s, 1H), 4.07-4.26 (m, 2H), 3.85-4.06 (m, 2H), 3.78 (br
    s, 1H), 3.37 (s, 2H), 2.93-3.12 (m, 2H), 2.59-2.76 (m,
    1H), 2.39-2.58 (m, 1H), 2.15 (br dd, J = 13.0, 6.7
    Hz, 1H), 1.12 (br d, J = 6.4 Hz, 6H); 1H not
    observed (NH or OH)
    298 MS m/z 410.3 [M + H]+; 1H NMR (methanol-d4) δ:
    8.93 (s, 1H), 7.89 (br s, 2H), 7.70 (d, J = 7.9 Hz,
    1H), 7.11 (dd, J = 8.2, 1.8 Hz, 1H), 7.08 (d,
    J = 1.5 Hz, 1H), 4.64-4.73 (m, 1H), 3.39 (br
    d, J = 7.9 Hz, 1H), 2.15 (br dd, J = 13.3,
    8.4 Hz, 1H), 1.78 (dd, J = 13.3, 6.3 Hz, 1H),
    1.33 (s, 3H), 1.31 (s, 3H), 1.22 (s, 3H), 1.18 (s, 3H);
    5Hs not observed (3 NHs and 2 OHs)
    306 MS m/z 364.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    10.05 (br s, 1H), 9.13 (s, 1H), 8.91 (br s, 1H), 8.10
    (s, 2H), 7.86 (d, J = 8.5 Hz, 1H), 7.42 (s, 1H),
    7.32 (s, 1H), 7.17-7.26 (m, 3H), 3.76-4.01 (m, 4H),
    3.51-3.69 (m, 1H), 2.85-2.97 (m, 1H), 2.73-2.85 (m,
    1H), 1.64-1.88 (m, 5H)
    309 MS m/z 339.3 [M + H]+
    310 MS m/z 378.4 [M + H]+; 1H NMR (DMSO-d6) δ:
    10.40 (br s, 1H), 9.10-9.19 (m, 1H), 8.12 (s, 2H), 7.86
    (d, J = 7.9 Hz, 1H), 7.19-7.29 (m, 2H), 4.15-
    4.32 (m, 2H), 3.62-3.70 (m, 2H), 3.30-3.40 (m, 1H),
    3.17 (s, 3H), 2.97-3.08 (m, 1H), 2.87-2.95 (m, 1H),
    1.72-1.95 (m, 5H); 1H not observed (OH or NH)
    311 MS m/z 380.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    12.38 (br s, 1H), 9.13 (s, 1H), 8.11 (s, 2H), 7.86
    (d, J = 7.9 Hz, 1H), 7.18-7.30 (m, 2H), 5.76
    (s, 1H), 4.50 (s, 3H), 4.14-4.22 (m, 2H), 3.99-4.03
    (m, 2H), 3.86-3.95 (m, 2H), 3.80-3.84 (m, 2H),
    3.36-3.49 (m, 1H), 3.26-3.29 (m, 1H)
    312 MS m/z 380.4 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.08 (s, 1H), 8.27-7.95 (m, 2H), 7.84 (d, J =
    7.9 Hz, 1H), 7.28-7.17 (m, 2H), 4.67 (q, J =
    6.3 Hz, 2H), 4.52-4.31 (m, 2H), 4.07-3.86 (m, 2H),
    3.76-3.53 (m, 4H), 2.14-2.02 (m, 1H), 1.82 (br s,
    1H); 3Hs not observed (2NHs and OH)
    313 MS m/z 394.4 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.10 (s, 1H), 8.16 (s, 1H), 7.90-7.82 (m, 2H), 7.20-
    7.14 (m, 2H), 4.80-4.871 (m, 2H), 4.58-4.55 (m,
    2H), 4.45-4.34 (m, 1H), 3.88 (s, 3H), 3.85-3.72
    (m, 3H), 3.70-3.59 (m, 2H), 2.35-2.22 (m, 1H),
    2.15-2.03 (m, 1H); 2Hs not observed (NH and OH)
    316 MS m/z 398.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.10 (s, 1H), 8.00 (br s, 2H), 7.83 (d, J = 8.0
    Hz, 1H), 7.22 (d, J = 8.5 Hz, 1H), 7.19 (s, 1H),
    4.52 (d, J = 47.5 Hz, 2H), 4.18-4.13 (m, 2H),
    3.96-3.93 (m, 1H), 3.72-3.64 (m, 2H), 2.58-2.55 (m,
    1H), 2.24-2.16 (m, 1H), 1.41 (s, 6H); 3Hs
    not observed (2 NHs and OH)
    317 MS m/z 352.4 [M + H]+; 1H NMR (methanol-d4) δ:
    8.50 (s, 2H), 7.69 (br d, J = 7.9 Hz, 1H), 7.33
    (br d, J = 8.5 Hz, 1H), 7.31 (s, 1H), 5.99 (s,
    1H), 4.04-4.29 (m, 2H), 3.94 (br d, J = 12.2
    Hz, 2H), 3.73-3.86 (m, 1H), 3.24 (dt, J = 12.6,
    6.1 Hz, 2H), 2.57-2.75 (m, 1H), 2.33-2.56 (m, 1H),
    1.43 (br t, J = 6.9 Hz, 3H) 3Hs not observed
    (2 NHs 1 OH)
    318 MS m/z 352.4 [M + H]+; 1H NMR (methanol-d4) δ:
    8.59 (br s, 2H), 7.70 (br d, J = 7.9 Hz, 1H),
    7.34 (br d, J = 8.2 Hz, 1H), 7.32 (br s, 1H),
    5.91-6.08 (m, 1H), 4.14-4.33 (m, 2H), 4.05-3.90
    (m, 2H), 3.72-3.83 (m, 1H), 3.04 (s, 3H), 3.04 (s,
    3H), 2.71 (br d, J = 6.1 Hz, 1H), 2.41-2.62
    (m, 1H); 2Hs not observed (NH and OH)
    322 MS m/z 412.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.02 (s, 1H), 8.00 (br s, 2H), 7.78 (br d, J =
    7.9 Hz, 1H), 7.20 (br d, J = 8.2 Hz, 1H),
    7.18 (s, 1H), 4.65-4.80 (m, 1H), 4.45-4.60 (m,
    1H), 1.78 (br d, J = 8.5 Hz, 2H), 1.38 (br
    d, J = 6.7 Hz, 6H), 1.27 (s, 6H); 4Hs not
    observed (3NHs and OH)
    323 MS m/z 412.5 [M + H]+; 1H NMR (methanol-d4) δ:
    9.05 (s, 1H), 8.01 (br s, 2H), 7.81 (br d, J =
    7.9 Hz, 1H), 7.22 (br d, J = 8.2 Hz, 1H), 7.20
    (s, 1H), 4.66-4.80 (m, 1H), 4.43-4.61 (m, 1H),
    1.78 (br d, J = 8.5 Hz, 2H), 1.38 (br d, J =
    7.0 Hz, 6H), 1.27 (s, 6H); 4Hs not observed (3NHs
    and OH)
    325 MS m/z 394.4 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.13 (s, 1H), 8.08 (br s, 2H), 7.86 (d, J =
    7.9 Hz, 1H), 7.31-7.16 (m, 2H), 4.84-4.70 (m,
    2H), 4.48 (d, J = 6.9 Hz, 2H), 4.18-4.04 (m,
    1H), 4.04-3.90 (m, 1H), 3.90-3.79 (m, 1H), 3.79-
    3.69 (m, 1H), 3.69-3.56 (m, 1H), 2.46-2.36 (m,
    1H), 2.23-2.09 (m, 1H), 1.73 (s, 3H); 3Hs not
    observed (2 NH and OH)
    327 MS m/z 364.2 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.08-9.24 (m, 2H), 8.94 (br s, 1H), 8.12 (s, 2H),
    7.84 (d, J = 7.9 Hz, 1H), 7.19-7.28 (m, 2H),
    3.56-3.80 (m, 4H), 3.20-3.29 (m, 1H), 3.00-3.13
    (m, 3H), 2.67-2.78 (m, 1H), 2.57-2.67 (m, 1H),
    1.91-2.04 (m, 1H), 1.68-1.81 (m, 1H); 1H not
    observed (OH or NH)
    328 MS m/z 324.2 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.13 (s, 1H), 8.24 (s, 2H), 7.87 (br d, J = 7.8
    Hz, 2H), 7.34-7.19 (m, 2H), 4.11 (br s, 4H), 3.22
    (br s, 4H); 3Hs not observed (2 NHs and OH)
    329 MS m/z 384.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.17 (s, 1H), 8.20 (br s, 2H), 7.84 (d, J = 7.3
    Hz, 1H), 7.26 (br s, 2H), 4.97-4.57 (m, 3H), 4.22-
    3.81 (m, 5H), 3.80-3.54 (m, 2H), 1.37 (br s, 3H);
    3Hs was not observed (2 NHs and OH)
    332 MS m/z 350.4 [M + H]+; 1H NMR (methanol-d4) δ:
    8.48 (s, 2H), 7.70 (br d, J = 8.5 Hz, 1H),
    7.33 (br d, J = 8.2 Hz, 1H), 7.30 (s, 1H),
    6.00 (s, 1H), 3.93-4.05 (m, 1H), 3.82-3.92 (m,
    1H), 3.48-3.62 (m, 2H), 3.39-3.48 (m, 1H),
    2.46-2.68 (m, 3H), 2.27-2.45 (m, 2H); 3Hs
    not observed (2 NHs and OH)
    333 MS m/z 368.5 [M + H]+; 1H NMR (methanol-d4) δ:
    8.47 (s, 2H), 7.68 (br d, J = 8.7 Hz, 1H), 7.33 (br d,
    J = 8.4 Hz, 1H), 7.30 (s, 1H), 5.99 (s, 1H), 4.20-
    4.33 (m, 1H), 4.19-4.09 (m, 2H), 3.91 (br s, 5H), 3.75-
    3.85 (m, 1H), 3.37 (s, 1H), 2.60-2.76 (m, 1H), 2.38-
    2.57 (m, 1H); 3Hs not observed (2 NHs and OH)
    334 MS m/z 366.3 [M + H]+; 1H NMR (DMSO-d6) δ:
    13.00 (br s, 1H), 11.43 (br s, 1H), 9.09 (s, 1H), 8.23 (br s,
    1H), 7.95 (br s, 1H), 7.85 (d, J = 7.3 Hz, 1H), 7.20-
    7.24 (m, 2H), 4.80-4.88 (m, 1H), 4.40-4.52 (m, 3H), 3.82-
    4.01 (m, 2H), 3.49-3.73 (m, 3H); 2Hs not observed (OH
    and/or NH)
    335 MS m/z 408.4 [M + H]+
    336 MS m/z 396.4 [M + H]+; 1H NMR (methanol-d4) δ:
    8.63 (br s, 2H), 7.70 (br s, 1H), 7.33 (br s, 2H), 5.99 (br s, 1H),
    4.36 (br s, 1H), 4.15 (br s, 1H), 4.05-3.87 (m, 2H), 3.79 (m,
    2H), 3.63-3.56 (m, 2H), 3.48 (br s, 3H), 2.78-2.33 (m, 2H),
    1.47 (br s, 3H); 3Hs was observed (2NHs and OH)
    337 MS m/z 350.3 [M + H]+; 1H NMR (methanol-d4) δ:
    8.81 (s, 2H), 7.72 (d, J = 7.93 Hz, 1H), 7.40-7.35 (m, 2H),
    5.98 (s, 1H), 3.98 (br s, 2H), 3.79-3.77 (m, 2H), 3.71-3.61
    (m, 2H), 3.49-3.40 (m, 4H); 3Hs not observed (2 NHs and
    OH)
    339 MS m/z 364.2 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.79 (br s, 1H), 9.68 (br s, 1H), 9.13 (s, 1H), 8.10 (s, 2H), 7.86
    (d, J = 8.5 Hz, 1H), 7.19-7.27 (m, 2H), 4.11-4.24 (m, 1H),
    3.78-3.85 (m, 1H), 3.66-3.69 (m, 1H), 3.28-3.33 (m, 2H), 2.55-
    2.61 (m, 1H), 2.25-2.39 (m, 2H), 1.96-2.17 (m, 4H); 1H not
    observed (OH or NH)
    340 MS m/z 378.4 [M + H]+; 1H NMR (methanol-d4) δ:
    8.65 (s, 2H), 7.68 (d, J = 8.1 Hz, 1H), 7.42-7.24 (m, 2H),
    6.04-5.91 (m, 1H), 4.50-4.36 (m, 1H), 4.22-4.11 (m, 1H),
    4.04-3.88 (m, 2H), 3.84-3.71 (m, 1H), 2.73-2.60 (m, 1H),
    2.60-2.42 (m, 1H), 1.58 (d, J = 2.9 Hz, 3H), 1.31 (br s,
    2H), 0.90 (br d, J = 4.0 Hz, 2H); 3Hs not observed (2
    NHs and OH)
    341 MS m/z 410.5 [M + H]+; 1H NMR (methanol-d4) δ:
    8.69 (s, 2H), 7.71 (d, J = 8.1 Hz, 1H), 7.42-7.30 (m,
    2H), 5.99 (s, 1H), 4.45-4.27 (m, 1H), 4.21-4.03 (m, 1H),
    4.02-3.87 (m, 2H), 3.85-3.73 (m, 1H), 3.62-3.47 (m,
    5H), 2.73-2.59 (m, 1H), 2.56-2.40 (m, 1H), 1.57-1.43
    (m, 6H); 3Hs not observed (2 NHs and OH)
    345 MS m/z 356.3 [M + H]+; 1H NMR (methanol-d4) δ:
    8.60 (br s, 2H), 7.80-7.51 (m, 1H), 7.45-7.16 (m, 2H),
    6.12-5.81 (m, 1H), 5.38-5.12 (m, 1H), 4.52-4.22 (m, 1H),
    3.93-3.71 (m, 1H), 3.67-3.41 (m, 3H), 2.45-2.10 (m, 2H);
    4Hs not observed (3 NHs and OH)
    346 MS m/z 368.3 [M + H]+; 1H NMR (methanol-d4) δ:
    8.55 (s, 2H), 7.63-7.55 (m, 1H), 7.30-7.15 (m, 2H), 5.89 (s,
    1H), 4.38 (br s, 1H), 4.11-3.90 (m, 4H), 3.70-3.59 (m, 1H),
    3.42 (d, J = 2.4 Hz, 3H), 2.78 (d, J = 3.8 Hz, 3H);
    3Hs not observed (2 NHs and OH)
    347 MS m/z 366.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.05 (s, 1H), 7.99 (br s, 2H), 7.80 (d, J = 8.0 Hz, 1H),
    7.20 (dd, J = 8.0, 2.0 Hz, 1H), 7.17 (d, J = 1.5
    Hz, 1H), 3.99 (dd, J = 11.5, 6.5 Hz, 1H), 3.89-3.85
    (m, 1H), 3.79-3.73 (m, 1H), 3.68-3.62 (m, 1H), 3.47 (dd,
    J = 11.5, 6.5 Hz, 1H), 3.10 (dt, J = 12.5, 6.0
    Hz, 1H), 2.39 (dq, J = 12.0, 6.0 Hz, 1H), 2.03-1.97
    (m, 1H), 1.20 (t, J = 5.5 Hz, 6H); 3Hs not observed
    (2 NHs and OH)
    348 MS m/z 366.3 [M + H]+; 1H NMR (methanol-d4) δ:
    9.05 (s, 1H), 7.99 (br s, 2H), 7.80 (d, J = 8.0 Hz, 1H),
    7.20 (dd, J = 8.0, 2.0 Hz, 1H), 7.17 (d, J = 1.5
    Hz, 1H), 3.99 (dd, J = 11.5, 6.5 Hz, 1H), 3.89-3.85
    (m, 1H), 3.79-3.73 (m, 1H), 3.68-3.62 (m, 1H), 3.47 (dd,
    J = 11.5, 6.5 Hz, 1H), 3.10 (dt, J = 12.5, 6.0
    Hz, 1H), 2.39 (dq, J = 12.0, 6.0 Hz, 1H), 2.03-1.97
    (m, 1H), 1.20 (t, J = 5.5 Hz, 6H); 3Hs not observed
    (2 NHs and OH)
    349 MS m/z 390.4 [M + H]+; 1H NMR (DMSO-d6) δ:
    11.20-11.34 (m, 1H), 9.50-9.59 (m, 1H), 9.13 (s, 1H),
    8.07-8.12 (m, 1H), 7.86 (d, J = 8.1 Hz, 1H), 7.24
    (dd, J = 8.1, 1.7 Hz, 1H), 7.21 (d, J = 1.5 Hz,
    1H), 4.03-4.08 (m, 1H), 3.95-4.00 (m, 1H), 3.78-3.84 (m,
    2H), 3.66-3.75 (m, 3H), 2.74 (s, 1H), 2.11-2.15 (m, 6H);
    2Hs not observed (2 NHs)
    353 MS m/z 380.6 [M + H]+; 1H NMR (methanol-d4) δ:
    8.64 (s, 2H), 7.70 (d, J = 8.1 Hz, 1H), 7.40-7.29
    (m, 2H), 5.97 (d, J = 10.1 Hz, 1H), 4.12-4.04 (m,
    2H), 4.02-3.95 (m, 1H), 3.94-3.70 (m, 3H), 3.59-3.44
    (m, 2H), 2.68-2.53 (m, 1H), 2.37-2.20 (m, 1H); 2Hs
    not observed (overlapped with residual solvent peak);
    3Hs not observed (2 NHs and OH)
    354 MS m/z 364.5 [M + H]+; 1H NMR (methanol-d4) δ:
    8.59 (br s, 2H), 7.68 (d, J = 8.2 Hz, 1H), 7.40-
    7.26 (m, 2H), 6.01-5.94 (m, 1H), 3.88-3.67 (m, 4H),
    3.59-3.43 (m, 4H), 2.41-2.10 (m, 4H); 3Hs not
    observed (2 NHs and OH)
    355 MS m/z 380.5 [M + H]+; 1H NMR (methanol-d4) δ:
    8.25 (br s, 2H), 7.63 (d, J = 8.0 Hz, 1H), 7.28 (dd,
    J = 8.5, 1.5 Hz, 1H), 7.24 (d, J = 1.5 Hz, 1H),
    5.96 (d, J = 3.0 Hz, 1H), 4.38-4.28 (m, 1H), 4.18-
    4.12 (m, 1H), 3.96-3.87 (m, 2H), 3.80-3.70 (m, 1H), 2.72-
    2.64 (m, 1H), 2.49-2.37 (m, 1H), 1.51 (s, 9H); 3Hs not
    observed (2NHs and OH)
    356 MS m/z 380.5 [M + H]+; 1H NMR (methanol-d4) δ:
    8.25-8.16 (m, 2H), 7.65 (d, J = 8.3 Hz, 1H), 7.29
    (d, J = 8.5 Hz, 1H), 7.25 (s, 1H), 5.98 (d, J =
    2.6 Hz, 1H), 4.40-4.29 (m, 1H), 4.20-4.13 (m, 1H), 3.96-
    3.87 (m, 2H), 3.80-3.71 (m, 1H), 2.76-2.64 (m, 1H), 2.49-
    2.37 (m, 1H), 1.53 (s, 9H); 3Hs not observed (2 NHs and
    OH)
    357 MS m/z 392.5 [M + H]+; 1H NMR (methanol-d4) δ:
    9.12 (s, 1H), 7.90-8.17 (m, 2H), 7.80 (d, J = 8.2 Hz,
    1H), 7.21 (s, 2H), 4.09-4.16 (m, 1H), 4.02-4.09 (m, 1H),
    3.89-4.00 (m, 1H), 3.74-3.83 (m, 2H), 3.59-3.70 (m, 1H),
    2.46-2.65 (m, 1H), 2.13-2.32 (m, 3H), 1.80-1.92 (m, 2H),
    1.58-1.78 (m, 4H); 3Hs not observed (2NHs and OH)
    361 MS m/z 380.6 [M + H]+; 1H NMR (methanol-d4) δ:
    8.62 (br s, 2H), 7.68 (d, J = 7.9 Hz, 1H), 7.42-7.28
    (m, 2H), 5.95 (d, J = 7.2 Hz, 1H), 4.02-3.89 (m,
    1H), 3.88-3.78 (m, 1H), 3.77-3.64 (m, 1H), 3.51-3.44
    (m, 1H), 3.30-3.17 (m, 2H), 2.89 (br s, 1H), 2.44 (br s,
    1H), 2.14-1.94 (m, 1H), 1.50-1.38 (m, 7H); 3Hs not
    observed (2NHs and OH)
    362 MS m/z 422.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.13 (s, 1H), 8.05 (d, J = 9.6 Hz, 2H), 7.30-7.16
    (m, 2H), 5.96 (s, 1H), 4.47-4.29 (m, 1H), 4.27-4.09
    (m, 1H), 4.04-3.98 (m, 2H), 3.83-3.69 (m, 2H), 3.65
    (br t, J = 11.6 Hz, 3H), 2.75-2.58 (m, 1H), 2.51-
    2.25 (m, 1H), 2.07-1.95 (m, 2H), 1.94-1.82 (m, 2H),
    1.64 (br s, 3H); 3Hs not observed (2 NHs and OH)
    367 MS m/z 397.5 [M + H]+; 1H NMR (methanol-d4) δ:
    8.11 (s, 1H), 7.95 (s, 1H), 7.62 (d, J = 8.2 Hz, 1H),
    7.22 (d, J = 7.9 Hz, 1H), 7.19 (s, 1H), 5.97 (d,
    J = 2.1 Hz, 1H), 4.28-4.42 (m, 1H), 4.09-4.22
    (m, 1H), 3.84-3.99 (m, 2H), 3.69-3.82 (m, 1H), 2.62-
    2.77 (m, 1H), 2.36-2.51 (m, 1H), 1.52 (s, 9H); 2Hs
    not observed (NH and OH)
    373 MS m/z 411.5 [M + H]+; 1H NMR
    (methanol-d4) δ: 8.14 (s, 1H), 7.99 (s, 1H), 7.62 (d,
    J = 8.5 Hz, 1H), 7.23 (dd, J = 8.2, 1.5 Hz,
    1H), 7.19 (d, J = 1.5 Hz, 1H), 5.92-6.03 (m, 1H),
    4.23-4.43 (m, 1H), 2.20-2.33 (m, 2H), 1.68-1.87 (m,
    2H), 1.63 (d, J = 8.9 Hz, 6H), 1.55 (d, J =
    6.4 Hz, 6H); 3Hs not observed (2 NHs and OH)
    369 MS m/z 378.4 [M + H]+; 1H NMR (methanol-d4) δ:
    8.63 (s, 2H), 7.69 (d, J = 7.8 Hz, 1H), 7.41-7.27
    (m, 2H), 5.96 (d, J = 6.4 Hz, 1H), 3.80 (br s,
    3H), 3.32-3.19 (m, 4H), 2.36-2.08 (m, 2H), 2.02-
    1.76 (m, 5H); 3Hs not observed (2 NHs and OH)
    370 MS m/z 350.3 [M + H]+; 1H NMR (methanol-d4) δ:
    8.54 (s, 2H), 7.69 (d, J = 8.2 Hz, 1H), 7.37-
    7.26 (m, 2H), 5.99 (d, J = 9.0 Hz, 1H), 4.63-
    4.50 (m, 1H), 4.26-4.16 (m, 1H), 4.10 (dd, J =
    6.3, 12.4 Hz, 1H), 4.06-.98 (m, 1H), 3.67-3.54 (m,
    2H), 3.54-3.43 (m, 2H), 2.48-2.36 (m, 1H), 2.22-2.12
    (m, 1H); 3Hs not observed (2 NHs and OH)
    371 MS m/z 382.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.15 (s, 1H), 8.15 (br s, 2H), 7.85 (d, J = 8.2
    Hz, 1H), 7.29-7.20 (m, 2H), 3.98 (br s, 2H), 3.94-
    3.84 (m, 2H), 3.72-3.61 (m, 1H), 3.52 (br t,
    J = 5.7 Hz, 2H), 3.11-2.98 (m, 2H), 2.45-
    2.35 (m, 2H), 1.92-1.80 (m, 2H); 4Hs not
    observed (2 NHs and 2 OHs)
    372 MS m/z 422.5 [M + H]+; 1H NMR (methanol-d4) δ:
    8.95 (s, 1H), 7.99 (br s, 2H), 7.72 (d, J = 8.2 Hz,
    1H), 7.18-7.08 (m, 2H), 4.09-4.02 (m, 2H), 3.94-3.86
    (m, 1H), 3.82-3.74 (m, 1H), 3.58-3.44 (m, 3H), 3.30-
    3.23 (m, 1H), 3.21-3.14 (m, 2H), 2.75-2.64 (m, 1H),
    2.37-2.25 (m, 1H), 2.11-2.01 (m, 2H), 1.91-1.79
    (m, 1H), 1.76-1.64 (m, 2H); 1H not observed
    (overlapped with solvent peak); 3Hs not observed (2
    NHs and OH)
    377 MS m/z 429.5 [M + H]+; 1H NMR (methanol-d4) δ:
    8.15 (s, 1H), 8.00 (s, 1H), 7.62 (d, J = 8.5 Hz, 1H),
    7.23 (dd, J = 8.2, 1.2 Hz, 1H), 7.20 (s, 1H), 6.01 (d,
    J = 10.1 Hz, 1H), 4.62-4.82 (m, 1H), 1.97-2.27 (m,
    3H), 1.65-1.72 (m, 6H), 1.55-1.63 (m, 6H); 3Hs not
    observed (2 NHs and OH)
    386 MS m/z 406.5 [M + H]+; 1H NMR (methanol-d4) δ:
    8.66 (s, 2H), 7.69 (d, J = 7.9 Hz, 1H), 7.42-7.29
    (m, 2H), 6.02-5.89 (m, 1H), 4.04-3.88 (m, 1H), 3.87-
    3.76 (m, 1H), 3.74-3.59 (m, 2H), 3.51-3.42 (m, 1H),
    3.31-3.20 (m, 2H), 3.00-2.81 (m, 1H), 2.53-2.37
    (m, 1H), 2.25-2.14 (m, 2H), 2.12-1.97 (m, 1H),
    1.89 (br s, 2H), 1.83-1.75 (m, 2H), 1.71 (br s, 2H);
    3Hs not observed (2 NHs and OH)
    387 MS m/z 378.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.17 (s, 1H), 8.19-8.09 (m, 2H), 7.80 (br d, J =
    5.6 Hz, 1H), 7.25 (br s, 2H), 3.93-3.74 (m, 1H), 3.65-
    3.51 (m, 1H), 3.51-3.32 (m, 2H), 3.28-3.08 (m, 2H),
    2.38-2.27 (m, 1H), 2.25-2.09 (m, 2H), 2.05-1.93
    (m, 2H), 1.93-1.78 (m, 2H), 1.73-1.56 (m, 1H);
    3Hs not observed (2 NHs and OH)
    388 MS m/z 429.4 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.10 (s, 1H), 8.68 (s, 1H), 8.09 (s, 2H), 7.99-7.79 (m,
    2H), 7.62-7.39 (m, 2H), 7.31-7.14 (m, 2H), 4.40 (br s,
    2H), 3.98-3.87 (m, 1H), 3.80-3.75 (m, 1H), 3.66-3.52
    (m, 1H), 3.51-3.38 (m, 1H), 3.19 (br s, 2H), 2.87-
    2.72 (m, 1H), 2.31-2.20 (m, 1H), 1.95-1.81 (m, 1H);
    3Hs not observed (2 NHs and OH)
    389 MS m/z 352.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.08 (s, 1H), 8.02 (s, 1H), 7.86 (s, 1H), 7.82 (d, J =
    8.00 Hz, 1H), 7.19 (d, J = 8.00 Hz, 1H), 7.16 (s,
    1H), 3.96 (s, 3H), 3.92-3.81 (m, 2H), 3.75 (d, J =
    11.00 Hz, 1H), 3.62 (d, J = 11.00 Hz, 1H), 2.16
    (s, 2H), 1.49 (s, 3H); 3Hs not observed (2 NHs and OH)
    390 MS m/z 394.5 [M + H]+; 1H NMR (methanol-d4) δ:
    8.68 (s, 2H), 7.69 (d, J = 7.9 Hz, 1H), 7.40-7.29
    (m, 2H), 5.96 (d, J = 7.8 Hz, 1H), 4.06-3.91 (m,
    1H), 3.90-3.78 (m, 1H), 3.77-3.64 (m, 1H), 3.61-3.44
    (m, 1H), 3.31-3.17 (m, 2H), 2.96-2.80 (m, 1H), 2.54-
    2.41 (m, 1H), 2.16-1.97 (m, 1H), 1.53-1.43 (s, 9H); 3Hs
    not observed (2 NHs and OH)
    391 MS m/z 436.6 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.11 (s, 1H), 8.50-8.64 (m, 1H), 8.46 (br dd, J = 3.7,
    1.8 Hz, 1H), 8.03-8.23 (m, 2H), 7.86 (br d, J = 8.4
    Hz, 2H), 7.19-7.28 (m, 2H), 3.88-4.02 (m, 2H), 3.85 (br
    dd, J = 10.5, 2.0 Hz, 2H), 3.71-3.82 (m, 2H), 3.56-
    3.70 (m, 2H), 3.42-3.52 (m, 3H), 3.04-3.25 (m, 3H), 2.60-
    2.75 (m, 1H), 2.16-2.37 (m, 2H), 1.77-1.94 (m, 3H),
    1.57-1.77 (m, 3H), 1.42 (s, 3H)
    392 MS m/z 378.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    11.48 (br s, 1H), 9.09 (s, 1H), 8.15 (s, 1H), 7.99-8.12
    (m, 1H), 7.85 (br d, J = 8.2 Hz, 1H), 7.17-7.26
    (m, 2H), 3.77-3.91 (m, 1H), 3.66-3.77 (m, 1H), 3.50-
    3.62 (m, 1H), 2.77-2.93 (m, 2H), 2.26-2.35 (m, 1H),
    2.08-2.25 (m, 1H), 1.80 (br d, J = 9.6 Hz, 1H),
    0.51 (br d, J = 5.6 Hz, 2H), 0.44 (br s, 2H); 4H
    not observed (2NHs, 2 aliphatic CHs obscured by
    solvent peak)
    395 MS m/z 408.5 [M + H]+; 1H NMR (methanol-d4) δ:
    8.41 (s, 2H), 7.66 (d, J = 8.2 Hz, 1H), 7.24-
    7.36 (m, 2H), 5.95 (d, J = 6.7 Hz, 1H), 4.05-
    4.15 (m, 2H), 3.90-4.01 (m, 2H), 3.87-3.89 (m, 1H),
    3.74-3.86 (m, 2H), 3.65-3.71 (m, 1H), 3.41-3.52 (m,
    2H), 2.82-2.92 (m, 1H), 2.40-2.50 (m, 2H), 2.16 (br s,
    1H), 2.00-2.17 (m, 2H); 3Hs not observed (OH and
    2NHs)
    397 MS m/z 422.4 [M + H]+; 1H NMR (methanol-d4) δ:
    9.07 (s, 1H), 8.01 (br d, J = 0.9 Hz, 2H), 7.83
    (br d, J = 7.3 Hz, 1H), 7.23 (br d, J = 8.2
    Hz, 1H), 7.20 (s, 1H), 3.92-4.05 (m, 3H), 3.82-3.90
    (m, 1H), 3.59-3.69 (m, 1H), 3.45 (br t, J = 11.7
    Hz, 2H), 2.83 (br d, J = 7.0 Hz, 3H), 2.53-2.64
    (m, 1H), 2.26-2.35 (m, 1H), 1.93 (br d, J = 12.8
    Hz, 2H), 1.80-1.88 (m, 1H), 1.42-1.54 (m, 2H), 1.28-
    1.38 (m, 1H); 3Hs not observed (2NHs and OH)
    398 MS m/z 422.4 [M + H]+; 1H NMR (1:3 chloroform-d:
    methanol-d4) δ: 9.04 (s, 1H), 7.94 (br s, 2H), 7.78
    (br d, J = 7.9 Hz, 1H), 7.15-7.23 (m, 2H), 4.03
    (br d, J = 11.0 Hz, 2H), 3.98 (br dd, J = 9.8,
    8.9 Hz, 1H), 3.84-3.92 (m, 1H), 3.62-3.71 (m, 1H), 3.46
    (br t, J = 11.6 Hz, 2H), 3.35-3.40 (m, 1H), 2.89-
    3.14 (m, 3H), 2.59-2.72 (m, 1H), 2.28-2.38 (m, 1H),
    1.98 (br d, J = 11.9 Hz, 2H), 1.82-1.93 (m, 1H),
    1.51-1.64 (m, 2H); 3Hs not observed (2 NHs and OH)
    399 MS m/z 378.5 [M + H]+; 1H NMR (methanol-d4) δ:
    1.94-2.09 (m, 2H) 2.28-2.52 (m, 4H) 2.54-2.69
    (m, 1H) 3.37 (s, 1H), 3.71-4.02 (m, 4H) 4.03-4.18
    (m, 2H) 5.98 (br s, 1H) 7.20-7.42 (m, 2H) 7.67 (br
    d, J = 8.24 Hz, 1H) 8.41 (br s, 2H); 3Hs not
    observed (2NHs and OH)
    400 MS m/z 378.5 [M + H]+; 1H NMR (methanol-d4) δ:
    1.91-2.09 (m, 2H) 2.28-2.50 (m, 5H) 2.52-2.71
    (m, 1H) 3.37 (s, 2H) 3.68-4.01 (m, 4H) 4.03-4.19
    (m, 2H) 5.93-6.03 (m, 1H) 7.31 (s, 1H) 7.32-7.37
    (m, 1H) 7.69 (br d, J = 7.93 Hz, 1H) 8.55 (s, 2H);
    1H not observed
    403 MS m/z 440.7 [M + H]+; 1H NMR (methanol-d4) δ:
    8.41 (s, 2H), 7.67 (d, J = 7.9 Hz, 1H), 7.25-7.34
    (m, 2H), 5.95 (d, J = 7.3 Hz, 1H), 5.11-5.13 (m,
    1H), 5.02-5.04 (m, 1H), 4.22 (t, J = 13.4 Hz,
    1H), 4.09 (d, J = 10.4 Hz, 1H), 3.95-4.01 (m,
    1H), 3.70-3.85 (m, 4H), 3.47-3.64 (m, 3H), 2.90-2.94
    (m, 1H), 2.46-2.50 (m, 1H), 1.97-2.20 (m, 3H); 3Hs
    not observed (OH and 2NHs)
    404 MS m/z 422.6 [M + H]+; 1H NMR (methanol-d4) δ:
    8.40 (s, 2H), 7.66 (d, J = 7.9 Hz, 1H), 7.25-7.35
    (m, 2H), 5.95 (d, J = 6.4 Hz, 1H), 3.90-4.05 (m,
    2H), 3.74-3.87 (m, 3H), 3.68-3.72 (m, 2H), 3.47-3.52
    (m, 2H), 3.35-3.37 (m, 2H), 2.88-2.94 (m, 1H), 2.44-
    2.48 (m, 1H), 2.19-2.22 (m, 1H), 1.92-2.10 (m, 3H),
    1.68-1.72 (m, 1H); 3Hs not observed (OH and 2NHs)
    405 MS m/z 448.7 [M + H]+; 1H NMR (methanol-d4) δ:
    8.42 (br s, 2H), 7.67 (d, J = 8.5 Hz, 1H), 7.26-
    7.36 (m, 2H), 5.95 (d, J = 6.7 Hz, 1H), 4.50-
    4.52 (m, 2H), 3.92-3.96 (m, 1H), 3.79-3.83 (m, 1H),
    3.66-3.72 (m, 1H), 3.47-3.52 (m, 2H), 3.15-3.28 (m,
    2H), 2.85-2.89 (m, 1H), 2.65-2.72 (m, 2H), 2.40-2.46
    (m, 1H), 2.00-2.10 (m, 2H), 1.82 (d, J = 7.3 Hz,
    2H), 1.45-1.62 (m, 2H), 1.26-1.31 (m, 1H); 3Hs not
    observed (OH and 2NHs)
    406 MS m/z 392.4 [M + H]+; 1H NMR (methanol-d4) δ:
    1.97-2.07 (m, 2H) 2.29-2.52 (m, 5H) 2.53-2.69
    (m, 1H) 3.71-4.02 (m, 4H) 4.08 (br s, 5H) 5.97 (br s,
    1H) 7.24 (br s, 1H) 7.26 (br d, J = 8.24 Hz, 1H)
    7.66 (br d, J = 8.24 Hz, 1H) 8.17-8.53 (m, 2H);
    3Hs not observed (2NHs and OH)
    407 MS m/z 392.4 [M + H]+; 1H NMR (methanol-d4) δ:
    1.89-2.08 (m, 2H) 2.23-2.51 (m, 5H) 2.60 (br d, J =
    5.80 Hz, 1H) 3.69-4.00 (m, 4H) 4.01-4.20 (m, 5H)
    5.97 (br s, 1H) 7.22 (s, 1H) 7.25 (br d, J = 7.93 Hz, 1H)
    7.65 (br d, J = 7.93 Hz, 1H) 8.17 (s, 1H) 8.29
    (s, 1H); 3Hs not observed (2 NHs and OH)
    408 MS m/z 420.6 [M + H]+; 1H NMR (methanol-d4) δ:
    9.10 (s, 1H), 8.02 (s, 1H), 7.86 (s, 1H), 7.83 (d,
    J = 8.54 Hz, 1H), 7.21 (d, J = 8.09 Hz,
    1H), 7.17 (s, 1H), 3.38-3.28 (m, 1H), 3.96 (s, 3H),
    3.20 (s, 3H), 2.36-2.30 (m, 2H), 2.14-1.99 (m, 6H),
    1.57 (s, 6H); 2Hs not observed (NH and OH)
    409 MS m/z 428.4 [M + H]+; 1H NMR (methanol-d4) δ:
    8.47 (br s, 2H), 7.69 (br d, J = 8.2 Hz, 1H), 7.33
    (br d, J = 8.2 Hz, 1H), 7.30 (s, 1H), 5.99 (s, 1H),
    4.20-4.30 (m, 1H), 4.07-4.19 (m, 1H), 3.86-4.07 (m,
    3H), 3.75-3.86 (m, 1H), 2.75-2.88 (m, 1H), 2.60-2.74
    (m, 1H), 2.32-2.56 (m, 4H), 2.15-2.30 (m, 1H), 2.02-
    2.12 (m, 1H); 3Hs not observed (2NHs and OH)
    410 MS m/z 366.5 [M + H]+; 1H NMR (methanol-d4) δ:
    8.42 (s, 2H), 7.66 (d, J = 7.8 Hz, 1H), 7.35-
    7.25 (m, 2H), 5.95 (d, J = 9.0 Hz, 1H), 4.07-
    3.92 (m, 1H), 3.89-3.76 (m, 1H), 3.74-3.61 (m,
    1H), 3.56-3.46 (m, 1H), 3.45-3.38 (m, 2H), 3.00
    (br s, 7H), 2.51-2.39 (m, 1H), 2.12-1.92 (m, 1H);
    2Hs not observed (NH and OH)
    413 MS m/z 352.4 [M + H]+; 1H NMR (methanol-d4) δ:
    8.46 (s, 2H), 7.71-7.62 (m, 1H), 7.36-7.26 (m, 2H),
    5.99-5.89 (m, 1H), 4.00-3.88 (m, 1H), 3.81 (br s, 1H),
    3.74-3.63 (m, 1H), 3.56-3.47 (m, 1H), 3.28-3.25 (m,
    2H), 2.95-2.84 (m, 1H), 2.84-2.77 (m, 3H), 2.43 (m,
    1H), 2.13-1.93 (m, 1H); 3Hs not observed (2NHs and
    OH)
    414 MS m/z 394.5 [M + H]+; 1H NMR (methanol-d4) δ:
    8.51 (s, 2H), 7.67 (d, J = 7.8 Hz, 1H), 7.40-7.25
    (m, 2H), 6.01-5.87 (m, 1H), 3.99-3.79 (m, 1H), 3.74-
    3.57 (m, 3H), 2.94-2.79 (m, 1H), 2.59-2.27 (m, 1H),
    2.16-1.99 (m, 1H), 1.52-1.35 (m, 11H); 3Hs not
    observed (2NHs and OH)
    415 MS m/z 392.4 [M + H]+; 1H NMR (methanol-d4) δ:
    1.89-2.08 (m, 2H) 2.23-2.51 (m, 5H) 2.60 (br d,
    J = 5.80 Hz, 1H) 3.69-4.00 (m, 4H) 4.01-
    4.20 (m, 5H) 5.97 (br s, 1H) 7.22 (s, 1H) 7.25 (br d,
    J = 7.93 Hz, 1H) 7.65 (br d, J = 7.93 Hz,
    1H) 8.17 (s, 1H) 8.29 (s, 1H); 3Hs not observed (2NHs
    and OH)
    416 MS m/z 406.4 [M + H]+; 1H NMR (methanol-d4) δ:
    1.20 (t, J = 6.87 Hz, 2H) 1.89-2.13 (m, 2H)
    2.25-2.51 (m, 5H) 2.86 (br dd, J = 12.51, 6.10
    Hz, 1H) 3.04-3.22 (m, 2H), 3.51 (q, J = 6.82
    Hz, 2H) 3.69 (br d, J = 6.10 Hz, 1H) 3.75-3.98
    (m, 3H) 4.00-4.08 (m, 3 H) 5.94 (br d, J = 7.32
    Hz, 1H) 7.22 (s, 1H) 7.25 (br d, J = 8.24 Hz, 1H)
    7.63 (br d, J = 8.54 Hz, 1H) 8.16 (s, 1H) 8.28 (s, 1H)
    418 MS m/z 398.5 [M + H]+; 1H NMR (DMSO-d6) δ:
    9.13 (s, 1H), 8.14 (s, 2H), 7.69 (d, J = 7 Hz, 1H),
    7.33 (t, J = 7 Hz, 1H), 4.16 (m, 1H), 4.07 (m, 1H),
    3.75-3.90 (m, 2H), 3.64 (m, 1H), 2.35 (m, 1H), 1.38 (s,
    9H); 3Hs not observed (NH, OH, and one aliphatic
    multiplet peak obscured by solvent peak)
    420 MS m/z 410.4 [M + H]+; 1H NMR (methanol-d4) δ:
    8.81 (s, 2H), 7.69 (br d, J = 7.9 Hz, 1H), 7.30-7.42
    (m, 2H), 5.98 (s, 1H), 5.27-5.35 (m, 1H), 4.28 (br s, 1H),
    4.11-4.22 (m, 1H), 3.93-4.09 (m, 3H), 3.83 (br s, 1H),
    2.69 (br d, J = 1.2 Hz, 1H), 2.48-2.64 (m, 2H),
    2.43 (br s, 1H), 1.92-2.35 (m, 4H); 3Hs not observed
    (2 NHs and OH)
    421 MS m/z 448.3 [M + H]+; 1H NMR (methanol-d4) δ:
    8.72 (br s, 2H), 7.70 (br d, J = 7.9 Hz, 1H),
    7.32-7.39 (m, 2H), 5.90-6.04 (m, 1H), 4.06 (br d,
    J = 7.6 Hz, 4H), 3.77-3.88 (m, 1H), 3.65-3.75
    (m, 1H), 3.48-3.63 (m, 3H), 3.16-3.27 (m, 1H), 2.34
    (br d, J = 4.6 Hz, 1H), 2.21 (br d, J = 6.1
    Hz, 1H), 2.14 (br d, J = 11.9 Hz, 1H), 1.79 (br s,
    3H), 1.14 (br d, J = 6.1 Hz, 4H); 3Hs not
    observed (2 NHs and OH)
    422 MS m/z 394.5 [M + H]+; 1H NMR (methanol-d4) δ:
    9.14 (s, 1H), 8.02 (s, 1H), 7.86 (s, 1H), 7.84 (d, J =
    10.00 Hz, 1H), 7.21 (d, J = 10.00 Hz, 1H), 7.18
    (s, 1H), 4.06-3.89 (m, 3H), 3.96 (s, 3H), 3.86-3.74 (m,
    2H), 2.44-2.37 (m, 2H), 1.65 (s, 3H), 1.46 (t, J =
    5.50 Hz, 6H); 2Hs not observed (NH and OH)
    • Example 7 Preparation of Compound 14
  • Figure US20230331725A1-20231019-C00154
    • Step 1.
  • To a dry round bottom flask were added: 6-bromo-3-methylsulfanyl-1,2,4-triazine (7.0 g, 34.0 mmol), 2-[4-chloro-2-(methoxymethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (10 g, 33.5 mmol), K2CO3 (9.5 g, 68 mmol), and PddppfCl2 (3.8 g, 5.1 mmol). The mixture was degassed with argon for 10 min, then dioxane (100 mL) and water (20 mL) were added and the reaction was heated at 90° C. for 16 h (overnight). The reaction was cooled down to room temperature, partitioned between EtOAc and water, and then the organic phase was dried over Na2SO4, concentrated, and then purified by silica-gel column chromatography eluting with a gradient of 0-20% EtOAc in pentanes. This provided 6-[4-chloro-2-(methoxymethoxy)phenyl]-3-methylsulfanyl-1,2,4-triazine (4.5 g, 44% yield) as a yellow solid. MS m/z 298.1, 300.1 [M+H]+.
    • Step 2.
  • 6-[4-Chloro-2-(methoxymethoxy)phenyl]-3-methylsulfanyl-1,2,4-triazine (1.84 g, 6.18 mmol) and mCPBA (2.67 g, 15.5 mmol) were dissolved in CH2Cl2 (26 mL). The reaction mixture was stirred at room temperature for 16 h. LCMS showed full conversion. The solvent was then removed in vacuo and the crude product was triturated in 20 mL Et2O. Filtration provided 6-[4-chloro-2-(methoxymethoxy)phenyl]-3-methylsulfonyl-1,2,4-triazine (1.69 g, 80.4% yield) as an off-white solid. MS m/z 330.1, 332.1 [M+H]+.
    • Step 3.
  • 6-[4-Chloro-2-(methoxymethoxy)phenyl]-3-methylsulfonyl-1,2,4-triazine (1.0 g, 2.9 mmol) was dissolved in dry DMF (8 mL). Then N,2,2,6,6-pentamethylpiperidin-4-amine (790 mg, 4.41 mmol) and DIPEA (5.2 mL, 30 mmol) were added. The reaction mixture was stirred at 50° C. for 16 h (overnight). The reaction mixture was purified directly by silica-gel column chromatography using 20% MeOH/CH2Cl2 eluent to provide the desired product 6-[4-chloro-2-(methoxymethoxy)phenyl]-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidyl)-1,2,4-triazin-3-amine (980 mg, 79% yield) as a yellow solid. MS m/z 420.5, 422.5 [M+H]+.
    • Step 4.
  • To a dry screw-cap vial were added 6-[4-chloro-2-(methoxymethoxy)phenyl]-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidyl)-1,2,4-triazin-3-amine (30 mg, 0.071 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(trideuteriomethyl)pyrazole (18.1 mg, 0.086 mmol), XPhos Pd G4 (6 mg, 0.007 mmol), and K2CO3 (30 mg, 0.2143 mmol). The mixture was degassed with argon for 10 min, then dioxane (2 mL) and water (0.5 mL) were added and the reaction was heated at 90° C. for 16 h (overnight). The reaction was cooled to room temperature, partitioned between EtOAc and water, and the organic phase was dried over Na2SO4, concentrated, and purified by silica-gel column chromatography eluting with a MeOH/CH2Cl2 gradient (0-20% MeOH) to provide 6-[2-(methoxymethoxy)-4-[1-(trideuteriomethyl)pyrazol-4-yl]phenyl]-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidyl)-1,2,4-triazin-3-amine (24 mg, 72% yield) as a brownish solid. MS m/z 469.8 [M+H]+.
    • Step 5.
  • To a solution 6-[2-(methoxymethoxy)-4-[1-(trideuteriomethyl)pyrazol-4-yl]phenyl]-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidyl)-1,2,4-triazin-3-amine (24 mg, 0.051 mmol) in 1 mL of CH2O2 and a few drops of MeOH was added HCl (4 mol/L) in 1,4-dioxane (26H), 0.10 mmol) and the mixture was stirred 16 h at room temperature. UPLC showed complete consumption of the starting material. The solvents were evaporated and the residue was purified by silica-gel column chromatography eluting with a MeOH/CH2Clz gradient (0-30% MeOH/2.5% NH4OH) to provided 2-[3-[methyl-(2,2,6,6-tetramethyl-4-piperidyl) amino]-1,2,4-triazin-6-yl]-5-[1-(trideuteriomethyl)pyrazol-4-yl]phenol; hydrochloride (7 mg, 3000 yield) as a tan solid.
  • MS m/z 425.5 [M+H]; 1H NMR (methanol-d4) d: 9.58 (br s, 1H), 8.23 (s, 1H), 8.09 (s, 1H), 7.66 (d, J=18.2 Hz, 1H), 7.26 (dd, J=8.2, 1.8 Hz, 1H), 7.22 (d, J=1.8 Hz, 1H), 4.50-4.61 (m, 1H), 3.18 (s, 3H), 2.08-2.27 (m, 4H), 1.72 (s, 6H), 1.60 (s, 6H); 2Hs not observed (OH and NH).
  • Using the procedure described for Example 7, additional compounds described herein may be prepared by substituting the appropriate starting material, suitable reagents and reaction conditions, obtaining compounds such as those selected from:
  • Cpd Data
     72 MS m/z 413.5 [M + H]+; 1H NMR (methanol-d4) δ: 9.34 (s,
    1H), 8.00 (d, J = 2.0 Hz, 1H), 7.95 (d, J = 9.0 Hz, 1H), 7.27-
    7.28 (m, 2H), 5.72-5.76 (m, 1H), 2.43-2.45 (m, 2H), 1.76-1.88
    (m, 2H), 1.57 (s, 6H), 1.51 (s, 6H); 3Hs not observed (2NHs
    and OH)
    213 MS m/z 380.3 [M + H]+; 1H MMR (methanol-d4) δ: 9.14 (s,
    1H), 7.88 (d, J = 8.2 Hz, 1H), 7.64 (s, 1H), 7.32-7.52 (m, 2H),
    6.67 (s, 1H), 4.06-4.25 (m, 2H), 3.98-4.03 (m, 1H), 3.97 (s, 3H),
    3.71-3.91 (m, 1H), 3.43-3.61 (m, 1H), 2.58 (s, 1H), 2.21-2.33
    (m, 1H), 2.28 (td, J = 13.0, 6.3 Hz, 1H), 1.42 (br t, J = 5.2 Hz,
    6H); 2Hs not observed (NH and OH)
    223 MS m/z 442.4 [M + H]+; 1H MMR (methanol-d4) δ: 9.10 (s,
    1H), 8.07 (s, 1H), 8.03 (s, 1H), 7.90 (d, J = 8.00 Hz, 1H). 7.7 (d,
    J = 8.50 Hz, 1H), 7.64 (d, J = 9.00 Hz, 1H), 7.31 (d, J = 8.5 Hz,
    1H), 7.28 (s, 1H), 4.16 (s, 2H), 4.10 (s, 3H), 4.05 (s, 2H), 3.53
    (d, J = 12.5 Hz, 2H), 3.11 (t, J = 12.5 Hz, 2H), 2.91 (s, 3H),
    2.32 (d, J = 14.5 Hz, 2H), 2.05 (t, J = 12.50 Hz, 2H); 1H not
    observed (OH)
    233 MS m/z 392.5 [M + H]+; 1H MMR (methanol-d4) δ: 7.82 (s,
    1H), 7.66 (d, J = 8.3 Hz, 1H), 7.41 (d, J = 8.6 Hz, 1H), 7.39 (s,
    1H), 6.81 (s, 1H), 5.95 (s, 1H), 4.25 (s, 2H), 4.14 (s, 2H), 4.02
    (s, 3H), 3.53 (d, J = 12.6 Hz, 2H), 3.14 (t, J = 12.7 Hz, 2H),
    2.90 (s, 3H), 2.36 (d, J = 14.4 Hz, 2H), 2.13 (t, J = 13.8 Hz,
    2H); 1 OH not observed
    224 MS m/z 443.5 [M + H]+; 1H MMR (methanol-d4) δ: 9.11 (s,
    1H), 8.85 (s, 1H), 8.46 (s, 1H), 8.15 (s, 1H), 7.96 (d, J = 8.5 Hz,
    1H), 7.32 (d, J = 8.00 Hz, 1H), 7.30 (s, 1H), 4.10-4.16 (m, 5H),
    4.06 (s, 2H), 3.53 (d, J = 12.5 Hz, 2H), 3.12 (t, J = 10.00 Hz,
    2H), 2.92 (s, 3H), 2.33 (d, J = 14.00 Hz, 2H), 2.05 (t, J = 14.50
    Hz, 2H); 1H not observed (OH)
    235 MS m/z 384.4 [M + H]+; 1H MMR (methanol-d4) δ: 9.04 (s,
    1H), 7.95 (s, 1H), 7.81 (d, J = 6.7 Hz, 1H), 7.09-7.27 (m, 2H),
    3.96 (br dd, J = 9.8, 6.7 Hz, 1H), 3.76-3.91 (m, 1H), 3.51-3.71
    (m, 2H), 3.35-3.42 (m, 1H), 2.98 (dt, J = 12.5, 6.3 Hz, 1H),
    2.20-2.40 (m, 1H), 1.84-1.98 (m, 1H), 1.14 (t, J = 5.8 Hz, 6H);
    3Hs not observed (2NHs and OH)
    236 MS m/z 381.5 [M + H]+; 1H MMR (methanol-d4) δ: 8.06 (s,
    1H), 7.70 (d, J = 8.2 Hz, 1H), 7.38-7.55 (m, 2H), 6.00 (d, J =
    3.1 Hz, 1H), 4.26-4.37 (m, 1H), 4.24 (s, 3H), 4.08-4.19 (m, 1H),
    3.74-4.02 (m, 3H), 3.51-3.65 (m, 1H), 2.58-2.74 (m, 1H), 2.34-
    2.53 (m, 1H), 1.47 (d, J = 6.4 Hz, 6H); 2Hs not observed (NH
    and OH)
    237 MS m/z 384.3 [M + H]+; 1H MMR (methanol-d4) δ: 8.82 (s,
    1H), 7.82 (d, J = 7.9 Hz, 1H), 7.59-7.73 (m, 2H), 6.03 (d, J =
    3.1 Hz, 1H), 4.25-4.37 (m, 1H), 4.09-4.19 (m, 1H), 3.85-4.03
    (m, 2H), 3.75-3.84 (m, 1H), 3.51-3.65 (m, 1H), 2.58-2.74 (m,
    1H), 2.36-2.56 (m, 1H), 1.47 (br d, J = 5.8 Hz, 6H); 2Hs not
    observed (NH and OH)
    260 MS m/z 476.5 [M + H]+; 1H MMR (DMSO-d6) δ: 9.51 (br d,
    J = 11.3 Hz, 1H), 9.10 (s, 1H), 8.21-8.31 (m, 1H), 8.15 (br d,
    J = 13.4 Hz, 1H), 8.13 (s, 1H), 8.06 (s, 1H), 7.96 (d, J = 8.2 Hz,
    1H), 7.75 (s, 1H), 7.31-7.36 (m, 2H), 4.71-4.92 (m, 2H), 4.09 (s,
    3H), 1.97-2.06 (m, 1H), 1.92 (br dd, J = 13.3, 4.1 Hz, 1H), 1.58
    (s, 3H), 1.54 (s, 3H), 1.48 (s, 3H), 1.47 (s, 3H); 1H not observed
    (OH)
    261 MS m/z 426.5 [M + H]+; 1H MMR (DMSO-d6) δ: 9.75 (br d,
    J = 11.3 Hz, 1H), 9.06 (s, 1H), 8.22 (br s, 1H), 8.13 (br d, J =
    11.6 Hz, 1H),7.87 (d, J = 7.9 Hz, 1H), 7.76 (d, J = 2.1 Hz, 1H),
    7.45 (d, J = 1.5 Hz, 1H), 7.38 (dd, J = 8.2, 1.5 Hz, 1H), 6.70 (d,
    J = 2.1 Hz, 1H), 4.68-4.89 (m, 2H), 3.90 (s, 3H), 1.95-2.05 (m,
    1H), 1.86-1.94 (m, 1H), 1.58 (s, 3H), 1.54 (s, 3H), 1.48 (br s,
    3H), 1.47 (s, 3H)
    263 MS m/z 366.4 [M + H]+; 1H MMR (methanol-d4) δ: 7.89 (d,
    J = 2.4 Hz, 1H), 7.75 (d, J = 8.2 Hz, 1H), 7.50-7.41 (m, 2H),
    6.88 (d, J = 2.4 Hz, 1H), 6.05 (s, 1H), 4.36 (d, J = 14.5 Hz, 1H),
    4.23 (d, J = 13.7 Hz, 1H), 4.07 (s, 3H), 3.71-3.60 (m, 2H), 3.51-
    3.38 (m, 2H), 1.50 (d, J = 6.4 Hz, 3H), 1.48 (d, J = 6.4 Hz, 3H);
    2Hs was not observed (NH and OH)
    289 MS m/z 381.4 [M + H]+; 1H MMR (methanol-d4) δ: 7.95 (s,
    1H), 7.76 (d, J = 8.2 Hz, 1H), 7.39 (br d, J = 8.2 Hz, 1H), 7.35-
    7.37 (m, 1H), 5.96-6.05 (m, 1H), 4.26-4.37 (m, 1H), 4.10-4.20
    (m, 1H), 3.89-4.05 (m, 2H), 3.75-3.85 (m, 1H), 3.49-3.64 (m,
    1H), 2.77 (s, 3H), 2.60-2.72 (m, 1H), 2.38-2.54 (m, 1H), 1.47
    (dd, J = 6.4, 1.8 Hz, 6H); 2Hs not observed (NH and OH)
    296 MS m/z 352.3 [M + H]+; 1H MMR (methanol-d4) δ: 7.72 (d, J =
    2 Hz, 1H), 7.68 (d, J = 8 Hz, 1H), 7.43 (dd, J = 8.5 Hz, 1.5 Hz,
    1H), 7.41 (s, 1H), 6.75 (d, J = 2 Hz, 1H), 5.99 (s, 1H), 4.03-4.18
    (m, 2H), 4.00 (s, 3H), 3.87-3.95 (m, 2H), 3.81 (m, 1H), 2.85 (s,
    3H), 2.59-2.74 (m, 1H), 2.37-2.53 (m, 1H); 2Hs not observed
    (NH and OH)
    299 MS m/z 393.3 [M + H]+; 1H MMR (methanol-d4) δ: 9.06 (s,
    1H), 7.87 (d, J = 8.2 Hz, 1H), 7.40 (s, 1H), 7.27 (d, J = 8.1 Hz,
    1H), 7.24 (s, 1H), 4.10 (s, 4H), 3.51 (s, 2H), 3.11 (s, 2H), 2.90
    (s, 3H), 2.54 (s, 3H), 2.29 (s, 2H), 2.09 (s, 2H); 1 OH not
    observed
    308 MS m/z 367.3 [M + H]+; 1H MMR (methanol-d4) δ: 8.05 (s,
    1H), 7.78 (d, J = 8.2 Hz, 1H), 7.64 (dd, J = 8.9, 1.5 Hz, 1H),
    7.62 (d, J = 1.5 Hz, 1H), 7.37 (s, 1H), 6.01 (d, J = 3.1 Hz, 1H),
    4.25-4.39 (m, 1H), 4.08-4.20 (m, 1H), 3.74-4.00 (m, 3H), 3.50-
    3.67 (m, 1H), 2.61-2.75 (m, 1H), 2.35-2.54 (m, 1H), 1.47 (dd,
    J = 6.1, 1.8 Hz, 6H); 2Hs not observed (NH and OH)
    319 MS m/z 458.4 [M + H]+; 1H MMR (methanol-d4) δ: 8.07 (s,
    1H), 7.83-7.88 (m, 2H), 7.74 (d, J = 8.5 Hz, 1H), 7.51 (d, J =
    8.5 Hz, 1H), 7.41 (dd, J = 8.5 Hz, 1.5 Hz, 1H), 7.38 (s, 1H),
    6.03 (s, 1H), 4.37 (m. 1H), 4.15 (s, 3H), 2.27 (m, 2H), 1.74-1.85
    (m, 2H), 1.64 (d, J = 8.5 Hz, 6H), 1.56 (d, J = 6 Hz, 6H); 2Hs
    not observed (NH and OH)
    330 MS m/z 430.5 [M + H]+; 1H MMR (methanol-d4) δ: 8.03 (s,
    1H), 7.77-7.89 (m, 2H), 7.71 (d, J = 8.2 Hz, 1H), 7.47 (d, J =
    8.2 Hz, 1H), 7.38 (d, J = 8.2 Hz, 1H), 7.34 (s, 1H), 5.97-6.05
    (m, 1H), 4.22-4.38 (m, 1H), 4.12 (s, 3H), 3.71-4.03 (m, 4H),
    3.50-3.64 (m, 1H), 2.58-2.71 (m, 1H), 2.35-2.54 (m, 1H), 1.46
    (d, J = 5.8 Hz, 6H); 2Hs not observed (NH and OH)
    350 MS m/z 353.5 [M + H]+; 1H MMR (DMSO-d6) δ: 9.05 (s, 1H),
    7.91 (d, J = 8 Hz, 1H), 7.56 (s, 1H), 7.29 (dd, J = 8 Hz, 1.5 Hz,
    1H), 7.27 (s, 1H), 3.93 (m, 2H), 3.75-3.90 (m, 2H), 3.71 (m,
    1H), 2.67 (s, 3H), 2.40-2.48 (m, 1H), 2.27 (m, 1H); 2Hs not
    observed (NH and OH); and one methyl singlet obscured by the
    DMSO peak)
    358 MS m/z 339.4 [M + H]+; 1H MMR (methanol-d4) δ: 8.05 (s,
    1H), 7.77 (d, J = 8 Hz, 1H), 7.60-7.67 (m, 2H), 7.37 (s, 1H),
    6.00 (s, 1H), 4.03-4.11 (m, 2H), 3.85-3.97 (m, 2H), 3.71-3.82
    (m, 1H), 2.83 (s, 3H), 2.58-2.70 (m, 1H), 2.35-2.45 (m, 1H);
    2Hs not observed (NH and OH)
    • Example 8 Preparation of Compound 73
  • Figure US20230331725A1-20231019-C00155
    Figure US20230331725A1-20231019-C00156
    • Step 1
  • To a suspension of 6-[4-chloro-2-(methoxymethoxy)phenyl]-3-methylsulfanyl-1,2,4-triazine (350 mg, 1.18 mmol) was added 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (750 mg, 2.9 mmol), KOAc (575 mg, 5.86 mmol), X Phos Pd G4 (175 mg, 0.20 mmol) in dry dioxane (5 mL) which was sparged with argon for 10 minutes, then heated to 90° C. under an argon atmosphere for 2 h, after which complete conversion to 6-(2-(methoxymethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(methylthio)-1,2,4-triazine was observed. The reaction mixture was then cooled to room temperature and used directly in the next step. MS m/z 390.4 [M+H]+.
    • Step 2
  • To the mixture from Step 1 was added aq. K2CO3 (350 mg, 2.5 mmol), 4-bromo-3-fluoro-1-tetrahydropyran-2-yl-pyrazole (200 mg, 0.80 mmol), X Phos Pd G4 (75 mg, 0.084 mmol) and water (1 mL). The reaction was degassed via bubbling with argon for 5 min and then heated to 90° C. for 12 h. The reaction was cooled to room temperature, diluted with water and extracted with EtOAc. The combined organic layers were dried over MgSO4 and then filtered and concentrated under reduced pressure. The residue was purified by column chromatography eluting with EtOAc/hexanes (0-50%) to afford 6-[4-(3-fluoro-1-tetrahydropyran-2-yl-pyrazol-4-yl)-2-(methoxymethoxy)phenyl]-3-methylsulfanyl-1,2,4-triazine (140 mg, 40% yield) as a yellow oil. MS m/z 432.4 [M+H]+.
    • Step 3
  • To a stirred solution of 6-[4-(3-fluoro-1-tetrahydropyran-2-yl-pyrazol-4-yl)-2-(methoxymethoxy)phenyl]-3-methylsulfanyl-1,2,4-triazine (140 mg, 0.32 mmol) in CH2Cl2 (5 mL) was added mCPBA (120 mg, 0.70 mmol) and the reaction was allowed to stir at room temperature for 1 h. It was then quenched with saturated aqueous NaHCO3. The organic layer was dried over MgSO4 and concentrated. The residue was purified by silica gel column chromatography eluting with EtOAc/hexanes (0-100% EtOAc) to afford 6-[4-(3-fluoro-1-tetrahydropyran-2-yl-pyrazol-4-yl)-2-(methoxymethoxy)phenyl]-3-methylsulfonyl-1,2,4-triazine (95 mg, 63% yield) as a yellow solid. MS m/z 464.5 [M+H]+.
    • Step 4
  • A mixture of 6-[4-(3-fluoro-1-tetrahydropyran-2-yl-pyrazol-4-yl)-2-(methoxymethoxy)phenyl]-3-methylsulfonyl-1,2,4-triazine (25 mg, 0.054 mmol), 2,2,6,6-tetramethylpiperidin-4-amine (17 mg, 0.11 mmol) and DIPEA (30 μL, 0.168 mmol) in dry DMF was heated to 50° C. for 1 h. UPLC showed full conversion. The solvent was removed by blowing a stream of air and the residue was purified by silica gel column chromatography eluting with MeOH/CH2Cl2 (0-30% MeOH) to afford 6-[4-(3-fluoro-1-tetrahydropyran-2-yl-pyrazol-4-yl)-2-(methoxymethoxy)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidyl)-1,2,4-triazin-3-amine (20 mg, 69% yield). MS m/z 540.7 [M+H]+.
    • Step 5:
  • 6-[4-(3-Fluoro-1-tetrahydropyran-2-yl-pyrazol-4-yl)-2-(methoxymethoxy)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidyl)-1,2,4-triazin-3-amine (20 mg, 0.037 mmol) was dissolved in MeOH (1 mL) and HCl (4 mol/L) in 1,4-dioxane (1.0 mL, 4 mmol) was then added. The reaction mixture was heated to 50° C. for 2 h. The solvents were removed and the residue was purified by silica gel column chromatography eluting with MeOH/CH2Cl2 (0-30% MeOH) to afford 5-(3-fluoro-1H-pyrazol-4-yl)-2-[3-[(2,2,6,6-tetramethyl-4-piperidyl)amino]-1,2,4-triazin-6-yl]phenol (12 mg, 77% yield) as a yellow solid.
  • MS m/z 412.5 [M+H]; 1H NMR (methanol-d4) δ: 9.05 (s, 1H), 7.97 (d, J=2.0 Hz, 1H), 7.83 (d, J=9.0 Hz, 1H), 7.20-7.22 (m, 2H), 4.54-4.58 (m, 1H), 2.30 (dd, J=13.5, 3.5 Hz, 2H), 1.62-1.64 (m, 2H), 1.61 (s, 6H), 1.49 (s, 6H); 4Hs not observed (3N s and OH).
  • Using the procedure described for Example 8, additional compounds described herein may be prepared by substituting the appropriate starting material, suitable reagents and reaction conditions, obtaining compounds such as those selected from:
  • Cpd Data
    149 MS m/z 396.4 [M + H]+; 1H NMR (DMSO-d6) δ: 9.00 (s, 1H),
    7.81 (d, J = 1.8 Hz, 1H), 7.76 (d, J = 8.2 Hz, 1H), 7.15-7.23 (m,
    2H), 4.06 (s, 4H), 2.84-3.25 (m, 4H), 2.74 (br s, 3H), 2.15 (br s,
    4H); 2Hs not observed (NH and OH)
    150 MS m/z 382.4 [M + H]+; 1H NMR (1:1 chloroform-d: methanol-
    d4) δ: 8.90 (s, 1H), 7.74 (d, J = 1.8 Hz, 1H), 7.68 (d, J = 7.9 Hz,
    1H), 7.08-7.13 (m, 2H), 4.31 (dt, J = 14.0, 4.9 Hz, 1H), 4.12
    (dd, J = 14.3, 6.1 Hz, 1H), 3.84-3.93 (m, 2H), 3.52 (ddd, J =
    13.7, 9.8, 3.7 Hz, 1H), 3.39 (dq, J = 11.9, 4.7 Hz, 1H), 3.26-
    3.33 (m, 1H), 2.57-2.68 (m, 1H), 2.06-2.19 (m, 2H), 1.78-1.92
    (m, 2H); 3Hs not observed (2NHs and OH)
    151 MS m/z 382.4 [M + H]+; 1H NMR (1:1 chloroform-d: methanol-
    d4) δ: 7.85 (d, J = 1.8 Hz, 1H), 7.50 (d, J = 8.9 Hz, 1H), 7.16-
    7.21 (m, 2H), 5.84 (s, 1H), 4.10-4.27 (m, 4H), 3.20-3.29 (m,
    4H), 2.20 (br s, 4H); 3Hs not observed (2NHs and OH)
    153 MS m/z 396.3 [M + H]+; 1 1H NMR (DMSO-d6) δ: 12.63-12.73
    (m, 2H), 11.04-11.30 (m, 4H), 9.03-9.08 (m, 1H), 8.22 (br s,
    1H), 7.88 (br d, J = 7.9 Hz, 1H), 7.21 (br s, 2H), 4.62-4.71 (m,
    1H), 4.48-4.56 (m, 1H), 4.19-4.30 (m, 1H), 3.35-3.43 (m, 1H),
    3.18 (s, 3H), 3.07-3.13 (m, 1H), 2.89 (br d, J = 4.6 Hz, 2H),
    2.74-2.81 (m, 1H), 2.18-2.28 (m, 1H), 2.08-2.16 (m, 1H), 1.98-
    2.07 (m, 1H), 1.63-1.72 (m, 1H); 2H not observed (1 NH 1
    OH).
    174 MS m/z 398.3 [M + H]+; 1H MMR (DMSO-d6) δ: 12.66 (br s,
    1H), 11.31 (br s, 1H), 9.04 (s, 1H), 8.21 (s, 1H), 7.86 (d, J = 8.5
    Hz, 1H), 7.19-7.16 (m, 2H), 3.96-3.82 (m, 1H), 3.79-3.68 (m,
    1H), 3.66-3.58 (m, 1H), 3.56-3.46 (m, 1H), 3.23-3.20 (m, 1H),
    2.25-2.18 (m, 1H), 1.87-1.79 (m, 1H), 1.12 (s, 9H);); 1H not
    observed (NH or OH)
    175 MS m/z 394.3 [M + H]+; 1H MMR (DMSO-d6) δ: 11.19 (br s,
    1H), 9.03 (s, 1H), 7.86 (d, J = 8.0 Hz, 1H), 7.74 (s, 1H), 7.41 (s,
    1H), 7.36 (d, J = 8.0 Hz, 1H), 6.69 (s, 1H), 3.90 (s, 3H), 3.79-
    3.65 (m, 2H), 3.59-3.45 (m, 2H), 3.23-3.08 (m, 1H), 2.23-2.13
    (m, 1H), 1.83-1.70 (m, 1H), 1.09 (s, 9H); 1H not observed (NH
    or OH)
    189 MS m/z 430.5 [M + H]+; 1H MMR (methanol-d4) δ: 9.10 (s,
    1H), 7.98 (s, 1H), 7.86 (d, J = 8.5 Hz, 1H), 7.20-7.27 (m, 2H),
    4.53-4.67 (m, 1H), 2.01-2.26 (m, 3H), 1.68 (s, 3H), 1.65 (s, 3H),
    1.59 (s, 3H), 1.56 (s, 3H); 4H not observed (3NHs and OH)
    247 MS m/z 413.5 [M + H]+; 1H MMR (DMSO-d6) δ: 9.75 (br d,
    J = 12.2 Hz, 1H), 9.07 (s, 1H), 8.38 (br s, 1H), 8.27 (br s, 1H),
    8.14 (br d, J = 12.2 Hz, 1H), 7.94 (d, J = 8.2 Hz, 1H), 7.53 (s,
    1H), 7.46 (br d, J = 7.9 Hz, 1H), 4.77 (br s, 2H), 1.96-2.05 (m,
    1H), 1.87-1.95 (m, 1H), 1.58 (s, 3H), 1.54 (s, 3H), 1.48 (br d,
    J = 6.4 Hz, 6H); 1H not observed (NH or OH)
    248 MS m/z 463.5 [M + H]+; 1H MMR (DMSO-d6) δ: 11.24 (br s,
    1H), 9.28 (s, 1H), 9.19 (s, 1H), 9.07 (s, 1H), 8.16 (s, 1H), 8.00
    (d, J = 8.5 Hz, 1H), 7.87 (s, 1H), 7.74 (s, 1H), 7.62 (br d, J =
    8.2 Hz, 1H), 4.41-4.73 (m, 2H), 1.57-1.79 (m, 2H), 1.06-1.37
    (m, 12H); 2Hs not observed (NH and OH)
    249 MS m/z 463.5 [M + H]+; 1H MMR (DMSO-d6) δ: 11.28 (br s,
    1H), 9.91-10.07 (m, 1H), 9.09 (s, 1H), 8.69 (s, 1H), 8.52 (br d,
    J = 9.5 Hz, 1H), 8.28 (br s, 1H), 8.25 (br d, J = 9.8 Hz, 1H),
    8.13 (br d, J = 13.1 Hz, 1H), 8.08 (d, J = 8.2 Hz, 1H), 7.80 (s,
    1H), 7.74 (br d, J = 8.2 Hz, 1H), 4.75-4.89 (m, 2H), 1.98-2.06
    (m, 1H), 1.87-1.94 (m, 1H), 1.59 (s, 3H), 1.56 (s, 3H), 1.49 (br
    s, 3H), 1.48 (br s, 3H)
    256 MS m/z 429.4 [M + H]+; 1H MMR (methanol-d4) δ: 9.14 (s,
    1H), 8.40 (s, 1H), 8,29 (d, J = 8.50 Hz, 1H), 8.11 (d, J = 10.00
    Hz, 1H), 8.05 (s, 1H), 8.03 (s, 1H), 7.73 (d, J = 8.50 Hz, 1H),
    7.73 (d, J = 12.50 Hz, 1H), 4.17 (s, 2H), 4.07 (s, 2H), 3.54 (d,
    J = 14.50 Hz, 2H), 3.12 (t, J = 10.0 Hz, 2H), 2.91 (s, 3H), 2.32
    (d, J = 14.50 Hz, 2H), 2.06 (t, J = 15.00 Hz, 2H); 1H not
    observed (OH)
    257 MS m/z 429.4 [M + H]+; 1H MMR (methanol-d4) δ: 9.42 (s,
    1H), 9.38 (s, 1H), 8.37 (s, 1H), 8.23 (s, 1H), 7.80-7.75 (m, 2H),
    7.74-7.70 (m, 1H), 6.00 (s, 1H), 4.26 (s, 2H), 4.15 (s, 2H), 3.48
    (d, J = 7.00 Hz, 2H), 3.12 (t, J = 13.00 Hz, 2H), 2.91 (s, 3H),
    2.38 (d, J = 16.00 Hz, 2H), 2.11 (t, J = 14.00 Hz, 2H); 1H not
    observed (OH)
    272 MS m/z 396.4 [M + H]+; 1H MMR (methanol-d4) δ: 9.10 (s,
    1H), 8.78 (s, 1H), 8.01 (d, J = 8.09 Hz, 1H), 7.76-7.61 (m, 2H),
    4.17 (s, 2H), 4.07 (s, 2H), 3.51 (d, J = 12.13 Hz, 2H), 3.11 (t,
    J = 12.50 Hz, 2H), 2.91 (s, 3H), 2.32 (d, J = 14.50 Hz, 2H), 2.06
    (t, J = 15.00 Hz, 2H); 1H not observed (NH or OH)
    378 MS m/z 398.5 [M + H]+; 1H MMR (methanol-d4) δ: 9.07 (s,
    1H), 7.96 (s, 1H), 7.82 (d, J = 8.5 Hz, 1H), 7.19 (d, J = 8.5 Hz,
    1H), 7.18 (s, 1H), 4.08 (dd, J = 11.5, 7.5 Hz, 1H), 3.91-3.37 (m,
    2H), 3.66-3.61 (m, 1H), 3.51-3.47 (m, 1H), 2.49-2.44 (m, 1H),
    2.10-2.03 (m, 1H), 1.32 (s, 9H); 3Hs not observed (2NHs and
    OH)
    379 MS m/z 398.5 [M + H]+; 1H MMR (methanol-d4) δ: 9.07 (s,
    1H), 7.96 (s, 1H), 7.82 (d, J = 8.5 Hz, 1H), 7.19 (d, J = 8.5 Hz,
    1H), 7.18 (s, 1H), 4.08 (dd, J = 11.5, 7.5 Hz, 1H), 3.91-3.37 (m,
    2H), 3.66-3.61 (m, 1H), 3.51-3.47 (m, 1H), 2.49-2.44 (m, 1H),
    2.10-2.03 (m, 1H), 1.32 (s, 9H); 3Hs not observed (2NHs and
    OH)
    385 MS m/z 403.6 [M + H]+; 1H MMR (methanol-d4) δ: 9.21 (s,
    1H), 8.57 (s, 1H), 8.50 (d, J = 9.8 Hz, 1H), 8.44-8.38 (m, 1H),
    8.25 (s, 1H), 8.14-8.07 (m, 1H), 7.83-7.73 (m, 2H), 5.18-5.04
    (m, 2H), 3.59-3.44 (m, 2H), 3.18-3.02 (m, 2H), 1.47 (d, J = 6.4
    Hz, 6H); 2Hs not observed (NH and OH)
    • Example 9 Preparation of Compound 380
  • Figure US20230331725A1-20231019-C00157
    • Step 1
  • A mixture of tert-butyl N-[1-[6-[2-(methoxymethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2,4-triazin-3-yl]pyrrolidin-3-yl]-N-methyl-carbamate (425 mg, 0.63 mmol), 4,6-dichloropyrimidine (450 mg, 3.02 mmol), Pd(dppf)Cl2—CH2Cl2 (50 mg, 0.06 mmol), 1,4-dioxane (3 mL), and aqueous K2CO3 (2 M, 1.5 mL, 3.0 mmol) was purged with argon for 10 min. The reaction was then heated at 90° C. for 16 h. The reaction mixture was partitioned between water and CH2Cl2. The organic layer was dried over MgSO4, filtered, and concentrated under vacuum. Purification by silica gel chromatography with MeOH/CH2Cl2 (0 to 5% MeOH) yielded tert-butyl N-[1-[6-[4-(6-chloropyrimidin-4-yl)-2-(methoxymethoxy)phenyl]-1,2,4-triazin-3-yl]pyrrolidin-3-yl]-N-methyl-carbamate (318 mg, 86% yield) as an orange oil.
  • 1H NMR (acetone-d6) δ: 9.08 (s, 1H), 8.84 (s, 1H), 8.23 (s, 2H), 8.04-8.11 (m, 2H), 5.49 (s, 2H), 4.94 (m, 1H), 3.80-4.10 (m, 2H), 3.55-3.75 (m, 2H), 3.51 (s, 3H), 2.91 (s, 3H), 2.27 (m, 2H), 1.50 (s, 9H).
    • Step 2
  • tert-Butyl N-[1-[6-[4-(6-chloropyrimidin-4-yl)-2-(methoxymethoxy)phenyl]-1,2,4-triazin-3-yl]pyrrolidin-3-yl]-N-methyl-carbamate (40 mg, 0.068 mmol) and methylamine (33% in EtOH) (0.5 mL, 6 mmol) were stirred at room temperature for 1 h. The volatiles were removed by a nitrogen stream. The residue was purified by silica gel chromatography eluting with MeOH/CH2Cl2 (0 to 5% MeOH) to afford tert-butyl N-[1-[6-[2-(methoxymethoxy)-4-[6-(methylamino)pyrimidin-4-yl]phenyl]-1,2,4-triazin-3-yl]pyrrolidin-3-yl]-N-methyl-carbamate (32 mg, 90% yield) as an off-white solid.
  • 1H NMR (methanol-d4) δ: 8.86 (s, 1H), 8.51 (s, 1H), 7.90 (m, 2H), 7.71 (d, J=7.5 Hz, 1H), 6.94 (s, 1H), 5.39 (s, 2H), 4.87 (s, 1H), 3.90-4.00 (m, 2H), 3.55-3.70 (m, 2H), 3.48 (s, 3H), 3.00 (s, 3H), 2.90 (s, 3H), 2.29 (m, 2H), 1.52 (s, 9H).
    • Step 3
  • To a solution of tert-butyl N-[1-[6-[2-(methoxymethoxy)-4-[6-(methylamino)pyrimidin-4-yl]phenyl]-1,2,4-triazin-3-yl]pyrrolidin-3-yl]-N-methyl-carbamate (30 mg, 0.057 mmol) in MeOH (0.4 mL) was added 4N HCl in dioxane (0.4 mL, 1.6 mmol). The reaction mixture was stirred at room temperature for 1 h. The solvents were then removed by a nitrogen stream. The product was dissolved in sat. aq. NaHCO3, and the free base was extracted with CH2C2. The organic layer was dried over MgSO4, filtered, and concentrated under vacuum. The title product, 5-[6-(methylamino)pyrimidin-4-yl]-2-[3-[3-(methylamino)pyrrolidin-1-yl]-1,2,4-triazin-6-yl]phenol (15 mg, 69% yield), was obtained as a yellow solid.
  • MS m/z 379.3 [M+H]+; 1H NMR (DMSO-d6) δ: 9.03 (s, 1H), 8.51 (s, 1H), 7.94 (d, J=8 Hz, 1H), 7.50-7.80 (m, 2H), 7.40 (br s, 1H), 6.92 (s, 1H), 3.55-3.80 (m, 3H), 3.44 (m, 1H), 3.30 (m, 1H), 2.87 (s, 3H), 2.31 (s, 3H), 2.11 (m, 1H), 1.89 (m, 1H); 2Hs not observed (NH and OH).
  • Using the procedure described for Example 9, additional compounds described herein may be prepared by substituting the appropriate starting material, suitable reagents and reaction conditions, obtaining compounds such as those selected from:
  • Cpd Data
     33 MS m/z 437.6 [M + H]+; 1H MMR (methanol-d4) δ: 9.13-9.28
    (m, 2H), 8.10-8.23 (m, 1H), 7.38-7.61 (m, 2H), 5.33-5.52 (m,
    1H), 3.26 (s, 3H), 2.04-2.14 (m, 2H), 2.00 (dd, J = 13.1, 2.4 Hz,
    2H), 1.66 (s, 6H), 1.58 (s, 6H); 3Hs not observed (NH and 2
    OHs)
    364 MS m/z 396.3 [M + H]+; 1H MMR (DMSO-d6) δ: 9.10 (s, 1H),
    9.01 (s, 1H), 7.95-8.03 (m, 2H), 7.88 (s, 1H), 7.80 (d, J = 8 Hz,
    1H), 3.80-4.00 (m, 4H), 3.63-3.76 (m, 1H), 2.66 (s, 3H), 2.62 (s,
    3H), 2.40-2.48 (m, 1H), 2.30 (m, 1H); 2Hs not observed (NH
    and OH)
    • Example 10 Preparation of Compound 396
  • Figure US20230331725A1-20231019-C00158
    Figure US20230331725A1-20231019-C00159
    • Step 1
  • To a stirred solution of 4-bromo-2-methoxy-benzoyl chloride (2.53 g, 10.1 mmol) in dry dichloromethane (80 mL) were added ethyl 2-aminoacetate hydrochloride (2.12 g, 15.2 mmol) and Et3N (4.28 mL, 30.4 mmol). After stirring for 1 h, the mixture was diluted with saturated NaHCO3 and the aqueous layer extracted twice with dichloromethane. The combined organic layers were dried over Na2SO4 and evaporated to dryness in vacuo to give ethyl (4-bromo-2-methoxybenzoyl)glycinate (3.2 g, 99% yield) which was taken on without further purification. MS m z 316.0, 318.0 [M+H]+.
    • Step 2
  • To a stirred solution of ethyl (4-bromo-2-methoxybenzoyl)glycinate (3.2 g, 10.0 mmol) in dry toluene (150 mL) was added phosphorous pentasulfide (2.5 g, 11.0 mmol) and the mixture was heated to 120° C. for 1 h. The mixture was filtered, evaporated to dryness and purified by silica gel chromatography eluting with a gradient EtOAc/hexanes (0-100% EtOAc) to yield ethyl 2-[(4-bromo-2-methoxy-benzenecarbothioyl)amino]acetate (1.38 g, 41% yield). MS m/z 331.3, 333.3 [M+H]+.
    • Step 3
  • To a solution of ethyl 2-[(4-bromo-2-methoxy-benzenecarbothioyl)amino]acetate (1.38 g, 4.2 mmol) in ethanol (10 mL) was added hydrazine (1.02 g, 31.4 mmol). The mixture was heated to 90° C. for 5 h until UPLC showed complete consumption of the starting material and allowed to cool to room temperature. Concentration in vacuo gave a yellow solid that was purified by silica gel chromatography eluting with a MeOH/CH2Cl2 gradient (0-10% MeOH) to give 3-(4-bromo-2-methoxy-phenyl)-4,5-dihydro-1H-1,2,4-triazin-6-one (560 mg, 47%) as an off-white solid. MS m z 284.0, 286.0 [M+H]+.
    • Step 4:
  • 3-(4-bromo-2-methoxy-phenyl)-4,5-dihydro-1H-1,2,4-triazin-6-one (1.0 g, 3.5 mmol) was dissolved in POCl3 (10 mL, 108 mmol) and heated to 85° C. for 16 h. The mixture was allowed to cool to room temperature and evaporated to dryness in vacuo. The residue was dissolved in dioxane (20 mL) and manganese dioxide (3.5 g, 40 mmol) was added. The mixture was stirred at 90° C. for 36 h. After filtering through celite and rinsing with hot dioxane, the combined organic phases were evaporated to dryness in vacuo. The crude residue was purified by silica gel chromatography eluting with a MeOH/CH2Cl2 gradient (0-10% MeOH) to give 3-(4-bromo-2-methoxy-phenyl)-6-chloro-1,2,4-triazine (420 mg, 40% yield) as a tan solid. MS m/z 299.9, 301.9 [M+H]+.
    • Step 5:
  • 3-(4-Bromo-2-methoxy-phenyl)-6-chloro-1,2,4-triazine (1.0 g, 3.3 mmol) was dissolved in CH2Cl2 (10 mL) and cooled to −50° C. Boron tribromide (5.0 mL, 5.0 mmol) was added slowly and the reaction mixture was stirred for 5 h at −50° C. Upon completion (as shown by LCMS), the reaction was quenched with water and saturated sodium bicarbonate solution (final pH=7-8) and extracted with CH2Cl2 three times. The combined organic layers were dried over Na2SO4, concentrated in vacuo and purified by silica gel column chromatography eluting with a EtOAc/hexanes gradient (10-80% EtOAc) to give 5-bromo-2-(6-chloro-1,2,4-triazin-3-yl)phenol (650 mg, 68% yield) as a brownish solid. MS m/z 285.8, 287.9 [M+H]+.
    • Step 6
  • A solution of 5-bromo-2-(6-chloro-1,2,4-triazin-3-yl)phenol (0.65 g, 2.3 mmol) in dry THE (5 mL) was cooled to 0° C. Sodium hydride (0.12 g, 3.0 mmol, 60 mass % in mineral oil) was added and the mixture was stirred for 1.5 h at 0° C. Bromo(methoxy)methane (0.37 g, 3.0 mmol) was added and the reaction mixture was stirred for an additional 3 h at 0° C. The reaction was quenched with water (10 mL) and extracted with EtOAc three times. The combined organic layers were dried over Na2SO4, concentrated in vacuo and purified by silica-gel column chromatography eluting with a EtOAc/hexanes gradient (10-80% EtOAc) to give 3-[4-bromo-2-(methoxymethoxy)phenyl]-6-chloro-1,2,4-triazine (430 mg, 57% yield). MS m/z 329.9, 331.9 [M+H]+; 1H NMR (methanol-d4) δ: 8.95 (s, 1H), 7.70 (d, J=8.2 Hz, 1H), 7.55 (s, 1H), 7.37 (d, J=7.9 Hz, 1H), 4.87 (s, 2H), 3.33 (s, 3H).
    • Step 7
  • To a solution of 3-[4-bromo-2-(methoxymethoxy)phenyl]-6-chloro-1,2,4-triazine (500 mg, 1.51 mmol) and 2,2,6,6-tetramethylpiperidin-4-amine (285 mg, 1.82 mmol) in dry DMSO (5 mL) was added DIPEA (0.67 mL, 3.8 mmol).The mixture was heated at 100° C. for 16 hours. LCMS showed complete conversion. The reaction was quenched with water (100 mL) and extracted with EtOAc five times. The combined organic layers were dried over Na2SO4, concentrated in vacuo and purified by silica gel column chromatography eluting with a MeOH/CH2Cl2 gradient (0-20% MeOH) to give 3-(4-bromo-2-(methoxymethoxy)phenyl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,2,4-triazin-6-amine (340 mg, 50% yield) as a greyish solid. MS m/z 449.9, 451.9 [M+H]+; 1H NMR (methanol-d4) δ: 8.19 (s, 1H), 7.52 (br d, J=7.9 Hz, 1H), 7.48 (s, 1H), 7.30 (d, J=8.2 Hz, 1H), 5.21 (s, 2H), 4.41-4.60 (m, 1H), 3.45 (s, 3H), 2.10 (br d, J=11.9 Hz, 2H), 1.37 (s, 6H), 1.24 (s, 6H), 1.18-1.23 (m, 2H), 2 Hs is not observed (NHs).
    • Step 8:
  • To a dry screw-cap vial were added 3-[4-bromo-2-(methoxymethoxy)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidyl)-1,2,4-triazin-6-amine (67 mg, 0.15 mmol), (1-tetrahydropyran-2-yl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (50 mg, 0.18 mmol), K2CO3 (62 mg, 0.45 mmol), and PddppfCl2 (11 mg, 0.015 mmol). The mixture was degassed with argon for 10 min, and then dioxane (2 mL) and water (0.5 mL) were added and the reaction was heated at 90° C. for 16 h (overnight). The reaction was cooled to room temperature, partitioned between EtOAc and water, and the organic phase was dried over Na2SO4 and concentrated. The crude product was purified by silica gel column chromatography, eluting with a MeOH/CH2Cl2 gradient (0-20% MeOH) to provide 3-[2-(methoxymethoxy)-4-(1-tetrahydropyran-2-ylpyrazol-4-yl)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidyl)-1,2,4-triazin-6-amine (59 mg, 76% yield) as a brownish solid. MS m/z 522.7 [M+H]+.
    • Step 9
  • To a solution of 3-[2-(methoxymethoxy)-4-(1-tetrahydropyran-2-ylpyrazol-4-yl)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidyl)-1,2,4-triazin-6-amine (59 mg, 0.11 mmol) in 1 mL of CH2C12 and MeOH (0.5 mL) was added HCl (4 mol/L) in 1,4-dioxane (56 μL, 0.23 mmol) and the mixture was stirred for 16 h at room temperature. UPLC showed complete consumption of the starting material. The solvents were evaporated, and the residue was purified by silica gel column chromatography eluting with a MeOH/CH2Cl2/2.5% NH4OH gradient (0-30% MeOH/NH4OH) to provide 5-(1H-pyrazol-4-yl)-2-[6-[(2,2,6,6-tetramethyl-4-piperidyl)amino]-1,2,4-triazin-3-yl]phenol (30 mg, 62% yield) as a tan solid
  • MS m/z 394.5 [M+H]+; 1H NMR (methanol-d4) δ: 8.32 (s, 1H), 8.18 (d, J=7.0 Hz, 1H), 8.02 (s, 2H), 7.13-7.25 (m, 2H), 4.43 (br t, J=11.3 Hz, 1H), 2.08 (br d, J=12.8 Hz, 2H), 1.39 (s, 6H), 1.20-1.32 (m, 8H); 4Hs not observed (3NHs and OH).
  • Using the procedure described for Example 11, additional compounds described herein may be prepared by substituting the appropriate starting material, suitable reagents and reaction conditions, obtaining compounds such as those selected from:
  • Cpd Data
     24 MS m/z 408.3 [M + H]+; 1H MMR (methanol-d4) δ: 8.64 (s,
    1H), 8.25 (d, J = 7.6 Hz, 1H), 7.92-8.13 (m, 2H), 7.19-7.24
    (m, 2H), 5.22-5.31 (m, 1H), 3.13 (s, 3H), 1.82-2.01 (m, 4H),
    1.53-1.64 (m, 6H), 1.38-1.52 (m, 6H); 3Hs not observed
    (2NHs and OH)
    190 MS m/z 426.4 [M + H]+; 1H MMR (methanol-d4) δ: 8.08 (s,
    1H), 7.60 (d, J = 7.9 Hz, 1H), 7.27-7.37 (m, 2H), 5.75 (br s,
    1H), 4.47-4.80 (m, 1H), 3.04 (s, 3H), 1.88-2.12 (m, 4H),
    1.58-1.66 (m, 6H), 1.57 (s, 6H); 3Hs not observed (2 NHs
    and OH)
    191 MS m/z 425.5 [M + H]+; 1H MMR (methanol-d4) δ: 8.63 (s,
    1H), 8.23 (d, J = 8.2 Hz, 1H), 8.01 (s, 1H), 7.86 (br s, 1H),
    7.09-7.21 (m, 2H), 5.16-5.57 (m, 1H), 3.14 (s, 3H), 1.92-
    2.09 (m, 4H), 1.66 (s, 6H), 1.56 (s, 6H); 2Hs not observed
    (NH and OH)
    196 MS m/z 422.5 [M + H]+; 1H MMR (methanol-d4) δ: 9.96 (s,
    1H), 9.46 (d, J = 7.9 Hz, 1H), 9.34 (s, 1H), 9.14 (s, 1H),
    8.39-8.53 (m, 2H), 6.52-6.64 (m, 1H), 5.20 (s, 3H), 4.44 (s,
    3H), 3.46 (br t, J = 12.2 Hz, 2H), 3.28 (br d, J = 12.8 Hz,
    2H), 2.95 (s, 6H), 2.86 (s, 6H); 2Hs not observed (NH and
    OH)
    342 MS m/z 472.4 [M + H]+; 1H MMR (methanol-d4) δ: 8.67 (s,
    1H), 8.37 (d, J = 8.5 Hz, 1H), 8.04 (s, 1H), 7.78-7.89 (m,
    2H), 7.52 (d, J = 9.5 Hz, 1H), 7.32-7.43 (m, 2H), 5.23-5.41
    (m, 1H), 4.15 (s, 3H), 3.15 (s, 3H), 1.88-2.15 (m, 4H), 1.65
    (s, 6H), 1.52 (s, 6H); 2Hs not observed (NH and OH)
    343 MS m/z 422.4 [M + H]+; 1H MMR (methanol-d4) δ: 8.57 (s,
    1H), 8.23 (d, J = 8.9 Hz, 1H), 7.64 (d, J = 2.1 Hz, 1H), 7.33-
    7.43 (m, 2H), 6.69 (d, J = 2.4 Hz, 1H), 5.12-5.36 (m, 1H),
    3.97 (s, 3H), 3.10 (s, 3H), 1.83-2.04 (m, 4H), 1.61 (s, 6H),
    1.50 (s, 6H); 2Hs not observed (NH and OH)
    363 MS m/z 380.4 [M + H]+; 1H MMR (methanol-d4) δ: 8.57 (s,
    1H), 8.27 (d, J = 8.7 Hz, 1H), 8.05-8.15 (m, 1H), 7.90-8.02
    (m, 1H), 7.21-7.25 (m, 2H), 4.21-4.31 (m, 1H), 4.17 (br dd,
    J = 11.3, 7.5 Hz, 1H), 3.93 (s, 1H), 3.68-3.77 (m, 2H), 2.60-
    2.72 (m, 1H), 2.24-2.36 (m, 1H), 1.49 (s, 9H); 3Hs not
    observed (2NHs and OH)
    382 MS m/z 419.3 [M + H]+; 1H MMR (DMSO-d6) δ: 12.74 (br
    s, 1H), 8.78 (s, 1H), 8.65 (d, J = 4.6 Hz, 2H), 8.29 (d, J = 8.8
    Hz, 1H), 7.78 (d, J = 4.9 Hz, 2H), 7.45 (br s, 2H), 4.84-5.08
    (m, 1H), 3.04 (s, 3H), 1.53-1.64 (m, 2H), 1.39-1.53 (m, 2H),
    1.26 (s, 6H), 1.10 (s, 6H); 1H not observed (OH or NH)
    384 MS m/z 419.3 [M + H]+; 1H MMR (DMSO-d6) δ:12.72 (br s,
    1H), 8.97 (br s, 1H), 8.78 (s, 1H), 8.60 (br s, 1H), 8.20-8.33
    (m, 1H), 8.16 (dt, J = 8.2, 1.9 Hz, 1H), 7.51 (dd, J = 7.8, 4.6
    Hz, 1H), 7.32-7.41 (m, 2H), 4.85-5.05 (m, 1H), 3.04 (s, 3H),
    1.55-1.59 (m, 2H), 1.44-1.48 (m, 2H), 1.26 (s, 6H), 1.10 (s,
    6H); 1H not observed (OH or NH)
    393 MS m/z 419.3 [M + H]+; 1H MMR (DMSO-d6) δ: 12.64 (s,
    1H), 8.77 (s, 1H), 8.69 (d, J = 4.0 Hz, 1H), 8.27 (d, J = 8.3
    Hz, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.83-7.95 (m, 1H), 7.66-
    7.79 (m, 2H), 7.39 (dd, J = 7.0, 5.0 Hz, 1H), 4.86-5.03 (m,
    1H), 3.04 (s, 3H), 1.57 (d, J = 11.8 Hz, 2H), 1.46 (t, J = 12.0
    Hz, 2H), 1.26 (s, 6H), 1.10 (s, 6H); 1H not observed (OH or
    NH)
    394 MS m/z 473.3 [M + H]+; 1H MMR (DMSO-d6) δ: 12.64 (s,
    1H), 8.77 (s, 1H), 8.31-8.37 (m, 1H), 8.27 (t, J = 8.5 Hz,
    2H), 8.11 (d, J = 9.0 Hz, 1H), 7.81 (dd, J = 8.3, 1.8 Hz, 1H),
    7.77 (d, J = 1.8 Hz, 1H), 4.87-5.05 (m, 1H), 4.12 (s, 3H),
    3.05 (s, 3H), 1.52-1.63 (m, 2H), 1.39-1.52 (m, 2H), 1.26 (s,
    6H), 1.10 (s, 6H); 1H not observed (OH or NH)
    402 MS m/z 420.3 [M + H]+; 1H MMR (DMSO-d6) δ: 12.61 (s,
    1H), 9.10-9.14 (br s, 1H), 8.95 (d, J = 5.0 Hz, 2H), 8.89 (s,
    1H), 8.32 (d, J = 8.5 Hz, 1H), 8.03 (d, J = 8.3 Hz, 1H), 7.98
    (d, J = 1.8 Hz, 1H), 7.49 (t, J = 4.9 Hz, 1H), 4.92-5.10 (m,
    1H), 3.09 (s, 3H), 1.97-2.01 (m, 2H), 1.81-1.85 (m, 2H),
    1.52 (s, 6H), 1.46 (s, 6H)
    411 MS m/z 420.3 [M + H]+; 1H MMR (DMSO-d6) δ: 12.57 (br
    s, 1H), 9.27 (d, J = 1.0 Hz, 1H), 8.89 (d, J = 5.5 Hz, 1H),
    8.78 (s, 1H), 8.32 (d, J = 8.3 Hz, 1H), 8.17 (dd, J = 5.3, 1.3
    Hz, 1H), 7.80-7.90 (m, 2H), 4.94-4.99 (m, 1H), 3.05 (s, 3H),
    1.57 (dd, J = 12.0, 3.3 Hz, 2H), 1.46 (t, J = 12.2 Hz, 2H),
    1.25 (s, 6H), 1.09 (s, 6H); 1H not observed (OH or NH)
    412 MS m/z 420.3 [M + H]+; 1H MMR (DMSO-d6) δ: 12.72 (br
    s, 1H), 9.33 (d, J = 1.3 Hz, 1H), 8.75 (s, 1H), 8.77 (s, 1H),
    8.65 (d, J = 2.5 Hz, 1H), 8.30 (d, J = 8.3 Hz, 1H), 7.70-7.86
    (m, 2H), 4.83-5.08 (m, 1H), 3.05 (s, 3H), 1.57 (dd, J = 11.9,
    3.4 Hz, 2H), 1.46 (t, J = 12.2 Hz, 2H), 1.26 (s, 6H), 1.10 (s,
    6H); 1H not observed (OH and NH)
    419 MS m/z 395.5 [M + H]+; 1H MMR (methanol-d4) δ: 8.61 (s,
    1H), 8.32 (br d, J = 8.2 Hz, 1H), 8.14 (br s, 1H), 7.99 (br s,
    1H), 7.25 (br s, 2H), 5.79 (br t, J = 10.4 Hz, 1H), 2.51 (br dd,
    J = 13.4, 2.5 Hz, 2H), 1.93 (br t, J = 12.1 Hz, 2H), 1.65 (s,
    6H), 1.56-1.62 (m, 6H); 3Hs not observed (2NHs and OH)
    423 MS m/z 412.4 [M + H]+; 1H MMR (methanol-d4) δ: 8.40 (s,
    1H), 8.22 (br d, J = 7.9 Hz, 1H), 7.90-8.11 (m, 2H), 7.11-
    7.27 (m, 2H), 4.63-4.83 (m, 1H), 1.73-2.00 (m, 2H), 1.48 (br
    d, J = 6.4 Hz, 6H), 1.19-1.41 (m, 7H); 4Hs not observed
    (3NHs and OH)
    424 MS m/z 411.6 [M + H]+; 1H MMR (methanol-d4) δ: 8.21 (s,
    1H), 8.03 (s, 1H), 7.57 (br d, J = 7.9 Hz, 1H), 7.31 (br d, J =
    7.9 Hz, 1H), 7.24 (s, 1H), 5.38 (s, 1H), 4.23-4.43 (m, 1H),
    2.16-2.43 (m, 2H), 1.61-1.69 (m, 2H), 1.59 (br d, J = 4.9 Hz,
    6H), 1.54 (s, 6H); 3Hs not observed (2NHs and OH)
    • Example 11 Preparation of Compound 401
  • Figure US20230331725A1-20231019-C00160
    • Step 1
  • A mixture of tris(dibenzylideneacetone)dipalladium(0) (15 mg, 0.016 mmol) and 2-di-tert-butylphosphino-3,4,5,6-tetramethyl-2′,4′,6′-triisopropyl-1,1′-biphenyl (21 mg, 0.042 mmol) in dioxane (0.2 mL) and toluene (0.8 mL) was purged with argon, then heated to 120° C. for 5 min. The solution was cooled to room temperature and 3-[4-bromo-2-(methoxymethoxy)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidyl)-1,2,4-triazin-6-amine (150 mg, 0.33 mmol), K3PO4 (145 mg, 0.67 mmol), and 1H-triazole (11 μL, 0.19 mmol) were added. Argon was bubbled thorough the reaction mixture for 5 min, and then the mixture was heated to 120° C. for 30 min. The reaction mixture was cooled to room temperature and purified by silica gel column chromatography eluting with a MeOH/CH2Clz gradient (0-25% MeOH) to afford 3-[2-(methoxymethoxy)-4-(triazol-2-yl)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidyl)-1,2,4-triazin-6-amine (43 mg, 29% yield) as a clear foam. MS m/z 439.6 [M+H]+.
    • Step 2
  • To a solution of 3-[2-(methoxymethoxy)-4-(triazol-2-yl)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidyl)-1,2,4-triazin-6-amine (43 mg, 0.098 mmol) in 1 mL of CH2Cl2 and MeOH (0.5 mL) was added HCl (4 mol/L) in 1,4-dioxane (50 μL, 0.2 mmol) and the mixture was stirred 5 h at room temperature until UPLC showed complete consumption of the starting material. After concentration, the residue was purified by silica gel chromatography eluting with a MeOH/CH2Cl2/2.5% NH4OH gradient (0-30% MeOH/NH4OH) to provide 2-[6-[(2,2,6,6-tetramethyl-4-piperidyl)amino]-1,2,4-triazin-3-yl]-5-(triazol-2-yl)phenol hydrochloride (35 mg, 82% yield) as a yellow solid.
  • MS m/z 395.5 [M+H]+; 1H NMR (methanol-d4) δ: 8.02 (s, 2H), 7.86 (s, 1H), 7.82 (br d, J=8.5 Hz, 1H), 7.70 (d, J=8.5 Hz, 1H), 5.41 (s, 1H), 4.34 (br t, J=11.9 Hz, 1H), 2.37 (br d, J=12.5 Hz, 1H), 2.26 (d, J=12.5 Hz, 1H), 1.62-1.84 (m, 2H), 1.59 (br d, J=4.6 Hz, 6H), 1.53 (s, 6H); 3Hs not observed (2NHs and OH).
  • Using the procedure described for Example 12, additional compounds described herein may be prepared by substituting the appropriate starting material, suitable reagents and reaction conditions, obtaining compounds such as those selected from:
  • Cpd Data
    255 MS m/z 409.4 [M + H]+; 1H MMR (methanol-d4) δ: 8.68 (s,
    1H), 8.39 (d, J = 8.5 Hz, 1H), 7.94 (s, 2H), 7.64-7.74 (m, 2H),
    5.23-5.39 (m, 1H), 3.14 (s, 3H), 1.94-2.08 (m, 4H), 1.64 (s,
    6H), 1.51 (s, 6H); 2Hs not observed (NH and OH)
    • Example 12 Preparation of Compound 286
  • Figure US20230331725A1-20231019-C00161
    • Step 1
  • A solution of racemic (3S,4S)-4-[[6-[2-(methoxymethoxy)-4-(1-tetrahydropyran-2-ylpyrazol-4-yl)phenyl]-1,2,4-triazin-3-yl]amino]-2,2,6,6-tetramethyl-piperidin-3-ol (20 mg, 0.038 mmol) in DMF (0.3 mL) was cooled to 0° C. Sodium hydride (60 mass % in mineral oil) (4.2 mg, 0.11 mmol) was added and stirring at 0° C. was continued for 15 minutes. A stock solution of iodomethane (0.027 mL) in DMF (2.0 mL) was prepared. A portion of this stock solution (0.20 mL) containing iodomethane (0.0027 mL, 0.043 mmol, 1.15 equiv) was added to the reaction and stirring was continued for 10 minutes at 0° C. H2O was added to quench the sodium hydride and the reaction was partitioned between brine and EtOAc. The layers were separated, and the aqueous layer was extracted twice with EtOAc. The combined organic layers were washed twice with brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by silica-gel column chromatography eluting with 0-30% MeOH/CH2Cl2 to yield 6-[2-(methoxymethoxy)-4-(1-tetrahydropyran-2-ylpyrazol-4-yl)phenyl]-N-[(3S,4S)-3-methoxy-2,2,6,6-tetramethyl-4-piperidyl]-1,2,4-triazin-3-amine (16.7 mg, 81% yield). MS m/z 552.7 [M+H]+.
    • Step 2:
  • 6-[2-(Methoxymethoxy)-4-(1-tetrahydropyran-2-ylpyrazol-4-yl)phenyl]-N-[(3S,4S)-3-methoxy-2,2,6,6-tetramethyl-4-piperidyl]-1,2,4-triazin-3-amine (16.7 mg, 0.030 mmol) was dissolved in methanol (0.5 mL) and a hydrogen chloride solution (2 mL, 4.0 M in dioxane) was added. The reaction mixture was stirred at room temperature for 16 h. The reaction was concentrated and the residue was purified by silica-gel column chromatography eluting with 0-100% MeOH (2.5% v/v NH4OH) in CH2Cl2 to yield 2-[3-[[(3 S,4S)-3-methoxy-2,2,6,6-tetramethyl-4-piperidyl]amino]-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol (2.5 mg, 20%).
  • MS m/z 424.5 [M+H]+; 1H NMR (methanol-d4) δ: 9.07 (s, 1H), 7.99 (br s, 2H), 7.81 (d, J=8.2 Hz, 1H), 7.21 (dd, J=8.1, 1.7 Hz, 1H), 7.18 (d, J=1.5 Hz, 1H), 5.52-5.63 (m, 1H), 3.48-3.61 (m, 1H), 3.20 (s, 3H), 1.94-2.08 (m, 2H), 1.40 (s, 3H), 1.36 (s, 3H), 1.24 (s, 3H), 1.14 (s, 3H); 4Hs not observed (3 NHs and OH).
  • Using the procedure described for Example 13, additional compounds described herein may be prepared by substituting the appropriate starting material, suitable reagents and reaction conditions, obtaining compounds such as those selected from:
  • Cpd Data
    293 MS m/z 438.5 [M + H]+; 1H NMR (methanol-d4) δ: 9.06 (s,
    1H), 7.99 (br s, 2H), 7.81 (d, J = 8.2 Hz, 1H), 7.21 (dd, J = 8.2,
    1.5 Hz, 1H), 7.18 (d, J = 1.5 Hz, 1H), 5.35 (br s, 1H), 3.23 (s,
    3H), 3.05-3.18 (m, 1H), 2.44-2.69 (m, 3H), 2.05 (br dd, J =
    13.1, 9.5 Hz, 1H), 1.79-1.97 (m, 1H), 1.27 (br d, J = 9.2 Hz,
    6H), 1.23 (s, 3H), 1.14 (br s, 3H); 3Hs not observed (2NHs and
    OH)
    • Example 13 Preparation of Compound 165
  • Figure US20230331725A1-20231019-C00162
    • Step 1
  • A solution of racemic tert-butyl 4-oxo-1,3,3a,5,6,6a-hexahydrocyclopenta[c]pyrrole-2-carboxylate (606 mg, 2.69 mmol) in THE (4 mL) was cooled to −78° C. A THE solution of lithium tri-sec-butylborohydride (3.2 mL, 1.0 M) was added dropwise over 20 minutes. Stirring was continued following complete addition at −78° C. and the reaction was slowly warmed to room temperature over 16 h. Upon completion, the reaction was quenched with methanol, and then concentrated in vacuo. The residue was partitioned between EtOAc and saturated aqueous sodium bicarbonate and the layers were separated. The aqueous layer was extracted once with EtOAc and the combined organic layers were dried over sodium sulfate, filtered and concentrated. The residue was purified by silica-gel column chromatography eluting with 0-100% EtOAc/hexanes to yield racemic tert-butyl (3aR,4R,6aS)-4-hydroxy-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxylate (583 mg, 95% yield).
  • MS m/z 250.2 [M+Na]+; 1H NMR (chloroform-d) δ: 4.28 (q, J=5.5 Hz, 1H), 3.64 (dd, J=11.9, 3.1 Hz, 1H), 3.57 (br dd, J=10.8, 7.8 Hz, 1H), 3.37 (br dd, J=11.7, 8.1 Hz, 1H), 3.18 (dd, J=11.0, 3.4 Hz, 1H), 2.63-2.74 (m, 2H), 1.83-1.93 (m, 2H), 1.75-1.82 (m, 1H), 1.55-1.64 (m, 1H), 1.48 (s, 9H); 1H not observed (OH).
    • Step 2
  • Racemic tert-butyl (3aR,4R,6aS)-4-hydroxy-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxylate (583 mg, 2.56 mmol) was cycled under N2, followed by the addition of CH2Cl2 (5 mL). The reaction was cooled to −78° C. with stirring. Methanesulfonyl chloride (0.34 mL, 4.39 mmol) was added followed by trimethylamine (0.69 mL, 4.95 mmol) and the reaction was stirred at −78° C. for 30 minutes, and then allowed to warm to room temperature over 3h. The reaction was partitioned between saturated aqueous sodium bicarbonate and CH2Cl2 and the layers were separated. The organic layer was washed once with saturated aqueous sodium bicarbonate, dilute aqueous acetic acid, and saturated aqueous sodium bicarbonate, and then dried over sodium sulfate, filtered and concentrated to yield tert-butyl (3aR,4R,6aS)-4-methylsulfonyloxy-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxylate (566 mg, 72% yield).
  • MS m/z 328.3 [M+Na]+; 1H NMR (chloroform-d) δ: 5.03 (q, J=6.1 Hz, 1H), 3.45-3.58 (m, 2H), 3.30-3.39 (m, 1H), 3.15 (br dd, J=11.0, 4.0 Hz, 1H), 2.96 (s, 3H), 2.77-2.86 (m, 1H), 2.60-2.71 (m, 1H), 1.99-2.09 (m, 1H), 1.92-1.97 (m, 1H), 1.82-1.91 (m, 1H), 1.50-1.63 (m, 1H), 1.34-1.44 (m, 9H).
    • Step 3
  • To a vial containing racemic tert-butyl (3aR,4R,6aS)-4-methylsulfonyloxy-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxylate (566 mg, 1.85 mmol) was added DMAc (3 mL) and sodium azide (155 mg, 2.38 mmol), which was sealed and warmed to 90° C. with stirring for 20 h. After cooling to room temperature, the reaction was partitioned between EtOAc and saturated aqueous sodium carbonate. The layers were separated, and the organic layer was washed twice with brine, dried over sodium sulfate, filtered and then concentrated to yield racemic tert-butyl (3aR,4S,6aS)-4-azido-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxylate (288 mg, 62% yield).
  • MS m/z 197.1 [M+H-tBu]+; 1H NMR (chloroform-d) δ: 3.65 (br s, 1H), 3.39-3.51 (m, 2H), 3.17 (br d, J=8.9 Hz, 1H), 3.11 (br d, J=8.5 Hz, 1H), 2.67-2.76 (m, 1H), 2.52 (tt, J=8.5, 4.2 Hz, 1H), 1.92-2.00 (m, 2H), 1.64-1.74 (m, 1H), 1.42-1.47 (m, 1H), 1.38 (s, 9H).
    • Step 4
  • Racemic tert-butyl (3aR,4S,6aS)-4-azido-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxylate (70 mg, 0.28 mmol) was dissolved in TFA (2.0 mL) and stirred at room temperature for 10 minutes. The reaction was concentrated, azeotroped with CH2Cl2, and then carried forward without purification. MS m/z 153.3 [M+H]+.
    • Step 5:
  • The residue from step 4 containing racemic (3aR,4S,6aS)-4-azido-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrole; 2,2,2-trifluoroacetic acid (106 mg, 0.28 mmol) was dissolved in DMF (2 mL), followed by the addition of N,N-diisopropylethylamine (0.4 mL, 2.29 mmol) and 6-[2-(methoxymethoxy)-4-(1-tetrahydropyran-2-ylpyrazol-4-yl)phenyl]-3-methylsulfonyl-1,2,4-triazine (86.0 mg, 0.19 mmol). The reaction was warmed to 80° C. with stirring for 3 h, and then cooled to room temperature and concentrated. The residue was purified by column chromatography eluting with 0-100% EtOAc in hexanes to yield racemic (3aR,4S,6aS)-4-azido-2-[6-[2-(methoxymethoxy)-4-(1-tetrahydropyran-2-ylpyrazol-4-yl)phenyl]-1,2,4-triazin-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole (64 mg, 64% yield). MS m/z 518.4 [M+H]+.
    • Step 6:
  • Racemic (3aR,4S,6aS)-4-azido-2-[6-[2-(methoxymethoxy)-4-(1-tetrahydropyran-2-ylpyrazol-4-yl)phenyl]-1,2,4-triazin-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole (64 mg, 0.12 mmol), triphenylphosphine (48 mg, 0.18 mmol), THE (2 mL), and H2O (1 mL) were combined and warmed to 80° C. with stirring for 3 h. The reaction was cooled to room temperature and concentrated. The residue was purified by column chromatography eluting with 0-100% EtOAc/hexanes to yield racemic (3aR,4S,6aS)-2-[6-[2-(methoxymethoxy)-4-(1-tetrahydropyran-2-ylpyrazol-4-yl)phenyl]-1,2,4-triazin-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-4-amine (45 mg, 75% yield).
  • MS m/z 492.4 [M+H]+; 1H NMR (methanol-d4) δ: 8.74 (s, 1H), 8.23 (s, 1H), 7.93 (s, 1H), 7.72 (d, J=7.9 Hz, 1H), 7.42 (s, 1H), 7.34 (br d, J=7.9 Hz, 1H), 5.42 (br d, J=10.1 Hz, 1H), 5.32 (s, 2H), 4.06 (br d, J=11.6 Hz, 1H), 3.69-3.88 (m, 4H), 3.55 (br dd, J=11.6, 4.0 Hz, 1H), 3.45 (s, 3H), 3.39-3.44 (m, 1H), 3.00-3.10 (m, 1H), 2.70-2.79 (m, 1H), 2.12-2.29 (m, 3H), 2.04 (br d, J=8.9 Hz, 2H), 1.67-1.82 (m, 3H), 1.57-1.66 (m, 2H); 2Hs not observed (2 NHs).
    • Step 7
  • Racemic (3aR,4S,6aS)-2-[6-[2-(methoxymethoxy)-4-(1-tetrahydropyran-2-ylpyrazol-4-yl)phenyl]-1,2,4-triazin-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-4-amine (3 mg, 0.0053 mmol) was dissolved in methanol (0.5 mL) and a hydrogen chloride solution in dioxane (2.0 mL, 4.0 M) and stirred at room temperature for 1 h. The reaction was concentrated, and the residue was dissolved in MeOH, followed by Et2O addition to precipitate solid. The solid was filtered, then rinsed through the filter with MeOH and the methanolic filtrate was concentrated to yield racemic 2-[3-[(3aR,4S,6aS)-4-amino-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl]-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)phenol; dihydrochloride (2.1 mg, 91% yield).
  • MS m/z 364.3 [M+H]+; 1H NMR (methanol-d4) δ: 8.18 (br s, 2H), 7.53 (d, J=8.2 Hz, 1H), 7.18 (br d, J=8.5 Hz, 1H), 7.15 (s, 1H), 5.83 (br s, 1H), 3.88 (br t, J=9.2 Hz, 1H), 3.72-3.81 (m, 1H), 3.52-3.71 (m, 2H), 3.40 (br t, J=11.0 Hz, 1H), 3.02-3.15 (m, 1H), 2.83-2.95 (m, 1H), 2.24-2.37 (m, 1H), 2.13 (br dd, J=12.8, 5.2 Hz, 1H), 1.69-1.81 (m, 1H), 1.54-1.69 (m, 1H); 4Hs not observed (3NHs and OH).
    • Biological Examples
  • The following in vitro biological examples demonstrate the usefulness of the compounds of the present description for treating Huntington's disease.
  • To describe in more detail and assist in understanding the present description, the following non-limiting biological examples are offered to more fully illustrate the scope of the description and are not to be construed as specifically limiting the scope thereof. Such variations of the present description that may be now known or later developed, which would be within the purview of one skilled in the art to ascertain, are considered to fall within the scope of the present description and as hereinafter claimed.
  • Compounds of Formula (I) or Formula (II) were tested using the Meso Scale Discovery (MSD) Assay provided in International Application No. PCT/US2016/066042, filed on Dec. 11, 2016 and claiming priority to United States Provisional Application U.S. 62/265,652 filed on Dec. 10, 2015, the entire contents of which are incorporated herein by reference.
  • The Endogenous Huntingtin Protein assay used in Example 1 was developed using the ELISA-based MSD electrochemiluminescence assay platform.
    • Example 1 Endogenous Huntingtin Protein Assay
  • Meso Scale Discovery (MSD) 96-well or 384-well plates were coated overnight at 4° C. with MW1 (expanded polyglutamine) or MAB2166 monoclonal antibody (for capture) at a concentration of 1 μg/mL in PBS (30 μL per well). Plates were then washed three times with 300 μL wash buffer (0.05% Tween-20 in PBS) and blocked (100 μL blocking buffer; 5% BSA in PBS) for 4-5 hours at room temperature with rotational shaking and then washed three times with wash buffer.
  • Samples (25 μL) were transferred to the antibody-coated MSD plate and incubated overnight at 4° C. After removal of the lysates, the plate was washed three times with wash buffer, and 25 μL of #5656S (Cell signaling; rabbit monoclonal) secondary antibody (diluted to 0.25 μg/mL in 0.05% Tween-20 in blocking buffer) was added to each well and incubated with shaking for 1 Hour at room temperature. Following incubation with the secondary antibody, the wells were rinsed with wash buffer after which 25 μL of goat anti-rabbit SULFO TAG secondary detection antibody (required aspect of the MSD system) (diluted to 0.25 μg/mL in 0.05% Tween-20 in blocking buffer) was added to each well and incubated with shaking for 1 hour at room temperature. After rinsing three times with wash buffer, 150 μL of read buffer T with surfactant (MSD) were added to each empty well, and the plate was imaged on a SI 6000 imager (MSD) according to manufacturers' instructions provided for 96- or 384-well plates. The resulting IC50 values (μM) for compounds tested are shown in Table 1.
  • As shown in Table 1, test compounds described herein had the following IC50 values, an IC50 value between >3 μM and ≤9 μM is indicated by a single star (*), an IC50 value between >1 μM and ≤3 μM is indicated by two stars (**), an IC50 value between >0.5 μM and ≤1 μM is indicated by three stars (***), an IC50 value between >0.1 μM and ≤0.5 μM is indicated by four stars (****) and an IC50 value of ≤0.1 μM is indicated by five stars (*****).
  • TABLE 1
    Cpd IC50
    1 ***
    2 *****
    3 *****
    4 *****
    5 *****
    6 *****
    7 *****
    8 *****
    9 *****
    10 *****
    11 *****
    12 *****
    13 *****
    14 *****
    15 *****
    16 *****
    17 ****
    18 *****
    19 *****
    20 ***
    21 *****
    22 *****
    23 *****
    24 ****
    33 **
    50 *****
    51 ***
    52 ****
    53 ****
    54 ***
    55 *****
    56 *****
    57 *****
    58 *****
    59 *****
    60 *****
    61 *****
    62 ****
    63 *****
    64 *****
    65 *****
    66 *****
    67 ****
    68 *****
    69 *****
    70 ****
    71 *****
    72 *****
    73 *****
    74 *****
    75 ***
    76 *****
    77 *****
    78 *****
    79 *****
    80 *****
    81 *****
    82 ****
    83 *****
    84 *****
    85 *****
    86 ****
    87 *****
    88 *****
    89 *****
    90 *****
    91 *****
    92 *****
    93 *****
    94 ****
    95 ****
    96 *****
    97 *****
    98 ****
    99 *****
    100 *****
    101 ****
    102 *****
    103 *****
    104 *****
    105 ****
    106 *****
    107 **
    108 ***
    109 ****
    110 ****
    111 *****
    112 ****
    113 ****
    114 *****
    115 ****
    116 ****
    117 ****
    118 ****
    119 *****
    120 ****
    121 *****
    122 ****
    123 *****
    124 ****
    125 *****
    126 *****
    127 ****
    128 ****
    129 ****
    130 ****
    131 *****
    132 ****
    133 *****
    134 *****
    135 ****
    136 *****
    137 *****
    138 *****
    139 ****
    140 *****
    141 *****
    142 *****
    143 *****
    144 *****
    145 *****
    146 *****
    147 *****
    148 *****
    149 *****
    150 *****
    151 *****
    152 *****
    153 ****
    154 *****
    155 *****
    156 *****
    157 ****
    158 **
    159 **
    160 **
    161 *****
    162 ****
    163 **
    164 ****
    165 *****
    166 *****
    167 *****
    168 ****
    169 *****
    170 *****
    171 *****
    172 *****
    173 *****
    174 *****
    175 **
    176 *****
    177 *****
    178 *****
    179 *****
    180 **
    181 ***
    182 ***
    183 ****
    184 *****
    185 *****
    186 *****
    187 ****
    188 *****
    189 *****
    190 *****
    191 *****
    192 ****
    193 **
    194 *****
    195 *****
    196 *****
    197 ****
    198 *****
    199 *****
    200 *****
    201 *****
    202 *****
    203 *****
    204 *****
    205 *****
    206 **
    207 **
    208 ****
    209 **
    210 *****
    211 *****
    212 ****
    213 **
    214 *****
    215 ****
    216 ****
    217 *****
    218 ****
    219 ****
    220 ***
    221 ***
    222 *****
    223 ****
    224 **
    225 *****
    226 *****
    227 *****
    228 *****
    229 ***
    230 ***
    231 ****
    232 *****
    233 **
    234 ****
    235 *****
    236 *****
    237 ****
    238 *****
    239 *****
    240 *****
    241 *****
    242 *****
    243 *****
    244 *
    245 *****
    246 *****
    247 *****
    248 *****
    249 *****
    250 ****
    251 ****
    252 ***
    253 *****
    254 *****
    255 *****
    256 ****
    257 **
    258 *****
    259 ****
    260 *****
    261 *****
    262 *****
    263 ****
    264 ****
    265 *****
    266 *****
    267 *****
    268 *****
    269 ****
    270 **
    271 ****
    272 ****
    273 *****
    274 *****
    275 *****
    276 *****
    277 *****
    278 *****
    279 *****
    280 *****
    281 *****
    282 ***
    283 **
    284 *****
    285 *****
    286 ****
    287 *****
    288 *****
    289 *****
    290 *****
    291 *****
    292 *****
    293 ****
    294 *****
    295 *****
    296 **
    297 *****
    298 **
    299 *****
    300 **
    301 *****
    302 ***
    303 *****
    304 *****
    305 *****
    306 ****
    307 ***
    308 ****
    309 ***
    310 ****
    311 **
    312 **
    313 **
    314 *****
    315 *****
    316 *****
    317 *****
    318 ****
    319 *****
    320 ****
    321 *****
    322 *****
    323 *****
    324 *****
    325 ****
    326 *****
    327 *****
    328 ****
    329 ****
    330 **
    331 ****
    332 *****
    333 *****
    334 **
    335 *****
    336 *****
    337 *****
    338 ****
    339 *****
    340 *****
    341 *****
    342 ****
    343 *****
    344 *****
    345 ****
    346 ***
    347 *****
    348 *****
    349 ****
    350 *****
    351 *****
    352 *****
    353 **
    354 *****
    355 *****
    356 *****
    357 *****
    358 ****
    359 *****
    360 ****
    361 *****
    362 *****
    363 *****
    364 ****
    365 *****
    366 *****
    367 *****
    368 ****
    369 *****
    370 *****
    371 *****
    372 *****
    373 *****
    374 *****
    375 *****
    376 *****
    377 *****
    378 *****
    379 *****
    380 *****
    381 *****
    382 *****
    383 *****
    384 *****
    385 *****
    386 ****
    387 *****
    388 *****
    389 *****
    390 *****
    391 *****
    392 *****
    393 *****
    394 *****
    395 *****
    396 *****
    397 *****
    398 *****
    399 *****
    400 *****
    401 *****
    402 *****
    403 *****
    404 *****
    405 *****
    406 *****
    407 *****
    408 *****
    409 *****
    410 *****
    411 *****
    412 *****
    413 *****
    414 *****
    415 *****
    416 *****
    417 *****
    418 *****
    419 *****
    420 *****
    421 *****
    422 *****
    423 *****
    424 *****
  • Without regard to whether a document cited herein was specifically and individually indicated as being incorporated by reference, all documents referred to herein are incorporated by reference into the present application for any and all purposes to the same extent as if each individual reference was fully set forth herein.
  • Having now fully described the subject matter of the claims, it will be understood by those having ordinary skill in the art that the same can be performed within a wide range of equivalents without affecting the scope of the subject matter or particular aspects described herein. It is intended that the appended claims be interpreted to include all such equivalents.

Claims (22)

1. A compound of Formula (I) or Formula (II):
Figure US20230331725A1-20231019-C00163
or a form thereof, wherein:
X is CHR1a, C═O, O, NR1b, or a bond;
R1a is hydrogen, halogen, hydroxyl, cyano, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl, amino or hydroxyl-C1-4alkyl;
R1b is hydrogen, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl or hydroxyl-C1-4alkyl;
B is heterocyclyl,
wherein heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2;
R2 is independently selected from halogen, hydroxyl, cyano, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl, amino, C1-6alkyl-amino, (C1-6alkyl)2-amino, halo-C1-4alkyl-amino, (halo-C1-6alkyl)2-amino, hydroxy-C1-4alkyl-amino, C1-4alkoxy-C1-4alkyl-amino, amino-C1-4alkyl, C1-4alkyl-amino-C1-4alkyl, (C1-4alkyl-amino)2-C1-4alkyl, C1-4alkoxy, halo-C1-4alkoxy, hydroxyl-C1-4alkoxy, C1-4alkyl-C1-4alkoxy, C3-10cycloalkyl, C3-10cycloalkyl-amino, C3-10cycloalkyl-amino-C1-4alkyl, heteroaryl-C1-4alkyl, heteroaryl-amino, heteroaryl-C1-4alkyl-amino, heterocyclyl, heterocyclyl-C1-4alkyl, heterocyclyl-amino, heterocyclyl-amino-C1-4alkyl, heterocyclyl-C1-4alkoxy, heterocyclyl-amino-C3-10cycloalkyl, phenyl, and phenyl-C1-4alkoxy,
wherein heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, or S,
wherein heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, wherein C3-10cycloalkyl is a saturated or partially unsaturated 3-7 membered monocyclic ring system, and
wherein each instance of phenyl, heteroaryl, heterocyclyl, or C3-10cycloalkyl is optionally substituted with 1 or 2 substituents each selected from R3;
R3 is independently selected from halogen, hydroxyl, cyano, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl, amino, C1-4alkoxy, and halo-C1-4alkoxy;
n is 1 or 2;
R4 is independently selected from halogen, hydroxyl, cyano, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl, amino, C1-4alkyl-amino, (C1-4alkyl)2-amino, C1-4alkoxy, halo-C1-4alkoxy, heteroaryl, heterocyclyl, and phenyl,
wherein heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, or S,
wherein heterocyclyl is a saturated or partially unsaturated 3-6 membered monocyclic or 9-10 membered bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and
wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R5;
R5 is independently selected from halogen, hydroxyl, cyano, nitro, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl, amino, C1-4alkyl-amino, (C1-4alkyl)2-amino, amino-C1-4alkyl, hydroxyl-C1-4alkyl, C1-4alkyl-carbonyl, C1-4alkoxy, C1-4alkylthio, halo-C1-4alkoxy, and C3-10cycloalkyl;
wherein a form of the compound is selected from the group consisting of a salt, hydrate, solvate, racemate, enantiomer, diastereomer, stereoisomer, and tautomer form thereof.
2. The compound of claim 1, or form thereof, wherein X is selected from NR1b and a bond.
3. The compound of claim 1, or form thereof, wherein B is heterocyclyl selected from azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, 1,4-diazepanyl, 1,2-dihydropyridinyl, 1,2,5,6-tetrahydropyridinyl, 1,2,3,6-tetrahydropyridinyl, hexahydrocyclopentapyrrol-(1H)-yl, hexahydropyrrolo[3,2-b]pyrrol-(2H)-yl, hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, (3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, octahydro-2H-pyrrolo[3,4-c]pyridinyl, octahydro-5H-pyrrolo[3,2-c]pyridinyl, octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, hexahydropyrrolo[1,2-a]pyrazin-(2H)-one, hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (7R,8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, hexahydro-1H-cyclobuta[1.2-c:1,4-c′]dipyrrol-(3H)-yl, (8aS)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, octahydro-2H-pyrido[1,2-a]pyrazinyl, hexahydropyrrolo[3,4-b][1,4]oxazin-(2H)-yl, 5-azaspiro[2.4]heptanyl, 2-oxa-6-azaspiro[3.4]octanyl, 3-azabicyclo[3.1.0]hexanyl, 8-azabicyclo[3.2.1]octanyl, (1R,5S)-8-azabicyclo[3.2.1]octanyl, 8-azabicyclo[3.2.1]oct-2-en-yl, (1R,5S)-8-azabicyclo[3.2.1]oct-2-en-yl, 9-azabicyclo[3.3.1]nonanyl, (1R,5S)-9-azabicyclo[3.3.1]nonanyl, 2,5-diazabicyclo[2.2.1]heptanyl, (1S,4S)-2,5-diazabicyclo[2.2.1]heptanyl, 1,4-diazabicyclo[3.1.1]heptanyl, 3,6-diazabicyclo[3.2.0]heptanyl, 2,5-diazabicyclo[2.2.2]octanyl, 1,4-diazabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, (1R,5S)-3,8-diazabicyclo[3.2.1]octanyl, 1,4-diazabicyclo[3.2.2]nonanyl, azaspiro[3.3]heptanyl, 4,7-diazaspiro[2.5]octanyl, 2,6-diazaspiro[3.3]heptan-2-yl, 2,6-diazaspiro[3.4]octanyl, 1,7,-diazaspiro[4.4]nonanyl, 1,7-diazaspiro[3.5]nonanyl, 2,6-diazaspiro[3.5]nonanyl, 2,7-diazaspiro[3.5]nonanyl, 5,8-diazaspiro[3.5]nonanyl, 2,7-diazaspiro[4.4]nonanyl, 2,7-diazaspiro[4.5]decanyl, 2,8-diazaspiro[4.5]decanyl, 6,9-diazaspiro[4.5]decyl, and 7-azadispiro[5.1.58.36]hexadecanyl, optionally substituted with 1, 2, 3, 4, or 5 R2 substituents.
4. The compound of claim 1, or form thereof, wherein B is selected from pyrrolidinyl, piperidinyl, piperazinyl, hexahydrocyclopentapyrrol-(1H)-yl, hexahydropyrrolo[3,2-b]pyrrol-(2H)-yl, hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, octahydro-2H-pyrrolo[3,4-c]pyridinyl, octahydro-5H-pyrrolo[3,2-c]pyridinyl, octahydro-6H-pyrrolo[3,4-b]pyridinyl, hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, hexahydropyrrolo[3,4-b][1,4]oxazin-(2H)-yl, 5-azaspiro[2.4]heptanyl, 2-oxa-6-azaspiro[3.4]octanyl, 3-azabicyclo[3.1.0]hexanyl, 8-azabicyclo[3.2.1]octanyl, 9-azabicyclo[3.3.1]nonanyl, 2,6-diazaspiro[3.3]heptanyl, 2,6-diazaspiro[3.4]octanyl, 1,7,-diazaspiro[4.4]nonanyl, 1,7-diazaspiro[3.5]nonanyl, 2,6-diazaspiro[3.5]nonanyl, 2,7-diazaspiro[3.5]nonanyl, 2,7-diazaspiro[4.4]nonanyl, 2,7-diazaspiro[4.5]decanyl, 2,8-diazaspiro[4.5]decanyl, 6-oxa-2,9-diazaspiro[4.5]decanyl, and 2,9-diazaspiro[5.5]undecanyl, optionally substituted with 1, 2, 3, 4, or 5 R2 substituents.
5. The compound of claim 1, or form thereof, wherein R4 is heteroaryl selected from thienyl, 1H-pyrazolyl, 1H-imidazolyl, 1,3-thiazolyl, oxazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-thiadiazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl, 1H-tetrazolyl, 2H-tetrazolyl, pyridinyl, pyridin-2(1H)-on-yl, pyrimidinyl, pyrimidin-4(3H)-on-yl, pyridazinyl, pyridazin-3(2H)-on-yl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1H-indolyl, 1H-indazolyl, 2H-indazolyl, indolizinyl, benzofuranyl, benzothienyl, 1H-benzimidazolyl, 1,3-benzoxazolyl, 1,3-benzothiazolyl, 1,3-benzodioxolyl, 1,2,3-benzotriazolyl, 9H-purinyl, furo[3,2-b]pyridinyl, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, 1,3-oxazolo[5,4-b]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-d]pyrimidinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-c]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, pyrrolo[1,2-a]pyrazinyl, pyrrolo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyridin-yl, pyrazolo[1,5-a]pyridinyl, 1H-pyrazolo[3,4-b]pyrazinyl, 1H-pyrazolo[3,4-b]pyridinyl, 1H-pyrazolo[3,4-b]pyridinyl, 1H-pyrazolo[3,4-c]pyridinyl, 1H-pyrazolo[3,4-c]pyridinyl, 1H-pyrazolo[4,3-b]pyridinyl, 1H-pyrazolo[4,3-b]pyridinyl, 1H-pyrazolo[4,3-d]pyrimidinyl, 2H-pyrazolo[4,3-b]pyridinyl, 2H-pyrazolo[4,3-c]pyridin-yl, 5H-pyrrolo[2,3-b]pyrazinyl, pyrazolo[1,5-a]pyrazinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-c]pyrimidinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, imidazo[1,2-a]pyrazinyl, 1H-imidazo[4,5-b]pyridinyl, 3H-imidazo[4,5-b]pyridinyl, imidazo[2,1-b][1,3]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, [1,3]oxazolo[4,5-b]pyridinyl, [1,2,3]triazolo[1,5-a]pyridinyl, [1,2,3]triazolo[1,5-a]pyridinyl, 1H-[1,2,3]triazolo[4,5-b]pyridinyl, 3H-[1,2,3]triazolo[4,5-b]pyridinyl, tetrazolo[1,5-a]pyridinyl, tetrazolo[1,5-b]pyridazinyl, quinolinyl, isoquinolinyl, and quinoxalinyl, optionally substituted with 1 or 2 R5 substituents.
6. The compound of claim 1, or form thereof, wherein R4 is heteroaryl selected from thienyl, 1H-pyrazolyl, 1H-imidazolyl, 1,3-thiazolyl, oxazolyl, 1,3,4-oxadiazolyl, 1,2,4-thiadiazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl, 2H-tetrazolyl, pyridinyl, pyrimidinyl, pyrimidin-4(3H)-on-yl, pyridazinyl, pyridazin-3(2H)-on-yl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1H-indazolyl, 1H-benzimidazolyl, 1,3-benzoxazolyl, 1,3-benzodioxolyl, 1,2,3-benzotriazolyl, 1,3-oxazolo[5,4-b]pyridinyl, 1H-pyrazolo[3,4-b]pyrazinyl, 1H-pyrazolo[3,4-b]pyridinyl, 1H-pyrazolo[3,4-c]pyridinyl, 1H-pyrazolo[4,3-b]pyridinyl, 1H-pyrazolo[4,3-d]pyrimidinyl, 5H-pyrrolo[2,3-b]pyrazinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, 1H-imidazo[4,5-b]pyridinyl, 3H-imidazo[4,5-b]pyridinyl, [1,2,3]triazolo[1,5-a]pyridinyl, 1H-[1,2,3]triazolo[4,5-b]pyridinyl, 3H-[1,2,3]triazolo[4,5-b]pyridinyl, tetrazolo[1,5-a]pyridinyl, tetrazolo[1,5-b]pyridazinyl, and quinolinyl, optionally substituted with 1 or 2 R5 substituents.
7. The compound of claim 1, wherein the form of the compound is a compound salt selected from hydrochloride, hydrobromide, trifluoroacetate, formate, dihydrochloride, dihydroiodide, trihydrochloride, tetrahydrochloride, dihydrobromide and ditrifluoroacetate.
8-9. (canceled)
10. A method for treating or ameliorating Huntington's Disease (HD) in a subject in need thereof comprising, administering to the subject an effective amount of the compound or form thereof of claim 1.
11. The method of claim 10, wherein the effective amount of the compound or form thereof is in a range of from about 0.001 mg/kg/day to about 500 mg/kg/day.
12-17. (canceled)
18. A pharmaceutical composition comprising the compound or form thereof of claim 1 in admixture with one or more pharmaceutically acceptable excipients.
19. A compound of Formula (I) or Formula (II):
Figure US20230331725A1-20231019-C00164
or a form thereof, wherein:
X is CHR1a, C═O, O, NR1b, or a bond;
R1a is hydrogen, halogen, hydroxyl, cyano, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl, amino or hydroxyl-C1-4alkyl;
R1b is hydrogen, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl or hydroxyl-C1-4alkyl;
B is heterocyclyl,
wherein heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2;
R2 is independently selected from halogen, hydroxyl, cyano, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl, amino, C1-6alkyl-amino, (C1-6alkyl)2-amino, halo-C1-4alkyl-amino, (halo-C1-6alkyl)2-amino, hydroxy-C1-4alkyl-amino, C1-4alkoxy-C1-4alkyl-amino, amino-C1-4alkyl, C1-4alkyl-amino-C1-4alkyl, (C1-4alkyl-amino)2-C1-4alkyl, C1-4alkoxy, halo-C1-4alkoxy, hydroxyl-C1-4alkoxy, C1-4alkyl-C1-4alkoxy, C3-10cycloalkyl, C3-10cycloalkyl-amino, C3-10cycloalkyl-amino-C1-4alkyl, heteroaryl-C1-4alkyl, heteroaryl-amino, heteroaryl-C1-4alkyl-amino, heteroaryl-C1-4alkyl-amino-C1-4alkyl, heterocyclyl, heterocyclyl-C1-4alkyl, heterocyclyl-amino, heterocyclyl-amino-C1-4alkyl, heterocyclyl-C1-4alkoxy, heterocyclyl-amino-C3-10cycloalkyl, phenyl, and phenyl-C1-4alkoxy,
wherein heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, or S,
wherein heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S,
wherein C3-10cycloalkyl is a saturated or partially unsaturated 3-7 membered monocyclic ring system, and
wherein each instance of phenyl, heteroaryl, heterocyclyl, or C3-10cycloalkyl is optionally substituted with 1 or 2 substituents each selected from R3;
R3 is independently selected from halogen, hydroxyl, cyano, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl, amino, C1-4alkoxy, and halo-C1-4alkoxy;
n is 1 or 2;
R4 is independently selected from halogen, hydroxyl, cyano, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl, amino, C1-4alkyl-amino, (C1-4alkyl)2-amino, C1-4alkoxy, halo-C1-4alkoxy, heteroaryl, heterocyclyl, and phenyl,
wherein heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, or S,
wherein heterocyclyl is a saturated or partially unsaturated 3-6 membered monocyclic or 9-10 membered bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and
wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R5;
R5 is independently selected from halogen, hydroxyl, cyano, nitro, C1-4alkyl, deutero-C1-4alkyl, halo-C1-4alkyl, amino, C1-4alkyl-amino, (C1-4alkyl)2-amino, amino-C1-4alkyl, hydroxyl-C1-4alkyl, C1-4alkyl-carbonyl, C1-4alkoxy, C1-4alkylthio, halo-C1-4alkoxy, and C3-10cycloalkyl;
wherein a form of the compound is selected from the group consisting of a salt, hydrate, solvate, racemate, enantiomer, diastereomer, stereoisomer, and tautomer form thereof.
20. The compound of claim 19, or form thereof, wherein X is selected from NR1b and a bond.
21. The compound of claim 19, or form thereof, wherein B is heterocyclyl selected from azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, 1,4-diazepanyl, 1,2-dihydropyridinyl, 1,2,5,6-tetrahydropyridinyl, 1,2,3,6-tetrahydropyridinyl, hexahydrocyclopentapyrrol-(1H)-yl, hexahydropyrrolo[3,2-b]pyrrol-(2H)-yl, hexahydropyrrolo [3,4-b]pyrrol-(2H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, (3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, octahydro-2H-pyrrolo[3,4-c]pyridinyl, octahydro-5H-pyrrolo[3,2-c]pyridinyl, octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, hexahydropyrrolo[1,2-a]pyrazin-(2H)-one, hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (7R,8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, hexahydro-1H-cyclobuta[1.2-c:1,4-c′]dipyrrol-(3H)-yl, (8aS)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, octahydro-2H-pyrido[1,2-a]pyrazinyl, hexahydropyrrolo[3,4-b][1,4]oxazin-(2H)-yl, 5-azaspiro[2.4]heptanyl, 2-oxa-6-azaspiro[3.4]octanyl, 3-azabicyclo[3.1.0]hexanyl, 8-azabicyclo[3.2.1]octanyl, (1R,5S)-8-azabicyclo[3.2.1]octanyl, 8-azabicyclo[3.2.1]oct-2-en-yl, (1R,5S)-8-azabicyclo[3.2.1]oct-2-en-yl, 9-azabicyclo[3.3.1]nonanyl, (1R,5S)-9-azabicyclo[3.3.1]nonanyl, 2,5-diazabicyclo[2.2.1]heptanyl, (1S,4S)-2,5-diazabicyclo[2.2.1]heptanyl, 1,4-diazabicyclo[3.1.1]heptanyl, 3,6-diazabicyclo[3.2.0]heptanyl, 2,5-diazabicyclo[2.2.2]octanyl, 1,4-diazabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, (1R,5S)-3,8-diazabicyclo[3.2.1]octanyl, 1,4-diazabicyclo[3.2.2]nonanyl, azaspiro[3.3]heptanyl, 4,7-diazaspiro[2.5]octanyl, 2,6-diazaspiro[3.3]heptan-2-yl, 2,6-diazaspiro[3.4]octanyl, 1,7,-diazaspiro[4.4]nonanyl, 1,7-diazaspiro[3.5]nonanyl, 2,6-diazaspiro[3.5]nonanyl, 2,7-diazaspiro[3.5]nonanyl, 5,8-diazaspiro[3.5]nonanyl, 2,7-diazaspiro[4.4]nonanyl, 2,7-diazaspiro[4.5]decanyl, 2,8-diazaspiro[4.5]decanyl, 6,9-diazaspiro[4.5]decyl, and 7-azadispiro[5.1.58.36]hexadecanyl, optionally substituted with 1, 2, 3, 4, or 5 R2 substituents.
22. The compound of claim 19, or form thereof, wherein B is selected from pyrrolidinyl, piperidinyl, piperazinyl, hexahydrocyclopentapyrrol-(1H)-yl, hexahydropyrrolo[3,2-b]pyrrol-(2H)-yl, hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, octahydro-2H-pyrrolo[3,4-c]pyridinyl, octahydro-5H-pyrrolo[3,2-c]pyridinyl, octahydro-6H-pyrrolo[3,4-b]pyridinyl, hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, hexahydropyrrolo[3,4-b][1,4]oxazin-(2H)-yl, 5-azaspiro[2.4]heptanyl, 2-oxa-6-azaspiro[3.4]octanyl, 3-azabicyclo[3.1.0]hexanyl, 8-azabicyclo[3.2.1]octanyl, 9-azabicyclo[3.3.1]nonanyl, 2,6-diazaspiro[3.3]heptanyl, 2,6-diazaspiro[3.4]octanyl, 1,7,-diazaspiro[4.4]nonanyl, 1,7-diazaspiro[3.5]nonanyl, 2,6-diazaspiro[3.5]nonanyl, 2,7-diazaspiro[3.5]nonanyl, 2,7-diazaspiro[4.4]nonanyl, 2,7-diazaspiro[4.5]decanyl, 2,8-diazaspiro[4.5]decanyl, 6-oxa-2,9-diazaspiro[4.5]decanyl, and 2,9-diazaspiro[5.5]undecanyl, optionally substituted with 1, 2, 3, 4, or 5 R2 substituents.
23. The compound of claim 19, or form thereof, wherein R4 is heteroaryl selected from thienyl, 1H-pyrazolyl, 1H-imidazolyl, 1,3-thiazolyl, oxazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-thiadiazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl, 1H-tetrazolyl, 2H-tetrazolyl, pyridinyl, pyridin-2(1H)-on-yl, pyrimidinyl, pyrimidin-4(3H)-on-yl, pyridazinyl, pyridazin-3(2H)-on-yl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1H-indolyl, 1H-indazolyl, 2H-indazolyl, indolizinyl, benzofuranyl, benzothienyl, 1H-benzimidazolyl, 1,3-benzoxazolyl, 1,3-benzothiazolyl, 1,3-benzodioxolyl, 1,2,3-benzotriazolyl, 9H-purinyl, furo[3,2-b]pyridinyl, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, 1,3-oxazolo[5,4-b]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-d]pyrimidinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-c]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, pyrrolo[1,2-a]pyrazinyl, pyrrolo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyridin-yl, pyrazolo[1,5-a]pyridinyl, 1H-pyrazolo[3,4-b]pyrazinyl, 1H-pyrazolo[3,4-b]pyridinyl, 1H-pyrazolo[3,4-b]pyridinyl, 1H-pyrazolo[3,4-c]pyridinyl, 1H-pyrazolo[3,4-c]pyridinyl, 1H-pyrazolo[4,3-b]pyridinyl, 1H-pyrazolo[4,3-b]pyridinyl, 1H-pyrazolo[4,3-d]pyrimidinyl, 2H-pyrazolo[4,3-b]pyridinyl, 2H-pyrazolo[4,3-c]pyridin-yl, 5H-pyrrolo[2,3-b]pyrazinyl, pyrazolo[1,5-a]pyrazinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-c]pyrimidinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, imidazo[1,2-a]pyrazinyl, 1H-imidazo[4,5-b]pyridinyl, 3H-imidazo[4,5-b]pyridinyl, imidazo[2,1-b][1,3]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, [1,3]oxazolo[4,5-b]pyridinyl, [1,2,3]triazolo[1,5-a]pyridinyl, [1,2,3]triazolo[1,5-a]pyridinyl, 1H-[1,2,3]triazolo[4,5-b]pyridinyl, 3H-[1,2,3]triazolo[4,5-b]pyridinyl, tetrazolo[1,5-a]pyridinyl, tetrazolo[1,5-b]pyridazinyl, quinolinyl, isoquinolinyl, and quinoxalinyl, optionally substituted with 1 or 2 R5 substituents.
24. The compound of claim 19, or form thereof, wherein R4 is heteroaryl selected from thienyl, 1H-pyrazolyl, 1H-imidazolyl, 1,3-thiazolyl, oxazolyl, 1,3,4-oxadiazolyl, 1,2,4-thiadiazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl, 2H-tetrazolyl, pyridinyl, pyrimidinyl, pyrimidin-4(3H)-on-yl, pyridazinyl, pyridazin-3(2H)-on-yl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1H-indazolyl, 1H-benzimidazolyl, 1,3-benzoxazolyl, 1,3-benzodioxolyl, 1,2,3-benzotriazolyl, 1,3-oxazolo[5,4-b]pyridinyl, 1H-pyrazolo[3,4-b]pyrazinyl, 1H-pyrazolo[3,4-b]pyridinyl, 1H-pyrazolo[3,4-c]pyridinyl, 1H-pyrazolo[4,3-b]pyridinyl, 1H-pyrazolo[4,3-d]pyrimidinyl, 5H-pyrrolo[2,3-b]pyrazinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, 1H-imidazo[4,5-b]pyridinyl, 3H-imidazo[4,5-b]pyridinyl, [1,2,3]triazolo[1,5-a]pyridinyl, 1H-[1,2,3]triazolo[4,5-b]pyridinyl, 3H-[1,2,3]triazolo[4,5-b]pyridinyl, tetrazolo[1,5-a]pyridinyl, tetrazolo[1,5-b]pyridazinyl, and quinolinyl, optionally substituted with 1 or 2 R5 substituents.
25. The compound of claim 19, wherein the form of the compound is a compound salt selected from hydrochloride, hydrobromide, trifluoroacetate, formate, dihydrochloride, dihydroiodide, trihydrochloride, tetrahydrochloride, dihydrobromide and ditrifluoroacetate.
26. A method for treating or ameliorating Huntington's Disease (HD) in a subject in need thereof comprising, administering to the subject an effective amount of the compound or form thereof of claim 19.
27. The method of claim 26, wherein the effective amount of the compound or form thereof is in a range of from about 0.001 mg/kg/day to about 500 mg/kg/day.
28. The compound of claim 1, wherein the compound is a compound salt, wherein the compound salt is 4-(3-hydroxy-4-13-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-ylphenyl)-1,3,5-triazin-2-ol dihydrochloride.
US18/211,134 2018-03-27 2023-06-16 Compounds for treating huntington's disease Abandoned US20230331725A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US18/211,134 US20230331725A1 (en) 2018-03-27 2023-06-16 Compounds for treating huntington's disease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862648699P 2018-03-27 2018-03-27
PCT/US2019/024278 WO2019191229A1 (en) 2018-03-27 2019-03-27 Compounds for treating huntington's disease
US202017040104A 2020-09-22 2020-09-22
US18/211,134 US20230331725A1 (en) 2018-03-27 2023-06-16 Compounds for treating huntington's disease

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US17/040,104 Continuation US11780839B2 (en) 2018-03-27 2019-03-27 Compounds for treating Huntington's disease
PCT/US2019/024278 Continuation WO2019191229A1 (en) 2018-03-27 2019-03-27 Compounds for treating huntington's disease

Publications (1)

Publication Number Publication Date
US20230331725A1 true US20230331725A1 (en) 2023-10-19

Family

ID=68060393

Family Applications (3)

Application Number Title Priority Date Filing Date
US17/040,751 Active US12103926B2 (en) 2018-03-27 2019-03-26 Compounds for treating huntington's disease
US17/040,104 Active US11780839B2 (en) 2018-03-27 2019-03-27 Compounds for treating Huntington's disease
US18/211,134 Abandoned US20230331725A1 (en) 2018-03-27 2023-06-16 Compounds for treating huntington's disease

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US17/040,751 Active US12103926B2 (en) 2018-03-27 2019-03-26 Compounds for treating huntington's disease
US17/040,104 Active US11780839B2 (en) 2018-03-27 2019-03-27 Compounds for treating Huntington's disease

Country Status (13)

Country Link
US (3) US12103926B2 (en)
EP (2) EP3774744B1 (en)
JP (2) JP7399870B2 (en)
KR (2) KR20210005559A (en)
CN (2) CN112135815A (en)
AU (2) AU2019243048A1 (en)
BR (2) BR112020019373A2 (en)
CA (2) CA3094703A1 (en)
EA (2) EA202092001A1 (en)
IL (2) IL277498A (en)
MX (2) MX2020009957A (en)
SG (2) SG11202009212WA (en)
WO (2) WO2019191092A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108697709A (en) 2015-12-10 2018-10-23 Ptc医疗公司 Method for treating Huntington's disease
CN111065626B (en) 2017-06-05 2024-09-27 Ptc医疗公司 Compounds for treating Huntington's disease
MX2019015578A (en) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Methods for treating huntington's disease.
CA3067592A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
RU2020105929A (en) 2017-08-04 2021-09-06 Скайхоук Терапьютикс, Инк. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
CN112020500A (en) * 2017-12-22 2020-12-01 拉文纳制药公司 Aminopyridine derivatives as phosphatidylinositol phosphokinase inhibitors
SG11202009212WA (en) 2018-03-27 2020-10-29 Ptc Therapeutics Inc Compounds for treating huntington's disease
CA3102598A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
CN112805280B (en) 2018-06-27 2024-12-06 Ptc医疗公司 Heteroaryl compounds for the treatment of Huntington's disease
LT3814357T (en) 2018-06-27 2024-06-25 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
JP7212781B2 (en) 2018-12-19 2023-01-25 ディスアーム セラピューティクス， インコーポレイテッド Inhibitors of SARM1 in combination with neuroprotective agents
EP3920917A4 (en) * 2019-02-04 2022-09-28 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING
CN114007613A (en) * 2019-02-05 2022-02-01 斯基霍克疗法公司 Methods and compositions for modulating splicing
JP2022519311A (en) * 2019-02-05 2022-03-22 スカイホーク・セラピューティクス・インコーポレーテッド Methods and compositions for regulating splicing
KR20210135507A (en) * 2019-02-06 2021-11-15 스카이호크 테라퓨틱스, 인코포레이티드 Methods and compositions for controlling splicing
TW202112767A (en) 2019-06-17 2021-04-01 美商佩特拉製藥公司 Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
WO2021084495A1 (en) 2019-11-01 2021-05-06 Novartis Ag The use of a splicing modulator for a treatment slowing progression of huntington's disease
MX2022012575A (en) 2020-04-09 2023-01-24 Ptc Therapeutics Inc Compounds for treating huntington's disease.
AU2021272972A1 (en) 2020-05-13 2022-12-08 Chdi Foundation, Inc. HTT modulators for treating Huntington's disease
TW202216671A (en) * 2020-06-25 2022-05-01 瑞士商諾華公司 Process for the manufacture of 1,4-disubstituted pyridazine compounds
WO2022031998A2 (en) * 2020-08-05 2022-02-10 Skyhawk Therapeutics, Inc. Process for the preparation of intermediates useful in the preparation of compounds that modulate splicing
WO2022032007A2 (en) * 2020-08-05 2022-02-10 Skyhawk Therapeutics, Inc. Process for the preparation of intermediates useful in the preparation of compounds that modulate splicing
MX2023001558A (en) 2020-08-05 2023-04-26 Skyhawk Therapeutics Inc Compositions for modulating splicing.
TW202304446A (en) 2021-03-29 2023-02-01 瑞士商諾華公司 The use of a splicing modulator for a treatment slowing progression of huntington’s disease
JPWO2022230912A1 (en) 2021-04-28 2022-11-03
WO2023028536A1 (en) * 2021-08-25 2023-03-02 Ptc Therapeutics, Inc. 1,2,4-triazine derivatives useful as inhibitors of nlrp3
WO2023034836A1 (en) * 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
CN116063307B (en) 2021-10-29 2025-08-19 中国药科大学 SHP2 and CDK4/6 double-target inhibition compound synthesis and preparation method and application thereof
IL312891A (en) 2021-11-17 2024-07-01 Chdi Foundation Inc HTT modulators for the treatment of Huntington's disease
JP2025501373A (en) * 2022-01-07 2025-01-17 薬捷安康（南京）科技股▲分▼有限公司 Nlrp3 inflammasome inhibitors and uses thereof
EP4558499A1 (en) * 2022-07-21 2025-05-28 F. Hoffmann-La Roche AG Nlrp3 inhibitors
UY40374A (en) 2022-08-03 2024-02-15 Novartis Ag NLRP3 INFLAMASOME INHIBITORS
WO2024097598A1 (en) * 2022-11-02 2024-05-10 Merck Sharp & Dohme Llc Triazines useful as inhibitors of nod-like receptor protein 3
TW202444714A (en) * 2023-03-20 2024-11-16 香港商英矽智能科技知識產權有限公司 Nlrp3 inflammasome inhibitors and uses thereof
WO2024259336A2 (en) * 2023-06-16 2024-12-19 Plexium, Inc. Compounds and pharmaceutical compositions that degrade swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily a
WO2025059069A1 (en) * 2023-09-12 2025-03-20 Zomagen Biosciences Ltd Nlrp3 modulators

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902695A (en) * 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists

Family Cites Families (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637271A (en) 1963-04-04 1900-01-01
US3558618A (en) 1968-04-01 1971-01-26 Dow Chemical Co Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones
GB1383409A (en) 1972-09-09 1974-02-12 Pfizer Ltd Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them
US4122274A (en) 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
JPS56150091A (en) 1980-03-28 1981-11-20 Janssen Pharmaceutica Nv 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine- 4-one derivative and its manufacture
US4342870A (en) 1980-03-28 1982-08-03 Janssen Pharmaceutica N.V. Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
FR2567518B1 (en) 1984-07-11 1987-11-13 Sanofi Sa NOVEL NITROGEN HETEROCYCLIC CORE COMPOUNDS, THEIR PREPARATION AND THE MEDICINAL PRODUCTS CONTAINING THE SAME
US5089633A (en) 1987-04-28 1992-02-18 Georgia Tech Research Corporation Substituted isocoumarins
US5726182A (en) 1990-05-02 1998-03-10 Abbott Laboratories Quinolizinone type compounds
WO1993023398A1 (en) 1992-05-13 1993-11-25 E.I. Du Pont De Nemours And Company Substituted pyrido[1,2-a]pyrimidinone derivatives as fungicides
CN1123038A (en) 1993-05-11 1996-05-22 北卡罗来纳大学查珀尔希尔分校 Antisense oligonucleotides preventing aberrant splicing and methods of use thereof
KR19990022524A (en) 1995-06-06 1999-03-25 웨인스톡 스티븐 에프. Quinolone type compound
US5916916A (en) 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
US5869500A (en) 1996-12-13 1999-02-09 Hoffmann-La Roche Inc. Pyridone compounds useful in treating Alzheimer's disease
CA2269561C (en) 1998-04-22 2007-06-05 Dainippon Ink And Chemicals, Inc. Naphthalene derivative and liquid crystal composition comprising the same
US6630488B1 (en) 1998-09-21 2003-10-07 Biochem Pharma, Inc. Quinolizinones as integrin inhibitors
US6172216B1 (en) 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
US6210892B1 (en) 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
US6214986B1 (en) 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
HK1048114A1 (en) 1999-10-28 2003-03-21 基本治疗公司 Drug discharge pump inhibitors
AU3042601A (en) 2000-01-24 2001-07-31 Thrombogenix Pty Ltd Therapeutic morpholino-substituted compounds
ATE544473T1 (en) 2000-11-09 2012-02-15 Cold Spring Harbor Lab CHIMERIC MOLECULES FOR MODULATION OF GENE EXPRESSION
US6774134B2 (en) 2000-12-20 2004-08-10 Bristol-Myers Squibb Company Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
MXPA03005610A (en) 2000-12-21 2003-10-06 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors.
EP1389463A4 (en) 2001-04-26 2008-09-17 Daiichi Seiyaku Co MEDICAMENT FOR INHIBITING A PUMP WHICH ELIMINATES MEDICINAL PRODUCTS
WO2003049739A1 (en) 2001-12-07 2003-06-19 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as gsk-3 inhibitors
GB0205281D0 (en) 2002-03-06 2002-04-17 Novartis Ag Organic compounds
AU2003256755A1 (en) 2002-07-24 2004-02-09 Ptc Therapeutics, Inc. Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
WO2004019002A2 (en) 2002-08-23 2004-03-04 The Board Of Trustees Of The Leland Stanford Junior University Fluorescent glycosides and methods for their use
US7220741B2 (en) 2002-09-30 2007-05-22 Neurosearch A/S 1,4-diazabicycloalkane derivatives, their preparation and use
MXPA05005116A (en) 2002-11-12 2005-07-01 Abbott Lab Bicyclic-substituted amines as histamine-3 receptor ligands.
US20070078144A1 (en) 2003-01-29 2007-04-05 Stockwell Brent R Agents for treating neurodegenerative diseases
US20040224952A1 (en) 2003-05-07 2004-11-11 Cowart Marlon D. Fused bicyclic-substituted amines as histamine-3 receptor ligands
CA2528771A1 (en) 2003-06-20 2004-12-29 Chiron Corporation Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents
GB0315494D0 (en) 2003-07-02 2003-08-06 Biofocus Plc Compounds which bind to the active site of protein kinase enzymes
CN1829709A (en) 2003-08-01 2006-09-06 健亚生物科技公司 Bicyclic imidazol derivatives against flaviviridae
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US20050074801A1 (en) 2003-09-09 2005-04-07 Monia Brett P. Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US7655657B2 (en) 2003-12-22 2010-02-02 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20050137203A1 (en) 2003-12-22 2005-06-23 Jianguo Ji 3-quinuclidinyl amino-substituted biaryl derivatives
US7309699B2 (en) * 2003-12-22 2007-12-18 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives
ATE496920T1 (en) 2003-12-24 2011-02-15 Biota Scient Management POLYCYCLIC AGENTS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
SE0400184D0 (en) 2004-01-30 2004-01-30 Fyrkloevern Scandinavia Ab New therapeutic use
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
CN101426772B (en) 2004-04-08 2014-01-08 塔尔基公司 benzotriazine inhibitors of kinases
EP1732560A4 (en) 2004-04-08 2010-08-18 Neurogen Corp Substituted cinnolin-4-ylamines
ES2292130T3 (en) 2004-05-04 2008-03-01 Warner-Lambert Company Llc PIRIDO (2,3-D) PIRIMIDIN-7-PIRROLIL-SUBSTITUTED WAVES AND DERIVED FROM THEMSELVES AS THERAPEUTIC AGENTS.
AU2006206446A1 (en) 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
US7879992B2 (en) 2005-01-31 2011-02-01 Isis Pharmaceuticals, Inc. Modification of MyD88 splicing using modified oligonucleotides
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
JP2006219453A (en) 2005-02-14 2006-08-24 Tokyo Univ Of Pharmacy & Life Science Metal discriminating dual-wavelength fluorescent molecules with quinoline ring as the core
US7563601B1 (en) 2005-06-01 2009-07-21 City Of Hope Artificial riboswitch for controlling pre-mRNA splicing
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
KR101286569B1 (en) 2005-07-04 2013-07-23 하이 포인트 파마슈티칼스, 엘엘씨 Novel medicaments
US7473784B2 (en) 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
US7576110B2 (en) 2005-09-22 2009-08-18 Abbott Laboratories Benzothiazole cyclobutyl amine derivatives
US8258109B2 (en) 2005-10-20 2012-09-04 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of LMNA expression
WO2007056580A2 (en) 2005-11-08 2007-05-18 Pharmadyn, Inc. Methods and compositions for treating diseases associated with pathogenic proteins
KR20170119730A (en) 2005-11-10 2017-10-27 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
EP2246352A1 (en) 2005-12-06 2010-11-03 NeuroSearch AS Novel diazabicyclic aryl derivatives and their medical use
EP1968968A1 (en) 2005-12-21 2008-09-17 PainCeptor Pharma Corp. Compositions and methods for modulating gated ion channels
US20070299027A1 (en) 2006-01-26 2007-12-27 Gene Hung Compositions and their uses directed to huntingtin
EP2388327A1 (en) 2006-01-27 2011-11-23 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
AR059339A1 (en) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd CUMARINE DERIVATIVES FOR PROLIFERATIVE DISORDERS OF CELLS, PHARMACEUTICAL COMPOSITION AND THERAPEUTIC AGENT CONTAINING THEM
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
NZ570524A (en) 2006-03-28 2011-08-26 High Point Pharmaceuticals Llc Benzothiazoles having histamine H3 receptor activity
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
US20080247964A1 (en) 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
WO2007133756A2 (en) 2006-05-15 2007-11-22 Neurogen Corporation Crf1 receptor ligands comprising heteroaryl fused bicycles
WO2007135121A1 (en) 2006-05-23 2007-11-29 Neurosearch A/S Novel 8,10-diaza-bicyclo[4.3.1]decane derivatives and their medical use
ES2344760T3 (en) 2006-07-20 2010-09-06 Amgen Inc. PIRIDONA SUBSTITUTED COMPOUNDS AND METHOD OF USE.
US8337941B2 (en) 2006-07-27 2012-12-25 The Trustees Of Columbia University In The City Of New York Fluorescent substrates for monoamine transporters as optical false neurotransmitters
CA2659696C (en) 2006-08-03 2014-04-22 Rottapharm S.P.A. 6-1h-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents
WO2008020302A2 (en) 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
EP2079734A1 (en) 2006-10-25 2009-07-22 NeuroSearch A/S Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
US8143268B2 (en) 2006-12-22 2012-03-27 Avexa Limited Bicyclic pyrimidinones and uses thereof
US20080171792A1 (en) 2006-12-28 2008-07-17 Jobdevairakkam Christopher New Use of highly concentrated formulations of 4-phenylbutyrate for treatment of certain disorders
FR2914188B1 (en) 2007-03-28 2012-06-22 Trophos NEW CHOLEST-4-EN-3-ONE OXIME COMPOSITION
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
CA2700841A1 (en) 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
DK2193133T3 (en) 2007-09-27 2015-10-05 Fundacion Ct Nac Investigaciones Oncologicas Carlos Iii IMIDAZOLOTHIADIAZOLES USED AS PROTEINKINASE INHIBITORS
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
US20090258907A1 (en) 2008-04-09 2009-10-15 Abbott Laboratories Compounds useful as inhibitors of rock kinases
US20090264433A1 (en) 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
WO2009151546A2 (en) 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
CA2728376C (en) 2008-06-20 2015-05-12 Rottapharm S.P.A. 6-1h-imidazo-quinazoline and quinolines derivatives/mao inhibitors for treating depression
EP2138493A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidone derivatives
MX2011000149A (en) 2008-07-02 2011-02-24 Avexa Ltd Compounds having antiviral properties.
US8986935B2 (en) 2008-08-13 2015-03-24 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
WO2010024903A1 (en) 2008-08-29 2010-03-04 Yangbo Feng BENZO[d]OXAZOLES AND BENZO[d]THIAZOLES AS KINASE INHIBITORS
US20110224187A1 (en) 2008-10-16 2011-09-15 Anandan Palani Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
EP2379564A1 (en) 2008-12-19 2011-10-26 Schering Corporation Bicyclic heterocyclic derivatives and methods of use thereof
US8063032B2 (en) 2009-02-11 2011-11-22 Sunovion Pharmaceuticals Inc. Histamine H3 inverse agonists and antagonists and methods of use thereof
FR2945289A1 (en) 2009-05-11 2010-11-12 Sanofi Aventis 2-CYCLOAMINO-5- (PYRIDIN-4-YL) IMIDAZO-2,1-B1 DERIVATIVES 1,3,4! THIADIAZOLE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
JP6073677B2 (en) 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Fused heterocyclic compounds and their use
AU2010262643B2 (en) 2009-06-19 2015-02-19 Abbvie Inc. Diazahomoadamantane derivatives and methods of use thereof
NZ714887A (en) 2009-09-11 2019-07-26 Ionis Pharmaceuticals Inc Modulation of huntingtin expression
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
US20150018301A1 (en) 2009-11-06 2015-01-15 The Johns Hopkins University LRRK-2-Mediated Neuronal Toxicity
EP2501231B1 (en) 2009-11-20 2016-12-21 Merck Sharp & Dohme Corp. Quinolizidinone carboxamide m1 receptor positive allosteric modulators
AU2011206761A1 (en) 2010-01-13 2012-07-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti - infective pyrido (1,2 -a) pyrimidines
US9006198B2 (en) 2010-02-08 2015-04-14 Isis Pharmaceuticals, Inc. Selective reduction of allelic variants
EP2536738A4 (en) 2010-02-08 2014-09-17 Isis Pharmaceuticals Inc METHODS AND COMPOSITIONS SUITABLE FOR THE TREATMENT OF CONDITIONS OR CONDITIONS IN RELATION TO THE EXPANSION OF REPETITIONS
DK2534248T3 (en) 2010-02-08 2018-11-19 Ionis Pharmaceuticals Inc SELECTIVE REDUCTION OF ALLELVARIANS
WO2011140160A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Bicyclic heteroaryl compounds as gpr119 modulators
CA2800509A1 (en) 2010-05-24 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
PL3031920T3 (en) 2010-07-19 2020-01-31 Ionis Pharmaceuticals, Inc. MODULATION OF PROTEIN KINASE EXPRESSION OF MYOTONIC DYSTROPHY (DMPK)
WO2012019106A2 (en) 2010-08-06 2012-02-09 Board Of Regents Of The University Of Nebraska Positive and negative modulators of nmda receptors
WO2012075393A2 (en) 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
CN102617548A (en) 2011-01-31 2012-08-01 北京赛林泰医药技术有限公司 Bicycloheteroaryl compounds as GPR Receptor stimulant, compositions and application thereof
WO2012104823A2 (en) 2011-02-04 2012-08-09 Novartis Ag Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
ES2772258T3 (en) 2011-02-07 2020-07-07 Biogen Ma Inc S1P modulating agents
US10017764B2 (en) 2011-02-08 2018-07-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US8703763B2 (en) 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
WO2013019938A1 (en) 2011-08-02 2013-02-07 The Brigham And Women's Hospital, Inc. Pyridazine derivatives as eaat2 activators
US8871756B2 (en) 2011-08-11 2014-10-28 Hoffmann-La Roche Inc. Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
WO2013022984A1 (en) 2011-08-11 2013-02-14 Isis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
EP2560008B1 (en) 2011-08-18 2016-11-30 Korea Institute of Science and Technology Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same
US9976138B2 (en) 2011-08-29 2018-05-22 Ionis Pharmaceuticals, Inc. Methods and compounds useful in conditions related to repeat expansion
WO2013059606A1 (en) 2011-10-21 2013-04-25 Tufts Medical Center, Inc. Compounds and methods for the treatment of muscular disease, and related screening methods
GB201119538D0 (en) 2011-11-10 2011-12-21 Viral Ltd Pharmaceutical compounds
ES2606630T3 (en) 2011-11-28 2017-03-24 Novartis Ag Novel trifluoromethyl oxadiazole derivatives and their use in the treatment of disease
WO2013101974A1 (en) 2011-12-30 2013-07-04 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
CA2862084C (en) 2012-01-26 2021-05-11 Ptc Therapeutics, Inc. 1h-isochromen-1-one derivatives and compositions thereof for treating spinal muscular atrophy
PH12018501711B1 (en) 2012-02-10 2023-05-05 Hoffmann La Roche Compounds for treating spinal muscular atrophy
WO2013130689A1 (en) 2012-03-01 2013-09-06 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
EA028382B1 (en) 2012-03-23 2017-11-30 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Compounds for treating spinal muscular atrophy
US9199946B2 (en) 2012-04-03 2015-12-01 Bristol-Myers Squibb Company Pyrimidinone carboxamide inhibitors of endothelial lipase
SI3459942T1 (en) 2012-04-24 2021-05-31 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
AU2013261130A1 (en) 2012-05-15 2014-10-23 Novartis Ag Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
EP2872493B1 (en) 2012-07-13 2018-11-14 Indiana University Research and Technology Corporation 5,6,7-trimethoxy 4-phenyl quinolin-2-one derivatives for treatment of spinal muscular atrophy
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
EP2906255B1 (en) 2012-10-12 2023-02-22 Ionis Pharmaceuticals, Inc. Antisense compounds and uses thereof
WO2014059356A2 (en) 2012-10-12 2014-04-17 Isis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
US9227976B2 (en) 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
PL2911671T3 (en) 2012-10-25 2018-11-30 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
JP6255711B2 (en) 2012-11-01 2018-01-10 株式会社リコー Electrochromic compound, electrochromic composition, and display element
US9040712B2 (en) 2013-01-23 2015-05-26 Novartis Ag Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
CA2899924A1 (en) 2013-02-04 2014-08-07 Isis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
AU2014224975B2 (en) 2013-03-05 2017-09-14 Merck Patent Gmbh Triazolo(4,5-d)pyrimidine derivatives for the treatment of diseases such as cancer
JP2016518421A (en) 2013-05-14 2016-06-23 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Aza-oxo-indoles for the treatment and prevention of respiratory syncytial virus infection
MX363456B (en) 2013-06-25 2019-03-25 Hoffmann La Roche Compounds for treating spinal muscular atrophy.
JP6461150B2 (en) 2013-07-31 2019-01-30 ノバルティス アーゲー 1,4-disubstituted pyridazine derivatives and their use to treat conditions associated with SMN deficiency
RU2016109324A (en) 2013-08-19 2017-09-26 Ф. Хоффманн-Ля Рош Аг SCREENING METHOD
US10195202B2 (en) 2013-12-19 2019-02-05 Ptc Therapeutics, Inc. Methods for modulating the amount of RNA transcripts
WO2015095446A1 (en) 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount of rna transcripts
WO2015095449A1 (en) 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount rna transcripts
CN106068325B (en) 2014-01-16 2021-07-09 波涛生命科学有限公司 Chiral design
US9815813B2 (en) 2014-01-17 2017-11-14 Novartis Ag 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
AR099134A1 (en) 2014-01-24 2016-06-29 Hoffmann La Roche PROCEDURE FOR THE PREPARATION OF N - [(3-AMINOOXETAN-3-IL) METHYL] -2- (1,1-DIOXO-3,5-DIHIDRO-1,4-BENZOTIAZEPÍN-4-IL) -6-METIL- QUINAZOLÍN-4-AMINA
MX379110B (en) 2014-03-14 2025-03-11 Raqualia Pharma Inc AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS.
WO2015143185A1 (en) 2014-03-19 2015-09-24 Amydis Diagnostics Amyloid targeting agents and methods of using the same
WO2015173181A1 (en) 2014-05-15 2015-11-19 F. Hoffmann-La Roche Ag Compounds for treating spinal muscular atrophy
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
US20170121197A1 (en) 2014-06-17 2017-05-04 Novozymes A/S Biological Phosphorus Removal from Wastewater
CA2952895C (en) 2014-06-25 2023-09-26 F. Hoffmann-La Roche Ag Imidazo[1,2-a]pyrazin-1yl-benzamide compounds for treating spinal muscular atrophy
JP6672296B2 (en) 2014-10-31 2020-03-25 ザ ジェネラル ホスピタル コーポレイション Powerful gamma-secretase modulator
GB201419579D0 (en) 2014-11-03 2014-12-17 Iomet Pharma Ltd Pharmaceutical compound
EP3227301A1 (en) 2014-12-02 2017-10-11 Bayer CropScience AG Bicyclic compounds as pest control agents
HK1246344B (en) 2014-12-24 2020-01-10 Uniqure Ip B.V. Rnai induced huntingtin gene suppression
PL3244891T3 (en) 2015-01-16 2022-12-27 The General Hospital Corporation Compounds for improving mrna splicing
WO2016128343A1 (en) 2015-02-09 2016-08-18 F. Hoffmann-La Roche Ag Compounds for the treatment of cancer
GB201502567D0 (en) 2015-02-16 2015-04-01 Sentinel Oncology Ltd Pharmaceutical compounds
CN107635984B (en) 2015-03-11 2021-04-13 Fmc公司 Heterocyclic Substituted Bicyclazole Pesticides
GB201506933D0 (en) 2015-04-23 2015-06-10 Sentinel Oncology Ltd Pharmaceutical compounds
WO2016184832A1 (en) 2015-05-20 2016-11-24 F. Hoffmann-La Roche Ag Compounds for treating spinal muscular atrophy
EP3310169B1 (en) 2015-05-30 2023-05-17 PTC Therapeutics, Inc. Methods for modulating rna splicing
MA43072A (en) 2015-07-22 2018-05-30 Wave Life Sciences Ltd COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
WO2017023987A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
TW201718546A (en) 2015-10-02 2017-06-01 英塞特公司 Heterocyclic compounds useful as PIM kinase inhibitors
CN108289959B (en) 2015-11-12 2021-07-16 豪夫迈·罗氏有限公司 Composition for treating spinal muscular atrophy
JP2018533594A (en) 2015-11-12 2018-11-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Compounds for treating amyotrophic lateral sclerosis
US10383867B2 (en) 2015-11-28 2019-08-20 Russell Dahl Quinoline derivatives and their use for treating endoplasmic reticulum stress-related diseases and disorders
CN108697709A (en) * 2015-12-10 2018-10-23 Ptc医疗公司 Method for treating Huntington's disease
JP6872550B2 (en) 2015-12-10 2021-05-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Crosslinked piperidine derivative
JP2019512491A (en) 2016-03-11 2019-05-16 エーシー・イミューン・エス・アー Bicyclic compounds for diagnosis and therapy
US10526345B2 (en) 2016-04-08 2020-01-07 Mankind Pharma Ltd. Compounds as GPR119 agonists
AR108325A1 (en) 2016-04-27 2018-08-08 Samumed Llc ISOQUINOLIN-3-IL CARBOXAMIDS AND PREPARATION AND USE OF THE SAME
MA45270A (en) 2016-05-04 2017-11-09 Wave Life Sciences Ltd COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
JP7044375B2 (en) 2016-05-31 2022-03-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Heterocyclic inhibitor of PTPN11
CN109689649B (en) 2016-07-14 2022-07-19 百时美施贵宝公司 Bicyclic heteroaryl substituted compounds
US20190264267A1 (en) 2016-07-25 2019-08-29 Wave Life Sciences Ltd. Phasing
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TW202500565A (en) 2016-10-24 2025-01-01 美商傳達治療有限公司 Shp2 phosphatase inhibitors and methods of use thereof
EP3606562A4 (en) 2017-04-03 2020-11-11 Acceleron Pharma Inc. COMPOSITIONS AND METHODS OF TREATMENT OF SPINAL MUSCLE ATROPHY
WO2018218133A1 (en) 2017-05-26 2018-11-29 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
CN111065626B (en) 2017-06-05 2024-09-27 Ptc医疗公司 Compounds for treating Huntington's disease
CA3067592A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
MX2019015578A (en) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Methods for treating huntington's disease.
RU2020105929A (en) * 2017-08-04 2021-09-06 Скайхоук Терапьютикс, Инк. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
WO2019165073A1 (en) 2018-02-21 2019-08-29 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
WO2019183364A1 (en) 2018-03-21 2019-09-26 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof
BR112020019385A2 (en) 2018-03-21 2021-03-30 Relay Therapeutics, Inc. SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE OF THE SAME
SG11202009212WA (en) 2018-03-27 2020-10-29 Ptc Therapeutics Inc Compounds for treating huntington's disease
CN112805280B (en) 2018-06-27 2024-12-06 Ptc医疗公司 Heteroaryl compounds for the treatment of Huntington's disease
LT3814357T (en) 2018-06-27 2024-06-25 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
WO2020190793A1 (en) 2019-03-15 2020-09-24 Skyhawk Therapeutics, Inc. Compositions and methods for correction of aberrant splicing
EP4219466A1 (en) 2019-05-13 2023-08-02 PTC Therapeutics, Inc. Compunds for treating huntington's disease
WO2021007378A1 (en) 2019-07-11 2021-01-14 Ptc Therapeutics, Inc. Compounds for use in treating huntington's disease
WO2021084495A1 (en) 2019-11-01 2021-05-06 Novartis Ag The use of a splicing modulator for a treatment slowing progression of huntington's disease
MX2022012575A (en) 2020-04-09 2023-01-24 Ptc Therapeutics Inc Compounds for treating huntington's disease.
MX2023005541A (en) 2020-11-12 2023-06-15 Ptc Therapeutics Inc Novel rna transcript.
EP4377317A1 (en) 2021-07-30 2024-06-05 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902695A (en) * 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists

Also Published As

Publication number Publication date
US20210009590A1 (en) 2021-01-14
WO2019191092A1 (en) 2019-10-03
BR112020019264A2 (en) 2021-01-12
WO2019191092A8 (en) 2020-05-07
KR20210005558A (en) 2021-01-14
EA202092001A1 (en) 2021-01-29
JP2021519318A (en) 2021-08-10
BR112020019373A2 (en) 2020-12-29
EP3773552A1 (en) 2021-02-17
WO2019191229A1 (en) 2019-10-03
AU2019243048A1 (en) 2020-10-15
AU2019243943A1 (en) 2020-10-15
IL277497A (en) 2020-11-30
EA202092003A1 (en) 2021-02-10
SG11202009211VA (en) 2020-10-29
MX2020009956A (en) 2021-01-15
IL277498A (en) 2020-11-30
US12103926B2 (en) 2024-10-01
KR20210005559A (en) 2021-01-14
EP3774744B1 (en) 2025-02-12
CA3094700A1 (en) 2019-10-03
EP3773552A4 (en) 2022-01-26
CN112135815A (en) 2020-12-25
US11780839B2 (en) 2023-10-10
WO2019191229A8 (en) 2019-12-19
JP7399869B2 (en) 2023-12-18
US20210024525A1 (en) 2021-01-28
CA3094703A1 (en) 2019-10-03
CN112203653B (en) 2024-08-16
CN112203653A (en) 2021-01-08
JP7399870B2 (en) 2023-12-18
JP2021519291A (en) 2021-08-10
SG11202009212WA (en) 2020-10-29
EP3774744A1 (en) 2021-02-17
MX2020009957A (en) 2021-01-15

Similar Documents

Publication Publication Date Title
US11780839B2 (en) Compounds for treating Huntington&#39;s disease
US11858941B2 (en) Heterocyclic and heteroaryl compounds for treating Huntington&#39;s disease
EP3969446B1 (en) Compounds for treating huntington&#39;s disease
US11685746B2 (en) Heteroaryl compounds for treating Huntington&#39;s disease
US20230234942A1 (en) Compounds for treating huntington&#39;s disease
US20240132509A1 (en) Heterocyclic and heteroaryl compounds for treating huntington&#39;s disease
EA046152B1 (en) COMPOUNDS FOR THE TREATMENT OF HUNTINGTON&#39;S DISEASE
EA045009B1 (en) HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF HUNTINGTON&#39;S DISEASE
HK40043148A (en) Heterocyclic and heteroaryl compounds for treating huntington&#39;s disease
HK40043148B (en) Heterocyclic and heteroaryl compounds for treating huntington&#39;s disease

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

AS Assignment

Owner name: PTC THERAPEUTICS, INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SYDORENKO, NADIYA;ALAM, RAUFUL, MD;AMEDZO, LUKIANA;AND OTHERS;SIGNING DATES FROM 20200218 TO 20200305;REEL/FRAME:067412/0087

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION